The Development of BSN272 From Prevention of Diet-Induced Hyperlipidemia in Mice to a Potential Therapy For Prader-Willi Syndrome in Humans by Williams, Jarrod B.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Pharmacy College of Pharmacy 
2017 
The Development of BSN272 From Prevention of Diet-Induced 
Hyperlipidemia in Mice to a Potential Therapy For Prader-Willi 
Syndrome in Humans 
Jarrod B. Williams 
University of Kentucky, jarrod.williams9@gmail.com 
Author ORCID Identifier: 
http://orcid.org/0000-0003-3962-2088 
Digital Object Identifier: https://doi.org/10.13023/ETD.2017.024 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Williams, Jarrod B., "The Development of BSN272 From Prevention of Diet-Induced Hyperlipidemia in Mice 
to a Potential Therapy For Prader-Willi Syndrome in Humans" (2017). Theses and Dissertations--
Pharmacy. 69. 
https://uknowledge.uky.edu/pharmacy_etds/69 
This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It 
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Jarrod B. Williams, Student 
Dr. Robert Lodder, Major Professor 
Dr. David Feola, Director of Graduate Studies 
THE	DEVELOPMENT	OF	BSN272	FROM	PREVENTION	OF	DIET-INDUCED	HYPERLIPIDEMIA	IN	
MICE	TO	A	POTENTIAL	THERAPY	FOR	PRADER-WILLI	SYNDROME	IN	HUMANS	
DISSERTATION	
A	dissertation	submitted	in	partial	fulfillment	of	the	
requirements	for	the	degree	of	Doctor	of	Philosophy	in	the	
College	of	Pharmacy	
	at	the	University	of	Kentucky	
By	
Jarrod	B.	Williams	
Lexington,	Kentucky	
Director:	Dr.	Robert	Lodder,	Professor	of	Pharmaceutical	Sciences	
Lexington,	Kentucky	
2017	
Copyright	©	Jarrod	B.	Williams	2016	
http://orcid.org/0000-0003-3962-2088
ABSTRACT	OF	DISSERTATION	
While	 type	 2	 diabetes	mellitus	 (T2DM)	 is	 distinguished	 as	 a	 disorder	 of	 blood	 glucose	
homeostasis,	the	vast	majority	of	patients	afflicted	with	this	disease	in	the	US	present	with	the	
entire	complement	of	the	metabolic	syndrome:	abdominal	obesity,	hypertriglyceridemia,	low	HDL	
levels,	elevated	blood	pressure,	and	elevated	fasting	plasma	glucose.		Current	guidelines	aim	to	
treat	 each	 of	 these	 disorders,	 but	 do	 so	 individually	 even	 though	 they	 are	manifestations	 of	
common	 pathologies.	 	 In	 other	 words,	 a	 patient	 will	 be	 prescribed	 different	 medications	 for	
diabetes,	 blood	 pressure,	 CVD	 prevention,	 etc.,	 while	 the	 only	 single	 treatment	 aimed	 at	 the	
myriad	of	disorders	together	is	changes	to	dietary	and	exercise	habits.		Diet	and	exercise,	when	
executed	properly,	has	been	shown	consistently	to	be	the	most	effective	treatment	for	T2DM.	
The	rate	of	type	2	diabetes	in	the	US	is	close	to	10%,	but	the	rate	of	type	2	diabetes	is	even	higher	
in	patients	with	Prader-Willi	Syndrome	(a	genetic	disease	that	causes	excessive	weight	gain	from	
overeating,	resulting	in	approximately	double	the	risk	of	diabetes).		BSN272	is	a	combination	of	2	
molecules	 (D-tagatose	 and	 trans-polydatin)	 that	 have	 shown	 benefits	 in	 treating	 individual	
manifestations	 of	 the	 metabolic	 syndrome	 presentation	 as	 monotherapy	 and	 have	 proved	
synergistic	when	taken	together	to	treat	the	entire	complement	of	the	disorders.	
Previous	research	in	our	lab	with	D-tagatose	included	safety	studies	in	animal	models	and	
humans	for	use	as	a	dietary	ingredient	which	culminated	with	the	generally	recognized	as	safe	
(GRAS)	designation	by	the	FDA	and	EU	for	use	in	foods.		Based	on	these	exposures	to	determine	
safety,	 an	 IND	 was	 granted	 to	 evaluate	 the	 safety	 and	 efficacy	 of	 D-tagatose	 in	 treating	
hyperglycemia	in	T2DM.			Phase	2	and	3	global	clinical	trials	were	completed	showing	D-tagatose	
to	be	highly	 safe	and	moderately	effective.	 	The	decision	was	made	 to	 search	 for	a	molecular	
complement	to	D-tagatose	that	could	more	completely	treat	T2DM.	
Dihydromyricetin	 and	 trans-polydatin	 were	 identified	 through	 literature	 searches	 as	
potentially	 synergistic	 with	 D-tagatose.	 	 Both	 molecules	 were	 tested	 in	 combination	 with	 D-
tagatose	for	their	ability	to	prevent	diet-induced	elevations	in	cholesterol	markers	in	ApoE-/-	mice.	
Dihydromyricetin	 appeared	 to	 be	 additively	 effective	 with	 D-tagatose	 for	 lipids,	 but	 trans-
polydatin	showed	synergy	in	prevention	of	cholesterol	elevations	as	results	were	greater	for	the	
combination	 than	were	 the	 additive	 benefits	 of	 either	 as	monotherapy.	 	 Trans-polydatin	 also	
showed	this	property	in	a	hyperlipidemic	hamster	model	and	a	LDLr-/-	mouse	model.	
THE	DEVELOPMENT	OF	BSN272	FROM	PREVENTION	OF	DIET-INDUCED	
HYPERLIPIDEMIA	IN	MICE	TO	A	POTENTIAL	THERAPY	FOR	PRADER-WILLI	SYNDROME	
IN	HUMANS	
Following	safety	and	efficacy	results	in	three	animal	models	for	BSN272,	an	exploratory	
Phase	1	PK	microdose	study	was	submitted	to	the	FDA	in	an	IND	filing	to	investigate	whether	the	
presence	of	D-tagatose	has	any	effects	on	the	kinetics	of	trans-polydatin	when	administered	in	
concert	 compared	 to	 trans-polydatin	 alone.	 	 The	 indication	 sought	 for	 the	 IND	 is	 Prader-Willi	
Syndrome	(PWS)	due	to	the	added	potential	of	D-tagatose	to	impart	satiety	and	reduce	weight	
gain.		PWS	is	a	genetic	disorder	in	which	patients	develop	insatiable	hunger	that	leads	to	obesity	
and	often	diabetes	while	 in	 childhood.	 	 There	 is	 currently	only	 symptomatic	 treatment	of	 the	
disease	 and	 none	 of	 the	 medications	 in	 treatment	 guidelines	 for	 adult	 type	 2	 diabetes	 are	
approved	for	pediatric	use.	
KEYWORDS:	Polydatin,	piceid,	D-tagatose,	tagatose,	type	2	diabetes,	Prader-Willi	
syndrome	
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Chapter	1	–	Introduction	
This	chapter	provides	an	introduction	to	the	concepts	and	previous	studies	conducted	that	are	
pertinent	 to	understanding	 the	 chapters	within	 this	dissertation.	 	 The	dissertation	 is	made	up	
primarily	of	published	articles.		Where	the	introduction	and	preface	to	each	chapter	of	this	work	
presents	background	information	sufficient	for	the	reader	that	information	is	excluded	from	this	
“Introduction”	chapter.		In	this	way,	the	reader	can	gain	the	best	understanding	of	the	material	
by	 reading	 this	 document	 straight	 through,	 feeling	 free	 to	 skip	 over	 repetitive	 portions	 of	
published	articles	that	may	be	present	in	the	introduction	sections	of	each	chapter.		The	tables,	
figures,	 and	 references	 of	 each	 of	 the	 published	 articles	 has	 been	 changed	 to	 be	 continues	
throughout	this	dissertation,	with	the	exception	of	the	articles	in	the	appendix	section	which	are	
presented	in	their	original	forms.	
This	dissertation	discusses	 studies	 involved	with	a	once	promising	drug	candidate,	D-tagatose.	
After	D-tagatose	ran	out	of	patent	life	before	being	approved	for	the	market	it	was	returned	to	
the	lab	and	re-worked	in	multiple	preclinical	animal	studies	with	combination	therapy	aimed	at	
overcoming	 some	of	 the	undesirable	effects	of	 the	drug	with	 the	goal	of	 creating	a	new	drug	
entity.		During	this	process	a	novel	and	unexpected	result	was	discovered	that	led	to	a	patent	for	
this	drug	combination	based	off	animal	data	from	multiple	mammalian	models	presented	here.	
This	combination	labeled	BSN272	is	now	working	its	way	through	the	regulatory	framework	of	
obtaining	an	IND	and	beginning	its	first-in-human	(FIH)	study.	
The	 process	 of	 guiding	 a	 drug	 candidate	 through	 the	 approval	 process	 in	 anything	 but	
straightforward.		If	a	molecule	shows	activity	in	a	dish,	an	animal	model,	or	is	discovered	to	have	
clinical	action	through	human	exposure	in	a	natural	setting,	it	is	the	job	of	the	development	team	
to	position	the	drug	candidate	in	an	environment	that	gives	it	the	best	chance	for	it	to	succeed.		
Succeeding	means	approval	by	the	Food	and	Drug	Administration	(FDA)	in	the	form	of	a	New	Drug	
Application	(NDA)	which	is	a	process	of	regulatory	action.		It	is	the	job	of	the	FDA	to	deny	drug	
approval	as	an	act	of	safety	 to	 the	public,	not	 to	do	the	 job	of	 the	drug	development	team	 in	
suggesting	 disease	 states	 to	 target,	 animal	models	 to	 pursue,	 or	 even	 a	marker	 of	 efficacy	 to	
evaluate	for	a	treatment	that	has	shown	activity,	although	they	will	provide	some	help	with	this	
when	 they	 can.	 	Ultimately,	 it	 is	 up	 to	 the	development	 team	 to	 scour	 the	 literature,	 consult	
experts	 and	 specialists	 at	 various	 points,	 conduct	 the	 necessary	 safety	 and	 efficacy	 studies,	
comply	with	 drug	 quality	 regulations	 through	 Good	Manufacturing	 Practices	 (GMP)	 tests	 and	
documentation	(GDP),	choose	a	disease	with	the	best	chance	of	surviving	the	approval	process,	
taking	a	drug	back	 into	animal	studies	after	clinical	 trials	when	appropriate	 to	 learn	more	and	
tweak,	and	then	take	back	into	the	clinic	with	more	information	and	a	better	development	plan.	
This	dissertation	presents	the	path	of	such	a	process	for	BSN272,	the	combination	of	D-tagatose	
and	 trans-polydatin,	 up	 to	 this	 point	 from	 the	 clinical	 development	 of	 D-tagatose	 for	 the	
treatment	of	type	2	diabetes,	to	new	pre-clinical	studies	 in	hyperlipidemic	mammalian	models	
with	synergistic	actions	of	trans-polydatin,	to	choosing	the	disease	state	of	Prader-Willi	Syndrome	
to	best	highlight	the	potential	benefits	of	the	drug,	and	the	pre-approval	to	begin	an	exploratory,	
first	in	human	PK	study	with	BSN272	in	healthy	volunteers.			
1.1	D-tagatose	
1.1.1	GRAS	
D-tagatose	is	a	naturally	occurring	epimer	of	fructose	at	the	C-4	carbon	found	in	small	amounts
in	dairy	products	as	an	isomerization	product	of	galactose.		It	was	originally	studied	and	patented
as	a	low	calorie	food	sweetener	with	a	reported	zero	net	energy	contribution.1		Various	pre-clinical
1
safety	and	toxicity	studies	as	well	as	a	handful	of	small	human	studies	were	conducted	in	order	to	
obtain	a	Generally	Recognized	as	Safe	 (GRAS)	 indication	by	the	FDA	for	use	as	a	 food	additive	
which	was	granted.2,3		During	this	process	D-tagatose	was	tested	for	safety	in	a	study	with	type	2	
diabetic	(T2DM)	participants	as	they	would	be	likely	consumers	of	a	low	calorie	sweetener.		While	
the	design	of	the	study	was	to	evaluate	the	safety	in	regards	to	worsening	of	their	blood	glucose	
disorder,	 it	was	observed	that	 the	patient’s	blood	glucose	returned	to	normal	after	a	75g	oral	
glucose	tolerance	test	more	quickly	than	those	given	sucrose	instead	of	D-tagatose.4,5		This	led	to	
a	series	of	small	human	studies	to	see	if	D-tagatose	could	possibly	have	any	efficacy	as	an	anti-
hyperglycemic	medication	for	diabetics.6,7			These	initial	studies	were	positive	and	Dr.	Lodder’s	lab	
at	the	University	of	Kentucky	was	asked	to	assist	with	putting	together	a	package	with	which	to	
ask	the	FDA	for	an	IND	to	pursue	D-tagatose	as	a	treatment	for	lowering	blood	sugar	in	type	2	
diabetics.		Most	of	the	safety	and	toxicology	studies	had	already	been	done	to	obtain	the	GRAS	
status	and	some	efficacy	had	been	shown	at	doses	used	for	the	earlier	human	studies	in	T2DM	
patients.	So	instead	of	granting	permission	to	move	forward	with	a	Phase	I	study,	the	FDA	asked	
for	a	Phase	III	study	with	a	large	number	of	T2DM	patients	powered	to	achieve	efficacy	results	for	
the	ability	of	D-tagatose	in	lowering	of	HbA1c.	
1.1.2	Large-Scale	Clinical	Trials	with	D-tagatose	for	Treatment	of	Hyperglycemia	
An	Investigational	New	Drug	(IND)	approval	by	the	FDA	is	required	to	ship	investigational	drugs	
across	state	lines	in	order	to	perform	clinical	trials.		Technically,	a	human	trial	can	be	conducted	
without	an	IND	if	the	investigational	drug	is	not	shipped	across	state	lines,	the	trial	must	simply	
be	 approved	 by	 the	 Investigational	 Review	 Board	 (IRB).	 	 In	 the	 90’s	 this	 was	 common	 and	
numerous	small	scale	human	trials	were	conducted	with	D-tagatose	to	assess	 its	safe	use	as	a	
food	additive4,8–14	for	which	is	was	given	Generally	Recognized	as	Safe	(GRAS)	status	by	the	FDA2,15	
and	many	 other	 foreign	 regulatory	 bodies.	 	 This	 led	 to	 small	 clinical	 trials	 to	 determine	 if	 D-
tagatose	could	be	efficacious	as	an	anti-hyperglycemic	medication	in	T2DM	patients.5–7,16,17	In	the	
regulatory	 world	 of	 clinical	 trials	 with	 investigational	 new	 drugs	 today,	 the	 IRB’s	 most	 often	
require	an	IND	before	they	will	approve	any	study,	regardless	of	the	need	(or	not)	for	the	drug	to	
cross	state	lines.	
These	studies	provided	positive	outcomes	and	the	decision	was	made	to	pursue	an	IND	with	an	
indication	for	treating	hyperglycemia.		The	protocol	submitted	was	for	a	Phase	1	study	to	evaluate	
pharmacokinetics	(PK)	and	safety	of	D-tagatose,	but	the	FDA	responded	with	an	okay	to	conduct	
a	Phase	III	 large-scale	clinical	trial	powered	to	determine	efficacy.	 	This	was	due	to	the	unique	
number	of	trials	and	data	that	D-tagatose	had	for	a	first	submission	of	an	IND	evaluating	safety	
and	 efficacy.	 	 Dr.	 Lodder	was	 recruited	 as	 the	 PI	 to	 plan	 and	 conduct	 this	 Phase	 III	 trial	 (and	
subsequent	 Phase	 II	 trial)	 due	 to	 his	 knowledge	 of	 the	 regulatory	 arena	 of	 pharmaceutical	
development.	
Both	of	these	studies	(Phase	III	and	Phase	II)	were	completed	just	prior	to	my	joining	the	lab.		I	
had	 the	 opportunity	 to	 become	 familiar	with	D-tagatose,	 T2DM,	 and	 regulation	 as	 I	 co-wrote	
these	 papers	 for	 academic	 submission.	 	 The	 Phase	 III	 article	 published	 in	 the	 Journal	 of	
Endocrinology	Diabetes	&	Obesity	is	presented	in	Appendix	A	(with	formatting	changes	to	match	
this	document).		In	this	study	15	g	of	D-tagatose	administered	three	times	a	day	proved	safe	and	
efficacious	 for	 the	 treatment	 of	 hyperglycemia	 in	 the	 subjects	 involved	 as	 seen	 by	 significant	
lowering	 of	 HbA1c	 values	 at	 all	 post-baseline	 time-points	 in	 the	 treatment	 group.	 	 Of	 some	
concern	was	a	 trend	of	 increased	 triglycerides	 in	 the	 treatment	group	 towards	 the	end	of	 the	
study	which	is	addressed	by	subsequent	studies	presented	here.		D-tagatose	was	well	tolerated.	
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The	second	was	a	Phase	II	trial	with	three	different	doses	of	D-tagatose	in	T2DM	patients	in	an	
attempt	to	further	establish	the	lowest	effective	dose	of	D-tagatose	that	is	able	to	lower	HbA1c	
by	>	0.5%	over	a	6-month	period.18		This	study	is	presented	in	Appendix	B.		Using	each	patient’s	
own	HbA1c	to	compare,	participants	were	given	2.5,	5.0,	or	7.5	g	of	D-tagatose	three	times	a	day	
for	6	months	with	blood	 levels	drawn	throughout	and	measured	for	various	variables	 that	are	
known	to	be	altered	in	the	T2DM	population.		5.0	g	of	D-tagatose	three	times	a	day	was	the	lowest	
effective	dose	at	lowering	HbA1c	in	this	study.	
1.2	Physiology	of	Type	2	Diabetes	Mellitus	(T2DM)	
Type	2	Diabetes	Mellitus	(T2DM,	or	type	2	diabetes,	or	diabetes	for	this	manuscript)	is	a	disorder	
of	blood	glucose	homeostasis	characterized	by	peripheral	insulin	resistance	and	progressive	loss	
of	pancreatic	beta	cell	 function,	that	affects	more	than	400	million	people	globally.19	 	 It	 is	also	
known	as	non-insulin	dependent	diabetes	mellitus	(NIDDM)	to	distinguish	the	disease	from	Type	
1	Diabetes	Mellitus	or	insulin	dependent	diabetes	mellitus.		In	the	latter	disease,	the	pancreas	of	
an	 individual	 completely	 loses	 its	 ability	 to	 produce	 insulin	 all	 at	 once,	 sometime	 usually	 in	
childhood,	and	these	patients	must	administer	exogenous	insulin	to	remain	alive	for	the	rest	of	
their	lives.		In	T2DM	the	loss	of	pancreatic	beta	cell	function	and	insulin	resistance	occurs	slowly,	
over	decades,	and	thus	these	patients	can	be	treated	with	oral	antihyperglycemic	agents	aimed	
at	improving	the	various	underlying	problems,	with	the	goal	of	avoiding	the	need	for	exogenous	
insulin	therapy,	which	is	an	eventuality	in	most	cases	and	a	point	of	no	return	for	these	patients.20		
D-tagatose	 is	 an	 example	 of	 an	 oral	 antihyperglycemic	 agent	 and	 for	 the	 remainder	 of	 this
manuscript	any	reference	to	diabetes	is	regarding	the	type	2	variety.
To	 understand	 the	 pathophysiology	 of	 T2DM	we	must	 first	 discuss	 glucose	 homeostasis	 in	 a	
healthy	individual.		In	the	fasted	state	of	a	healthy	individual	blood	glucose	concentrations	stay	
between	80-100	mg/dl.		Upon	consumption	of	a	meal	the	glucose	concentration	rises	to	140-180	
mg/dl.		This	increase	in	glucose	concentration	signals	the	pancreatic	beta	cells	to	release	insulin	
into	 the	 bloodstream.	 	 Insulin	 activities	 glucose	 transporters	 in	 the	 periphery	 to	 uptake	 the	
glucose	from	the	blood	which	is	eventually	stored	as	glycogen	to	be	used	later	for	energy.21	
In	T2DM	fasting	glucose	is	maintained	above	120	mg/dl	and	glucose	in	the	fed	state	increases	to	
well	above	180	mg/dl,	often	reaching	250+	mg/dl.		Glucose	homeostasis	is	disrupted	because	of	
the	 inability	of	 the	body	 to	maintain	 it	 at	a	normal	 level	with	 insulin.	 	 The	2	hallmarks	of	 this	
disruption	is	progressive	loss	of	pancreatic	beta	cell	function	in	releasing	insulin	and	progressive	
resistance	to	insulin	by	peripheral	tissues.21	
The	 consequences	 of	 long	 standing	 hyperglycemia	 fall	 into	 two	 categories;	microvascular	 and	
macrovascular	complications.		Microvascular	complications	are	the	major	causes	of	morbidity	and	
include	retinopathy,	neuropathy,	and	nephropathy.		While	these	are	often	the	focus	of	treatment	
for	diabetics,	 it	 is	the	macrovascular	complications	of	the	disease	that	are	the	major	causes	of	
mortality.	 	 Heart	 attack	 and	 stroke	 accounts	 for	 almost	 80%	 of	 all	 deaths	 in	 the	 T2DM	
population.21		The	treatment	of	diabetic	dyslipidemia	will	be	a	major	effort	of	BSN272	as	we	will	
see	later	in	this	manuscript.	
1.2.1	HbA1c	
While	blood	glucose	elevation	is	the	main	characteristic	of	T2DM,	it	makes	for	a	poor	diagnostic.	
The	disease	can	be	diagnosed	with	2	fasting	blood	glucose	readings	>	120	mg/dl,	however,	too	
many	things	affect	blood	glucose	acutely	making	the	test	susceptible	to	false	positives.		Instead,	
practitioners	use	hemoglobin	A1c	as	a	proxy	for	the	blood	glucose	environment	over	an	extended	
period	of	time.		Hemoglobin	can	become	irreversibly	glycosylated	in	the	presence	of	glucose.		This	
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process	occurs	opportunistically	and	thus	is	a	direct	reflection	of	the	glucose	environment	that	
the	 hemoglobin	 is	 in.	 	 Because	 the	 lifespan	 of	 a	 red	 blood	 cell	 is	 around	 3-4	 months,	 the	
percentage	 of	 hemoglobin	 that	 is	 glycosylated	 can	 be	 thought	 of	 as	 representing	 the	 glucose	
environment	of	the	bloodstream	over	the	previous	3	months.		HbA1c	<	6%	is	normal.		Diabetes	is	
diagnosed	at	HbA1c	>	6.5%.22	
A	major	treatment	goal	for	oral	anti-hyperglycemic	agents	is	reductions	in	HbA1c	as	we	will	see	
in	many	of	the	studies	presented	here.		These	reductions	change	clinical	outcomes	as	for	every	
decrease	in	HbA1c	by	1%	the	likelihood	of	microvascular	complications	is	reduced	by	25-35%.21	
1.3	D-tagatose	in	Treating	Diabetes	
A	brief	introduction	to	T2DM	has	been	previously	presented.		What	has	yet	to	be	discussed	is	the	
scope	 and	 impact	 of	 T2DM	 specifically	 in	 the	 United	 States,	 and	 the	 current	 approaches	 to	
treatment.		The	Center	for	Disease	Control	and	Prevention	determined	from	records	from	2009-
2012	that	37%	of	U.S.	adults	20	years	of	age	or	older	had	a	conditional	known	as	prediabetes,	as	
did	over	half	of	adults	over	the	age	of	65.	Prediabetes	is	a	condition	of	hyperglycemia	trending	
towards	diabetes	but	not	yet	high	enough	to	classify	patients	as	having	T2DM.		These	patients	are	
still	 at	 higher	 risk	 than	 healthy	 individuals	 for	 developing	 heart	 disease	 or	 having	 a	 stroke.	
Treatment	 at	 this	 stage	 is	 limited	 to	 changes	 in	 lifestyle	 including	 diet	 and	 exercise,	 with	
pharmaceutical	treatment	limited	to	the	comorbidities	that	may	be	present	such	as	high	blood	
pressure	 or	 hyperlipidemia.23	 	 If	 a	 patient	 progresses	 to	 T2DM	 usually	 one	 or	 two	 oral	 anti-
hyperglycemic	drugs	are	added.24	 	 In	2012,	according	the	American	Diabetes	Association,	$245	
billion	 was	 spent	 on	 patients	 that	 had	 been	 diagnosed	 with	 T2DM,	 which	 didn’t	 include	 an	
estimated	8	million	people	that	were	undiagnosed.25	
There	has	been	a	large	introduction	of	new	medications	into	the	market	over	the	last	decade	for	
the	 treatment	 of	 T2DM,	 however,	 it	 is	 estimated	 that	 over	 60%	of	 patients	 continue	 to	 have	
HbA1c	 levels	 above	 target	 goals	 even	 with	 aggressive	 therapies.24	 	 A	 recent	 review	 of	 140	
controlled	trials	and	26	observational	studies	concluded	that	the	long-term	benefits	and	harms	
for	 currently	available	 treatments	 remains	unclear.26	 	 It	 is	 clear	 that	 there	 remains	a	need	 for	
medications	 in	 this	 disease	 state	 both	 as	 monotherapy	 and	 adjuvant	 therapy	 with	 existing	
regimens.			Moreover,	many	of	the	current	pharmaceuticals	have	undesirable	side	effect	profiles,	
such	as	hypoglycemia,	weight	gain,	GI	distress,	or	even	more	serious	adverse	events	such	as	liver	
damage	or	pancreatitis.27,28		Preferably,	such	a	drug	would	have	a	unique	mode	of	action	to	make	
it	 useful	 as	 an	 additive	 to	 current	 therapies	 and	 possibly	 synergistic	 with	 them,	 produce	 no	
hypoglycemia,	weight	 gain,	 or	 other	 dose	 limiting	 side	 effect	 encouraging	 its	 use	 early	 in	 the	
disease	 process,	 and	 aid	 in	 resolving	 any	 co-morbidities	 associated	 with	 the	 disease	 such	 as	
atherosclerosis,	hyperlipidemia,	and	cardiovascular	disease	in	general.	
As	previously	mentioned,	D-tagatose	had	undergone	a	number	of	preclinical	experiments	in	mice,	
rats,	hamsters,	cell	culture,	and	clinical	experiments	in	healthy	and	diabetic	humans.		From	these	
experiments	and	exposures,	a	mechanism	by	which	D-tagatose	produces	its	anti-hyperglycemic	
effects	has	been	proposed,	although	not	definitively	so.		D-tagatose	appears	to	be	metabolized	
through	the	exact	same	pathway	as	D-fructose.6		After	oral	administration	D-tagatose	is	absorbed	
into	the	bloodstream	from	the	intestines	and	shuttled	to	the	liver	where	it	is	phosphorylated	to	
D-tagatose-1-phopshate	 by	 fructokinase.	 	 This	 metabolite	 (D-tagatose-1-phosphate)	 has	 been
shown	 in	 isolated	 rat	 hepatocytes	 to	 increase	 glucokinase	 activity,29,30	 which	 phosphorylates
glucose	to	glucose-6-phosphate	facilitating	removal	of	glucose	from	the	blood	by	the	 liver	and
increasing	glycogen	synthesis.31	An	additional	shift	to	glycogen	synthesis	occurs	from	an	increase
of	fructose-1-phosphate.		While	this	has	not	been	shown	directly	for	D-tagatose-1-phosphate,	co-
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administration	of	D-tagatose	and	fructose,	which	happens	when	D-tagatose	is	consumed	with	a	
meal,	 causes	 an	 increase	 in	 fructose-1-phosphate	 through	 competitive	 inhibition	 of	 the	 same	
metabolizing	 enzymes	 for	 both	 carbohydrates.6	 Furthermore,	 cleavage	 of	 D-tagatose-1-P	 by	
aldolase	occurs	at	about	half	the	rate	as	it	does	for	the	same	actions	on	fructose-1-P.		This	again	
causes	an	 increase	 in	 fructose-1-P	 concentrations.32,33	 	 The	 increase	of	 glycogen	 synthesis	 and	
inhibition	of	glycogen	utilization	is	thought	to	at	least	in	part	explain	the	anti-hyperglycemic	effect	
of	the	molecule	(Figure	1.0).	
1.3.1	Effect	of	D-tagatose	on	Co-Administration	with	Other	Carbohydrates	
It	is	known	that	carbohydrates	have	variable	absorption	when	consumed	in	isolation	and	when	
co-administered	with	other	carbohydrates,	as	would	be	present	if	given	D-tagatose	with	a	meal.	
Notwithstanding	 the	experiments	 that	 led	 to	 the	proposed	mechanism	of	action	 in	Figure	1.0,	
there	was	the	possibility	that	the	main	driver	of	reductions	in	blood	sugar	with	administration	of	
D-tagatose	was	actually	due	 to	 its	 inhibition	of	absorption	of	other	carbohydrates	when	given
with	 a	 meal.	 	 Conversely,	 co-administration	 of	 glucose	 with	 fructose	 has	 been	 shown	 to
dramatically	reduce	the	number	of	“poor-absorbers”	of	fructose,	meaning	that	D-tagatose	could
potentially	increase	the	absorption	of	fructose	when	administered	together.34		Therefore,	it	was
pertinent	to	determine	what	effect	if	any	D-tagatose	administration	would	have	on	the	absorption
of	 fructose,	 as	 the	 method	 of	 administration	 in	 practice	 was	 likely	 to	 be	 with	 meals	 often
containing	high	amounts	of	fructose.
In	Chapter	2	a	study	is	presented	in	which	radiolabeled	[14C]-fructose	was	administered	with	and	
without	 D-tagatose	 to	male	 SD	 rats	 in	 order	 to	 determine	 the	 effect	 of	 administration	 of	 D-
tagatose	concomitantly	with	fructose.		2000	mg	of	D-tagatose	per	kilogram	of	rat	weight	displayed	
the	ability	to	inhibit	fructose	absorption	as	measured	by	scintillation	counts.		However,	600	mg/kg	
of	D-tagatose	did	not	have	a	significant	effect	on	fructose	absorption,	and	this	is	the	dose	deemed	
comparable	to	the	15	gm	dose	used	in	the	Phase	III	study	according	to	FDA	recommended	BSA	
D-Tagatose D-Tagatose-1-P DHAP	+	GA	 CO2	+	H2O	
Glucose	 Glucose-6-P	
Glucose	
Glycogen	
Aldolase	B	
Glucokinase	
D-Tagatose-1-P	induces
translocation	of	glucokinase
(GK)29,30,178	by	binding	to
regulatory	protein	(RP)	of
the	GK-RP	complex.183,184
Metabolism	of	D-tagatose	in	liver	is	identical	to	that	of	
fructose.		But,	the	cleavage	of	D-tagatose-1-P	occurs	at	only	
about	half	the	rate	of	that	of	fructose-1-P.32,33
Glycogen	
Synthase	
Glucose-6-P	produced	by	glucokinase	
promotes	the	activation	of	hepatic	
glycogen	synthase.31
Glucose-1-P	
Glycogen	
Phosphorylase	
Similar	to	fructose-1-P,	D-tagatose-1-P	is	an	
inhibitor	of	glycogen	phosphorylase.180,179
Figure	 1.1	 Proposed	Mechanism	
of	Action	for	D-tagatose	
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	normalization	 conversion	 factor.35	 	 Furthermore,	 the	 reduction	 did	 not	 appear	 to	 be	 dose	
dependent	 as	 6000	mg/kg	 was	 not	 able	 to	 further	 inhibit	 fructose	 absorption.	 	 This	 led	 to	 a	
conclusion	that	the	inhibition	of	[14C]-fructose	was	due	to	intolerance	of	the	carbohydrate	load	as	
evident	by	osmotic	diarrhea	present	in	the	rats.36		A	more	thorough	discussion	of	this	study	and	
the	evidence	leading	up	to	it	is	presented	in	Chapter	2.	
1.4	Approval	Problems	and	Back	to	the	Bench	
The	Phase	II	and	III	trials	for	D-tagatose	resulted	in	positive	outcomes	in	the	T2DM	population.		
However,	the	landscape	for	oral	anti-hyperglycemic	medications	is	crowded,	so	the	FDA	asked	for	
an	additional	2	Phase	III	studies	as	well	as	a	long-term	cardiovascular	toxicity	study	in	order	to	
grant	 and	 NDA.	 	 The	 original	 patent	 on	 D-tagatose	was	 obtained	 for	 its	 use	 as	 a	 sweetening	
alternative,	so	work	on	its	medical	use	development	began	late	in	its	patent	life	and	it	had	only	2	
years	left	by	this	time.		It	was,	therefore,	not	feasible	to	spend	the	money	on	all	those	additional	
studies	without	protection	from	a	generic	alternative	undercutting	the	market.	
This	warranted	a	re-examination	of	the	data	from	the	D-tagatose	studies	to	see	if	there	were	any	
other	 avenues	 for	 the	 drug	 that	 we	 could	 pursue.	 	 In	 addition	 to	 glucose	 and	 HbA1c	
measurements,	 there	 were	 secondary	 aims	 in	 the	 Phase	 II	 and	 III	 studies	 that	 were	 geared	
towards	blood	cholesterol	and	lipid	profile	effects	of	D-tagatose.		There	was	some	indication	of	a	
positive	effect	towards	these	aims	which	would	be	highly	beneficial	in	the	T2DM	population	that	
is	at	an	increased	risk	for	developing	cardiovascular	disease.		A	concern,	however,	was	a	possible	
increase	in	triglycerides	witnessed	in	the	Phase	III	trial	for	patients	on	D-tagatose	compared	to	
placebo	(Splenda).37			
It	 was	 hypothesized	 that	 the	 addition	 of	 an	 agent	 to	 D-tagatose	 with	 the	 ability	 to	 lower	 or	
maintain	triglyceride	levels	could	produce	a	product	able	to	treat	a	myriad	of	developments	of	
T2DM;	 hyperglycemia,	 hyperlipidemia,	 hypercholesterolemia,	 and	 the	 development	 of	
atherosclerosis.		Traditionally	these	are	categorized	and	treated	separately	even	though	they	have	
common	 etiologies	 and	 with	 pathways	 that	 overlap.	 	 A	 search	 of	 the	 literature	 revealed	 2	
candidates	that	could	fulfill	this	role;	trans-polydatin	and	dihydromyricetin.	
1.4.1	BSN272	in	LDLr-/-	Mice			
Hyperglycemia	 is	 the	 hallmark	 manifestation	 of	 type	 2	 diabetes	 mellitus	 (T2DM).	 However,	
macrovascular	complications	from	long	standing	hyperglycemia,	such	as	heart	attacks	and	stroke,	
lead	to	80%	of	the	deaths	reported	in	this	disease	state.21		In	fact	T2DM	has	been	designated	a	
cardiovascular	disease	(CVD)	equivalent	and	Haffner	et	al.	reported	that	the	7-year	incidence	of	
myocardial	 infarction	 in	 T2DM	 patients	 is	 equal	 that	 of	 non-diabetic	 individuals	 that	 had	
previously	 had	 a	 heart	 attack.38	 	 This	was	 an	 important	 consideration	 for	D-tagatose	 because	
previous	 groups	 have	 shown	 that	 diets	 high	 in	 carbohydrates	 lead	 to	 elevated	 circulating	
cholesterol,39–42	which	increases	the	risks	of	developing	cardiovascular	disease.		D-tagatose	being	
a	carbohydrate	similar	in	structure	to	fructose,	investigations	into	the	possibility	of	administration	
of	D-tagatose	as	a	therapeutic	drug	actually	contributing	to	hyperlipidemia	and/or	atherosclerosis	
were	necessary	and	were	conducted.	
Merkel	 et	 al.	 had	 previously	 demonstrated	 that	 LDLr-/-	mice	 fed	 a	 diet	 enriched	with	 sucrose	
resulted	in	more	elevated	LDL	cholesterol	and	resulting	atherosclerosis	than	did	a	diet	enriched	
with	an	energy	matched	equivalent	of	free	fatty	acids.43	 	Police	et	al.	 thus	conducted	a	similar	
study	with	D-tagatose	to	see	if	it	had	a	similar	effect.		LDLr-/-	mice	were	fed	normal	diet	(control),	
diet	high	in	sucrose,	or	diet	high	in	D-tagatose	for	16	weeks.		Consistent	with	other	studies,	the	
sucrose	group	led	to	significant	increases	in	VLDL,	LDL,	and	formation	of	atherosclerotic	plaques	
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	compared	to	control	group.		Replacement	of	sucrose	in	the	diet	with	D-tagatose	did	lead	to	minor	
elevations	in	these	same	parameters	(VLDL,	LDL,	and	plaque)	but	was	drastically	lower	than	the	
sucrose	group.	
These	results	were	enough	to	warrant	monitoring	of	the	lipid	profile	of	patients	during	the	Phase	
III	 and	 II	 trials	 of	 D-tagatose	 in	 T2DM	 patients	 as	 secondary	 aims.	 	 The	 Phase	 III	 study	 was	
described	previously	and	 the	publication	 is	available	 in	Appendix	A.	 	 LDL	and	 total	 cholesterol	
were	slightly	but	significantly	reduced	in	the	D-tagatose	group	compared	to	placebo	from	month	
6	 on	 in	 the	 ITT	 population,	 although	 there	 was	 also	 a	 slight	 but	 significant	 reduction	 in	 HDL	
cholesterol.		Of	more	concern	was	a	somewhat	robust	elevation	in	triglycerides	in	the	D-tagatose	
group	that	became	significant	in	month	8	and	reached	its	peak	at	the	completion	of	the	study.37		
These	 results	 were	 concerning	 given	 the	 CVD	 risks,	 outlined	 above,	 in	 this	 population.		
Additionally,	the	phenotype	of	dyslipidemia	in	the	T2DM	population	favors	increased	circulation	
of	 triglyceride-rich	 lipoproteins	 (TRL),	 as	 opposed	 to	 increased	 LDL	 as	 seen	 in	 the	 general	
hyperlipidemic	 population,	 which	 have	 increased	 atherogenic	 potential.	 	 Recent	 research	 has	
shown	that	statins	fail	to	correct	these	features	present	in	diabetic	dyslipidemia,	and	the	addition	
of	niacin	or	fibrates	to	statin	therapy	show	no	benefit.44	
The	 first	 combination	 study	 with	 a	 lipid	 lowering	 therapy	 involving	 D-tagatose	 was	 with	 a	
derivative	of	trans-resveratrol	known	as	trans-polydatin	(or	polydatin).		The	studies	were	part	of	
a	 collaboration	 between	 labs	 in	 the	 pharmaceutical	 sciences	 and	 physics	 departments	 at	 the	
University	of	Kentucky.		The	initial	study	involved	administering	doses	of	D-tagatose	and	polydatin	
to	LDL-/-	mice	fed	a	high	fat,	cholesterol,	and	carbohydrate	(Western)	diet	in	a	modeling	system	
that	 develops	 dyslipidemia	 and	 atherosclerosis.	 	 The	 treatment	 group	was	 sub-sectioned	 into	
multiple	groups	that	were	given	different	combinations	of	doses	of	D-tagatose	and	polydatin	that	
were	forced	to	be	uncorrelated	using	principal	axis	theorem.		This	allowed	the	efficacy	of	each	
component	of	the	treatment	(D-tagatose	or	polydatin)	to	be	evaluated	independently	while	being	
in	the	presence	of	the	other	component.		In	this	way,	a	computer	algorithm	could	be	developed	
that	could	predict	the	effects	of	changing	the	dose	of	either	component	in	order	to	fine	tune	the	
treatment.45		I	had	the	opportunity	to	contribute	to	writing	this	first	study	using	the	combination	
of	D-tagatose	and	trans-polydatin	(labeled	BSN272)	for	publication	and	it	is	presented	in	Appendix	
C.	
BSN272	administration	to	LDLr-/-	mice	significantly	prevented	the	development	of	increased	VLDL	
and	 LDL	 cholesterol	 as	well	 as	 formation	 of	 atherosclerosis.	 	 There	was	 also	 a	 trend	 towards	
prevention	of	increased	triglycerides,	although	it	was	not	significant.	
The	goal	of	the	collaboration	was	to	create	a	computational	model	of	a	complex	system	that	is	
dynamic	and	allows	for	changes	of	inputs	in	real-time	with	predictable	results.		In	this	case	the	
aim	was	to	use	the	results	from	a	trial	in	mice	measuring	changes	in	lipid	levels	and	atherosclerosis	
formation	 when	 administered	 D-tagatose,	 trans-polydatin,	 and	 the	 combination	 of	 the	 two	
molecules,	to	create	a	model	of	the	complex	metabolic	disease	pathway	that	could	simulate	the	
various	results	that	could	be	expected	by	differing	doses	of	D-tagatose	and	trans-polydatin.		This	
was	known	as	a	Dynamic	Data-Driven	Application	Simulation	(DDDAS).	
The	modeling	system	that	was	developed	successfully	predicted	the	results	of	the	study	as	the	
molecules	were	fed	to	ApoE-/-	mice	for	8	weeks.		BSN272	fed	mice	showed	significantly	reduced	
total	cholesterol	and	VLDL	and	increased	HDL	compared	to	control	group.		The	combination	also	
showed	a	difference	in	LDL	and	triglycerides,	however	not	significantly.		This	was	thought	to	be	
due	 to	 insufficient	group	numbers	and	 it	was	hypothesized	 that	a	greater	number	of	 subjects	
would	have	led	to	significant	results	based	on	the	trends	seen.46	
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	In	 both	 studies,	 however,	 the	 lowering	 of	 triglycerides	 appeared	 to	 be	 synergistic	 as	 neither	
component	of	BSN272	as	monotherapy	showed	any	activity	towards	triglycerides.		This	set	the	
stage	further	studies	presented	in	Chapter	4	and	summarizes	later	here	in	Chapter	1.	
1.4.2	BSN723T	in	ApoE-/-	Mice	
Dihydromyricetin	 (DMY)	 is	 a	 flavonoid	 found	 in	many	 plants	 that	 is	 used	 in	medicinal	 teas	 in	
Eastern	culture	for	treatment	of	hang-overs	and	other	ailments.		It	has	recently	been	investigated	
in	a	clinical	trial	for	patients	with	non-alcoholic	fatty	liver	disease.		Patients	in	that	trial	developed	
lowered	LDL	cholesterol	levels.47	A	subsequent	study	in	which	an	extract	from	plants	that	DMY	is	
derived	 from	was	 administered	 to	 rats	 reduced	 total	 cholesterol	 and	 triglycerides,	 as	 well	 as	
increased	HDL	cholesterol,	reported	that	a	drink	of	the	same	extract	given	to	humans	had	similar	
results.48		In	Chapter	3	a	study	is	presented	in	which	dihydromyricetin	and	D-tagatose	(BSN723T)	
were	 added	 to	 the	 food	 of	 ApoE-/-	mice	 (genetically	modified	 to	 produce	 hyperlipidemia	 and	
atherosclerosis)	 to	determine	the	ability	of	 the	combination	of	 the	two	agents	 to	prevent	diet	
induced	 increases	 in	 triglycerides,	 total	 cholesterol,	 and	 ultimately	 the	 formation	 of	
atherosclerotic	plaques.			
While	 dihydromyricetin	 and	D-tagatose	 alone	were	 able	 to	 prevent	 some	of	 the	 diet	 induced	
increases	in	total	cholesterol	and	atherosclerotic	plaques,	and	prevent	triglyceride	increases	to	
what	would	be	expected	from	wild	type	mice,	the	combination	of	the	two	agents	(BSN723T)	were	
no	more	effective	than	monotherapy.49		There	appeared	to	be	no	synergistic	effects	between	the	
molecules	and	this	study	presented	a	good	comparator	study	to	display	the	unique	potential	of	
BSN272	to	warrant	further	study	for	that	combination.	
1.4.3	16	Week	ApoE-/-	Mice	Study	with	BSN272	
The	unfortunate	finding	of	increases	in	triglycerides	in	the	Phase	III	trial	persisted,	however,	as	
BSN723T	 did	 no	 better	 at	 reducing	 serum	 triglycerides	 than	D-tagatose	 in	 the	 ApoE-/-	 8-week	
study.	Furthermore,	an	unpublished	study	using	Syrian	golden	hamsters	showed	that	polydatin	
monotherapy	 greatly	 increased	 triglyceride	 levels.	 	 However,	 BSN272	 dramatically	 reduced	
triglyceride	levels	despite	a	lack	of	activity	towards	this	measurement	for	D-tagatose	or	polydatin	
alone	(unpublished	study	reviewed	in	the	Introduction	section	of	Chapter	4).	The	trend	toward	
reduced	 triglycerides	 in	 the	 BSN272	 8-week	 study46	 and	 the	 significant	 drop	 in	 triglycerides	
witnessed	in	the	unpublished	hamster	study	warranted	a	follow-up	study	with	this	combination	
in	ApoE-/-	mice	powered	to	specifically	see	if	a	significant	reduction	in	triglycerides	could	be	obtain	
in	a	longer	study.			
Chapter	4	details	a	study	using	ApoE-/-	mice	as	a	model	of	diet	induced	hyperlipidemia.		Mice	were	
fed	diets	 containing	BSN272	 for	16	weeks	and	measured	 for	 serum	 levels	of	 total	 cholesterol,	
triglycerides,	 and	 the	 development	 of	 atherosclerosis	 in	 the	 aortic	 arch.	 	 BSN272	was	 able	 to	
significantly	 prevent	 diet	 induced	 increases	 in	 total	 cholesterol	 and	 the	 development	 of	
atherosclerotic	plaques.		Most	importantly,	the	diet	with	BSN272	was	able	to	dramatically	reduce	
triglycerides	even	significantly	below	control	group	levels.45	
1.5	IND	Submission	
1.5.1	Toxicology	
The	last	of	the	first-in-human	enabling	studies	required	for	an	IND	submission	was	a	rat	toxicology	
study	of	polydatin,	as	D-tagatose	already	had	this	from	the	GRAS	studies.		Appendix	D	presents	
this	 study	which	 found	 the	only	adverse	 test	article-related	 finding	 to	be	chronic	active	pelvic	
inflammation	and	 transitional	 cell	 hyperplasia	 in	one	 female	 given	3000	mg/kg/day.	Based	on	
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these	results,	the	no	observed	adverse	effect	level	(NOAEL)	was	1200	mg/kg/day	for	females	and	
3000	mg/kg/day	for	males.50	
1.5.2	Future	Work	
Chapter	5	offers	conclusions	and	future	work.		BSN272	was	submitted	and	granted	a	patent	for	
its	use	in	treating	T2DM	and	the	metabolic	syndrome.		Prader-Willi	syndrome	was	established	as	
a	potential	 indication	 for	 future	 clinical	 trials	 as	patients	with	 the	disease	develop	T2DM	very	
young	and	at	an	extremely	high	 rate.	 	 I	have	written	 the	 IND	which	 is	 in	 the	process	of	being	
submitted,	 some	 of	which	 can	 be	 reviewed	 in	 Chapter	 5.	 	 Appendix	 E	 contains	 the	 proposed	
exploratory	Phase	1	microdose	study	with	BSN272	in	healthy	volunteers	that	is	contained	in	the	
IND	submission.	
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	Chapter	2	–	The	Effect	of	Oral	D-Tagatose	on	Fructose	Absorption	in	a	Rat	Model36	
2.1	Preface	
A	thorough	background	for	D-tagatose	was	presented	in	Chapters	1	as	well	as	in	Phase	II	and	III	
clinical	studies	attached	in	Appendices	A	and	B.		D-tagatose	showed	the	ability,	through	multiple	
animal	models	and	clinical	studies,	to	lower	blood	glucose	and	HbA1c	in	the	presence	of	chronic	
hyperglycemia.6,18,37		The	reduced	energy	contribution	of	low	energy	bulk	sweeteners	is	often	due	
to	malabsorption,16	however,	D-tagatose	has	been	shown	to	be	absorbed	to	a	greater	extent	than	
other	 lower	 energy	 bulk	 sweeteners,	 measured	 by	 a	 68%	 conversion	 of	 14C	 radiolabeled	 D-
tagatose	 oral	 dose	 to	 14CO2,	 while	maintaining	 a	 lower	 net	 energy	 content	 than	 sucrose.1	 	 A	
mechanism	 of	 action	 had	 been	 proposed	 to	 explain	 how	 D-tagatose	 derives	 these	 outcomes	
which	has	been	pieced	together	from	in	vitro	and	in	vivo	studies	and	is	presented	in	Figure	1.0.			
If	D-tagatose	indeed	is	absorbed	orally	to	a	greater	extent	than	other	low	calorie	bulk	sweeteners	
and	contributes	zero	net	energy	to	the	organism	then	a	thermogenic	effect	must	be	present,	as	
previously	 suggested,1,51	 in	which	more	energy	 is	 required	 to	metabolize	 the	molecule	 than	 is	
produced.		However,	an	indirect	calorimetry	study	in	humans	did	not	support	this	claim	finding	
no	thermic	effect	and	suggesting	that	a	different	mechanism	must	be	in	place	to	explain	the	lack	
of	net	energy.16		Additionally,	Saunders	et	al.	used	germ-free	rats	to	demonstrate	that	the	majority	
of	 14CO2	produced	from	orally	dosed	radiolabeled	D-tagatose	was	 formed	by	gut	 fermentation	
and	the	actual	intestinal	absorption	in	rats	was	estimated	to	only	be	20%.52	
While	these	findings	may	help	explain	some	of	the	net	zero	energy	contribution	of	D-tagatose	it	
still	doesn’t	explain	the	effects	of	reducing	blood	glucose.		In	addition,	as	most	of	the	pre-clinical	
studies	replaced	sucrose	in	the	diet	of	the	animals	with	D-tagatose,	there	had	not	been	a	study	
on	 absorption	 or	 effects	 on	 blood	 glucose	 of	 D-tagatose	when	 co-administered	with	 another	
carbohydrate,	as	it	would	be	in	practice	when	consumed	with	a	meal.	Previous	works	in	multiple	
labs	 have	 explored	 the	 phenomenon	 that	 the	 absorption	 of	 carbohydrates	 vary	 when	
administered	alone	or	in	conjunction	with	other	carbohydrates.53		Truswell	et	al.	determined	that	
fructose	exhibits	a	saturable	effect	upon	oral	absorption.		When	given	50	g	orally	of	pure	fructose,	
58	 of	 100	 subjects	 were	 classified	 as	 poor	 absorbers	 while	 only	 19	 of	 these	 previous	 poor	
absorbers	were	unable	to	properly	absorb	25	g	of	pure	fructose.		Interestingly,	when	glucose	was	
given	with	50	g	of	fructose,	the	number	of	poor	absorbers	of	fructose	was	cut	in	half.34		This	study	
was	 confirmed	 years	 later	 in	 a	 rat	model	 in	which	 researchers	 at	 the	 University	 of	 California	
claimed	 the	mechanism	 of	 the	 effect	 is	 due	 to	 the	 disaccharidase-related	 transport	 system.54		
Prieto	et	al.	then	demonstrated	that	the	alterations	in	absorption	between	glucose	alone,	fructose	
alone,	and	the	combination	of	glucose	and	fructose,	did	in	fact	manifest	into	changes	in	glycemia	
and	insulin	responses.55	
In	light	of	these	findings	and	the	increasing	prevalence	of	fructose	in	modern	foods,	 it	became	
important	to	distinguish	the	consequence	that	D-tagatose	would	have	on	fructose	absorption	if	it	
were	to	be	given	therapeutically	as	an	anti-hyperglycemic	medication.		I	wrote	this	paper	which	
was	published	in	the	Journal	of	Developing	Drugs.		The	article	is	presented	below	with	the	table	
and	figure	numbers	changed	to	be	consistent	with	this	dissertation.	
2.2	Introduction36	
A	naturally	occurring	epimer	of	fructose,	D-tagatose	is	present	 in	small	amounts	 in	many	dairy	
products,	such	as	milk,	numerous	cheeses,	and	certain	kinds	of	yogurts.1,56	Interest	in	D-tagatose	
as	a	sweetening	alternative	to	conventional	sugar	manifested	from	the	finding	that	it	provided	no	
available	 energy	 when	 fed	 to	 rats,51	 yet	 it	 maintains	 a	 sweetness	 equivalent	 to	 92%	 that	 of	
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sucrose.1	D-tagatose	was	subsequently	examined	and	granted	US	patent	approval	in	1988,	as	a	
low	calorie	full	bulk	sweetening	agent.57	
The	majority	of	research	in	the	following	years	revolved	around	elucidating	the	toxicity	profile	of	
the	substance,	with	the	aim	of	pursuing	FDA	approval	as	a	food	additive.	Multiple	in	vitro	and	in	
vivo	studies	were	completed	with	the	results	establishing	that	D-tagatose	was	not	genotoxic,58	no	
evidence	of	treatment-related	effects	were	seen	at	low	doses,	and	at	high	doses,	the	transient	
toxicity	 of	 soft	 stools	 consistent	 with	 osmotic	 diarrhea	 (from	 incomplete	 absorption	 of	 the	
carbohydrate)	occurred.59,60	Human	studies	then	commenced	with	results	closely	mimicking	that	
of	the	animal	models.8,10	A	decade	of	human,	animal	and	other	toxicity	and	safety	data	led	to	D-
tagatose	gaining	“Generally	Recognized	As	Safe”	(GRAS)	approval	by	the	FDA,2	allowing	its	use	in	
food	and	beverages	in	limited	amounts.	No	incidence	of	toxicity	has	been	reported	to	date	from	
usage	in	food	and	beverages.	Following	this,	the	European	Union	(EU)	allowed	D-tagatose	as	a	
‘novel	food	ingredient’,	with	no	restrictions	on	the	amount	in	which	it	can	be	used.6	
Interest	 in	 the	molecule	as	a	pharmaceutical	agent	began	as	a	 result	of	discovering	 it	 to	have	
antidiabetic	properties	in	animal	models.61	Previous	GRAS	approval	allowed	prompt	entry	of	D-
tagatose	into	human	studies	as	an	antihyperglycemic	agent.	Early	results	indicated	that	there	was	
no	change	in	glucose	or	insulin	levels,	following	oral	administration	of	D-tagatose	in	the	fasted	
state.7	Even	more	interestingly,	D-tagatose	showed	the	ability	to	blunt	the	rise	in	blood	glucose,	
when	given	prior	to	oral	glucose	intake.4	These	studies	conducted	at	the	University	Of	Maryland	
School	 Of	 Medicine	 and	 subsequently	 confirmed	 at	 the	 Research	 Department	 of	 Nutrition,	
Copenhagen9	 led	 to	 the	consensus	 that	D-tagatose	held	 the	potential	of	becoming	an	adjunct	
therapy	for	patients	with	Type	II	Diabetes	mellitus.	
In	2010,	a	phase	II	dose	ranging	study	over	6	months	and	a	phase	III	efficacy	study	over	12	months	
were	completed	using	D-tagatose	to	reduce	HbA1c	in	161	and	494	patients,	respectively,	in	the	
US	and	in	India	(clinicaltrials.gov	identifier	NCT00961662	and	NCT00955747).	The	results	showed	
statistically	significant	reductions	in	HbA1c	compared	to	placebo,	with	the	only	adverse	effects	
being	of	the	GI	variety,	consistent	with	prior	studies.	The	exciting	results	of	these	studies	offered	
promise	for	D-tagatose	as	a	diabetic	medication	and	warranted	further	examination	into	how	D-
tagatose	 achieves	 its	 effects,	 and	how	 it	 interacts	with	 other	 components	 of	 the	human	diet,	
especially	other	carbohydrates.53	
Previous	work	 in	multiple	 labs	has	explored	the	variable	absorption	of	different	carbohydrates	
when	 administered	 alone,	 or	 in	 conjunction	 with	 other	 carbohydrates.	 Truswell	 et	 al.34	
determined	that	fructose	exhibits	a	saturable	effect	upon	oral	absorption.	When	given	50	g	orally	
of	pure	 fructose,	58	of	100	 subjects	were	 classified	as	poor	absorbers,	while	only	19	of	 these	
previous	poor	absorbers	were	unable	to	properly	absorb	25	g	of	pure	fructose.	Interestingly,	when	
glucose	was	given	with	50	g	of	fructose,	the	number	of	poor	absorbers	of	fructose	was	cut	in	half.	
This	 study	was	confirmed	years	 later	 in	a	 rat	model,	 in	which	 researchers	at	 the	University	of	
California	 claimed	 the	mechanism	of	 the	 effect	 is	 due	 to	 the	 disaccharidase-related	 transport	
system.54	Prieto	et	al.55	then	demonstrated	that	the	alterations	 in	absorption	between	glucose	
alone,	fructose	alone,	and	the	combination	of	glucose	and	fructose,	in	fact	manifested	as	changes	
in	glycemia	and	insulin	responses.	
In	light	of	these	findings	and	the	increasing	prevalence	of	fructose	in	modern	foods,	it	became	
important	to	distinguish	the	consequences	of	D-tagatose	on	fructose	absorption,	if	it	were	to	be	
given	therapeutically	as	an	antihyperglycemic	medication.	The	present	study	aimed	to	provide	
new	 information	D-tagatose	 consumption	with	 fructose	 through	 administration	 of	 14C	 labeled	
fructose	 and	 D-tagatose	 concomitantly,	 and	 comparing	 the	 radioactivity	 present	 in	 plasma	
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	samples	collected	at	various	time	points	to	that	of	fructose	monotherapy	in	a	rat	model.	We	first	
completed	 a	 pilot	 study	 using	 [14C]-fructose	 with	 glucose,	 to	 establish	 the	 viability	 of	 our	
procedure	to	measure	changes	in	carbohydrate	absorption,	and	subsequent	plasma	levels,	and	to	
derive	 the	 amount	 of	 radioactivity	 that	 would	 be	 needed	 in	 the	 fructose	 batch	 to	 obtain	
interpretable	scintillation	count	data.	From	the	results	of	this	initial	study,	we	aimed	to	establish	
the	effect	that	a	graduated	change	in	concentration	of	D-tagatose	would	have	on	absorption	of	2	
g/kg	 of	 fructose,	 with	 a	 secondary	 aim	 of	 determining	 how	 the	 resulting	 absorption	 would	
manifest	in	terms	of	blood	glucose.	
2.3	Materials	and	Methods36	
Animals	
Male	Sprague-Dawley	FVC	(FVC	=	femoral	venous	catheter)	rats	from	Harlan	weighing	275	to	300	
g	were	used	for	these	studies.	The	Sprague-Dawley	FVC	rats	had	femoral	vein	cannulas	(implanted	
by	the	animal	vendor)	tunneled	under	the	skin	that	exit	superior	to	the	scapula.	Catheters	were	
checked	for	patency	and	maintained	with	heparin	+	glycerol	(1000	IU/ml).	Patency	checks	were	
conducted	 on	 the	 day	 of	 receipt	 and	 at	 regular	 intervals	 until	 use.	 Locking	 solutions	 were	
composed	of	an	equal	mixture	of	USP	grade	glycerol	and	heparin	(1000	IU/ml).	Rats	were	housed	
in	solid	bottom	cages	with	bedding	in	ventilated	stainless-steel	racks	and	were	individually	caged	
to	prevent	cage	mates	from	gnawing	on	the	cannulae.	The	rats	were	placed	in	a	normal	light	cycle,	
12	hours	light	and	12	hours	dark,	and	were	housed	for	3	to	7	days	in	a	vivarium	prior	to	testing.	
Animals	were	conditioned	to	hooded	restrainers	for	approximately	15	min	on	days	(-5	to	-3)	and	
(-3	to	-1)	prior	to	the	start	of	the	study.	
All	 animal	 care	 and	 procedures	 of	 the	 study	 were	 performed	 in	 compliance	 with	 the	 U.S.	
Department	of	Agriculture’s	(USDA)	Animal	Welfare	Act	(9	CFR	Parts	1,2,	and	3);	the	Guide	for	the	
Care	and	Use	of	Laboratory	Animals,	Institute	of	Laboratory	Animal	Resources,	National	Academy	
Press,	Washington,	D.C.,	1996;	and	the	National	Institutes	of	Health,	Office	of	Laboratory	Animal	
Welfare.	
Plasma	 [14C]-Fructose	 Measurement	 Following	 Oral	 Administration	 of	 a	 Bolus	 [14C]-
Fructose/Glucose	Preparation	
Two	Fructose/Glucose	dosing	solutions	containing	either	250	uCi/g	or	83.5	uCi/g	[14C]-Fructose	
were	prepared	to	deliver	2	g/kg	of	each	sugar	via	oral	gavage.	Radiolabeled	fructose	came	from	
American	 Radiolabeled	 Chemicals,	 St.	 Louis,	MO.	 	 Two	 additional	 dosing	 solutions	 containing	
either	250	uCi/g	or	83.5	uCi/g	[14C]-Fructose	were	prepared	to	deliver	2	g/kg	Fructose	alone	via	
oral	gavage.	Four	groups	of	rats	(8	rats	per	group)	were	dosed	as	follows:	Group	1	–	2000	mg/kg	
[14C]-Fructose	(250	uCi/g);	Group	2	-	2000	mg/kg	[14C]-Fructose	(250	uCi/g)	+	2000	mg/kg	Glucose;	
Group	3	–	2000	mg/kg	[14C]-Fructose	(83.5	uCi/g);	Group	4	-	2000	mg/kg	[14C]-Fructose	(83.5	uCi/g)	
+	2000	mg/kg	Glucose.	At	0,	1,	3,	5,	10,	15,	30,	45,	and	60-minute	time	points,	whole	blood	was	
obtained	from	the	venous	catheter,	measured	for	total	glucose,	centrifuged,	and	plasma	retained	
for	scintillation	counting	of	14C.	
Effect	of	D-tagatose	on	Plasma	[14C]-Fructose	Absorption	Following	Oral	Administration	
of	a	Bolus	[14C]-Fructose/D-tagatose	Preparation	
A	Fructose	dosing	solution	containing	250	uCi/g	[14C]-Fructose	was	prepared	to	deliver	2	g/kg	of	
fructose	alone	or	with	either	vehicle,	0.6	g/kg,	2	g/kg,	6	g/kg,	or	15	g/kg	D-tagatose	via	oral	gavage.	
Five	groups	of	rats	(8	rats	per	group)	were	dosed	as	follows:	Group	1	-	2000	mg/kg	[14C]-Fructose	
(250	uCi/g);	Group	2	-	2000	mg/kg	[14C]-Fructose	(250	uCi/g)	+	D-tagatose	600	mg/kg;	Group	3	-	
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	2000	mg/kg	 [14C]-Fructose	 (250	uCi/g)	 +	D-tagatose	 2000	mg/kg;	Group	4	 -	 2000	mg/kg	 [14C]-
Fructose	(250	uCi/g)	+	D-tagatose	6000	mg/kg;	Group	5	-	2000	mg/kg	[14C]-Fructose	(250	uCi/g)	+	
D-tagatose	12000	mg/kg.	At	0,	1,	3,	5,	10,	15,	30,	45,	60-minute	time	points	whole	blood	was	
obtained	from	the	venous	catheter,	measured	for	total	glucose,	centrifuged,	and	plasma	retained	
for	scintillation	counting	of	14C.	
Sample	Analysis	
Blood	samples	were	analyzed	for	total	glucose	using	a	MediSense™	Precision	PCx®	Glucometer	
(Model	M6012-0014)	with	MediSense™	Precision	 PCx®	Glucose	 Test	 Strips	 (Model	 99565-01).	
Scintillation	counting	for	14C	was	conducted	on	10-30	uL	of	plasma	in	10	mL	of	Fisher	ScintiSafe	
Gel	(SX24-5)	scintillation	fluid,	using	a	Beckman	scintillation	counter	(Model	LS6500).			
2.4	Results36	
The	pilot	study	aimed	to	set	the	level	of	radioactivity	to	be	used	later	in	the	fructose/D-tagatose	
portion	by	use	of	a	well-known	pairing	(glucose:fructose)	and	to	verify	that	changes	in	systemic	
carbohydrate	levels	could	be	measured	accurately	using	this	procedure.		Figure	2.1A	shows	the	
accumulation	of	radioactivity	 in	the	plasma	at	various	time	points.	 	The	AUC	for	each	group	 is	
superimposed	over	each	other	and	the	amount	of	activity	in	nCi/ml	over	the	60-minute	study	is	
displayed.		Addition	of	glucose	to	fructose	in	equal	amounts	(2	g/kg	weight	of	rat)	resulted	in	a	
decrease	in	plasma	fructose	of	26%	in	the	250	uCi/g	group	and	27%	in	the	83.5	uCi/g	group.		Figure	
2.1B	compares	 the	effect	glucose	had	on	 fructose	absorption.	 	Administration	of	glucose	with	
fructose	resulted	 in	a	mean	difference	of	1634	and	600	nCi·hr/ml	 in	the	250	and	83.5	uCi/g	of	
fructose	groups,	respectively,	and	reached	significance	as	calculated	by	the	Bonferroni’s	Multiple	
Comparison	Test.	
Figure	2.136	
14C	Scintillation	Counts	in	Plasma,	Pilot	Study	Results		
A:	Radioactivity	measured	in	nCi/mL	is	plotted	over	the	1-hour	study	for	each	of	the	4	arms.		The	AUC	for	each	
group	is	also	included	in	the	table	below	the	figure.36		
B:	Display	of	the	relative	differences	between	AUC	of	the	different	treatment	arm	measured	in	nCi*hr/ml.	
The	table	below	the	figure	gives	the	numerical	values	for	these	differences.36	
Figure	2.2A	compares	the	different	treatment	arms	with	respect	to	blood	glucose	throughout	the	
study.		Administration	of	fructose	via	oral	gavage	resulted	in	an	increase	in	glucose	levels	in	all	
arms	of	the	study.		Figure	2.2B	shows	the	change	in	glucose	concentration	from	baseline	(taken	
at	time	0	before	administration	of	treatment).		Oral	fructose	resulted	in	a	change	in	blood	glucose	
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that	peaked	at	a	concentration	of	80	mg/dl	in	the	fructose	alone	groups.		When	glucose	was	given	
with	fructose	the	amount	of	glucose	in	the	blood	peaked	near	140	mg/dl.		Additionally,	the	time	
to	peak	glucose	concentration	occurred	at	the	30	or	45-minute	time	point	in	the	fructose	alone	
arms	and	at	the	15-minute	time	point	in	the	fructose/glucose	co-administration	groups.	
The	results	of	the	pilot	study	established	that	250	uCi	of	radioactivity	per	gram	of	fructose	would	
provide	 adequate	 scintillation	 counts	 to	 measure	 a	 change	 in	 fructose	 absorbance	 with	 co-
administration	of	another	carbohydrate.		The	following	figures	document	the	simultaneous	intake	
of	[14C]-Fructose	with	250	uCi/g	of	radioactivity	administered	at	2g/kg	of	body	weight	with	either	
vehicle,	0.6	g/kg,	2	g/kg,	and	6	g/kg	of	D-tagatose	via	oral	gavage.		Figure	2.3	shows	the	effect	that	
tagatose	had	on	the	AUC	of	radioactivity	from	[14C]-Fructose	in	the	plasma	over	the	60	minutes	of	
the	 study.	 	 Figure	 2.3A	 represents	 this	 by	 overlapping	 the	 graphs	 of	 AUC	 from	 the	 different	
treatment	arms.		Figure	2.3B	shows	that	600,	2000,	and	6000	mg	of	D-tagatose	per	kg	of	body	
weight	decreased	the	AUC	of	fructose	absorption	by	71	(1%	decrease),	1801	(26%	decrease),	and	
2072	 (30%	 decrease)	 nCi·hr/ml,	 respectively.	 	 The	 2000	 and	 6000	 mg/kg	 doses	 reached	
significance	whereas	the	600	mg/kg	group	did	not	(the	12000	mg/kg	group	was	stopped	early	in	
the	study	due	to	intolerance	and	1	fatality).	
Figure	2.236	
Blood	Glucose	in	Plasma,	Pilot	Study	Results	
A:	Displays	the	blood	glucose	concentrations	given	in	mg/dl	at	each	time	point	during	treatment.36	
B:	Displays	the	blood	glucose	readings	as	a	percentage	change	from	baseline.36	
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Figure	2.336	
14C	Scintillation	Counts	in	Plasma,	D-tagatose	Study	Results		
A:	Radioactivity	measured	in	nCi/mL	is	plotted	over	the	1-hour	study	for	each	of	the	4	arms.		The	AUC	for	
each	group	is	also	included	in	the	table	below	the	figure.36	
B:	Display	of	the	relative	differences	between	AUC	of	the	different	treatment	arm	measured	in	nCi*hr/ml.	
The	table	below	the	figure	gives	the	numerical	values	for	these	differences.36	
Figure	2.4	illustrates	the	effect	that	blood	glucose	had	on	administration	of	2	mg	of	fructose	per	
kg	of	body	weight	along	with	either	vehicle,	600,	2000,	or	6000	mg/kg	of	D-tagatose.		The	600	and	
2000	mg/kg	of	D-tagatose	groups	produced	blood	glucose	levels	that	were	no	different	than	with	
administration	of	fructose	alone	(vehicle).		At	6000	mg/kg	an	elevation	in	blood	glucose	was	seen	
at	 the	 30-minute	 time	 point	 that	 continued	 to	 rise,	 reaching	 232	mg/dl	 at	 the	 last	 sampling	
(minute	60).		This	represented	nearly	a	75	mg/dl	difference	from	the	vehicle,	600	and	2000	mg/kg	
groups.	
Figure	2.436	
Blood	Glucose	in	Plasma,	D-tagatose	Study	Results	
	
A:	Displays	the	blood	glucose	concentrations	given	in	mg/dl	at	each	time	point	during	treatment.36	
B:	Displays	the	blood	glucose	readings	as	a	percentage	change	from	baseline.36	
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	readily	measurable	scintillation	counts	in	plasma	samples	and	(2)	to	validate	that	the	procedure	
that	was	used	could	determine	changes	in	the	systemic	levels	of	carbohydrates	with	significance.		
The	second	portion	of	the	protocol	held	the	answers	to	the	questions	that	motivated	the	study.		
Here	the	exercise	validated	 in	the	pilot	study	was	used	to	elucidate	the	effect	 that	D-tagatose	
would	have	on	absorption	of	fructose	co-administered	with	it	in	an	in	vivo	rat	model.		The	effect	
that	 the	absorbed	 fructose	had	on	glycemia,	or	more	 importantly,	 the	ability	of	D-tagatose	 to	
blunt	the	glycemic	effect	of	fructose	was	established.	
The	pilot	 study	determined	 that	a	 radioactivity	 level	of	250	uCi/g	of	 fructose	was	sufficient	 to	
accurately	measure	the	amount	of	fructose	in	the	plasma	after	oral	administration	via	oral	gavage.		
The	amount	of	fructose	present	in	plasma	when	administered	with	equal	amounts	of	glucose	was	
reduced	compared	 to	 fructose	monotherapy.	 	Additionally,	 fructose	administration	 resulted	 in	
hyperglycemia	in	all	arms	of	the	study.		Both	these	findings	appear	to	be	controversial	in	light	of	
other	literature,34,54,55	yet	there	are	multiple	reasons	this	conclusion	may	be	unwarranted.		Firstly,	
the	 pilot	 study	 wasn’t	 designed	 for	 external	 validity	 of	 previous	 studies,	 only	 to	 lay	 the	
groundwork	 for	 the	second	part	of	 the	 fructose/D-tagatose	study	 to	 follow.	 	For	 instance,	our	
study	lacked	a	sham	group	(receiving	the	catheter	but	no	active	substance).		Because	of	this,	it	is	
impossible	 to	determine	 the	effect	 that	 the	procedure	 itself	 had	on	absorption.	 	 Boudry	et	 al	
established	in	a	study	conducted	in	2007,	that	stress	induced	to	rats	can	cause	an	upregulation	of	
GLUT2	 at	 the	 apical	membrane	 of	 the	 brush	 border	 of	 the	 intestines	 and	 cause	 a	 shift	 from	
absorption	 of	 glucose	 through	 SGLT1	 to	 absorption	 through	 GLUT2.62	 	 GLUT2	 is	 a	 known	
transporter	of	glucose,	fructose,	and	galactose	in	high	amounts	(low	selectivity,	high	capacity).63	
Even	though	the	animals	were	preconditioned	to	the	procedure,	 it’s	possible	that	the	stress	of	
the	procedure	itself,	or	the	placement	of	the	catheter,	caused	an	upregulation	in	GLUT2	at	the	
luminal	membrane,	which	has	been	documented	to	occur	in	the	span	of	minutes.64	Stress	could	
cause	 increased	 absorption	 of	 fructose	 during	 monotherapy	 and	 a	 reduction	 in	 fructose	
absorption	in	the	presence	of	glucose,	as	it	competes	for	transit	via	the	same	GLUT2	transporter	
that	is	facilitating	a	major	portion	of	the	fructose	absorption.		Additionally,	the	lack	of	a	glucose	
alone	group	inhibits	us	from	comparing	the	ability	that	fructose	itself	had	to	decrease	glycemia	as	
shown	in	some	of	the	studies	mentioned	previously.		Again,	the	pilot	study	was	not	designed	to	
be	compared	to	these	studies,	simply	to	provide	a	reference	for	the	second	study	of	the	effect	
that	D-tagatose	would	have	on	glycemia,	when	administered	with	fructose	(compared	to	fructose	
alone).	
In	the	second	portion	of	the	study,	we	showed	that	D-tagatose	was	able	to	decrease	the	amount	
of	fructose	absorbed	when	co-administered	via	oral	gavage.	This	reduction	was	most	prevalent	at	
the	2000	mg/kg	dose.	This	reduction	did	not	seem	to	be	strongly	dose	dependent.	The	6000	mg/kg	
dose	of	D-tagatose	was	only	slightly	better	at	 inhibiting	fructose	absorption.	We	believe	this	 is	
simply	a	situation	of	saturation	of	carbohydrates.	There	was	no	run-in	period	to	acclimate	the	rats	
to	D-tagatose	or	fructose.	In	fact,	the	12000	mg/kg	dosing	group	had	to	be	stopped	due	to	fatality.	
At	an	acute	dose	of	6000	mg/kg	group	and	up,	and	even	with	2	g/kg	of	fructose,	the	rats	seem	to	
be	in	a	state	of	malabsorption,	characterized	by	osmotic	diarrhea	and	symptoms	of	overt	stress.	
D-tagatose	is	an	epimer	of	fructose,	and	the	rats	responded	to	the	treatment	as	if	they	had	been	
given	a	single	dose	of	fructose	that	grossly	exceeded	their	ability	to	absorb	it.	Previous	studies	
have	shown	fructose	malabsorption	to	be	around	2	g/kg,	so	with	the	addition	of	D-tagatose,	all	of	
our	arms	were	above	this	range.	We	also	suspect	that	the	stress	of	malabsorption	and	correlating	
symptoms	explains	the	rise	in	blood	glucose	in	the	6000	mg/kg	dosing	group.	
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	The	mechanism	 by	which	 D-tagatose	 is	 able	 to	 reduce	 HbA1c	 in	 diabetic	 patients	 is	 not	 fully	
established.	 The	 phase	 2	 and	 3	 clinical	 trials	 showed	 that	 with	 a	 2-week	 run-in	 period	
malabsorption	could	be	controlled	even	with	high	doses	of	D-tagatose	three	times	daily,	while	
maintaining	HbA1c	 reduction.	 In	 the	1-year	phase	3	 trial,	HbA1c	 continued	 to	drop	month	by	
month	throughout	the	trial	with	no	signs	of	tachyphylaxis.	The	present	study	provides	another	
small	piece	of	the	puzzle,	and	a	future	study	will	determine	the	ultimate	fate	of	dietary	fructose	
in	D-tagatose	treated	patients.	
When	AUC	is	used	to	measure	exposure	of	a	drug,	integration	of	peak	area	is	usually	performed	
until	 drug	 is	 completely	 eliminated	 from	 the	 body.	 As	 we	 were	 measuring	 a	 radioisotope	 of	
carbon,	it	was	impossible	to	do	this	in	our	study,	because	we	could	not	establish	when	the	carbon	
would	have	been	metabolized	from	fructose	into	another	molecule.	Therefore,	the	absorption	of	
fructose	may	have	simply	been	delayed	and	would	have	shown	up,	had	we	performed	a	different	
study	over	a	longer	period.	A	full	metabolic	study	of	the	fructose	in	a	given	dose	in	the	presence	
of	D-tagatose	will	answer	many	such	questions.	Elucidation	of	 the	mechanisms	of	action	of	D-
tagatose	may	 help	 to	 optimize	 an	 interesting	 candidate	 for	 anti-diabetic	 therapy,	 or	 isolate	 a	
population	of	diabetics	in	which	this	drug	could	be	maximally	effective.	
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Chapter	3	-	BSN723T	Prevents	Atherosclerosis	and	Weight	Gain	in	ApoE	Knockout	Mice	
Fed	a	Western	Diet49	
3.1	Preface	
Treating	hyperglycemia	and	hyperlipidemia	in	T2DM	patients	runs	along	the	same	lines	of	treating	
the	greater	disorder	of	dysfunctions	in	energy	homeostasis,	and	it	is	clear	that	statins	and	other	
currently	available	anti-lipid	medications	are	unable	to	properly	treat	this	patient	population.		The	
potential	became	apparent	that	adding	a	molecule	to	D-tagatose	aimed	at	lowering	triglyceride	
levels	could	be	advantageous	and	possibly	even	synergistic	with	the	activities	of	D-tagatose.		In	
the	 current	 study	 the	 flavonoid	dihydromyricetin	 (DMY)	was	 added	 to	D-tagatose	 (designated	
BSN723T)	and	administered	to	a	hyperlipidemic	mouse	model.	
Dihydromyricetin	(designated	BSN723	or	DMY),	also	known	as	ampelopsin,	is	a	flavonoid	isolated	
from	 a	 number	 of	 plants,	 such	 as	Ampelopsis	 grossedentata,	 and	 used	 in	 traditional	 eastern	
medicine.	DMY	has	shown	positive	results	for	numerous	health	benefits	including	inflammation,65	
anti-oxidant,66	 anti-hypertensive,67	 and	 atherosclerosis.68	 	 It	 also	 appears	 to	 be	 beneficial	 as	 a	
treatment	for	alcohol	intoxication69	and	early	studies	suggest	it	may	have	potential	as	a	treatment	
for	Alzheimer’s	disease.70	
What	made	DMY	stand	out	for	combining	with	D-tagatose	was	a	recent	clinical	study	from	Chen	
et	al.	which	looked	at	the	effects	of	dihydromyricetin	on	nonalcoholic	fatty	liver	disease	(NAFLD).	
The	 pathogenesis	 of	 NAFLD	 includes	 insulin	 resistance,	 oxidative	 stress,	 mitochondrial	
dysfunction,	 and	 liver	 inflammation.	 	 The	 study	 focused	 on	 inflammatory	 mediators	 and	
biomarkers	of	NAFLD	but	also	looked	at	glucose	and	lipid	metabolism.		While	DMY	was	not	able	
to	effect	fatty	infiltrations	of	the	liver,	it	did	improve	levels	for	several	liver	enzymes,	and	led	to	
decreased	LDL	cholesterol	levels.47	A	second	study	reported	that	a	drink	made	from	Ampelopsis	
grossedentata	extract	given	to	humans	lowered	triglycerides	and	total	cholesterol	levels.68	
The	decision	was	made	to	go	ahead	with	this	D-tagatose	and	dihydromyricetin	study	on	the	heels	
of	the	successful	D-tagatose	and	trans-polydatin	study	(Appendix	C)	in	order	to	have	a	comparator	
study	of	D-tagatose	with	a	lipid	lowering	therapy.		The	results	of	the	BSN272	studies	appeared	to	
show	that	D-tagatose	and	trans-polydatin	were	synergistic	in	their	effects.		As	DMY	had	shown	
efficacy	in	lowering	of	triglycerides	and	cholesterol	as	monotherapy	it	had	the	potential	to	offer	
synergistic	effects	as	well.		If	the	results	were	that	no	synergistic	effects	existed,	then	that	would	
give	more	weight	 to	 the	 idea	 that	 BSN272	was	 unique	 and	worth	 pursuing	 as	 a	 combination	
therapy.	 	 ApoE-/-	 mice	 were	 used	 in	 this	 study	 instead	 of	 LDLr-/-	 because	 they	 develop	
atherosclerosis	more	robustly	when	fed	a	Western	diet.		I	led	the	investigation	and	writing	of	this	
study	and	it	was	published	to	Webmed	Central.		The	article	is	presented	here	with	the	figure	and	
table	numbers	changed	to	be	consistent	with	this	dissertation.	
3.2	Introduction49	
Evidence	strongly	supports	a	 link	between	obesity	and	a	spectrum	of	diseases	including	type	2	
diabetes,	hypertension,	hyperlipidemia,	and	cardiovascular	disease.	Hyperlipidemia	is	commonly	
seen	 in	 those	 who	 are	 obese	 and	 those	 with	 type	 2	 diabetes	 and	 is	 thought	 to	 be	 a	 major	
contributor	to	the	 increased	 incidence	of	cardiovascular	disease	seen	 in	these	populations.71,72	
Such	secondary	hyperlipidemia	 is	 typically	characterized	by	elevated	 levels	of	 triglycerides	and	
low-density	 lipoprotein	 (LDL)	 cholesterol	 and	 by	 low	 levels	 of	 high-density	 lipoprotein	 (HDL)	
cholesterol.	Reduction	of	elevated	LDL	and	raising	of	HDL	have	been	major	drug	treatment	goals,	
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and	 drugs	 have	 been	 developed	 that	 alter	 blood	 lipids	 and	 produce	 significant	 reduction	 in	
cardiovascular	events	in	patients	with	cardiovascular	disease	and	diabetes.73,74	
Elevated	serum	cholesterol	 levels	have	been	noted	 in	rodents,39	dogs,40	nonhuman	primates,41	
and	 humans42	 consuming	 a	 high-carbohydrate	 diet,	 particularly	 one	 including	 fructose	 and	
sucrose.	 Studies	 have	 provided	 evidence	 that	 fructose	 causes	 hypertriacylglycerolemia	
postprandially	both	directly	through	decreased	triglyceride	clearance,	and	indirectly	by	increasing	
liver	re-esterification	of	fatty	acids.75	Low-density	lipoprotein	receptor	deficient	(LDLr−/−)	mice	fed	
a	 high	 sucrose	 diet	 exhibited	 elevated	 serum	 LDL	 cholesterol	 concentrations	 and	 increased	
atherosclerosis	compared	to	mice	fed	an	energy-matched	diet	enriched	in	saturated	fatty	acids.43	
D-tagatose,	a	naturally	occurring	epimer	of	 fructose,	was	originally	developed	as	a	 low-calorie
sweetener	 (1.5	 kcal/g	 compared	 to	 4	 kcal/g	 for	 sucrose)	 but	 was	 found	 to	 have	 an
antihyperglycemic	effect	in	animal	and	human	studies	and	shows	promise	as	a	treatment	for	type
2	diabetes	and	obesity.4,17,18,37	After	more	than	10	years	of	animal	and	human	studies,	D-tagatose
was	classified	as	being	“generally	recognized	as	safe	(GRAS)”	by	the	FDA	and	has	been	used	since
in	food	and	beverage	products	with	no	serious	adverse	events	reported.6
The	mechanism	by	which	D-tagatose	produces	its	antihyperglycemic	effect	in	response	to	a	meal	
is	not	clear.	Based	on	studies	with	fructose	and	D-tagatose,	 it	was	proposed	that	D-tagatose	is	
metabolized	following	a	pathway	that	is	essentially	the	same	as	that	of	fructose.6	After	absorption	
from	the	intestine	and	transport	to	the	liver,	fructokinase	phosphorylates	D-tagatose	to	produce	
D-tagatose-1-phosphate.	D-tagatose-1-phosphate	can	stimulate	glucokinase	activity29,30	 leading
to	increased	phosphorylation	of	glucose	to	glucose-6-phosphate	and	further	activating	glycogen
synthase.31	 It	 has	 been	 suggested	 that	 D-tagatose-1-phosphate	 can	 inhibit	 glycogen
phosphorylase	 in	 the	 same	 manner	 that	 fructose-1-phosphate	 does,6	 but	 this	 has	 not	 been
directly	shown.	By	activating	glycogen	synthase	and	possibly	inhibiting	glycogen	phosphorylase,
D-tagatose-1-phosphate	 increases	 glycogen	 synthesis	 and	 inhibits	 glycogen	utilization,	 at	 least
partly	explaining	the	antihyperglycemic	effect	of	the	sugar.	In	addition	to	the	effect	on	glycogen
regulation,	D-tagatose	inhibits	sucrase,76	 leading	to	the	suppression	of	sucrose	digestion	in	the
small	intestine	and	inhibits	the	activity	of	maltase,	at	least	in	vitro,	which	could	slow	the	digestion
of	starch.	The	net	effect	of	the	regulation	of	these	enzymes	is	an	increase	in	glycogen	synthesis
and	storage	and	a	decrease	in	glycogen	utilization.	In	addition,	D-tagatose	reduces	the	absorption
and	digestion	of	 sucrose	 and	other	 carbohydrates	 in	 the	 small	 intestine.	D-tagatose	has	 been
shown	in	both	animal	and	human	studies	to	have	multiple	effects	including	increase	in	satiety	and
weight	control,	a	beneficial	effect	on	abnormal	blood	lipids,	a	reduction	in	atherosclerotic	plaque
formation,	and	a	reduction	 in	blood	glucose	and	HbA1c	 levels	 in	patients	with	type	2	diabetes
mellitus.4–6,13,18,37,58–60,77,78
In	addition	to	its	antihyperglycemic	effects,	D-tagatose	has	been	found	to	have	an	effect	on	blood	
lipid	levels	in	animals	and	in	humans.	In	one	study,	LDL-/-	mice	fed	a	diet	in	which	high	sucrose	
content	was	replaced	with	an	equivalent	amount	of	D-tagatose	exhibited	reduced	cholesterol,	
triglycerides,	and	atherosclerosis	compared	to	mice	on	the	diet	containing	sucrose.78	In	a	human	
clinical	trial,	patients	with	type	2	diabetes	taking	D-tagatose	were	found	to	have	improved	HDL	
levels,	increasing	from	30	to	41.7	mg/dL	over	the	course	of	the	14	month	study.5	This	is	interesting	
in	light	of	evidence	suggesting	that	increasing	HDL	levels	decrease	the	risk	of	incurring	a	coronary	
event.	The	mechanism	by	which	D-tagatose	raises	HDL	is	not	clear,	but	it	should	be	noted	that	
these	patients	did	lose	weight	during	the	study	and	this	may	have	contributed	to	the	improvement	
in	HDL.	In	other	studies,	type	II	diabetics	taking	D-tagatose	showed	a	decrease	in	HbA1c	and	serum	
triglycerides.4,5	
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Dihydromyricetin	 (BSN723	 or	 DMY),	 also	 known	 as	 ampelopsin,	 is	 a	 flavonoid	 that	 has	 been	
isolated	from	a	number	of	plants,	including	Ampelopsis	grossedentata,	Cedrus	deodara,	Hovenia	
dulcis,	and	Erythrophleum	africanum,	that	have	been	used	in	traditional	medicine.	Many	claims	
have	been	made	 regarding	 dihydromyricetin's	 numerous	 health	 benefits	 including	 antioxidant	
properties,66	 anti-cancer,79–81	 anti-hypertensive,67	 anti-inflammatory,65	 and	 anti-atherosclerotic	
effects.68	 Dihydromyricetin	 is	 also	 indicated	 as	 a	 treatment	 for	 alcohol	 intoxication69	 and	 a	
preliminary	study	suggests	it	as	a	possible	treatment	for	Alzheimer's	disease.70	
A	number	of	published	studies	provide	evidence	that	dihydromyricetin	can	protect	cells	against	
oxidative	injury	(for	example,	see	Zhang	et	al.	2003,66	Ye	et	al.	2008,82	Lin	et	al.	2014,83	Zou	et	al.	
2014).84	 Recently,	 Jiang	 et	 al.	 (2014)85	 examined	 the	 effects	 of	 dihydromyricetin	 on	 oxidative	
stress	and	glucose	transport	activity	in	a	methylglyoxal	(MG)-induced	PC12	cell	line	to	explore	the	
possibility	 of	 using	 dihydromyricetin	 for	 the	 treatment	 of	 MG-induced	 diabetes-associated	
cognitive	decline.	They	found	that	DMY	protected	PC12	cells	against	MG-induced	apoptosis	and	
glycometabolic	disorders,	at	 least	 in	part	by	restraining	the	hyperactivation	of	p-AMPK	activity	
and	normalizing	 the	 translocation	of	GLUT4	 from	the	 intracellular	compartment,	 resulting	 in	a	
balance	in	glucose	uptake.	
Much	attention	has	been	focused	on	the	use	of	dihydromyricetin	in	the	treatment	of	a	variety	of	
cancers	and	there	have	been	many	studies,	both	 in	vitro	and	 in	vivo,	demonstrating	 inhibitory	
activity	of	dihydromyricetin	against	cell	lines	of	breast	cancer,86	liver	cancer,80,81,83	melanoma,87	
osteosarcoma,88	and	lung	cancer.89,90	Dihydromyricetin	has	also	shown	anticancer	activity	against	
bladder	cancer,91	lung	cancer,92	and	prostate	cancer79	xenografts,	and	showed	synergistic	effects	
with	adriamycin	for	treating	leukemia	xenografts.93	
Recently,	Chen	et	al.	(2015)47	looked	at	the	effects	of	dihydromyricetin	on	nonalcoholic	fatty	liver	
disease	 (NAFLD)	 in	 a	 clinical	 study.	 The	 pathogenesis	 of	 NAFLD	 includes	 insulin	 resistance,	
oxidative	stress,	mitochondrial	dysfunction,	and	inflammation	in	the	liver.	
The	study	looked	at	inflammatory	mediators	and	biomarkers	of	NAFLD	as	well	as	glucose	and	lipid	
metabolism.	They	found	that	while	dihydromyricetin	did	not	alter	the	severity	of	fatty	infiltration	
in	the	liver,	it	did	produce	significant	improvements	in	several	liver	enzymes	and	reduced	serum	
levels	 of	 several	markers	 including	 tumor	 necrosis	 factor-alpha,	 cytokeratin-18,	 and	 fibroblast	
growth	 factor	 21.	 They	 also	 found	 that	 the	 HOM-IR	 level	 was	 decreased	 in	 dihydromyricetin	
treated	 patients,	 but	 insulin	 and	 C-peptide	 levels	 were	 not	 affected.	 Levels	 of	 low-density	
lipoprotein-cholesterol	(LDL-C)	and	apolipoprotein	B	(Apo	B)	were	also	significantly	decreased	by	
dihydromyricetin,	 but	 the	 total	 cholesterol,	 triglyceride,	 high-density	 lipoprotein-cholesterol	
(HDL-C),	 and	 Apo-A-I	 concentrations	 did	 not	 significantly	 differ	 between	 treated	 and	 control	
groups.	Other	evidence	that	dihydromyricetin	can	affect	glucose	metabolism	include	studies	that	
found	that	DMY	activated	insulin	signaling	and	increased	glucose	uptake	in	skeletal	muscle	in	vitro	
and	in	vivo.94,95	
Recent	studies	have	begun	to	offer	clues	about	dihydromyricetin's	mechanism	of	action.	It	is	now	
known	 that	 a	 number	 of	 cell	 signaling	 pathways	 are	 affected	 by	 dihydromyricetin.	 Zou,	et	 al.	
(2014)84	found	that	dihydromyricetin	fed	to	rats	for	7	days	increased	the	expression	of	peroxisome	
proliferator-activated	receptor	γ	coactivator	1α	(PGC-1α)	in	skeletal	muscle.	PGC-1α	is	known	to	
regulate	 irisin,	an	exercise-induced	myokine	that	can	stimulate	 the	browning	of	white	adipose	
tissue.	In	a	follow-up	study	(Zhou,	et	al.,	2015)96	the	effect	of	dihydromyricetin	on	irisin	secretion	
through	 the	 PGC-1α	 pathway	 was	 investigated	 in	 vivo	 (in	 rats	 and	 humans)	 and	 in	 vitro	 (L6	
myotubes).	 The	 results	 were	 an	 increase	 in	 irisin	 secretion	 with	 the	 administration	 of	
dihydromyricetin.	
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Dihydromyricetin	has	also	been	 found	to	 increase	 the	 levels	of	phosphorylated	AMP	activated	
protein	kinase	(AMPK)	and	Ulk1,	and	decrease	phosphorylated	mTOR	levels.94	The	same	group	
also	found	that	dihydromyricetin	increased	levels	of	peroxisome	proliferator-activated	receptor	
coactivator-1α	 (PGC-1α),	 and	Sirt3	 in	 skeletal	muscle	 in	 vitro	and	 in	 vivo.95	 Jiang,	et	al.	 (2014)	
found	that	dihydromyricetin	ameliorates	the	oxidative	stress	response	induced	by	methylglyoxal	
via	the	AMPK/GLUT4	signaling	pathway.85	
A	previous	study	combining	D-tagatose	with	another	naturally	occurring	antioxidant,	polydatin,	
found	the	combination	to	be	effective	in	lowering	total	cholesterol	and	preventing	the	formation	
of	atherosclerosis	in	ApoE-/-	mice.46	There	has	been	relatively	little	published	research	regarding	
DMY	combination	drugs	or	dihyromyricetin's	effect	on	cardiovascular	health.	Chen	et	al.	(2015)47	
recently	 reported	 that	 dihydromyricetin	 lowered	 LDL	 cholesterol	 in	 a	 human	 clinical	 trial.	 A	
second	study	reported	that	administering	an	extract	from	A.	grossedentata	to	rats	reduced	serum	
total	cholesterol	and	triglycerides	and	increased	high-density	lipoprotein,	and	that	humans	given	
a	drink	made	from	A.	grossedentata	showed	a	reduction	in	serum	triglycerides,	total	cholesterol,	
and	plasma	lipid.68	
In	the	present	study,	we	aim	to	examine	the	effect	of	BSN723T,	a	combination	of	D-tagatose	and	
dihydromyricetin,	 on	 blood	 lipids	 and	 atherosclerosis	 in	 ApoE-/-	 knockout	 mice.	 The	 ApoE	
lipoprotein	resides	on	very	low,	intermediate,	and	high	density	lipoproteins	(VLDL,	IDL,	and	HDL,	
respectively)	and	mediates	the	removal	of	lipoproteins	from	plasma	by	acting	as	a	ligand	for	low	
density	 lipoprotein	 (LDL)	 receptors.	 Mice	 are	 normally	 resistant	 to	 the	 development	 of	
atherosclerosis,	however	inactivation	of	the	ApoE	gene	in	mice	results	in	elevated	cholesterol	and	
triglycerides	 in	 these	 mice.	 Severe	 hypercholesterolemia	 and	 the	 rapid	 development	 of	
atherosclerosis	results	when	these	mice	are	fed	a	Western	type	diet	consisting	of	high	fat,	high	
cholesterol	and	high	 sucrose.97–99	The	progression	and	histopathology	of	 lesions	 in	 this	animal	
model	show	features	similar	to	those	observed	in	humans	and	other	species,	making	these	mice	
good	 models	 for	 evaluating	 diet	 composition	 and	 potential	 drugs	 for	 their	 effect	 on	
atherosclerotic	 development.98	 We	 tested	 the	 hypothesis	 that	 BSN723T	 lowers	 serum	
triglycerides	and	cholesterol,	and	prevents	the	formation	of	atherosclerosis	in	ApoE-/-	mice	fed	a	
Western	diet.	This	 is	 the	 first	known	study	examining	 the	combined	effects	of	D-tagatose	and	
BSN723	on	blood	lipids	and	the	development	of	atherosclerosis.	
3.3	Methods49	
Materials	
D-tagatose	 was	 obtained	 from	 Inalco,	 S.p.A.	 (Milano,	 Italy).	 Dihydromyricetin	 [(2R,	 3R)-3,5,7-
trihydroxy-2-(3,4,5--trihydroxyphenyl)-	2,3-dihydro--chromen-4-one]	was	obtained	from	Qingdao
Ai	Weisheng	Chemical	Co.	Ltd.	(Shandong,	China).
Mice	and	Diets	
The	animal-use	protocol	was	approved	by	the	University	of	Kentucky	 Institutional	Animal	Care	
and	 Use	 Committee.	 Male	 ApoE-/-	 mice	 (C57BL/6	 background)	 14	 to	 18	 weeks	 of	 age	 were	
obtained	from	Taconic	Biosciences.	The	mice	were	given	water	and	kept	on	a	12-hour	light/dark	
cycle.	Mice	were	randomized	into	5	groups	(n	=	10	per	group)	to	ad	libitum	produce	groups	with	
the	equivalent	mean	body	weights.	
Group	1	(Standard	diet)	is	a	negative	control	group	for	atherosclerosis	and	was	fed	Standard	chow	
(TD.2018,	see	Table	3.1	for	diet	compositions)	for	the	duration	of	the	study.	
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Group	2	(Western	diet)	is	a	positive	control	group	for	atherosclerosis	and	was	fed	Standard	chow	
for	 the	 two-week	D-tagatose	 run-in	 period	 (see	 below)	 and	 then	 switched	 to	 a	 high	 fat,	 high	
cholesterol,	high	sucrose,	Western	diet	(TD.88137)	for	the	remainder	of	the	study.	
Group	3	(D-tagatose	diet)	was	on	Standard	chow	during	the	two-week	run-in	period	during	which	
the	mice	of	this	group	were	given	gradually	increasing	concentrations	of	D-tagatose	in	the	water	
every	day	until	the	total	daily	mass	of	D-tagatose	drank	by	the	mice	matched	the	mass	consumed	
in	the	study	chow,	assuming	average	daily	consumption	of	water	and	chow	(see	Table	3.2).	These	
mice	were	then	switched	to	a	Western	diet	chow	(TD.140143),	in	which	the	sucrose	was	replaced	
by	D-tagatose,	for	the	remainder	of	the	study.	
Group	 4	 (BSN723	 diet)	 was	 on	 Standard	 chow	 during	 the	 two-week	 run-in	 period	 and	 then	
switched	to	a	Western	diet	with	dihydromyricetin	(BSN723)	added	(TD.140144)	and	kept	on	this	
diet	for	the	remainder	of	the	study.	
Group	5	(BSN723T	diet)	was	on	Standard	chow	during	the	two-week	run-in	period	during	which	
the	mice	of	this	group	were	given	gradually	increasing	concentrations	of	D-tagatose	in	the	water	
every	day	until	the	total	daily	mass	of	D-tagatose	drank	by	the	mice	matched	the	mass	consumed	
in	the	study	chow	(see	Table	3.2),	assuming	average	daily	consumption	of	water	and	chow.	These	
mice	were	then	switched	to	normal	water	and	a	Western	diet,	in	which	the	sucrose	was	replaced	
by	D-tagatose	and	with	dihydromyricetin	added	(TD.	140145),	for	the	remainder	of	the	study.	
TD.140143,	TD.140144,	and	TD.140145	were	custom	formulations	by	Harlan	Teklad.	
Table	3.149	
Comparisons	of	the	5	Diets	Fed	to	the	ApoE-/-	Mice	
Group	 Diet	 Sucrose	%	by	weight	 Cholesterol	
D-tagatose
%	by	weight	
Fat	%	
by	
weight	
Dihydromyricetin	 Kcal/g	
1	 Standard	
TD.2108	
0	 0	 0	 6.2%	 0	 3.1	
2	 Western	
TD.88137	
34%	 1.5	g/Kg	 0	 21%	 0	 4.5	
3	 D-tagatose
TD.140143
0%	 1.5	g/Kg	 34%	 21%	 0	 3.7	
4	 BSN723	
TD.140144	
34%	 1.5	g/Kg	 0	 21%	 1.11	g/Kg	 4.5	
5	 BSN723T	
TD.140145	
0	 1.5	g/Kg	 34%	 21%	 1.11	g/Kg	 3.7	
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Table	3.249	
D-tagatose	Run-In	Schedule
Day	 D-tagatose	(g)	/	100	ml	water
Day	1	 2.4	
Day	2	 4.9	
Day	3	 7.3	
Day	4	 9.7	
Day	5	 12.1	
Day	6	 14.5	
Day	7	 17.0	
Day	8	 19.4	
Day	9	 21.8	
Day	10	 24.2	
Day	11	 26.6	
Day	12	 29.0	
Day	13	 31.5	
Day	14	 34.2	
Addition	of	D-tagatose	to	drinking	water	during	the	two-week	run-in	phase.	Increasing	amounts	of	D-tagatose	
were	added	to	drinking	water	to	acclimate	mice	to	D-tagatose.	Mice	in	Groups	3	and	5	had	D-tagatose	added	
to	their	drinking	water.49	
Study	Design	
An	outline	of	the	time	course	of	the	study	is	shown	in	Figure	3.1.	
Figure	3.149	
Outline	of	the	Study	Protocol	
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	Due	 to	 the	 potential	 for	 gastrointestinal	 distress	 that	 results	 from	 the	 poor	 absorption	 of	 D-	
tagatose,	ApoE-/-	mice	receiving	D-tagatose	in	their	diets	(Groups	3	and	5)	were	acclimated	to	the	
sugar	by	adding	increasing	amounts	of	D-tagatose	to	their	drinking	water	daily	during	a	two-week	
run-in	phase	before	beginning	their	respective	diets	(Table	3.2).	D-tagatose	was	not	placed	in	the	
chow	for	the	tagatose	run-in	period	because	previous	experience	with	powdered	chow	feeders	
had	shown	that	much	of	 the	chow	was	 lost	 in	 the	 litter	and	 it	was	 too	difficult	 to	weigh	 food	
consumption.	Additionally,	because	 there	 is	a	minimum	order	 for	 custom	chows,	 it	would	not	
have	been	cost	effective	to	make	pelleted	chow	for	all	of	the	different	D-tagatose	doses	used	in	
the	run-in	period.	
After	the	D-tagatose	run-in	period,	mice	were	maintained	on	their	diets	for	8	weeks.	The	diets	
consumed	are	shown	in	Table	3.1.	Most	of	the	carbohydrate	content	of	the	Western	diet	comes	
from	 sucrose.	 In	 contrast,	 while	 having	 the	 highest	 carbohydrate	 caloric	 content,	 the	
carbohydrate	in	the	Standard	chow	is	from	complex	carbohydrates	found	in	grain	components,	
there	is	no	sucrose	added.	In	the	TD.140143	and	TD.140145	chows,	the	sucrose	has	been	replaced	
by	 D-tagatose.	 The	 ratios	 of	 calories	 from	 fat,	 protein	 and	 carbohydrates	
(fat/protein/carbohydrates)	are	as	follows:	TD.2108	(Standard)	=	18/24/58;	TD.88137	(Western)	
=	42/15/43;	TD.140143	(D-tagatose)	=	52/19/29;	TD.140144	(BSN723)	=	42/15/43;	TD.140145	(D-
tagatose	+	BSN723)	=	52/19/29.	
Body	weight	and	food	consumption	was	measured	during	the	D-tagatose	run-in	phase	and	weekly	
thereafter	during	the	dosing	phase.	Blood	was	sampled	by	submandibular	bleeds	after	overnight	
fasts	at	multiple	time	points	throughout	the	treatment	period	(see	Figure	3.1),	and	total	serum	
cholesterol	and	triglyceride	levels	were	determined.	
At	the	study	end	point,	mice	were	euthanized	using	CO2	followed	by	cervical	dislocation,	and	the	
left	 ventricle	 was	 punctured	 to	 obtain	 blood.	 After	 the	 right	 atrium	 was	 cut,	 mice	 were	
exsanguinated	by	perfusion	with	saline	through	the	left	ventricle	and	tissues	were	removed	(liver,	
kidneys,	spleen,	epididymal	fat,	retroperitoneal	fat,	subcutaneous	fat,	and	aortic	tissue	from	the	
heart	to	iliac	bifurcation).	The	livers,	kidneys,	spleens	and	fat	tissues	were	weighed.	The	hearts	
with	 the	aortas	attached	were	 fixed	overnight	 in	4%	paraformaldehyde	made	with	phosphate	
buffered	solution,	and	then	transferred	to	phosphate	buffered	solution	for	storage.	
Blood	Analysis	
Total	 serum	 cholesterol	 and	 total	 serum	 triglyceride	 levels	 were	 determined	 using	 enzymatic	
assay	kits	(Wako	Pure	Chemical,	Richmond,	VA).	
Atherosclerosis	Measurements	
Aortas	were	prepared	for	atherosclerosis	measurements	via	en	face	presentation,	in	which	the	
entire	length	of	the	aorta	was	removed	from	the	animal,	the	entire	intimal	surface	and	greater	
curvature	 of	 the	 aortic	 arch	 exposed,	 and	 the	 resulting	 tissue	 pinned	 to	 a	 dark	 surface.	 For	
determining	the	area	of	the	aortic	arch,	a	3	mm	line	was	drawn	in	software	downward	from	the	
root	of	the	left	subclavian	artery.	Using	the	bottom	of	this	line	as	a	base,	the	intimal	area	of	the	
arch	 was	 traced	 to	 determine	 the	 area.	 The	 atherosclerotic	 plaques	 were	 then	 traced	 and	
quantified	using	Nikon	NIS	Elements	software.78	Atherosclerotic	lesions	were	quantified	by	two	
independent	observers	(labeled	SG	and	JW).	Data	are	expressed	as	the	percentage	of	the	aortic	
arch	covered	with	grossly	discernable	atherosclerotic	lesions.	
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	Calculations	and	Statistics	
Data	are	presented	as	the	mean	±	standard	error	of	the	mean	(s.e.m.).	1-way	ANOVA	was	utilized	
for	analyses.	Values	of	p	<	0.05	were	considered	to	be	statistically	significant.	
3.4	Results49	
One	mouse	in	Group	1	died	on	day	42	after	being	bled.	One	mouse	in	Group	4	died	on	day	44	and	
was	found	on	necropsy	to	have	had	encephalitis	and	meningitis	of	unknown	origin.	Data	gathered	
from	these	two	mice	up	until	the	time	of	their	deaths	were	included	in	the	analysis.	
Food	Consumption	
Based	upon	the	weight	of	food	eaten	by	each	group	of	mice	and	the	number	of	Kcal/g	available	
for	each	diet,	average	daily	energy	consumption	per	mouse	was	calculated	(Table	3.3).	The	mice	
on	the	Western	and	BSN723	diets	consumed	the	highest	number	of	calories	per	day	(15.77	±	1.13	
Kcal/day	and	16.34	±	0.98	Kcal/day,	respectively,	the	difference	not	being	significant,	p	=	0.69)	
followed	by	the	BSN723T	(13.86	±	0.98	Kcal/day),	D-tagatose	(11.65	±	1.33	Kcal/day)	and	Standard	
diet	 (11.23	 ±	 0.49	 Kcal/day)	 groups.	 The	 caloric	 intake	 between	 the	 following	 groups	 was	
statistically	significant;	Standard	and	Western	diets	(+,	p	<	0.001),	Standard	and	BSN723	diet	(+,	p	
<	0.001),	Standard	and	BSN723T	diet	(+,	p	=	0.004),	Western	and	D-tagatose	diet	(*,	p	<	0.001),	D-
tagatose	and	BSN723	diet	(*,	p	<	0.001)	and	the	BSN723	and	BSN723T	diet	groups	(▲,	p	=	0.014).			
There	 was	 no	 significant	 difference	 in	 caloric	 intake	 between	 the	 Standard	 and	 D-tagatose,	
Western	and	BSN723,	Western	and	BSN723T,	or	D-tagatose	and	BSN723T	diet	groups.	There	was	
no	significant	difference	between	the	five	groups	in	terms	of	food	consumption	by	weight	of	chow	
eaten.	 One	 possible	 caveat	 regarding	 the	 estimated	 caloric	 values	 assigned	 to	 the	 chows	
containing	D-tagatose	is	that	the	exact	caloric	value	of	the	sugar	is	not	a	certainty	and	probably	
varies	depending	on	the	individual	consuming	it.	Upon	initial	consumption	of	the	sugar,	it	is	poorly	
absorbed	by	the	intestine,	but	absorption	may	increase	over	time	with	continued	consumption.	
A	value	of	1.5	kcal/g	of	D-tagatose	has	been	agreed	upon	for	the	use	on	food	labels	by	the	FDA	
and	this	is	the	value	used	to	calculate	the	number	of	kcal/g	in	the	chows	containing	D-tagatose.3	
Oxygen	 consumption	 measurements	 for	 each	 mouse	 in	 each	 study	 may	 be	 the	 best	 way	 to	
determine	energy	 consumption	 in	a	particular	 study,	but	given	 the	dependence	of	D-tagatose	
caloric	content	on	the	gut	microbiome,	such	results	may	not	be	transferrable	to	other	studies.	
Table	3.349	
Comparison	of	food	consumption	and	average	caloric	intake	of	mice	according	to	diet 
Diet	 Grams	of	food/mouse/day	 Kcal/gram	chow	 Kcal/mouse/day	
Standard	TD.2018	 3.62	±	0.16	 3.1	 11.23	±	0.49	
Western	TD.88137	 3.50	±	0.23	 4.5	 15.77	±	1.13,	+	*	
TD.140143	(D-tagatose)	 3.15	±	0.36	 3.7	 11.65	±	1.33	
TD.140144	(BSN723)	 3.63	±	0.22	 4.5	 16.34	±	0.98,	+	*	
TD.140145	(BSN723T)	 3.75	±	0.26	 3.7	 13.86	±	0.98,	+	◆	
Values	are	reported	as	mean	±	s.e.m.49	
+	=	significant	compared	to	Standard	group	
*	=	significant	compared	to	D-tagatose	group	
◆	=	significant	compared	to	BSN723	group	
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	Body	Weights	
Mice	in	all	five	groups	were	on	the	Standard	diet	at	the	beginning	of	the	study	and	during	the	two-
week	D-tagatose	run-in	period.	At	the	end	of	the	run-in	period	the	body	weights	of	the	mice	in	all	
five	groups	were	not	significantly	different	(Figure	3.2A).	On	day	15	the	mice	were	placed	on	their	
respective	diets	for	8	weeks.	
There	was	a	drop	in	weight	in	the	D-tagatose	and	BSN272T	groups	(Groups	3	and	5)	between	day	
15,	when	 the	mice	were	 started	on	 their	 respective	D-tagatose	 containing	 chows,	 and	day	21	
when	the	mice	were	next	weighed.	The	mice	in	these	two	groups	then	gained	weight	at	a	rate	
comparable	 to	 the	 Standard	 diet	 mice	 and	 at	 the	 end	 of	 the	 study	 there	 was	 no	 significant	
difference	between	the	weights	of	the	mice	in	these	three	groups.	Food	consumption	by	mice	in	
the	D-tagatose	and	BSN272T	groups	was	decreased	compared	to	the	other	three	groups	during	
the	first	week	the	mice	were	placed	on	their	respective	diets	and	this	is	the	likely	explanation	for	
the	 weight	 loss.	 After	 the	 first	 week,	 their	 food	 consumption	 increased	 and	 there	 was	 no	
significant	difference	between	the	five	groups	in	terms	of	food	consumption	by	weight	of	chow	
eaten.	At	the	end	of	the	study,	mice	on	the	Western	diet	weighed	the	most	(37.5	±	1.46	g)	but	not	
significantly	more	than	mice	on	the	BSN723	diet	(34.6	±	1.04	g,	P	=	0.13).	Mice	on	the	Western	
and	BSN723	diets	weighed	significantly	more	(*,	p	≤	0.024)	than	mice	on	the	other	three	diets	
while	 there	 was	 no	 significant	 difference	 between	 the	 weights	 of	 mice	 on	 those	 three	 diets	
(Standard	 diet,	 31.2	 ±	 0.89	 g;	 D-tagatose	 diet,	 29.5	 ±	 1.40	 g;	 BSN723T	 diet,	 29.2	 ±	 0.83	 g).	
Differences	in	caloric	intake	between	the	5	groups	directly	correlates	with	the	final	body	weights	
of	each	group	of	mice	and	could	account	for	any	differences	between	the	groups	(Figure	3.2B).	
Adipose	Tissue	and	Organ	Weights	
Mice	 on	 the	Western	 diet	 had	 increased	 total	 adipose	 tissue	 (epidydimal	 +	 retroperitoneal	 +	
subcutaneous	adipose	tissue)	compared	to	mice	on	the	Standard	diet	(Figure	3.3).	The	addition	
of	D-tagatose,	either	alone	or	 in	combination	with	BSN723,	prevented	the	 increase	 in	adipose	
tissue	brought	on	by	the	Western	diet	and,	in	fact,	mice	consuming	D-tagatose	(Groups	3	and	5)	
were	leaner	than	the	mice	on	the	Standard	diet.	Mice	on	the	BSN723	diet	were	also	leaner	than	
those	on	the	Western	diet	but	were	not	significantly	different	from	mice	on	the	Standard	diet.	
While	mice	on	the	BSN723	had	more	epididymal	fat	than	mice	on	the	Standard	diet	(0.67	±	0.14	
g	 vs	0.47	±	0.09	g,	 respectively),	 the	difference	was	not	 statistically	 significant	 (p	 =	 0.26).	 The	
amount	of	 subcutaneous	 (0.2	±	0.03	 g)	 and	 retroperitoneal	 fat	 (0.23	±	0.06	 g)	 in	mice	on	 the	
BSN723	mice	was	similar	to	that	found	in	mice	on	the	Standard	diet	(0.19	±	0.04	g	and	0.29	±	0.07	
g,	respectively).	
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	Figure	3.249	
Comparison	of	Body	Weights	and	Caloric	Intake	Throughout	the	Study	
All	mice	were	kept	on	the	Standard	diet	during	the	two-week	D-tagatose	run-in	phase	(days	0	to	14).	Mice	
were	then	placed	on	their	respective	diets	for	eight	weeks.	(A)	Change	in	body	weights	over	time.	(B)	Caloric	
intake	per	group;	*	=	greater	compared	to	Standard,	D-tagatose,	and	BSN723T	groups;	+	=	greater	compared	
to	Standard	and	D-tagatose	groups;	▲=	greater	than	D-tagatose	group.		(C)	body	weights	at	the	end	of	the	
study;	*	=	greater	compared	to	Standard,	D-tagatose,	and	BSN723T	groups.		Standard	diet,	n	=	9-10;	Western	
diet,	n	=	10;	D-tagatose	diet,	n	=	10;	BSN723	diet,	n	=	9-10;	BSN723T	diet,	n	=	10.		Results	are	reported	as	
mean	±	s.e.m.49	
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Figure	3.349	
Fat	Pad	Measurements	
Adipose	tissues	from	mice.	Standard	diet,	n	=	9;	Western	diet,	n	=	10;	D-tagatose	diet,	n	=	10;	BSN723	diet,	n	
=	9;	BSN723T	diet,	n	=	10.	Results	are	reported	as	mean	+/-	s.e.m.49	
Livers	from	mice	on	the	Western	diet	weighed	significantly	more	than	livers	from	mice	on	all	the	
other	diets	(p	<	0.02)	(Figure	3.4A).	There	was	no	difference	between	livers	of	mice	from	any	of	
the	other	groups.	The	only	significant	differences	in	the	weights	of	spleens	were	from	mice	on	the	
Western	and	BSN723	diets	compared	to	spleens	from	mice	on	the	Standard	diet	(p	<	0.02)	(Figure	
3.4B).	There	was	no	difference	between	spleens	of	mice	from	any	of	the	other	groups.	The	lungs	
from	mice	on	the	D-tagatose	diet	(Group	3)	were	slightly	smaller	(p	=	0.012)	than	the	lungs	from	
the	Standard	diet	 fed	mice	(Figure	3.4C).	There	were	no	differences	between	any	of	the	other	
groups.	Kidneys	from	mice	that	received	D-tagatose	in	their	diets	(groups	3	and	5)	were	slightly	
smaller	than	kidneys	from	mice	in	the	other	groups	(p	<	0.02)	(Figure	3.4D).		
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	Figure	3.449	
Measurement	of	Organ	Weights	
 
Organ	weights.	A)	 Livers.	B)	 Spleens.	C)	 Lungs.	D)	Kidneys.	 Standard	diet,	n	=	9;	Western	diet,	n	=	10;	D-
tagatose	diet,	n	=	10;	BSN723	diet,	n	=	9;	BSN723T	diet,	n	=	10.	Results	are	reported	as	mean	+/-	s.e.m.49	
Total	Cholesterol	
During	the	D-tagatose	14-day	run-in	period	all	of	the	mice	were	on	the	Standard	diet	(day	1	to	
14).	At	the	end	of	the	14-day	run-in	period,	there	were	no	significant	differences	in	serum	total	
cholesterol	levels	between	any	of	the	groups	(Figure	3.5).	On	day	15,	the	mice	we	started	on	their	
respective	diets.	By	day	36,	cholesterol	had	increased	in	the	mice	on	the	Western	diet	and	the	
three	treatment	diets	(Groups	3,	4,	and	5)	compared	to	mice	on	the	Standard	diet.	However,	the	
increase	was	significantly	less	in	the	two	groups	receiving	D-tagatose	(*,	Group	3	and	5,	p	<	0.0001	
for	both	groups)	compared	to	mice	on	the	Western	diet.	There	was	no	significant	difference	in	
cholesterol	between	the	mice	on	the	Western	and	BSN723	diets	on	day	36.	By	Day	71	(end	of	
study)	 total	 cholesterol	 in	 all	 three	 treatment	 groups	was	 significantly	 less	 (+,	D-tagatose,	p	 =	
0.034;	BSN723,	p	=	0.005;	and	BSN723T,	p	=	0.016)	than	that	of	mice	on	the	Western	diet,	but	
significantly	higher	than	mice	on	the	Standard	diet	(+,	D-tagatose,	p	=	0.0006;	BSN723,	p	=	0.012;	
and	BSN723T,	p	=	0.0007).	
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	Figure	3.549	
Total	Serum	Cholesterol
 
Time	course	of	total	serum	cholesterol.	All	mice	were	fed	Standard	diet	during	the	D-tagatose	run-in	(Days	1	
to	14)	and	then	placed	on	their	respective	diets.	Standard	diet,	n	=	9;	Western	diet,	n	=	10;	D-tagatose	diet,	n	
=	10;	BSN723	diet,	n	=	9;	BSN723T	diet,	n	=	10.	Results	are	reported	as	mean	+/-	s.e.m.	*	=	D-tagatose	and	
BSN723T	diet	groups	significantly	different	than	Western	and	BSN723	diet	groups.		+	=	all	treatment	groups	
are	significantly	lower	than	Western	diet	group	and	higher	than	Standard	diet	group.49	
BSN723	 and	 D-tagatose	 Lower	 Serum	 Triglycerides	 Compared	 to	 Mice	 on	 Both	 the	
Standard	and	Western	Diets	
At	 the	 end	 of	 the	 14-day	 run-in	 period,	 there	 were	 no	 significant	 differences	 in	 triglycerides	
between	any	of	the	groups	(Figure	3.6).	There	was	also	no	significant	difference	 in	triglyceride	
levels	in	mice	on	the	Standard	or	Western	diets	at	any	time	point	during	the	study.	The	D-tagatose,	
BSN723,	and	BSN723T	diets	lowered	triglycerides	compared	to	mice	on	the	Standard	and	Western	
diets	 during	 the	 course	 of	 the	 study.	 By	 day	 71,	 triglycerides	 in	 Groups	 3,	 4,	 and	 5	 were	
approximately	 half	 or	 better	 than	 the	 levels	 in	 either	 the	 Standard	 or	 Western	 diet	 groups	
(Standard	diet,	263.7	±	33.1	mg/dL;	Western	diet,	256.0	±	31.9	mg/dL;	D-tagatose,	102.9	±	5.65	
mg/dL;	BSN723,	155.0	±	15.1	mg/dL;	BSN723T,	124.7	±	12.3	mg/dL;	*,	p	≤	0.014	Groups	3,	4,	and	
5	compared	to	Groups	1	and	2.)	On	Day	71,	triglycerides	were	also	significantly	lower	in	the	D-
tagatose	group	than	in	the	BSN723	group	(p	=	0.009).	
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	Figure	3.649	
Serum	Triglycerides
 
All	mice	were	on	the	Standard	diet	during	the	two-week	D-tagatose	run-in	period	(Days	1	to	14)	and	then	
placed	on	their	respective	diets.	Standard	diet,	n	=	9;	Western	diet,	n	=	10;	D-tagatose	diet,	n	=	10;	BSN723	
diet,	n	=	9;	BSN723T	diet,	n	=	10.	Results	are	reported	as	mean	+/-	s.e.m.		*	=	All	treatment	groups	significantly	
lower	 than	Standard	diet	and	Western	diet	groups.	 	On	day	71	D-tagatose	and	BSN723	groups	were	also	
significantly	different.49	
Atherosclerosis	
The	surface	area	of	aortas	covered	by	atherosclerotic	lesion	was	greater	in	mice	on	the	Western	
diet	compared	to	mice	on	the	Standard	diet	(p	=	0.001)	(Figure	3.7).	The	addition	of	D-tagatose,	
BSN723,	or	BSB723T	to	the	diets	inhibited	the	formation	of	plaque	in	aortas	compared	to	mice	on	
the	Western	diet	(p	=	0.007,	p	=	0.04,	p	=	0.016,	respectively).	The	aortas	from	mice	that	were	on	
the	D-tagatose,	BSN723,	and	BSN723T	diets	all	had	greater	plaque	formation	compared	to	mice	
on	the	Standard	diet	(p	=	0.023,	p	<	0.0001,	p	=	0.02,	respectively).	Significant	differences	were	
found	between	mice	from	Group	1	(Standard	diet)	and	all	other	groups	(+,	p	<	0.022),	between	
Group	2	(Western	diet)	and	all	other	groups	(*,	p	<	0.04),	and	between	Groups	3	(D-tagatose	diet)	
and	4	(BSN723	diet)	(p	=	0.014).	
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	Figure	3.749	
Atherosclerotic	Plaque	Coverage	in	the	Aortic	Arch	
Comparison	of	the	percent	area	of	the	aortic	arch	that	has	plaque.	Aortas	were	prepared	for	atherosclerosis	
measurements	 via	en	 face	presentation.	 The	addition	of	D-tagatose,	dihydromyricetin	or	BSN723T	 to	 the	
Western	diet	significantly	prevented	the	formation	of	atherosclerotic	plaques.	Standard	diet,	n	=	9;	Western	
diet,	n	=	10;	D-tagatose	diet,	n	=	10,	BSN723,	n	=	9,	BSN723T,	n	=	10.	Results	are	shown	as	mean	+/-	s.e.m.		+	
=	significantly	greater	than	Standard	diet.		*	=	significantly	lower	than	Western	diet	group.		The	D-tagatose	
and	BSN723	groups	were	also	significantly	different.49	
3.5	Discussion49	
Flavonoids	 are	derivatives	 of	 2-phenyl-1-benzopyran-4-1	 and	 are	present	 in	 fruits,	 vegetables,	
nuts,	 and	 seeds.	 Many	 studies	 have	 found	 an	 association	 between	 flavonoid	 intake	 and	 a	
reduction	of	risk	for	coronary	events.100–102	The	flavonoid	dihydromyricetin	is	the	major	bioactive	
compound	in	Ampelsis	grossedentata,	making	up	15-20%	(wt/wt)	of	the	total	dry	weight	of	stems	
and	 leaves.103	Many	of	 the	preliminary	studies	 touting	 the	positive	effects	of	dihydromyricetin	
have	 utilized	 plant	 extracts	 which,	 in	 addition	 to	 containing	 high	 concentrations	 of	
dihydromyricetin,	 also	 contained	complex	mixtures	of	other	 flavonoids.	Chen	et	al.68	 reported	
that	the	intragastric	administration	of	extract	from	A.	grossedentata	to	rats	reduced	serum	total	
cholesterol	 and	 triglycerides	 and	 increased	 high-density	 lipoprotein.	 In	 a	 study	 using	 human	
subjects	with	hyperlipidemia,	the	administration	of	a	drink	made	from	A.	grossedentata	for	45	
days	reduced	serum	triglycerides,	total	cholesterol,	and	plasma	lipids.48		Up	to	now	few	studies	
have	 evaluated	 the	 serum	 lipid	 altering	 and	 anti-atherosclerotic	 activities	 of	 purified	
dihydromyricetin.	
Considerable	 attention	has	been	 focused	on	 the	antioxidant	 activity	of	dihydromyricetin.104,105	
Liao	 et	 al.105	 crystallized	 dihydromyricetin	 from	 A.	 grossedentata	 and	 demonstrated	 it	 was	
effective	 at	 inhibiting	 the	 production	 of	 reactive	 oxygen	 species	 in	 treated	 cells	 thereby	
attenuating	 plasma	 lipid	 peroxidation.	 It	 also	 inhibited	 AAPH-induced	 production	 of	
malondialdehyde,	an	indicator	of	lipid	peroxidation	and	a	biomarker	for	oxidative	stress.	Evidence	
suggests	 that	 oxidative	 stress	 can	 lead	 to	 endothelial	 dysfunction	 and	 is	 involved	 in	 the	
development	of	atherosclerotic	plaque.106	
To	our	knowledge	this	is	the	first	study	that	combines	D-tagatose	and	BSN723	(dihydromyricetin)	
for	the	treatment	of	hyperlipidemia	and	the	prevention	of	atherosclerosis.	This	study	examined	
the	effect	of	the	administration	of	BSN723,	D-tagatose,	or	a	combination	of	the	two,	on	weight	
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	gain,	blood	lipids,	and	the	development	of	atherosclerosis,	in	ApoE-/-	mice	consuming	a	Western	
diet	 (high	 fat,	 high	 cholesterol,	 high	 sucrose	 diet).	 In	 the	 diets	 containing	 D-tagatose,	 the	 D-
tagatose	replaced	the	sucrose	in	the	Western	diet	formulation.	For	the	mice	treated	with	BSN723	
alone	 (Group	 4),	 sucrose	 was	 still	 present	 in	 the	 diet,	 BSN723	 was	 just	 added	 to	 the	 chow	
formulation.	 The	 Western	 diet	 promoted	 obesity,	 increased	 total	 serum	 cholesterol,	 and	
markedly	stimulated	the	development	of	atherosclerosis	in	the	ApoE-/-	mice	compared	to	mice	on	
Standard	chow.	In	contrast,	a	diet	that	replaced	gram-for-gram	the	sucrose	in	the	Western	diet	
with	D-tagatose,	with	or	without	BSN723,	prevented	the	weight	gain	seen	with	animals	on	the	
Western	diet	and	had	a	marked	effect	on	blood	lipids	and	the	development	of	atherosclerosis.	
The	mice	on	the	D-tagatose	diets	did	not	exhibit	a	gain	in	body	weight	witnessed	in	the	Western	
diet	group	and	weighed	slightly,	but	not	significantly,	less	than	the	Standard	diet	mice.	A	previous	
study	also	showed	that	replacing	sucrose	with	D-tagatose	 in	a	Western	diet	fed	to	LDLr-/-	mice	
prevented	 the	 development	 of	 obesity.78	 We	 obtained	 the	 same	 result	 with	 ApoE-/-	 mice.	
Differences	in	caloric	intake	between	the	5	groups	directly	correlates	with	the	final	body	weights	
of	 each	 group	 of	mice	 and	 could	 account	 for	 any	 differences	 between	 the	 groups.	While	 not	
significantly	different,	mice	on	the	diet	containing	BSN723	weighed	less	than	mice	on	the	Western	
diet	(34.6	±	1.04	g	compared	to	37.5	±	1.46	g,	respectively)	even	though	the	caloric	intake	of	the	
BSN723	group	(16.34	±	0.98	Kcal/mouse/	day)	was	slightly,	but	not	significantly,	greater	than	mice	
on	the	Western	diet	(15.77	±	1.13	Kcal/mouse/day).	
There	was	a	significant	(p	<	0.01)	drop	in	weight	in	the	two	groups	(Groups	3	and	5)	on	the	diets	
containing	D-tagatose	between	day	15,	when	the	mice	were	started	on	their	respective	diets	and	
day	21	when	they	were	next	weighed.	The	mice	then	gained	weight	at	a	rate	comparable	to	the	
Standard	diet	mice	and	at	the	end	of	the	study	there	was	no	significant	difference	in	the	weight	
of	the	mice	in	the	two	groups	on	D-tagatose	and	the	group	on	the	Standard	diet.	D-tagatose	is	
known	 to	 cause	 gastrointestinal	 upset	 when	 taken	 in	 large	 enough	 doses	 without	 a	 gradual	
increase	 in	 intake,	 which	 was	 the	 reason	 for	 the	 14-day	 run-in	 period.	While	 there	 were	 no	
outward	symptoms	of	gastrointestinal	distress	in	the	mice	placed	on	the	D-tagatose	containing	
diets,	 they	 did	 eat	 less	 during	 the	 first	 week.	 After	 the	 first	 week,	 their	 food	 consumption	
increased	and	was	comparable	to	the	other	two	groups.	
Interestingly,	while	there	was	no	significant	difference	 in	the	body	weights	of	 the	mice	on	the	
Standard	diet	and	the	two	D-tagatose	containing	diet	groups	(Groups	3	and	5),	the	mice	on	D-
tagatose	 were	 leaner,	 as	 evidenced	 by	 the	 significantly	 lower	 amount	 of	 epididymal,	
retroperitoneal	and	subcutaneous	fat	compared	to	the	Standard	diet	group.	Similar	results	were	
seen	in	another	study	using	LDLr-/-	mice.78	The	addition	of	BSN723	to	the	Western	diet	(Group	4)	
resulted	in	mice	that	were	leaner	than	those	on	the	Western	diet,	even	though	the	caloric	intake	
of	these	two	groups	was	essentially	the	same,	but	not	as	lean	as	mice	on	the	Standard	diet	or	the	
two	D-tagatose	containing	diets.	
While	D-tagatose	fed	mice	(Groups	3	and	5)	exhibited	increased	serum	cholesterol	compared	to	
Standard	diet	mice,	the	extent	of	these	changes	was	far	less	than	those	observed	in	the	mice	on	
the	 Western	 diet	 (Figure	 3.5).	 The	 livers	 of	 ApoE-/-	 mice	 are	 unable	 to	 remove	 circulating	
cholesterol	 efficiently	 and	 as	 a	 result	 these	 mice	 exhibit	 elevated	 serum	 cholesterol.	
Atherosclerotic	lesion	development	is	very	dramatic	in	ApoE-/-	mice	fed	a	Western-type	diet	and	
the	beginning	stages	of	the	disease	can	be	found	at	6	weeks.97	With	the	ApoE-/-	and	LDLr-/-	mouse	
models,	 dietary	 cholesterol,	 rather	 than	 the	 level	 of	 fat,	 exerts	 a	 major	 influence	 on	 the	
development	of	atherosclerosis.107–109	In	addition	to	cholesterol,	the	fatty	acid	profile	and	even	
the	carbohydrate	form	(i.e.	fructose,	sucrose)	can	be	manipulated	to	modify	the	atherosclerosis	
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	phenotype.43,108,110	 Replacement	 of	 sucrose	 with	 D-tagatose	 in	 a	Western	 diet	 was	 shown	 to	
decrease	 serum	 total	 cholesterol	 in	 LDLr-/-	 mice	 compared	 to	mice	 on	 the	Western	 diet	 with	
sucrose.78	 We	 obtained	 similar	 results	 with	 the	 ApoE-/-	 mice.	 Total	 cholesterol	 increased	
somewhat	 in	 the	 D-tagatose,	 BSN723,	 and	 BSN723T	 fed	 mice,	 upon	 placing	 them	 on	 their	
respective	 diets	 compared	 to	 Standard	 diet,	 but	 never	 reached	 the	 levels	 of	 the	mice	 on	 the	
Western	diet.	In	future	work	the	effect	of	BSN723	on	HDL	and	LDL	cholesterol	should	be	measured	
and	compared	to	D-tagatose.	
In	ApoE-/-	mice,	 there	 is	no	significant	change	 in	 triglyceride	 levels	when	mice	are	placed	on	a	
Western	diet	compared	to	mice	fed	a	Standard	diet	(Fig.	3.6).	Serum	triglyceride	levels	in	ApoE-/-	
mice	are	elevated	compared	to	wild-type	mice,	even	when	fed	the	Standard	diet.	The	addition	of	
D-tagatose,	BSN723,	or	a	combination	of	the	two,	lowered	serum	triglycerides	in	these	mice	back	
toward	 what	 would	 be	 considered	 normal	 levels	 (see	 negative	 control).	 D-tagatose	 alone	
appeared	 to	 be	 more	 effective	 at	 lowering	 triglycerides	 than	 BSN723	 alone	 or	 the	 BSN723T	
combination.	
The	ApoE-/-	mice	in	this	study	developed	little	atherosclerosis	when	maintained	on	the	Standard	
diet,	which	does	not	contain	sucrose	or	added	cholesterol,	and	is	lower	in	fat	compared	to	the	
Western	diet.	All	three	modified	diets,	D-tagatose,	BSN723,	and	BSN723T,	reduced	the	amount	of	
plaque	formed	in	the	aortas	compared	to	mice	on	the	Western	diet	(Figure	3.7).	
One	 of	 the	 objectives	 of	 this	 study	 was	 to	 determine	 if	 the	 addition	 of	 BSN723	 to	 the	 diet	
containing	 D-tagatose	 would	 have	 any	 additive	 or	 synergistic	 effect	 on	 blood	 lipids	 or	
atherosclerotic	plaque	formation.	Addition	of	BSN723	to	D-tagatose	did	not	increase	the	efficacy	
for	reducing	cholesterol	or	atherosclerosis	compared	to	D-tagatose	alone.	While	no	such	effect	
was	observed,	BSN723	by	itself	did	significantly	prevent	diet	 induced	rises	 in	blood	cholesterol	
and	the	formation	of	atherosclerosis,	with	efficacy	increasing	over	time	in	the	latter	part	of	the	
study.	A	longer	study	seems	warranted.	Administration	of	BSN723	with	polydatin,	which	yielded	
a	synergistic	reduction	of	lipids	with	D-tagatose,46	might	also	prove	effective.	
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	Chapter	4	-	BSN272	Prevents	Western	Diet-Induced	Atherosclerosis	and	Excess	Weight	
Gain	in	ApoE-/-	Mice111	
4.1	Preface	
Although	BSN723T	was	efficacious	in	preventing	diet	induced	increases	in	total	cholesterol	and	
formation	of	atherosclerosis,	it	did	not	have	activity	towards	triglycerides	(TG)	as	was	the	goal.		
However,	it	did	provide	a	comparator	for	the	BSN272	study	(Appendix	C)	and	studies	to	come.	
Metts	et	al.46	followed	that	BSN272	LDLr-/-	study	by	conducting	an	8-week	study	in	ApoE-/-	mice	to	
study	 the	 Dynamic	 Data-Driven	 Application	 Simulation	 (DDDAS)	 developed	 from	 the	 previous	
LDLr-/-	study	(Appendix	C)	using	uncorrelated	doses	by	principal	axis	transformation.		ApoE-/-	mice	
were	fed	a	standard	diet,	a	Western	diet,	or	a	Western	diet	with	the	sucrose	replaced	with	D-
tagatose	and	1	g	of	trans-polydatin	added	per	kg	of	chow	for	8	weeks.46			
Treatment	with	BSN272	resulted	in	approximately	25-33%	less	development	of	atherosclerosis	in	
every	area	of	the	dissected	aortas	that	was	measured	compared	to	positive	control	group	which	
was	significant.		Western	diet	mice	had	significantly	greater	fat	pad	mass	than	did	BSN272	mice:	
epididymal	fat	1.9	vs.	0.3g,	retroperitoneal	fat	0.6	vs.	0.03g,	and	subcutaneous	fat	0.9	vs.	0.2g.		
Total	serum	cholesterol	was	significantly	lower	in	the	BSN272	group	compared	to	positive	control	
(930	vs.	630	mg/dl,	p=0.025).		Most	importantly	for	our	purposes,	triglyceride	levels	were	lower	
in	the	BSN272	group,	although	this	result	was	not	significant	(141	vs.	110	mg/dl,	p=0.16).46	
When	the	results	of	the	study	above	were	reintegrated	into	the	DDDAS	system	and	extrapolated	
it	appeared	as	though	the	triglyceride	results	were	not	random	and	that	a	longer	study	with	larger	
number	of	animals	powered	to	obtain	significance	towards	triglycerides	would	find	a	distinction	
between	BSN272	treated	mice	and	control.	
This	would	be	a	substantial	finding	due	to	the	fact	that	in	the	Phase	III	study	D-tagatose	led	to	an	
increase	in	triglycerides,	and	no	study,	to	our	knowledge,	had	shown	the	ability	of	D-tagatose	to	
lower	triglycerides	(apart	from	one	study	by	Police	et	al.	that	showed	D-tagatose	could	prevent	
diet	 induced	 increases	 in	 triglycerides	 compared	 to	 positive	 control	 (sucrose/Western	 diet),	
although	D-tagatose	caused	an	 increase	 in	 triglycerides	compared	 to	negative	control	 (normal	
chow)).78	 	 In	addition,	an	unpublished	study	in	our	lab	using	Syrian	golden	hamsters	fed	a	high	
fat/carbohydrate	Western	diet	(Untreated)	showed	that	trans-polydatin	actually	led	to	increased	
triglycerides	 greater	 than	 the	 increase	 caused	 by	 Western	 Diet	 alone	 (Figure	 4.1,	 compare	
untreated	and	polydatin	columns).		In	the	same	study	BSN272	using	100	mg/kg	of	the	polydatin	
component	 was	 able	 to	 significantly	 reduce	 triglycerides	 from	 baseline	 (Figure	 4.1,	 D-
tag/polydatin	100	mg/kg	column).	
It	 should	be	noted	 that	 the	 increase	 in	 triglycerides	 from	polydatin	 in	our	 study	 is	 contrary	 to	
Arichi	et	al.,112	Du	et	al.,113	and	Xing	et	al.114	which	all	reported	a	reduction	in	TG	with	polydatin,	
which	was	partly	responsible	for	its	early	selection	for	a	combination	with	D-tagatose.		In	fact	Du	
et	 al.,113	 using	 the	 same	 Syrian	 golden	hamster	model	 as	 in	 our	 study,	 reported	 the	 ability	 of	
polydatin	 to	 significantly	 prevent	 the	 diet	 induced	 increase	 in	 TG	 established	 with	 the	 high	
fat/cholesterol	diet.		A	key	difference	between	our	studies	is	that	the	polydatin	was	initiated	with	
the	 introduction	of	 the	high	 fat/cholesterol	 diet	 in	 the	Du	 study,	meaning	 that	 the	 study	was	
actually	 designed	 to	 measure	 the	 ability	 of	 polydatin	 to	 prevent	 diet	 induced	 increases	 in	
atherosclerotic	precursors.		In	our	study,	we	allowed	the	hamsters	to	develop	hyperlipidemia	for	
28	days	prior	to	initiation	of	polydatin,	and	were	therefore	measuring	the	ability	of	polydatin	to	
reverse	hyperlipidemia.		TG’s	in	the	Du	study	were	around	16	mmol/L	(142	mg/dL	equivalent)115	
for	the	high	fat/cholesterol	group	(positive	control)	at	day	15	(study	conclusion).113		In	our	study	
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	28	 days	 after	 the	 initiation	 of	 the	Western	 diet	 the	 serum	 TG	 average	was	 126	mg/dL	 in	 the	
positive	control	group.		This	is	the	point	at	which	we	began	treatments	for	21	days.		During	this	
time	period	the	TG	level	in	the	Western	diet	group	increased	122	mg/dL	to	a	final	end	of	study	
measurement	of	245	mg/dl	(change	depicted	in	Figure	4.1).		While	polydatin	was	able	to	prevent	
the	diet	induced	increase	in	serum	TG’s	in	the	Du	study,113	it	appears	unable	to	reverse	developed	
hypertriglyceridemia	and	in	fact	resulted	in	worsening	TG	levels	that	at	the	end	of	the	study	after	
21	days	of	 treatment	with	100	mg/kg	of	polydatin	averaged	359	mg/dL	 in	 the	polydatin	alone	
group.	
Figure	4.1	
Change	in	Serum	Triglycerides	
Graph	depicts	 the	change	from	day	1-21	 (end	of	study)	 in	serum	triglycerides	relative	to	baseline	of	each	
subject	as	an	average	+	SE.		Hamsters	were	placed	on	a	high	fat/cholesterol/carbohydrate	Western	Diet	on	
day	-26	as	those	receiving	D-tagatose	began	a	D-tagatose	run-in	period	until	day	1	at	which	time	all	groups	
began	the	full	study	dose	for	21	days.		Polydatin	alone	group	(100	mg/kg)	received	no	treatment	until	day	1.	
(Unpublished	study).	
Regardless,	 the	 most	 important	 finding	 in	 our	 Syrian	 golden	 hamster	 study	 was	 that	 the	
combination	of	 trans-polydatin	and	D-tagatose	 reversed	developed	hypertriglyceridemia	more	
than	could	be	expected	from	adding	the	results	of	the	combo	as	monotherapy.	 	TG’s	 in	the	D-
tag/polydatin	100	mg/kg	group	were	reduced	from	286	to	189	mg/dL	throughout	the	course	of	
the	 study	 (change	 depicted	 in	 Figure	 4.1).	 	 This	 was	 especially	 intriguing	 because	 hamsters	
naturally	have	cholesterol	ester	transfer	protein	(CETP)	as	do	humans	and	are	considered	to	have	
a	lipid	metabolism	profile	similar	to	humans.116	
There	were	complications	in	this	study,	the	principal	of	which	was	that	a	miscalculation	in	the	D-
tagatose	dose	led	to	overdosing	the	D-tagatose	groups	for	the	first	11	days	and	resulted	in	the	
death	of	12	hamsters	from	complications	with	diarrhea	(likely	due	to	the	osmotic	laxative	effect	
of	the	carbohydrate	load).		The	D-tagatose	dose	was	subsequently	cut	in	half	for	the	remainder	
of	the	study	but	it’s	impossible	to	say	what	affect	this	may	have	had	on	D-tagatose	administered	
groups.		However,	we	had	the	original	results	from	the	LDLr-/-	mice	uncorrelated	doses	study	that	
showed	a	trend	towards	lowering	of	TG’s,45	the	follow-up	study	by	Metts	et	al.46	in	ApoE-/-	mice	
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	that	 came	 just	 short	 of	 significance	 for	 lowering	 of	 TG’s	 with	 the	 algorithm	 that	 predicted	
significance	 given	 a	 larger	 sample	 size,	 and	 now	what	 appeared	 to	 be	 a	 robust	 result	 in	 diet	
induced	hyperlipidemic	hamsters	with	a	questionable	procedural	mistake.		It	was	time	to	perform	
a	 study	 with	 a	 large	 number	 of	 subjects	 over	 a	 lengthy	 period	 of	 time	 in	 the	 model	 of	
atherosclerosis	 and	 hyperlipidemia	 that	 we	 had	 had	 the	 most	 success	 with	 to	 determine	
definitively	 if	 BSN272	 has	 efficacy	 against	 hyperlipidemia	 and	 atherosclerosis.	 	 In	 the	 study	
presented	below,	ApoE-/-	mice	were	fed	a	Western	diet	and	treated	with	BSN272	for	16	weeks.		
The	figure	and	table	numbers	have	been	changed	from	the	publication	in	order	to	be	consistent	
for	this	dissertation.			
4.2	Introduction111	
Evidence	supports	a	link	between	obesity	and	a	spectrum	of	diseases	including	type	2	diabetes,	
hypertension,	abnormal	blood	lipids	(usually	in	the	form	of	hyperlipidemia),	and	increased	risk	for	
cardiovascular	disease.	Hyperlipidemia	is	typically	characterized	by	elevated	levels	of	triglycerides	
and	low-density	lipoprotein	(LDL)	cholesterol	and	by	low	levels	of	high-density	lipoprotein	(HDL)	
cholesterol.	 This	 disease	 commonly	manifests	 in	 those	who	 are	 obese	 and	 those	with	 type	 2	
diabetics,	and	is	thought	to	be	a	major	contributor	to	the	increased	incidence	of	cardiovascular	
disease	seen	in	these	two	populations.71,72	Reduction	of	elevated	LDL	is	a	major	drug	treatment	
goal	 and	 has	 produced	 significant	 reduction	 in	 cardiovascular	 events	 in	 patients	 with	
cardiovascular	disease	and	diabetes.73	In	addition	to	lowering	LDL,	research	has	also	shown	that	
raising	HDL	in	persons	with	low	HDL	can	reduce	the	number	of	coronary	events,	a	finding	that	has	
led	to	an	interest	in	the	development	of	drugs	that	can	accomplish	this	HDL	improvement.74	
Elevated	serum	cholesterol	 levels	have	been	noted	 in	rodents,39	dogs,40	nonhuman	primates,41	
and	 humans42	 consuming	 a	 high-carbohydrate	 diet,	 particularly	 one	 including	 fructose	 and	
sucrose.	 Recent	 studies	 have	 provided	 evidence	 that	 fructose	 causes	 hyperlipidemia	
postprandially,	both	directly	through	the	synthesis	of	fatty	acids,	and	indirectly	by	increasing	liver	
re-esterification	of	 fatty	acids.75	Low-density	 lipoprotein	 receptor	deficient	 (LDLr−/−)	mice	 fed	a	
high	 sucrose	 diet	 exhibited	 elevated	 serum	 LDL	 cholesterol	 concentrations	 and	 increased	
atherosclerosis	compared	to	mice	fed	an	energy-matched	diet	enriched	in	saturated	fatty	acids.43		
D-tagatose,	a	naturally	occurring	epimer	of	 fructose,	was	originally	developed	as	a	 low-calorie	
sweetener	 (1.5	 kcal/g	 compared	 to	 4	 kcal/g	 for	 sucrose)	 but	 was	 found	 to	 have	 an	
antihyperglycemic	effect	in	animal	and	in	human	studies	and	showed	promise	as	a	treatment	for	
type	2	diabetes	and	obesity.4,6,17	After	over	10	years	of	animal	and	human	studies	for	use	as	a	food	
sweetener,	D-tagatose	was	classified	as	being	“generally	recognized	as	safe	(GRAS)”	by	the	FDA	
and	has	been	used	since	in	food	and	beverage	products	with	no	adverse	events	reported.	
The	mechanism	by	which	D-tagatose	produces	its	antihyperglycemic	effect	in	response	to	a	meal	
is	not	clear.	However,	based	on	studies	with	fructose	and	D-tagatose,	it	has	been	proposed	that	
D-tagatose	is	metabolized	following	a	pathway	that	is	essentially	the	same	as	that	of	fructose.6	
After	 absorption	 from	 the	 intestine	and	 transport	 to	 the	 liver,	 fructokinase	phosphorylates	D-
tagatose	to	produce	D-tagatose-1-phosphate.	D-tagatose-1-phosphate	can	stimulate	glucokinase	
activity29,30	 leading	 to	 increased	phosphorylation	of	 glucose	 to	glucose-6-phosphate	 leading	 to	
further	 activation	 of	 glycogen	 synthase.31	 There	 has	 been	 speculation	 that	 D-tagatose-1-
phosphate	 can	 inhibit	 glycogen	phosphorylase	 in	 the	 same	manner	 that	 fructose-1-phosphate	
does,6	 but	 this	 has	 not	 been	 directly	 shown.	 By	 activating	 glycogen	 synthase	 and	 possibly	
inhibiting	 glycogen	 phosphorylase,	 D-tagatose-1-phosphate	 increases	 glycogen	 synthesis	 and	
inhibits	glycogen	utilization,	explaining,	at	least	in	part,	the	antihyperglycemic	effect	of	the	sugar.	
In	 addition	 to	 the	 effect	 on	 glycogen	 regulation,	 D-tagatose	 inhibits	 sucrase,76	 leading	 to	 the	
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	suppression	of	sucrose	digestion	in	the	small	intestine	and	inhibits	the	activity	of	maltase,	at	least	
in	vitro,	and	could	slow	the	digestion	of	starch.	The	net	effect	of	the	regulation	of	these	enzymes	
is	an	increase	in	glycogen	synthesis	and	storage	and	a	decrease	in	glycogen	utilization.	In	addition,	
D-tagatose	reduces	the	absorption	and	digestion	of	sucrose	and	other	carbohydrates	in	the	small	
intestine.	D-tagatose	has	been	shown	in	both	animal	and	human	studies	to	have	multiple	effects	
including	 increase	 in	satiety	and	weight	control,	a	beneficial	effect	on	abnormal	blood	lipids,	a	
reduction	in	atherosclerotic	plaque	formation,	and	a	reduction	in	blood	glucose	and	HbA1c	levels	
in	patients	with	type	2	diabetes	mellitus.4–6,13,18,37,58–60,77,78	
In	addition	to	its	antihyperglycemic	effects,	D-tagatose	has	been	found	to	have	an	effect	on	blood	
lipid	levels	in	animals	and	in	humans.	In	one	study,	LDL−/−	mice	fed	a	diet	in	which	high	sucrose	
was	replaced	with	an	equivalent	amount	of	D-tagatose	had	reduced	cholesterol,	triglycerides	and	
atherosclerosis	 compared	 to	 mice	 on	 the	 diet	 containing	 sucrose.78	 In	 a	 human	 clinical	 trial,	
patients	 with	 type	 2	 diabetes	 taking	 D-tagatose	 were	 found	 to	 have	 improved	 HDL	 levels,	
increasing	from	30	to	41.7	mg/dL	over	the	course	of	the	14	month	study.5	This	is	interesting	in	
light	of	evidence	suggesting	that	increasing	HDL	levels	decrease	the	risk	of	coronary	events.	The	
mechanism	by	which	D-tagatose	raises	HDL	is	not	clear,	but	it	should	be	noted	that	these	patients	
did	lose	weight	during	the	study	and	this	may	have	contributed	to	the	improvement	in	HDL.	In	
other	 studies,	 type	 II	 diabetics	 taking	 D-tagatose	 showed	 a	 decrease	 in	 HbA1c	 and	 serum	
triglycerides.4,17	
There	is	considerable	interest	in	the	use	of	trans-resveratrol	and	its	derivatives,	including	trans-
polydatin,	 for	 the	 treatment	 of	 many	 human	 diseases.117	 Extracts	 derived	 from	 Polygonum	
cuspidatum	have	long	been	a	part	of	traditional	Chinese	herbal	medicine	being	used	to	treat	pain,	
fever,	coughs,	 inflammation	and	a	variety	of	other	ailments.118	 	Polydatin,	otherwise	known	as	
trans-resveratrol	or	piceid,	is	a	glucoside	derivative	of	resveratrol	and	is	the	major	component	of	
these	extracts.	 In	addition	to	Polygonum,	polydatin	has	been	 found	 in	wines	and	grapes,119–122	
cocoa,123	 peanuts	 and	 peanut	 butter,124	 pistachios,125	 and	 almonds.126	 	 As	 a	 derivative	 of	
resveratrol,	 polydatin	 is	 believed	 to	 have	 many	 of	 the	 same	 beneficial	 effects	 but	 has	 some	
properties	that	may	make	it	more	effective	from	a	pharmacological	standpoint	than	resveratrol.	
Polydatin	is	structurally	the	same	as	resveratrol	except	that	it	has	a	glucoside	group	attached	to	
the	 C-3	 position	 in	 place	 of	 a	 hydroxyl	 group.	 This	 substitution	makes	 polydatin	more	 water	
soluble	and	possibly	more	resistant	to	enzymatic	breakdown	than	resveratrol.	It	is	also	actively	
taken	up	by	cells	via	glucose	carriers	in	the	cell	membrane	instead	of	being	passively	transported	
like	 resveratrol.127,128	 	 These	 properties	 would	 suggest	 that	 polydatin	 would	 have	 greater	
bioavailability	than	resveratrol.	
Claims	for	the	many	health	benefits	of	polydatin	abound.	A	multitude	of	studies	have	presented	
evidence	 that	 polydatin	 has	 many	 positive	 health	 effects	 including	 anti-inflammatory,129,130	
hepatoprotective,131–134	 anti-cancer,135–138	 neuroprotective,129,139–141	 and	 cardioprotective	
activities.113,114,118,142,143	 	 Pharmacological	 studies	 and	 clinical	 practice	 have	 demonstrated	 that	
polydatin	 also	 has	 protective	 effects	 against	 shock,144,145	 ischemia/reperfusion	 injury,146,147	
congestive	 heart	 failure,148	 endometriosis,149	 and	 prevention	 of	 fatty	 liver	 disease	 and	 insulin	
resistance,150	and	that	it	can	regulate	glucose	and	lipid	metabolism.151	Polydatin	has	found	its	way	
into	clinical	trials	for	the	treatment	of	hemorrhagic	shock	and	irritable	bowel	syndrome.130,152	
How	polydatin	is	able	to	have	all	of	these	activities	is	still	being	studied	but	multiple	mechanisms	
of	 action	 are	 evident,	 including;	 an	 antioxidant,	 free	 radical-elimination	 mechanism,153,154	
activation	of	protein	kinase	C,155,156	suppression	of	NF-kappaB,156	 inhibition	of	the	activation	of	
renin-angiotensin-aldosterone	system	and	decreasing	the	excretion	of	endothelin	1,	TNF-α,	and	
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	angiotensin	 II,142	 reduction	of	 lipid	peroxidation	 levels,127,157	up	regulation	of	 the	expression	of	
hippocampal	 brain-derived	 neurotrophic	 factor,141	 enhanced	 insulin	 sensitivity	 in	 the	 liver	 as	
shown	by	 improved	 insulin	 receptor	 substrate	2	expression	 levels	 and	Akt	phosphorylation,151	
decreasing	 the	 content	 of	 malonydialdehyde	 (MDA),140	 promoting	 the	 activities	 of	 total	
superoxide	 dismutase	 (T-SOD),	 catalase	 and	 glutathione	 peroxidase	 (GSH-Px)	 in	 plasma,	 and	
increasing	 the	 content	 of	 glutathione	 (GSH)	 in	 myocardial	 tissue,154	 restoring	 decreased	
deacetylase	sirtuin1	activity	and	protein	expression	in	liver	tissue	following	severe	shock158	and	
activation	 of	 sirtuin,159,160	 suppressing	 oxidative	 stress-induced	 lysosomal	 instability	 and	
mitochondrial	injury	by	increasing	the	protein	expression	of	SOD2.158		
The	use	of	polydatin	as	a	potential	therapy	for	dyslipidemia	has	been	suggested	primarily	by	three	
studies	using	animal	models.112–114		Arichi	et	al.112	discovered	that	orally	administered	polydatin	
(100	mg/kg	body	weight)	significantly	lowered	low-density	lipoprotein	(LDL)-derived	cholesterol	
by	 approximately	 18%	 and	 serum	 triglycerides	 by	 40%	 in	 rats	 consuming	 standard	 chow	
containing	a	mixture	of	corn	oil,	10%	cholesterol,	and	1%	cholic	acid.	Although	 lower	doses	of	
trans-polydatin	(50	mg/kg	body	weight)	were	ineffective	at	preventing	hyperlipidemia,	they	were	
able	 to	 prevent	 the	 accumulation	 of	 cholesterol	 and	 triglycerides	 in	 the	 liver,	 suggesting	 that	
lower	doses	may	also	be	effective	but	 to	a	much	 lesser	extent.	 In	a	 study	using	Syrian	golden	
hamsters,	polydatin	was	found	to	decrease	total	cholesterol	levels	and	total	triglyceride	levels	by	
47%	 and	 63%,	 respectively,	 compared	 to	 standard	 diet.113	 In	 another	 study	 using	 rabbits,	 the	
administration	of	polydatin	decreased	the	serum	levels	of	total	cholesterol,	triglycerides,	and	LDL.	
The	ratio	of	total	cholesterol	to	HDL	was	also	reduced.114	
Insulin,	 through	 activation	 of	 the	 Akt	 pathway	 and	 other	 metabolic	 pathways,	 is	 a	 major	
component	of	metabolic	regulation.161	Hao	et	al.	recently	found	that	polydatin	activated	the	Akt	
signaling	pathway	in	diabetic	rats,	possibly	by	phosphorylation	of	the	insulin	receptor	substrate	
(IRS),	 thus	 reducing	 blood	 glucose	 levels.151	 Polydatin	 may	 also	 decrease	 the	 expression	 of	
intercellular	adhesion	molecule	1	(ICAM-1)	and	may	reduce	white	blood	cell	adhesion,	as	well	as	
the	effects	of	other	cell	adhesion	molecules	and	inflammatory	cytokines,	thought	to	be	active	in	
early	atherosclerotic	development.162	Additionally,	polydatin	is	also	thought	to	provide	protection	
from	oxidative	peroxidation	which	can	result	in	cell	damage127,163	and	inhibition	of	oxidation	of	
LDLs	which	may	also	play	a	role	in	atherosclerosis.118	
In	the	present	study,	we	have	examined	the	effect	of	BSN272,	a	combination	of	D-tagatose	and	
trans-polydatin,	on	blood	lipids	and	atherosclerosis	in	ApoE-/-	mice.	The	apoE	lipoprotein	resides	
on	 very	 low,	 intermediate,	 and	 high	 density	 lipoproteins	 (VLDL,	 IDL,	 HDL,	 respectively)	 and	
mediates	the	removal	of	atherogenic	particles	from	plasma	by	acting	as	a	ligand	for	low	density	
lipoprotein	(LDL)	receptors.	Mice	are	normally	resistant	to	the	development	of	atherosclerosis.	
However,	inactivation	of	the	apoE	gene	in	mice	results	in	severe	hypercholesterolemia	and	the	
rapid	development	of	atherosclerosis,	particularly	when	fed	a	Western	type	diet	consisting	of	high	
fat,	high	cholesterol	and	high	sugar.97–99,164	The	progression	and	histopathology	of	lesions	in	this	
animal	model	show	features	similar	to	those	observed	in	humans	and	other	species,	making	these	
mice	 good	 models	 for	 evaluating	 diet	 composition	 and	 potential	 drugs	 for	 their	 effect	 on	
atherosclerotic	 development.98	We	 tested	 the	 hypothesis	 that	 BSN272	 prevents	Western	 diet	
induced	 elevations	 in	 serum	 triglycerides	 and	 cholesterol,	 and	 reduces	 the	 formation	 of	
atherosclerosis	in	ApoE-/-	mice.	
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	4.3	Methods111	
Materials	
D-tagatose	and	trans-polydatin	were	provided	by	Biospherics.net.	
Mice	and	Diets		
Male	 Jax	 ApoE-/-	 mice	 14	 to	 18	 weeks	 of	 age	 that	 were	 12X	 backcrossed	 to	 C57BL/6J,	 were	
obtained	from	an	in-house	breeding	colony	at	the	University	of	Kentucky.	The	mice	were	given	
water	ad	libitum	and	kept	on	a	12-hour	light/dark	cycle.	The	animal-use	protocol	was	approved	
by	the	University	of	Kentucky	Institutional	Animal	Care	and	Use	Committee.	
Mice	were	randomized	to	produce	three	groups	with	the	same	mean	body	weight.	All	mice	were	
started	on	ground	TD.2014	(Harlan	Teklad),	a	14%	protein,	low	fat,	complex	carbohydrate	diet.	
Mice	 in	 the	 group	 receiving	 BSN272	were	 acclimated	 to	 D-tagatose,	 due	 to	 the	 potential	 for	
gastrointestinal	distress	that	may	result	from	the	poor	absorption,	by	adding	increasing	amounts	
of	D-tagatose	to	their	drinking	water	daily	during	a	two-week	run-in	phase	before	beginning	their	
respective	diets	(Table	4.1).	
Table	4.1111	
D-tagatose	Run-In	Schedule	
Day	 D-tagatose	(g)	/	100	ml	water	
Day	1	 2.4	
Day	2	 4.9	
Day	3	 7.3	
Day	4	 9.7	
Day	5	 12.1	
Day	6	 14.5	
Day	7	 17.0	
Day	8	 19.4	
Day	9	 21.8	
Day	10	 24.2	
Day	11	 26.6	
Day	12	 29.0	
Day	13	 31.5	
Day	14	 34.2	
Addition	of	D-tagatose	to	drinking	water	during	the	two-week	run-in	phase.	Increasing	amounts	of	D-tagatose	
were	added	to	drinking	water	to	acclimate	mice	to	D-tagatose.	Mice	in	Groups	3	and	5	had	D-tagatose	added	
to	their	drinking	water.111	
After	the	14-day	lead-in	phase,	the	mice	in	each	group	were	fed	as	follows:	Group	1	-	standard	
diet	(TD.2014);	Group	2	-	Western	diet	(high	fat,	cholesterol,	and	sucrose	containing	21%	milk	fat,	
0.15%	cholesterol,	 34%	 sucrose	 (TD.88137));	Group	3	 -	Western	diet	 formulated	with	BSN272	
(341g	 D-tagatose/kg	 feed	 replacing	 341g	 of	 sucrose,	 plus	 1g	 polydatin/kg	 feed,	 (TD.110527	
custom	 formulation	 by	 Harlan	 Teklad)).	 Mice	 were	 maintained	 on	 these	 diets	 for	 16	 weeks.	
Compositions	of	the	three	diets	are	shown	in	Table	4.2.	
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Table	4.2111	
Comparisons	of	the	Three	Diets	Fed	to	ApoE-/-	Mice	
Diet	 Sucrose	
%	by	
weight	
Cholesterol	 D-tagatose
%	by	weight	
Polydatin	 Fat	%	by	
weight	
Kcal/g	
Standard	
TD.2014	
0	 0	 0	 0	 4%	 2.9	
Western	
TD.88137	
34%	 1.5	g/kg	 0	 0	 21%	 4.5	
BSN272	
TD.110527	
0	 1.5	g/kg	 34%	 1	g/kg	 21%	 3.7	
The	ratios	of	kilocalories	provided	by	fat,	protein,	and	carbohydrates	(fat/protein/carbohydrates)	
are	 as	 follows:	 TD.2014	 (standard	 diet)	 -	 13/20/67;	 TD.88137	 (Western	 diet)	 -	 42/15/43;	
TD.110527	 (BSN272	 diet)	 -	 52/19/29.	Most	 of	 the	 carbohydrate	 content	 of	 the	Western	 diet	
comes	 from	 sucrose.	 In	 contrast,	 while	 having	 the	 highest	 carbohydrate	 caloric	 content,	 the	
carbohydrate	in	the	standard	chow	is	from	complex	carbohydrates	found	in	grain	components,	
there	is	no	sucrose	added.	In	the	chow	containing	BSN272,	the	sucrose	in	the	Western	diet	has	
been	replaced	by	D-tagatose.	The	energy	content	of	the	tagatose	containing	chows	was	calculated	
using	the	1.5	Kcal	per	gram	accepted	in	the	US	by	the	FDA	for	labeling	purposes.	Other	countries	
use	different	values.	From	a	physics	viewpoint,	all	sugars	have	the	same	energy	content	when	
burned	in	a	bomb	calorimeter.	However,	the	energy	that	an	organism	can	extract	from	a	sugar	
depends	upon	its	ability	to	metabolize	the	sugar,	and	this	varies	in	humans	as	well	as	animals	with	
gut	microflora	and	other	factors.	The	initial	two-week	run	in	phase	provides	an	adaptation	period	
that	increases	the	useful	energy	content	of	D-tagatose	from	near	zero	to	something	higher.	
At	the	study	end	point,	mice	were	euthanized	using	CO2	followed	by	cervical	dislocation	and	then	
the	 left	 ventricle	 was	 punctured	 to	 obtain	 blood.	 After	 the	 right	 atrium	 was	 cut,	 mice	 were	
exsanguinated	 by	 perfusion	 through	 the	 left	 ventricle	 followed	 by	 removal	 of	 tissues	 (liver,	
kidneys,	spleen,	epididymal	fat	and	retroperitoneal	fat	(both	sides),	subcutaneous	fat	(one	side	
only)	and	aortic	tissue	from	the	heart	to	the	iliac	bifurcation).	The	livers,	kidneys,	spleens,	and	fat	
tissues	 were	 weighed.	 The	 hearts	 with	 aortas	 attached	 were	 fixed	 overnight	 in	 4%	
paraformaldehyde	made	with	phosphate	buffered	solution,	and	then	transferred	to	phosphate	
buffered	solution	for	storage.	
Blood	Analysis	
Total	cholesterol	and	total	triglyceride	levels	were	determined	using	enzymatic	assay	kits	(Wako	
Pure	Chemical,	Richmond,	VA).	
Atherosclerosis	Measurements	
Aortas	were	prepared	for	atherosclerosis	measurements	via	en	face	presentation,	whereby	the	
entire	length	of	the	aorta	was	removed	from	the	animal,	the	entire	intimal	surface	and	greater	
curvature	 of	 the	 aortic	 arch	 exposed,	 and	 the	 resulting	 tissue	 pinned	 to	 a	 dark	 surface.	 The	
atherosclerotic	plaques	were	then	traced	and	quantified	using	Nikon	NIS	Elements	software.78	
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	Calculations	and	Statistics	
Data	are	presented	as	the	mean	±	s.e.m.	1-way	ANOVA	was	utilized	for	analyses.	Values	of	p	<	
0.05	were	considered	 to	be	statistically	 significant.	Standard	diet,	n	=	9;	Western	diet,	n	=	13;	
BSN272	diet,	n	=	15.	
4.4	Results111	
Food	Consumption	
Based	upon	the	weight	of	food	eaten	by	each	group	of	mice	and	the	number	of	Kcal/g	available	
for	each	diet,	average	daily	energy	consumption	per	mouse	was	calculated.	Food	consumed	was	
recorded	beginning	the	first	day	each	group	was	placed	on	their	respective	diets	(day	15)	and	not	
during	the	14-day	D-tagatose	lead-in	phase.	
Mice	 on	 the	 Western	 diet	 consumed	 the	 highest	 number	 of	 calories	 per	 day	 (12.75	 ±	 0.63	
Kcal/mouse/day)	followed	by	the	standard	diet	group	(11.5	±	0.87	Kcal/mouse/day)	and	then	the	
BSN272	 diet	mice	 (10.08	 ±	 0.43	 Kcal/mouse/day)	 (Table	 4.3).	 The	 difference	 in	 caloric	 intake	
between	BSN272	and	standard	diet	groups	was	significant	(p	<	0.01),	as	it	was	between	Western	
and	BSN272	diet	groups	(p	<	0.01)	and	the	Western	and	standard	diet	groups	(p	<	0.05).	Mice	on	
the	standard	diet	ate	more	food	by	weight	than	mice	on	Western	or	BSN272	diets.	There	was	no	
significant	difference	in	the	weight	of	food	eaten	between	the	Western	and	BSN272	diet	groups	
(p	=	0.17).	The	difficulties	in	measuring	solid	food	consumption	as	well	as	the	variable	amount	of	
energy	 that	 can	 be	 extracted	 from	 D-tagatose	 suggest	 that	 these	 energy	 results	 must	 be	
interpreted	cautiously.	
Table	4.3111	
Comparison	of	Food	Consumption	and	Average	Caloric	Intake	of	Mice	According	to	Diet	
Diet	 Grams	of	food/mouse/day	 Kcal/gram	 Kcal/mouse/day	
Standard	 3.97	±	0.30	 2.9	 11.51	±	0.87	
Western	 2.83	±	0.14	 4.5	 12.75	±	0.63	
BSN272	 2.72	±	0.12	 3.7	 10.08	±	0.43	
Food	consumption	was	determined	by	weighing	food	given	to	the	animals	and	food	remaining	after	every	3	
to	4	days.	Results	are	shown	as	mean	±	s.e.m.	Standard	diet,	n	=	9;	Western	diet,	n	=	13;	BSN272	diet,	n	=	
15.111	
Body,	Tissue,	and	Organ	Weights		
Body	Weights	
Mice	in	all	three	groups	were	on	the	standard	diet	at	the	beginning	of	the	study	and	during	the	
two-week	D-tagatose	lead-in	period.	At	the	end	of	the	lead-in	period	the	body	weights	of	the	mice	
in	the	three	groups	were	not	significantly	different	(Figure	4.2).	On	day	15	the	mice	were	placed	
on	their	respective	diets	for	16	weeks.	Mice	in	the	BSN272	group	lost	weight	during	the	first	week	
they	were	put	on	the	BSN272	diet	and	then	gained	weight	at	essentially	the	same	rate	as	mice	on	
the	standard	diet.	Mice	on	the	Western	diet	gained	weight	at	a	faster	rate	during	the	16	weeks	
and	weighed	considerably	more	(40.78	±	1.72	g)	at	the	end	of	the	study	than	mice	on	standard	
(31.51	±	1.11	g,	p	<	0.01)	or	BSN272	diets	 (30.53	±	0.56	g,	p	<	0.01).	There	was	no	significant	
difference	between	mice	in	the	standard	diet	and	BSN272	groups	(p	=	0.39).	
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	Figure	4.2111	
Body	Weights	
BSN272	prevented	weight	gain	in	mice	associated	with	the	Western	diet.	All	mice	were	kept	on	the	standard	
Diet	during	the	two-week	D-tagatose	lead-in	phase	(days	0	to	14)	during	which	mice	in	Group	3	were	given	
increasing	amounts	of	D-tagatose	in	their	water	until	the	concentration	of	D-tagatose	resulted	in	equivalent	
consumption	that	would	be	obtained	from	the	TD.110527	chow	(BSN272).	All	mice	were	then	placed	on	their	
respective	diets	 for	the	remainder	of	 the	study.	Results	are	shown	as	mean	±	s.e.m.	Standard	diet,	n	=	9;	
Western	diet,	n	=	13;	BSN272	diet,	n	=	15.	*	p	<	0.01	compared	to	both	Standard	and	BSN272	diets.111	
Adipose	Tissue	and	Organ	Weights	
Mice	 on	 the	Western	 diet	 had	 increased	 total	 adipose	 tissue	 (epididymal	 +	 retroperitoneal	 +	
subcutaneous	adipose	tissue)	compared	to	mice	on	both	the	standard	and	BSN272	diets	(Figure	
4.3).	Consistent	with	the	slight	decrease	 in	body	weights	seen	 in	the	mice	on	the	BSN272	diet	
compared	to	the	standard	diet,	mice	on	the	BSN272	diet	were	leaner	with	smaller	amounts	of	
epididymal,	retroperitoneal,	and	subcutaneous	fat	compared	to	mice	on	the	standard	diet	(p	<	
0.01).	
There	was	a	significant	increase	in	liver	weights	in	mice	on	the	Western	(2.18	±	0.19	g)	and	BSN272	
diets	(1.74	±	0.061	g)	compared	to	the	Standard	group	(1.29	±	0.054	g,	p	<	0.01)	(Figure	4.4A).	The	
BSN272	diet	prevented	some	of	the	gain	in	liver	size	seen	in	the	mice	on	the	Western	diet	(p	<	
0.05).	 Spleens	 of	 the	mice	 on	 the	 BSN272	 diet	were	 enlarged	 (0.135	 ±	 0.036	 g)	 compared	 to	
spleens	of	mice	on	both	the	standard	(0.100	±	0.017	g)	and	Western	diets	(0.126	±	0.046)	(Figure	
4.4B).	There	was	no	significant	difference	in	the	sizes	of	the	spleen	from	the	mice	on	the	standard	
and	Western	diets,	or	from	the	BSN272	and	Western	diet	mice.	There	was	a	significant	difference	
in	 the	spleens	 from	the	mice	on	 the	BSN272	and	standard	diets	 (p	=	0.013).	These	 results	are	
consistent	with	the	results	of	Kruger	et	al.	who	found	in	a	toxicology	study	of	D-tagatose	that	the	
spleens	of	both	male	and	 female	 rats	consuming	D-tagatose	as	20%	(w/w)	of	 their	diets	were	
significantly	 larger	 than	 spleens	 from	 the	 control	 group	 that	was	not	 consuming	D-tagatose.59	
Interestingly,	 in	 an	 unpublished	 toxicology	 study	 spleen	 weights	 of	 rats	 given	 3000	 mg	
polydatin/kg/day	were	less	than	the	control	group	not	getting	polydatin,	although	the	difference	
was	not	statistically	significant	(Biospherics.net,	unpublished	study).	
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	Figure	4.3111	
Adipose	Tissue	Measurements	
On	day	127	fat	pads	were	removed	and	weighed.	Epididymal	fat	and	retroperitoneal	fat	pads	were	removed	
from	both	sides	of	each	animal	and	weighed,	while	subcutaneous	fat	was	taken	from	one	side	only.	Mice	fed	
BSN272	were	leaner	compared	to	mice	on	the	Western	diet.	(*,	+,	p	<	0.01,	comparisons	between	all	groups).	
Results	are	shown	as	mean	±	s.e.m.	Standard	diet,	n	=	9;	Western	diet,	n	=	13;	BSN272	diet,	n	=	15.111	
Figure	4.4111	
Organ	Weights	
(A)	Livers.	✻,	p	=	0.001,	Westen	vs	Standard;	+,	p	<	0.001,	BSN	vs	Standard;	*,	p	=	0.027,	BSN	vs	Western.	(B)	
Spleens.	*,	p	=	0.013,	BSN	vs	Standard.	(C)	Hearts.	+,	p	<	0.001,	BSN	vs	Western;	*,	p	=	0.047,	BSN	vs	Standard.		
Results	are	shown	as	mean	±	s.e.m.	Standard	diet,	n	=	9;	Western	diet,	n	=	13;	BSN272	diet,	n	=	15.111	
Hearts	from	mice	on	the	BSN272	diet	weighed	slightly	less	(0.144	±	0.0137	g),	than	those	from	
standard	(0.164	±	0.0297	g)	or	Western	diet	mice	(0.166	±	0.015)	(p	<	0.01	for	Western	vs.	BSN272	
and	p	<	0.05	for	standard	vs.	BSN272)	(Figure	4.3C).	
Serum	Lipids	
BSN272	blunts	increase	in	total	cholesterol	produced	by	Western	diet	
During	the	D-tagatose	14-day	lead-in	period	all	of	the	mice	were	on	the	standard	diet	(day	1	to	
14).	At	the	end	of	the	14	days	serum	total	cholesterol	levels	were	similar	in	all	groups	(Figure	4.5).	
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	On	day	15	the	mice	in	the	Western	and	BSN272	diet	groups	were	started	on	their	respective	diets.	
By	day	36,	cholesterol	had	increased	dramatically	in	both	of	these	groups	but	with	a	significantly	
greater	 increase	 seen	 in	 the	 Western	 diet	 mice.	 Mice	 on	 the	 BSN272	 diet	 exhibited	 lower	
cholesterol	levels	than	mice	on	the	Western	diet	at	all	time	points	through	the	course	of	the	study.	
The	 effectiveness	 of	 BSN272	 for	 lowering	 cholesterol	 increased	 over	 the	 time	 course	 of	 the	
experiment,	with	elevated	cholesterol	peaking	at	day	57	and	then	steadily	decreasing	over	the	
remaining	weeks	of	treatment.	At	the	end	of	the	study,	mice	on	the	BSN272	diet	had	significantly	
lower	cholesterol	 than	mice	on	the	Western	diet	 (591	±	35.6	mg/dL	vs.	904	±	28.1	mg/dL,	p	<	
0.01).	
Figure	4.5111	
Total	Serum	Cholesterol	
BSN272	blunts	the	rise	in	serum	total	cholesterol	of	mice	fed	a	Western	diet.	All	mice	were	on	the	standard	
diet	during	the	two-week	D-tagatose	lead-in	phase	and	then	all	groups	were	placed	on	their	respective	diets.		
Results	are	shown	as	mean	±	s.e.m.	Standard	diet,	n	=	9;	Western	diet,	n	=	13;	BSN272	diet,	n	=	15.	*,	p	<	0.02	
BSN272	vs	Western	diet;	✻,	p	<	0.001	compared	to	both	Standard	and	BSN272	diets;	+,	p	<	0.02	BSN272	vs	
Standard	diet.111 
BSN272	lowers	serum	triglycerides	compared	to	mice	on	either	the	standard	or	Western	diets	
At	the	end	of	the	14-day	lead-in	period,	triglycerides	in	the	mice	in	each	group	were	essentially	
the	same	(Figure	4.6).	Mice	placed	on	the	Western	diet	showed	elevated	levels	of	triglycerides	
compared	to	both	standard	and	BSN272	groups.	Interestingly,	mice	treated	with	BSN272	showed	
significantly	 lower	triglycerides	(108	±	5.76	mg/dL)	than	mice	on	the	standard	diet	(157	±	9.51	
mg/dL,	p	<	0.01)	or	the	Western	diet	(175	±	14.86	mg/dL,	p	<	0.01)	at	the	end	of	the	study	period.	
The	drop	in	triglycerides	in	the	BSN272	diet	group	occurred	after	the	two	weeks.	
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	Figure	4.6111	
Serum	Triglycerides	
All	mice	were	on	the	standard	diet	during	the	two-week	D-tagatose	lead-in	phase	and	then	placed	on	their	
respective	diets.	Mice	fed	BSN272	had	lower	serum	triglyceride	levels	than	mice	on	both	the	standard	and	
Western	diets.	Results	are	shown	as	mean	±	s.e.m.	Standard	diet,	n	=	9;	Western	diet,	n	=	13;	BSN272	diet,	n	
=	15.	*,	p	<	0.02	BSN272	vs	Western	diet;	✻,	p	<	0.02	Western	vs.	Standard	diet;	+,	p	<	0.02	BSN272	vs	Standard	
diet;	Δ,	p	<	0.03	Western	vs.	Standard	diet.111	
Atherosclerosis	
Mice	on	the	BSN272	diet	develop	less	atherosclerosis	than	mice	on	the	Western	diet	
The	elevations	in	serum	cholesterol	were	associated	with	a	dramatic	increase	in	atherosclerotic	
lesion	 surface	 area	 in	mice	 on	 the	Western	 diet	 (Figure	 4.7).	 The	 addition	 of	 BSN272	 to	 the	
Western	diet	significantly	prevented	atherosclerotic	plaque	formation	 in	the	area	of	the	aortic	
arch.	The	mean	area	covered	by	plaque	in	mice	on	the	Western	diet	was	25.36	±	2.51%	compared	
to	5.30	±	1.31%	for	mice	treated	with	BSN272.	Mice	on	the	standard	diet	developed	very	little	
plaque	(0.497	±	0.195%),	p	<	0.01	for	all	comparisons.	
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	Figure	4.7111	
Plaque	Formation	in	the	Aortic	Arch	
 
Comparison	of	the	area	of	the	aortic	arch	that	has	plaque	formation	by	percentage	of	measured	area	between	
the	 groups.	 Aortas	 were	 prepared	 for	 atherosclerosis	 measurements	 via	 en	 face	 presentation.	 The	
atherosclerotic	plaques	were	then	traced	and	quantified	using	Nikon	NIS	Elements	software.	The	addition	of	
BSN272	to	the	Western	diet	significantly	prevented	accumulation	of	plaque	in	the	area	of	the	aortic	arch.	
Results	are	shown	as	mean	±	s.e.m.	Standard	diet,	n	=	9;	Western	diet,	n	=	13;	BSN272	diet,	n	=	15.	*,	p	<	
0.001	between	all	groups.111	
4.5	Discussion111	
This	study	examined	the	effect	of	replacing	sucrose	in	a	high	fat,	high	cholesterol,	high	sugar	diet	
(Western	diet)	with	a	combination	of	D-tagatose	and	trans-polydatin.	The	high	sucrose	Western	
diet	 promoted	obesity,	 increased	 total	 serum	 cholesterol	 and	 triglyceride	 concentrations,	 and	
markedly	 stimulated	 the	development	of	atherosclerosis	 in	ApoE-/-	mice	compared	 to	mice	on	
standard	chow	(low	fat,	 low	cholesterol,	 low	sugar).	 In	contrast,	a	diet	that	replaced	gram-for-
gram	 the	 sucrose	 in	 the	 Western	 diet	 with	 D-tagatose	 along	 with	 polydatin	 (BSN272	 diet)	
prevented	the	weight	gain	seen	with	animals	on	the	Western	diet.	
The	mice	on	the	BSN272	diet	did	not	exhibit	a	gain	in	body	weight	witnessed	in	the	Western	diet	
group	and	weighed	 slightly,	but	not	 significantly,	 less	 than	 the	 standard	diet	mice.	A	previous	
study	also	showed	that	replacing	sucrose	with	D-tagatose	 in	a	Western	diet	fed	to	LDLr-/-	mice	
prevented	the	development	of	obesity.78	We	obtained	the	same	result	with	ApoE-/-	mice.	Mice	on	
the	Western	diet	exhibited	a	higher	energy	uptake	per	day	compared	to	standard	diet	and	BSN272	
mice	and	this	likely	contributed	to	the	development	of	obesity	in	mice	on	the	Western	diet.	The	
average	caloric	uptake	of	mice	on	the	BSN272	diet	was	less	than	that	of	standard	diet	mice	which	
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	would	 account	 for	 the	 overall	 slightly	 less	 body	weights	 of	mice	 in	 this	 group.	 But	 again,	 the	
difference	between	the	BSN272	and	standard	diet	mice	was	not	significant.	
There	was	a	significant	(p	<	0.01)	drop	in	weight	in	the	BSN272	group	between	day	15,	when	the	
mice	were	started	on	the	BSN272	chow,	and	day	21	when	they	were	next	weighed.	The	mice	then	
gained	weight	at	a	rate	comparable	to	the	standard	diet	mice	and	at	the	end	of	the	study	there	
was	no	significant	difference	in	the	weight	of	the	mice	in	these	two	groups.	Food	consumption	by	
mice	in	the	BSN272	group	was	decreased	compared	to	the	other	two	groups	during	the	first	week	
the	mice	were	placed	on	 their	 respective	diets.	D-tagatose	 is	 known	 to	 cause	 gastrointestinal	
upset	when	 taken	 in	 large	 enough	doses	without	 a	 gradual	 increase	 in	 intake,	which	was	 the	
reason	for	the	14-day	lead-in	period.	While	there	were	no	outward	symptoms	of	gastrointestinal	
distress	in	the	mice	in	the	BSN272	group,	they	did	eat	less	during	the	first	week.	After	the	first	
week,	their	food	consumption	increased	and	was	comparable	to	the	other	two	groups.	
Interestingly,	while	 there	was	no	 significant	difference	 in	 the	body	weights	of	 the	mice	 in	 the	
standard	and	BSN272	diet	groups,	the	amount	of	epididymal,	retroperitoneal,	and	subcutaneous	
fat	in	the	BSN272	group	was	significantly	lower	than	in	the	standard	diet	group.	Similar	results	
were	seen	in	another	study	using	LDLr-/-	mice.78	Polydatin	may	act	as	a	caloric	restriction	mimetic	
like	resveratrol.	
Mice	on	 the	Western	diet	 had	 livers	 that	weighed	 about	 1.6	 times	more	 than	 the	 livers	 from	
standard	diet	mice.	The	replacement	of	sucrose	with	BSN272	in	the	Western	diet	prevented	some	
of	the	increase	in	liver	weight	compared	to	standard	diet.	Previous	studies	found	there	was	an	
increase	in	the	size	of	livers	in	rats	fed	D-tagatose.	This	enlargement	was	found	to	be	characterized	
by	increased	glycogen	deposition,	with	an	absence	of	histopathological	changes	and	no	evidence	
of	 increased	deposition	of	 lipids.165,166	After	D-tagatose	 is	 absorbed	 into	 the	bloodstream,	 it	 is	
metabolized	 in	 the	 liver	 by	 the	 same	 pathway	 used	 in	 fructose	metabolism	 and	 can	 activate	
glycogen	synthase.31,32	Similar	enlargement	of	the	liver	is	seen	in	rats	fed	fructose.	Furthermore,	
this	 liver	enlargement	was	reversible	upon	removal	of	D-tagatose	from	the	rat’s	diets	and	was	
concluded	that	the	observed	liver	enlargement	had	no	relevance	for	the	assessment	of	human	
safety	of	D-tagatose.	
While	 BSN272	 fed	 mice	 exhibited	 slightly	 increased	 serum	 cholesterol	 and	 atherosclerosis	
compared	to	standard	diet	mice,	the	extent	of	these	changes	was	far	less	than	those	observed	in	
the	 mice	 on	 the	 Western	 diet.	 The	 livers	 of	 ApoE-/-	 mice	 are	 unable	 to	 remove	 circulating	
cholesterol	efficiently	and	as	a	result	these	mice	have	elevated	serum	cholesterol.	Atherosclerotic	
lesion	development	is	very	dramatic	in	ApoE-/-	mice	fed	a	Western-type	diet	and	the	beginning	
stages	of	the	disease	can	be	found	at	6	weeks.97	With	the	ApoE-/-	and	LDLr-/-	mouse	models,	dietary	
cholesterol,	 rather	 than	 the	 level	 of	 fat,	 exerts	 a	 major	 influence	 on	 the	 development	 of	
atherosclerosis.107–109	In	addition	to	cholesterol,	the	fatty	acid	profile	and	even	the	carbohydrate	
form	(i.e.	fructose,	sucrose)	can	be	manipulated	to	modify	the	atherosclerosis	phenotype.43,108,110	
Replacement	of	sucrose	with	D-tagatose	in	a	Western	diet	was	shown	to	decrease	serum	total	
cholesterol	 in	LDLr-/-	mice	compared	to	mice	on	the	Western	diet	with	sucrose.78	We	obtained	
similar	results	in	this	study	with	the	ApoE-/-	mice.	Total	cholesterol	increased	in	the	BSN272	mice	
upon	placing	them	on	their	diet,	but	never	reached	the	levels	of	the	mice	on	the	Western	diet.	
After	day	56,	cholesterol	began	to	steadily	decline	in	the	BSN272	group.	
Mice	on	the	BSN272	diet	had	significantly	lower	triglycerides	at	the	end	of	the	study,	while	there	
was	no	significant	difference	in	serum	triglyceride	levels	between	the	mice	on	the	Western	and	
standard	diets.	Unlike	with	cholesterol,	which	showed	an	increase	in	the	BSN272	group	upon	start	
of	their	diet,	triglycerides	dropped	between	the	time	when	the	mice	were	placed	on	the	BSN272	
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	diet	(day	15)	and	the	next	time	that	triglycerides	were	assayed	on	day	36	and	remained	reduced	
during	the	course	of	the	study.	At	the	end	of	the	study,	triglycerides	in	the	BSN272	mice	were	
significantly	lower	than	in	the	standard	diet	group	(p	<	0.01).	
Elevations	 in	 serum	 cholesterol	 concentrations	 were	 associated	 with	 a	 striking	 increase	 in	
atherosclerotic	 lesion	 surface	 area	 in	 mice	 fed	 the	 Western	 diet	 compared	 to	 BSN272	 and	
standard	 diet	 mice.	 The	 addition	 of	 BSN272	 to	 the	 Western	 diet	 dramatically	 reduced	 the	
formation	 of	 atherosclerotic	 plaques.	 Although	 BSN272	 fed	 mice	 exhibited	 increased	
atherosclerosis	compared	to	standard	diet	mice,	the	extent	of	these	changes	were	far	less	than	
those	observed	in	Western	diet	fed	mice.	
The	results	obtained	in	this	study	are	consistent	with	a	previous	8-week	study	in	which	ApoE-/-	
mice	were	 placed	 on	 the	 same	 BSN272	 diet	 used	 here.46	 That	 study	 also	 showed	 lower	 total	
cholesterol,	triglycerides	and	occurrence	of	atherosclerotic	plaque	formation	seen	in	the	present	
study.	Results	between	the	studies	were	very	consistent.	For	instance,	plaque	area	in	the	eight-
week	study	for	Western	diet	group	was	4%	versus	1%	for	the	BSN272	group,	and	in	the	16-week	
study	25%	for	the	Western	diet	group	versus	5%	in	the	BSN272	treated	mice,	a	4-5	fold	difference	
in	both	studies.	Additionally,	the	difference	in	cholesterol	between	the	Western	diet	groups	and	
BSN272	groups	was	approximately	300	mg/dL	(8-week	study)	and	313	mg/dL	(16-week	study),	
demonstrating	 increasing	 efficacy	 with	 a	 longer	 study	 period.	 The	 16-week	 BSN272	 group	
triglycerides	levels	(108	±	5.76	mg/dL)	were	significantly	less	than	mice	on	the	standard	diet	(157±	
9.51	mg/dL,	p	<	0.01)	or	the	Western	diet	(175	±	14.86	mg/dL,	p	<	0.01).	These	triglyceride	results	
mirror	 the	 earlier	 eight-week	 study46	which,	 although	 not	 statistically	 significant,	 did	 result	 in	
reduced	triglycerides	in	the	BSN272	group	(110.8	±	62.5	mg/dL)	compared	to	the	Western	diet	
group	(141.7	±	43.1	mg/dL),	mitigating	concerns	regarding	any	potential	rebound	effect	in	terms	
of	loss	of	effectiveness	of	BSN272	over	time.	This	study	extends	the	length	of	time	of	treatment	
from	8	weeks	 to	16	weeks	and	demonstrates	 the	benefits	of	D-tagatose	and	polydatin	extend	
beyond	the	8	weeks	of	the	original	study.	
In	 conclusion,	 replacing	 the	 sucrose	 with	 D-tagatose	 and	 trans-polydatin	 in	 a	 Western	 diet	
prevented	obesity,	elevations	in	serum	cholesterol,	and	formation	of	atherosclerosis	compared	
to	mice	on	the	Western	diet	and	resulted	in	triglyceride	levels	below	that	seen	in	mice	on	both	
the	Western	and	standard	diets.	The	combination	of	D-tagatose	and	polydatin	could	be	useful	in	
the	management	of	obesity	and	hyperlipidemia.	
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Chapter	5	-	Conclusions	and	Future	Work	
5.1	Preface	
The	 16-week	 BSN272	 study	 in	 ApoE-/-	 mice	 and	 the	 toxicology	 study	 of	 trans-polydatin	
represented	 the	 last	of	 the	“First-in-Human	 (FIH)-enabling”	nonclinical	 studies	 required	by	 the	
FDA.		The	task	then	turned	to	packaging	the	various	studies	and	data	associated	with	D-tagatose,	
trans-polydatin,	 and	 BSN272,	 designing	 a	 phase	 1	 first	 in	 humans	 study,	 and	 submiting	 an	
indication	 with	 which	 to	 develop	 the	 IND	 towards.	 	 In	 this	 chapter	 is	 a	 summary	 of	 the	 IND	
submission,	 a	 presentation	 of	 the	 proposed	 Phase	 1	 PK	 study	 in	 healthy	 volunteers,	 and	 a	
discussion	of	Prader-Willi	syndrome,	the	proposed	indication	for	BSN272	for	future	work.	
I	 spent	 the	 last	 8	 months	 packaging	 the	 IND	 submission.	 	 Even	 in	 a	 small	 company	 the	
recommended	size	for	an	“IND	team”	is	a	minimum	of	3-4	people	in	order	to	properly	package	
the	submission	and	costs	between	$50-100,000	 to	outsource.	 	While	we	collaborated	as	a	 lab	
team	to	write	various	sections	of	the	submission,	I	compiled	the	entire	submission,	placed	studies,	
descriptors,	arguments,	in	the	correct	places,	cross-linked	the	entire	submission,	and	formatted	
it	 into	the	FDA’s	required	structure.	 	Each	module	was	around	200	pages	and	the	entire	folder	
structure	of	documents,	xml	files,	and	pdfs	was	almost	2	GB	in	size.	
A	short	overview	of	the	IND	application	and	the	CTD	structure	is	presented	in	section	5.2.		The	
“Introduction	to	Summary”	section	of	Module	2	is	presented	in	section	5.3	to	give	an	overview	of	
the	depth	of	studies	conducted	with	BSN272	and	its	2	components,	as	well	as	an	introduction	to	
Prader-Willi	Syndrome.		Section	5.4	provides	an	introduction	to	the	proposed	exploratory	phase	
1	PK	microdose	study	of	BSN272	in	healthy	subjects.		The	entire	PK	study	proposal	that	will	was	
included	in	the	IND	submission	is	available	in	Appendix	E,	with	links	disabled.		Conclusions	from	
the	various	studies	and	works	presented	in	this	dissertation	are	presented	in	section	5.5.		Finally,	
a	short	look	at	the	future	work	ahead	can	be	viewed	in	section	5.6.	
5.2	Overview	
Investigational	New	Drug	(IND)	Application	
In	order	to	conduct	clinical	trials	a	new	drug	candidate	must	be	approved	by	the	FDA	through	the	
process	of	 an	 individual	new	drug	application.	 	BSN272	was	an	unusually	 complex	 submission	
because	 it	 contained	 two	 molecules	 with	 plentiful	 studies	 conducted	 each	 as	 single	 agents,	
although	 the	 drug	 was	 treated	 as	 a	 single	 entity	 due	 to	 the	 synergistic	 nature	 in	 which	 the	
molecules	 work	 together.	 	 However,	 this	 required	 the	 submission	 of	 toxicity	 data	 for	 each	
molecule	as	well	as	efficacy	 in	preclinical	studies,	and	for	 the	combination	where	appropriate.		
The	toxicity	profile	needs	to	include	the	target	organs	and	the	types	of	toxicities	to	expect,	the	
levels	of	drug	exposures	that	cause	these	toxicities,	 the	maximum	tolerated	dose,	and	the	no-
observed-adverse-effect-level	 (NOAEL).	 	 In	 addition	 to	 these	 concerns,	 as	 this	 is	 the	 first	 time	
trans-polydatin	will	be	administered	 in	 the	presence	of	D-tagatose	 in	a	 clinical	 study,	 the	FDA	
requested	a	micro-dosing	PK	protocol	for	the	trans-polydatin	component	of	BSN272.	
Common	Technical	Documents	(CTD)	
Common	Technical	Documents	(CTD)	is	the	format	the	FDA	requires	the	IND	to	be	submitted	in,	
in	an	effort	to	harmonize	submissions	across	the	US,	Europe,	and	Japan.		The	CTD	consists	of	5	
modules.		Module	1	contains	administrative	information.		Module	2	contains	the	summaries	of	
Modules	3-5.		Module	3	contains	the	quality	information	for	manufacturing	of	the	drug.		Module	
4	contains	the	non-clinical	studies.		Module	5	contains	the	clinical	studies.		Relevant	information	
from	Module	2	will	be	presented	here	as	a	summary	of	the	IND	submission.		The	CTD	grows	as	
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	studies	are	completed	on	its	way	to	a	New	Drug	Application	(NDA)	and	areas	are	filled	in	more	
thoroughly	over	time.		The	FIH	filing	must	contain	at	least	one	safety/efficacy	study	in	2	separate	
mammalian	 models	 as	 well	 as	 a	 toxicology	 study,	 in	 this	 case	 one	 for	 D-tagatose	 and	 trans-
polydatin	each.		The	drug	substance	must	also	have	a	material	safety	data	sheet	(MSDS)	from	the	
manufacturer	and	proof	of	good	manufacturing	practices	(GLP).		Section	5.3	below	should	be	used	
as	 a	 reference	 to	 understand	 what	 went	 into	 the	 BSN272	 submission	 and	 where	 the	 drug	
development	process	is	headed.		This	is	the	Introduction	to	Summary	section	that	has	been	cut	of	
Module	2	from	the	IND	submission.	
5.3	Module	2	(CTD	Summaries)	-	Introduction	to	Summary	
Biospherics.net	LLC	 is	developing	 the	new	combination	drug	product	BSN272,	composed	of	D-
tagatose,	also	known	as	D-lyxo-hexulose	(C6H12O6,	CAS	RN	17598811),	and	trans-polydatin,	also	
known	as	polydatin	or	piceid	(C20H22O8,	CAS	RN	27208-80-6),	for	the	treatment	of	dyslipidemia,	
diabetes,	satiety,	and	obesity	in	Prader-Willi	Syndrome	(PWS).	Biospherics.net	intends	to	conduct	
an	exploratory	Phase	1	pharmacokinetic	(PK)	microdose	study	to	determine	if	the	presence	of	D-
tagatose	affects	the	PK	profile	of	polydatin	before	filing	a	complete	IND	application	for	BSN272.	
Studies	 have	 shown	 that	 persons	with	 Prader-Willi	 Syndrome	 (PWS)	 are	 at	 risk	 of	 premature	
death.	PWS	 is	 the	most	commonly	known	genetic	cause	of	 life-threatening	obesity	 (estimated	
prevalence	of	1:15,000),	resulting	from	obesity-related	problems	such	as	respiratory	failure	and	
pulmonary	hypertension,	obstructive	sleep	apnea,	hypertension,	cardiovascular	disease,	and	type	
2	 diabetes	mellitus	 (T2DM).	 The	 cause	 of	 death	 in	 adults	 is	 usually	 related	 to	 failures	 of	 the	
circulatory	or	respiratory	systems.	There	is	currently	no	single	drug	available	that	can	successfully	
treat	all	of	the	symptoms	of	this	complex	disorder.	
The	 major	 medical	 concern	 for	 patients	 with	 PWS	 is	 morbid	 obesity.	 Compulsive	 eating	 and	
obsession	with	food	usually	begins	between	the	ages	of	1	and	6.	The	urge	to	eat	is	physiological	
and	 overwhelming;	 it	 is	 difficult	 to	 control	 and	 requires	 constant	 vigilance.	 Weight	 control	
depends	 on	 food	 restriction	 and	 daily	 exercise.	 Currently	 there	 is	 no	 medication	 or	 surgical	
intervention	that	can	eliminate	the	need	for	strict	dieting	and	supervision	around	food.	Studies	
have	repeatedly	shown	that	PWS	patients	are	at	risk	of	premature	death.	Mortality	in	children	is	
most	commonly	associated	with	respiratory	infection	and	high	temperature	resulting	in	sudden	
death.	Common	in	adults	with	PWS	are	obesity-related	problems	such	as	respiratory	failure	and	
pulmonary	 hypertension,	 obstructive	 sleep	 apnea,	 hypertension,	 and	 type	 2	 diabetes	mellitus	
(T2DM).167–170	A	high	 incidence	of	alterations	 in	glucose	metabolism	 including	 impaired	 fasting	
glucose,	 impaired	 glucose	 tolerance,	 and	 T2DM,	 has	 been	 observed	 in	 patients	 with	 PWS,	
particularly	after	adolescence.171	Mean	age	at	onset	of	diabetes	is	about	20.	A	prevalence	rate	of	
20-25%	for	T2DM	is	found	in	patients	with	long	standing	PWS.171,172	
Obesity	 and	diabetes	 are	well-established	 risk	 factors	 for	premature	 cardiovascular	disease.	A	
limited	 number	 of	 studies	 have	 looked	 at	 cardiovascular	 fitness	 and	 disease	markers	 in	 PWS	
patients.	Cardiovascular	risk	factors	are	evident	in	a	large	percentage	of	children	with	PWS.	de	
Lind	van	Wijngaarden	et	al.	(2010)	looked	at	the	cardiovascular	and	metabolic	risk	profile	in	85	
children	 with	 PWS.	 They	 found	 that	 infants	 and	 prepubertal	 children	 had	 at	 least	 one	
cardiovascular	risk	factor.	In	63%	of	the	infants	and	73%	of	prepubescent	children,	at	least	one	of	
the	following	factors	was	present:	elevated	systolic	or	diastolic	blood	pressure;	elevated	serum	
total	 cholesterol,	 low	 density	 lipoprotein	 cholesterol,	 triglycerides,	 or	 lipoprotein(a)	 levels;	 or	
reduced	 high	 density	 lipoprotein	 cholesterol	 levels,	 indicating	 an	 unfavorable	 cardiovascular	
profile	in	addition	to	a	high	fat%,	indicating	an	unfavorable	cardiovascular	profile.173	Patel,	et	al.	
(2007)	 assessed	 cardiac	 and	 vascular	 structure	 and	 function	 in	 nine	 PWS	 patients	 and	 found	
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	significantly	elevated	high-sensitivity	C-reactive	protein	(hs-CRP),	hs-CRP	has	been	shown	to	be	
significantly	 elevated	 in	 patients	 dying	 suddenly	 with	 severe	 coronary	 artery	 disease,174	 and	
evidence	 of	 microcirculatory	 dysfunction	 as	 evidenced	 by	 decreased	 peak	 hyperaemic	 flow	
response.175		In	a	small	study	involving	36	adults	with	PWS	who	were	followed	for	10	years	there	
were	 10	 deaths.176	 The	 average	 age	 at	 death	 was	 33.2	 years	 with	 60%	 of	 the	 deaths	 due	 to	
cardiovascular	reasons	including	coronary	occlusion,	stroke,	or	heart	failure.		Lionti,	et	al.	(2012)	
also	concluded	that	cardiac	or	respiratory	conditions	were	common	causes	of	death	of	those	with	
PWS	after	the	age	of	15	years.168	
D-tagatose	 (D-lyxo-hexulose)	 is	 an	 enantiomer	 of	 D-fructose	 and	 occurs	 naturally	 in	 small	
amounts	 in	 dairy	 products.	 Heat	 treatment	 causes	 D-tagatose	 to	 form	 from	 galactose	 by	
isomerization.	 D-tagatose	 is	 approved	 as	 a	 safe	 food	 ingredient	 (Joint	 FAO/WHO	 Expert	
Committee	on	Food	Additives	(JECFA),	61st	JECFA	(2003),	published	in	FNP	52	Add11	(2003))177	
and	has	been	determined	Generally	Recognized	As	Safe	under	the	intended	conditions	of	use	in	
foods	by	the	FDA	(GRAS;	GRN	0000782	and	3523).	Extensive	human	studies	have	been	completed	
showing	the	safety	of	D-tagatose	for	use	in	foods.	A	number	of	clinical	trials	demonstrating	the	
potential	antidiabetic	activity	of	D-tagatose	were	conducted	on	healthy	subjects	and	patients	with	
type	2	diabetes	mellitus	 (T2DM)	without	an	 IND	by	considering	D-tagatose	as	a	 food	additive.	
These	trials	demonstrated	that	D-tagatose	did	not	raise	postprandial	blood	glucose	and	blunted	
the	 rise	 in	 blood	 glucose	 when	 taken	 with	 meals.2,3	 In	 November	 2005,	 after	 review	 of	
pharmacological,	 toxicological,	 and	 efficacy	 data	 from	 completed	 Phase	 1	 and	 2	 trials,	 the	
FDA/CDER	activated	an	IND	(#	70971)	for	D-tagatose	and	found	it	to	be	qualified	for	a	Phase	3	
trial	for	the	treatment	of	T2DM,	largely	because	of	its	safety	profile.	D-tagatose	has	since	been	
clinically	tested	in	one	Phase	3	safety/efficacy	and	one	Phase	2	dose	ranging	trial.18,37		D-tagatose	
has	 been	 safely	 administered	 to	 humans	 up	 to	 0.64	 g/day,	 although	 some	 consumers	 have	
experienced	 mild	 and	 transient	 gastrointestinal	 tolerance	 such	 as	 diarrhea,	 flatulence,	 and	
abnormal	gastrointestinal	sounds	at	that	dose.		
The	exact	mechanism	of	action	by	which	D-tagatose	blunts	the	glycemic	response	to	a	meal	is	not	
entirely	understood.	However,	based	on	the	results	of	a	number	of	studies	with	D-fructose	and	
D-tagatose,	a	plausible	mechanism	of	actions	for	the	use	of	D-tagatose	for	glycemic	control	has	
been	proposed.	D-tagatose	is	metabolized	in	the	liver	in	an	identical	manner	to	that	of	D-fructose.	
D-tagatose	 is	 phosphorylated	 to	 D-tagatose-1-phosphate	 by	 fructokinase,	 which	 is	 further	
metabolized	by	aldolase	to	yield	glyceraldehyde	(GA)	and	dihydroxy-acetone	phosphate	(DHAP).	
Although	aldolase	acts	on	both	D-fructose-1-P	and	D-tagatose-1-P,	the	cleavage	of	D-tagatose-1-
P	occurs	at	only	about	half	the	rate	of	that	of	D-fructose-1-P.32,33	Like	D-fructose-1-P,	the	increase	
of	 D-tagatose-1-P	 concentration	 stimulates	 glucokinase	 activity29,30,178	 leading	 to	 an	 increased	
phosphorylation	 of	 glucose	 to	 glucose-6-P,	 which	 further	 activates	 glycogen	 synthase.31	 In	
addition,	a	literature	review	also	suggests	that	D-tagatose-1-P,	in	a	manner	similar	to	D-fructose	
1-P,	has	 the	ability	 to	 inhibit	 glycogen	phosphorylase.179,180	 The	net	effect	of	 the	 regulation	of	
these	two	enzymes	is	an	increase	in	glycogen	synthesis	and	storage	and	a	decrease	in	glycogen	
utilization.	In	addition	to	its	effect	on	glycogen	regulation,	D-tagatose-1-P	is	capable	of	inhibiting	
sucrase	activity	leading	to	the	suppression	of	sucrose	digestion	in	the	small	intestine.2	
At	least	one	unconfirmed	study,	also	found	D-tagatose	to	inhibit	maltase	activity,	and,	thus,	to	
delay	the	digestion	of	starch.2	Thus,	it	seems	plausible	that	D-tagatose	is	capable	of	depressing	
the	 hyperglycemic	 response	 to	 a	meal	 or	 to	 a	 glucose	 load	 by	 several	 mechanisms	 including	
increasing	glycogen	synthesis	and	storage,	decreasing	glycogen	utilization,	and,	possibly,	also	by	
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	reducing	the	digestion	of	sucrose	and	other	carbohydrates	in	the	small	intestine.	The	net	effect	is	
a	reduction	of	glycemic	levels	and	HbA1c	closer	to	normal,	healthy	levels.	
In	addition	to	its	antihyperglycemic	effects,	D-tagatose	has	been	found	to	have	an	effect	on	blood	
lipid	levels	in	animals	and	in	humans.	In	one	study,	LDL−/−	mice	fed	a	diet	in	which	high	sucrose	
was	replaced	with	an	equivalent	amount	of	D-tagatose	had	reduced	cholesterol,	triglycerides,	and	
atherosclerosis	 compared	 to	 mice	 on	 the	 diet	 containing	 sucrose.78	 In	 a	 human	 clinical	 trial,	
patients	 with	 type	 2	 diabetes	 taking	 D-tagatose	 were	 found	 to	 have	 improved	 HDL	 levels,	
increasing	from	30	to	41.7	mg/dL	over	the	course	of	the	14-month	study.37	This	is	interesting	in	
light	of	evidence	suggesting	that	increasing	HDL	levels	decrease	the	risk	of	coronary	events.	The	
mechanism	by	which	D-tagatose	raises	HDL	is	not	clear,	but	it	should	be	noted	that	these	patients	
did	lose	weight	during	the	study	and	this	may	have	contributed	to	the	improvement	in	HDL.	In	
other	 studies,	 type	 2	 diabetics	 taking	 D-tagatose	 showed	 a	 decrease	 in	 HbA1c	 and	 serum	
triglycerides.4,5	
Trans-polydatin	(t-PD	or	polydatin),	a	glucoside	derivative	of	resveratrol,	is	purified	from	the	roots	
of	Polygonum	cuspidatum	and	is	found	naturally	in	a	number	of	foods	including	grapes,	grape-
containing	 products,	 cocoa,	 peanuts,	 peanut-containing	 products,	 pistachios,	 almonds,	 and	
hops.			As	a	derivative	of	resveratrol,	polydatin	is	believed	to	have	many	of	the	same	beneficial	
effects	 but	 has	 some	 properties	 that	 may	 make	 it	 more	 effective	 from	 a	 pharmacological	
standpoint	than	resveratrol.	Polydatin	is	structurally	the	same	as	resveratrol	except	that	it	has	a	
glucoside	group	attached	to	the	C-3	position	in	place	of	a	hydroxyl	group.	This	substitution	makes	
polydatin	more	water	soluble	and	more	resistant	to	enzymatic	breakdown	than	resveratrol.	It	is	
also	actively	taken	up	by	cells	via	glucose	carriers	in	the	cell	membrane	instead	of	being	passively	
transported	 like	 resveratrol.127,128	 	 These	 properties	 would	 suggest	 that	 polydatin	 may	 have	
greater	bioavailability	than	resveratrol.	
There	are	many	reported	health	benefits	of	trans-polydatin.	Numerous	studies	have	presented	
evidence	 that	 polydatin	 has	 positive	 health	 effects	 including	 anti-inflammatory,129,130	
hepatoprotective,131–134	 anti-cancer,135–138	 neuroprotective,129,139–141	 and	 activities	 deemed	
cardioprotective.113,114,142,143	 Additionally,	 trans-polydatin	 has	 shown	 through	 pharmacological	
studies	and	clinical	practice	to	have	protective	effects	against	shock,144,145,181	ischemia/reperfusion	
injury,146,147	congestive	heart	failure,148	endometriosis,149	and	prevention	of	fatty	liver	disease	and	
insulin	resistance,150	and	that	it	also	may	regulate	glucose	and	lipid	metabolism.151		Polydatin	has	
entered	clinical	trials	for	the	treatment	of	hemorrhagic	shock	and	irritable	bowel	syndrome.130,152	
The	mechanism	for	each	of	 these	outcomes	 is	still	being	 investigated.	 	Some	of	 the	suggested	
mechanisms	from	evidence	are:	an	antioxidant,	free	radical-elimination	mechanism,153,154	protein	
kinase	 C	 activation,155,156	 NF-kappaB	 suppression,157	 inhibiting	 of	 the	 activation	 of	 renin-
angiotensin-aldosterone	 system	 which	 decreases	 the	 excretion	 of	 endothelin	 1,	 TNF-α,	 and	
angiotensin	II,142	reduction	of	lipid	peroxidation	levels,127,157	increased	expression	of	hippocampal	
brain-derived	 neurotrophic	 factor,141	 	 enhanced	 insulin	 sensitivity	 in	 the	 liver	 as	 shown	 by	
improved	insulin	receptor	substrate	2	expression	levels	and	Akt	phosphorylation,151		decreasing	
the	content	of	malonydialdehyde	(MDA),140	promoting	activities	of	total	superoxide	dismutase	(T-
SOD),	 catalase	 	 and	 glutathione	 peroxidase	 (GSH-Px)	 in	 plasma,	 increasing	 glutathione	 (GSH)	
content	in	myocardial	tissue,154	decreasing	deacetylase	sirtuin1	activity	and	protein	expression	in	
liver	 tissue	 following	severe	shock158	and	 thereby	activating	 sirtuin,159,160	 suppressing	oxidative	
stress-induced	lysosomal	instability	and	mitochondrial	injury	by	increasing	the	protein	expression	
of	SOD2.158	
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	The	use	of	trans-polydatin	as	a	potential	therapy	for	dyslipidemia	has	been	suggested	principally	
by	 three	 studies	 using	 various	 animal	 models.112–114	 Arichi	 et	 al.	 discovered	 that	 orally	
administered	 trans-polydatin	 (100	 mg/kg	 body	 weight)	 significantly	 lowered	 low-density	
lipoprotein	(LDL)-derived	cholesterol	(by	18%)	and	serum	triglycerides	(by	40%)	in	rats	consuming	
standard	chow	containing	a	mixture	of	corn	oil,	10%	cholesterol,	and	1%	cholic	acid	 to	 induce	
increased	blood	lipids.	Lower	doses	of	trans-polydatin	(50	mg/kg	body	weight)	were	ineffective	at	
preventing	hyperlipidemia,	however,	they	were	able	to	prevent	the	accumulation	of	cholesterol	
and	triglycerides	 in	the	 liver,	suggesting	that	 lower	doses	may	also	be	effective	but	to	a	 lesser	
extent.112	In	a	study	using	Syrian	golden	hamsters,	polydatin	was	decreased	total	cholesterol	(TC)	
levels	and	total	 triglyceride	 levels	by	47%	and	63%,	respectively,	when	co-administered	with	a	
high	 fat/cholesterol	diet	and	compared	to	standard	diet.113	 In	another	study	using	rabbits,	 the	
administration	of	polydatin	decreased	total	cholesterol	in	the	serum	as	well	as	triglycerides	and	
LDL.114	The	ratio	of	TC	to	HDL	was	also	reduced.		
Insulin	is	a	major	component	of	metabolic	regulation	through	activation	of	the	Akt	pathway	and	
other	metabolic	 pathways.161	 Hao	et	 al.	 recently	 found	 that	 trans-polydatin	 activated	 the	 Akt	
signaling	pathway	 in	 diabetic	 rats.	 	 This	was	possibly	 accomplished	by	phosphorylation	of	 the	
insulin	 receptor	 substrate	 (IRS),	 thereby	 reducing	 blood	 glucose	 levels.151	 Polydatin	 may	 also	
decrease	the	expression	of	intercellular	adhesion	molecule	1	(ICAM-1),	reducing	white	blood	cell	
adhesion,	 as	well	 as	 the	effects	of	other	 cell	 adhesion	molecules	and	 inflammatory	 cytokines.		
These	 are	 thought	 to	 be	 major	 components	 active	 in	 early	 atherosclerotic	 development.162	
Additionally,	polydatin	is	thought	to	provide	protection	from	cell	damage	resulting	from	oxidative	
peroxidation127,163	and	inhibition	of	oxidation	of	LDLs,	which	plays	a	large	role	in	atherosclerosis.118	
Polydatin	has	been	administered	to	humans	up	to	85.5	mg/70	kg	of	body	weight	and	no	adverse	
events	 were	 reported.182	 To	 determine	 whether	 higher	 levels	 of	 trans-polydatin	 could	 be	
administered	 to	 humans,	 Biospherics.net	 evaluated	 the	 safety	 of	 polydatin	 (batch	 number	
BIPL110714)	in	a	28-day	GLP	rat	toxicology	study	with	a	toxicokinetic	test-arm	and	established	a	
no	observed	adverse	effect	level	(NOAEL)	of	3.0	g/kg/day	(the	highest	dose	tested)	in	males	and	
1.2	 g/kg/day	 in	 females.	 The	 1.2	 g/kg/day	 in	 females	was	 based	 on	 bilateral	moderate	 pelvic	
inflammation	and	transitional	cell	hyperplasia	in	the	kidneys	of	one	female	given	3.0	g/kg/day.	
The	approach	to	the	proposed	initial	Phase	1	Exploratory	IND	PK	study	is	to	orally	administer	a	
single	dose	of	D-tagatose,	trans-polydatin,	and	BSN272	to	healthy	males,	collect	blood	samples	
prior	to	and	after	dosing,	and	quantify	the	serum	levels	of	trans-polydatin	and	metabolites.	The	
doses	of	D-tagatose	and	trans-polydatin	when	administered	alone	or	in	combination	would	not	
exceed	70	mg/kg	and	100	ug	respectively	and	the	batch	of	trans-polydatin	that	will	be	used	will	
be	the	same	one	that	was	tested	in	the	28-day	rat	toxicology	study.		The	study	medications	will	
be	 provided	 in	 powdered	 form	 with	 no	 excipients	 to	 be	 mixed	 with	 6	 ounces	 of	 water	 for	
administration.	
5.4	Exploratory	Phase	1	PK	Microdose	Study	in	Healthy	Volunteers	
The	primary	objective	of	this	phase	1	exploratory,	microdose	study	is	to	determine	whether	the	
tmax	 and	 Cmax	 of	 trans-polydatin	 (t-PD)	 change	 significantly	 when	 co-administered	 with	 D-
lyxohexulose	(DLH,	or	D-tagatose)	in	healthy	male	and	female	volunteers	over	a	24hour	period.	
BSN272	 is	 a	 potential	 drug	 therapy	 for	 the	 treatment	 of	 persons	with	 Prader-Willi	 Syndrome	
(PWS).	 Healthy	 volunteers	 will	 be	 administered	 doses	 of	 trans-polydatin	 or	 BSN272.	 Blood	
samples	will	be	taken	pre-dose	(t	=	0)	and	at	approximately	0.167	(10	min),	0.333	(20	min),	0.5,	1,	
2,	4,	6,	8,	12	and	24-36	hours	post	drug	administration.	Urine	samples	will	also	be	collected	during	
the	12	hour	onsite	clinical	period,	with	one	subsequent	sample	collected	at	visit	3,	which	should	
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	approximate	 the	 24-hour	 posttreatment	 period.	 Serum	and	urine	 samples	will	 be	 assayed	 for	
trans-polydatin	 and	 the	 metabolite	 trans-resveratrol	 at	 each	 time	 point	 to	 determine	 the	
pharmacokinetic	effects	of	the	combination	BSN272	drug.	
Healthy	male	 and	 female	 volunteers,	 aged	 between	 18	 and	 30	 years	 old	will	 be	 recruited	 by	
advertisement	at	the	University	of	Kentucky.	Acceptance	into	the	trial	will	be	based	upon	the	full	
inclusion	 and	 exclusion	 criteria	 listed	 below.	 After	 giving	 informed	 consent,	 initial	 screening	
performed	 (physical	 exam,	 blood	 analysis	 including	 HIV	 and	 Hep	 C,	 and	 urinalysis)	 and	when	
acceptability	of	the	subject	has	been	determined	they	will	be	invited	to	participate	in	the	study.	
Subjects	will	be	compensated	for	their	 time.	 	 Inclusion	and	exclusion	criteria	can	be	viewed	 in	
Appendix	E.	
The	main	objective	of	 this	phase	1	clinical	 trial	 is	 to	 test	 the	hypothesis	 that	administration	of	
trans-polydatin	 with	 D-lyxohexulose	 (D-tagatose)	 does	 not	 change	 the	 tmax	 or	 Cmax	 of	 trans-
polydatin.	All	volunteers	will	be	healthy	male	and	female	aged	18-30	years	old,	must	not	be	taking	
other	medications,	prescription	or	nonprescription,	with	no	excessive	alcohol	 intake,	and	have	
not	 previously	 participated	 in	 a	 clinical	 trial	within	 the	 last	 30	 days.	 Those	 potentially	 eligible	
subjects	meeting	 the	 initial	 inclusion	 and	 exclusion	 requirements,	 and	 after	 signing	 informed	
consent,	will	undergo	a	basic	physical	examination,	hematology,	blood	chemistry,	and	urinalysis.	
This	screening	and	recruitment	process	should	be	complete	within	35	days.	After	meeting	all	trial	
criteria,	eligible	subjects	are	invited	to	participate	in	the	trial.	They	will	be	asked	to	attend	the	trial	
facility	and	will	be	randomly	assigned	to	one	of	the	two	treatment	groups	for	the	duration	of	the	
study.	Randomization	 is	 to	be	 stratified	according	 to	 sex	 to	achieve	a	balanced	distribution	of	
subjects	across	the	2	treatment	groups.	The	treatment	groups	will	be	(1)	trans-polydatin	and	(2)	
BSN272	(trans-polydatin	+	D-lyxohexulose).	Six	subjects,	3	male	and	3	female,	will	be	assigned	to	
each	group	for	a	total	of	12	subjects.	On	the	trial	day	subjects	will	be	given	study	medication	and	
then	timed	blood	samples	will	be	taken	for	pharmacokinetic	analysis.	Urine	samples	will	also	be	
collected	during	the	12	hours	the	volunteers	are	at	the	CCTS,	with	one	subsequent	urine	collection	
at	visit	3,	which	should	approximate	24	hours	post-treatment,	and	will	be	stored	for	contingent	
analysis.	Serum	and	urine	trans-polydatin	and	trans-resveratrol	will	be	determined.	
For	this	study,	potential	subjects	will	be	screened	to	identify	16	study	healthy	volunteers	(8	male,	
8	 female)	of	which	12	participants	 (6	male,	6	 female)	will	be	used	 for	 the	actual	 study	with	4	
alternates	(2	male,	2	female)	in	case	a	participant	cannot	complete	the	study.	Six	subjects,	3	male	
and	3	female,	will	be	assigned	to	each	group.	
Each	 subject	 will	 drink	 the	 study	 drug(s)	 assigned	 to	 their	 group	 dissolved	 in	 volume	 of	
approximately	4	ounces	of	water	per	drug.	Each	drug	will	be	dissolved	separately	in	water	and	
subjects	will	drink	both	solutions	(trans-polydatin	in	the	trans-polydatin	group,	or	trans-polydatin	
and	 D-lyxohexulose	 in	 the	 BSN272	 group)	 from	 separate	 cups	 in	 rapid	 succession.	 The	 study	
dosage	is	shown	in	Figure	5.1.	
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	Figure	5.1	
Dosing	Schedule	
	
After	administration	of	the	study	drugs,	blood	samples	will	then	be	taken	at	approximately	0.167	
(10	mins),	0.333	(20	mins),	0.5,	1,	2,	4,	6,	8,	12	and	once	between	24-36	hours	post	dose.	Urine	
samples	will	also	be	collected	during	the	12	hr	clinical	period,	with	one	subsequent	collection	at	
the	24-hour	time	point	 (visit	3).	Subjects	will	be	required	to	attend	the	trial	 facility	after	a	12-
hours	overnight	fast.	Subjects	will	remain	in	the	facility,	and	monitored	constantly	for	safety	for	
the	duration	of	the	timed	pharmacokinetic	blood	collection	(12	hours).	The	subjects	will	receive	
a	 light,	 low	polydatin	 lunch	 after	 the	 4-hour	 blood	 sample	 has	 been	 taken.	After	 the	 12-hour	
sample	draw	they	will	be	allowed	to	leave	but	will	be	required	to	return	for	the	following	day	for	
the	24-hour	sample	collection.	
Figure	5.2	
Trial	Time-line	Overview	
	
Determination	of	Sample	Size	
Potential	subjects	will	be	screened	to	identify	16	study	healthy	volunteers	(8	male,	8	female)	of	
which	 12	 participants	 (6	 male,	 6	 female)	 will	 be	 used	 for	 the	 actual	 study.	 There	 will	 be	 2	
treatment	 groups	 each	 having	 6	 volunteers	 randomly	 assigned.	 The	 determination	 of	 the	
minimum	study	group	numbers	is	based	upon	a	28-day	rat	toxicology	study	taken	at	1-hour	post	
trans-polydatin,	2-sided,	confidence	interval	of,	(alpha	0.025)	and	a	power	of	90%.	
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	Statistical	Analysis	
The	primary	objective	of	this	phase	1	microdose	study	is	to	determine	whether	the	tmax	and	Cmax	
of	 t-PD	 change	 significantly	 when	 co-administered	 with	 DLH	 in	 healthy	 male	 and	 female	
volunteers.	
Non-compartmental	 analysis	 will	 be	 applied	 to	 the	 mean	 plasma	 trans-polydatin	 and	 trans-
resveratrol	concentration	data	from	the	volunteers.	The	following	parameters	will	be	estimated	
whenever	possible:	
1.	Cmax	-	Maximum	observed	concentration	
2.	tmax	-	Time	to	maximum	observed	concentration.	
Cmax	and	tmax	will	be	determined	by	visual	inspection	of	the	concentration-time	data.	If	any	maxima	
appear	identical,	a	computer	sort	will	identify	the	highest	data	value.		
AUC0-8			-				Area	under	the	concentration-time	curve	from	hour	0	to	hour	8,	estimated	by	the	linear	
trapezoidal	rule.		
AUC0-t	 -	 Area	 under	 the	 concentration-time	 curve	 from	 hour	 0	 to	 the	 last	 measurable	
concentration,	estimated	by	the	linear	trapezoidal	rule.	
AUC0-∞		-		Area	under	the	concentration-time	curve	from	hour	0	to	infinity	for	Day	1	calculated	as	
follows:	
AUC0-∞	=	AUC0-t	+	Ct/λz	
Where	Ct	is	the	last	measurable	concentration	and	λz	is	the	elimination	rate	constant	estimated	
using	log-linear	regression	during	the	terminal	elimination	phase.	The	number	of	points	used	in	
λz	calculation	will	be	determined	by	visual	inspection	of	the	data	describing	the	terminal	phase.	
At	least	the	last	three	time	points	with	measurable	values	will	be	used	in	λz	calculation.		
M/P	 ratio	 Metabolite	 to	 Parent	 ratio	 calculated	 as:	 AUC0-8	 metabolite/AUC0-8	 parent	
pharmacokinetic	 analysis	 will	 be	 performed	 using	 WinNonlin	 Professional	 Edition	 (Pharsight	
Corporation,	 Version	 5.2).	 Nominal	 doses	 and	 sampling	 times	 will	 be	 used.	 Dose	 normalized	
parameters,	 ratios,	 and	descriptive	 statistics	will	 be	 calculated	using	WinNonlin	and	Microsoft	
Excel	(Version	11.0).	Concentration	values	found	below	the	lower	limit	of	quantification	(<	20.0	
ng/mL	 for	 trans-polydatin	 and	 <	 10.0	 ng/mL	 for	 trans-resveratrol)	 will	 be	 treated	 as	 zero	 for	
descriptive	statistics	and	toxicokinetic	analysis.	
A	t-test	(p=0.05)	will	be	used	to	calculate	the	significance	of	the	difference	between	the	Cmax	and	
tmax	of	t-PD	with	and	without	DLH.	
The	rest	of	the	Phase	1	protocol	can	be	view	in	Appendix	E.	
5.5	Conclusions	
D-tagatose	participated	in	numerous	studies,	both	clinical	and	non-clinical,	over	2	decades	for	use	
as	both	a	low	calories	food	sweetener	and	subsequently	as	a	treatment	for	hyperglycemia.		These	
studies	led	to	a	GRAS	designation	for	D-tagatose	for	use	in	foods	and	ushered	its	development	as	
a	 pharmaceutical,	 all	 prior	 to	 obtaining	 an	 IND	 designation	 with	 the	 FDA.	 	 Our	 lab	 was	
commissioned	to	navigate	the	acquisition	of	the	IND	for	D-tagatose	and	orchestrate	the	execution	
of	 a	 Phase	 III37	 and	 II18	 trial	 to	 access	 safety	 and	 efficacy	 in	 the	 T2DM	population.	 	 I	 had	 the	
opportunity	upon	joining	the	lab	off	the	heels	of	these	trials	to	parse	through	the	resulting	data	
and	contribute	their	publications	into	the	academic	literature.	
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	While	the	trials	showed	D-tagatose	to	be	safe	and	efficacious	in	lowering	blood	glucose	levels	the	
patent	on	the	molecule	came	to	an	end	as	the	FDA	requested	an	additional	Phase	3	study	as	well	
as	 a	 full	 2-year	 cardiotoxicity	 study	 due	 to	 negative	 outcomes	 in	 some	 already	 approved	
medications	 for	 T2DM	 patients.	 	 This	made	 further	 traditional	 development	 of	 D-tagatose	 as	
monotherapy	impossible	but	turned	out	to	be	opportunistic,	as	bringing	D-tagatose	back	into	the	
laboratory	and	conducting	numerous	pre-clinical	studies	combining	D-tagatose	with	2	potential	
lipid-lowering	candidates	proved	to	be	fruitful.	
Trans-polydatin	and	dihydromyricetin	were	identified	through	literature	searches	as	potentially	
good	candidates	to	administer	along	with	D-tagatose	(BSN272	and	BSN723T	respectively)	due	to	
studies	 showing	 them	 to	 have	 activity	 in	 lowering	 markers	 of	 atherosclerotic	 development	
including	 increased	 blood	 levels	 of	 LDL,	 total	 cholesterol,	 and	 triglycerides	 as	 well	 as	
hyperglycemia.	 	 This	 was	 desirable	 due	 to	 studies	 showing	 that	 increased	 consumption	 of	
carbohydrates	leads	to	greater	dyslipidemia	than	energy	matched	diets	with	increased	free	fatty	
acids.43		As	cardiovascular	disease	is	the	primary	cause	of	mortality	in	diabetics,	this	was	a	concern	
for	 the	 patient	 population	 that	 D-tagatose	 was	 intended	 to	 treat.	 	 In	 fact,	 Police	 et	 al.	
demonstrated	 in	LDLr-/-	mice	 that	D-tagatose	administration	could	produce	dyslipidemia	when	
supplemented	 in	 feed,	 although	 not	 to	 the	 extent	 as	 a	 similar	 amount	 of	 sucrose.	 	 Of	more	
concern,	10-months	of	treatment	with	D-tagatose	in	T2DM	human	patients	led	to	elevations	in	
triglycerides.37	
A	study	using	doses	of	D-tagatose	and	trans-polydatin	that	were	forced	to	be	uncorrelated	using	
principal	axis	theorem	allowed	us	to	determine	the	contribution	of	each	molecule	in	the	presence	
of	 the	 other	molecule	 towards	 reductions	 in	markers	 of	 dyslipidemia.45	 	 This	 allowed	 for	 the	
development	of	predictive	algorithms	that	aided	us	in	tweaking	the	doses	of	each	of	the	molecules	
to	 get	 the	 maximum	 affects.	 	 Administration	 of	 BSN272	 led	 to	 significant	 prevention	 of	 diet	
induced	elevations	in	LDL	and	VLDL	as	well	as	weight	gain	and	the	development	of	atherosclerosis.		
Triglycerides	 were	 also	 lower	 in	 the	 treatment	 groups	 throughout	 the	 course	 of	 the	 study	
although	it	did	not	reach	significance.45		A	follow-up	study	confirmed	the	predictive	ability	of	the	
algorithm,	 and	 found	 similar	 results,	 but	 failed	 to	 reach	 significance	 again	 with	 lowering	 of	
triglycerides.46		In	both	studies,	however,	the	lowering	of	triglycerides	appeared	to	be	synergistic	
as	neither	component	of	BSN272	as	monotherapy	showed	any	activity	towards	triglycerides.	
The	combined	efficacy	of	D-tagatose	and	dihydromyricetin	was	tested	next	 in	a	ApoE-/-	mouse	
study.		While	both	molecules	appeared	somewhat	efficacious	at	lowering	total	cholesterol	and	
triglycerides	as	monotherapy,	the	combination	did	not	appear	to	be	synergistic	as	BSN723T	was	
not	any	better	than	D-tagatose	or	DMY	alone.49		However,	this	study	did	provide	a	comparator	
study	to	assess	a	longer	study	with	BSN272	to	see	if	this	combination	product	was	truly	synergistic.	
The	last	push	to	conduct	the	lengthy	16	week	ApoE-/-	mouse	study	with	BSN272	came	with	results	
from	an	unpublished	study	in	Syrian	golden	hamsters	in	which	monotherapy	with	polydatin	led	
to	marked	elevations	in	triglycerides	and	the	combination	of	D-tagatose	and	polydatin	led	to	a	
significant	reduction	in	triglycerides.		The	16-week	study	was	powered	specifically	for	a	significant	
result	for	prevention	of	a	diet	induced	increase	in	triglycerides,	and	that	is	what	it	delivered.		Mice	
given	 BSN272	 showed	 lower	 triglycerides	 at	 the	 end	 of	 the	 study	 then	 could	 be	 expected	 by	
combining	 the	 results	 of	 each	 as	monotherapy,	 and	 the	 results	were	 even	 below	 that	 of	 the	
normal	diet	group.111	 	The	culmination	of	these	non-obvious	findings	was	 in	the	awarding	of	a	
patent	for	BSN272.	
Following	 these	 results,	 we	 began	 to	 prep	 for	 an	 IND	 submission.	 	 Part	 of	 this	 process	 was	
conducting	a	toxicology	study	for	polydatin,	as	this	had	already	been	done	for	D-tagatose.	 	No	
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	glaring	problems	arose	from	these	experiments	and	a	NOAEL	of	1200	mg/kg/day	was	established	
for	females	and	3000	mg/kg/day	for	males.50	
I	spent	a	considerable	amount	of	time	after	these	studies	packaging	the	IND	to	submit	to	the	FDA	
and	conversing	back	and	forth	with	them	as	they	added	in	positioning	and	submitting	our	drug	
candidate.	 	We	 identified	Prader-Willi	Syndrome	as	a	potential	orphan	disease	 to	 target	as	no	
treatments	are	available	aimed	at	treating	the	underlying	cause	of	this	disease	which	begins	as	
inability	 to	obtain	satiety	and	eventually	develops	 into	T2DM	at	a	very	young	age.	 	The	future	
tasks	and	directions	for	this	work	are	presented	in	section	5.6	below.	
5.6	Future	Work	
Much	of	the	work	 in	the	near	 future	 is	pretty	straight	 forward.	 	The	submission	of	an	 IND	 is	a	
process	that	requires	communicating	with	numerous	groups	of	people.		The	IND	package	is	ready	
to	submit	to	the	FDA	once	the	timing	is	right	for	our	lab.		At	that	point	the	FDA	has	30	days	to	
respond	at	which	time	we	can	move	forward	with	the	Phase	1	study.	
Once	an	IND	number	is	established	the	protocol	will	be	submitted	to	the	IRB	where	the	study	is	
going	to	be	conducted,	most	likely	by	the	CCTS	at	the	University	of	Kentucky.		That	will	require	a	
period	of	back	and	forth	to	get	the	protocol	and	other	documentation	to	meet	the	expectations	
that	they	express.	 	The	 informed	consent	for	volunteers	 in	the	study	has	already	been	written	
pending	 IRB	approval,	as	has	the	 investigators	brochure	for	anyone	 involved	with	the	study	to	
consult.	
All	of	these	documents,	including	the	IND,	will	require	continuous	updating	and	re-submitting	to	
the	various	regulatory	units	 involved	as	studies	are	conducted.	 	A	re-submission	is	required	on	
most	documents	at	least	once	a	year.	
Our	lab	will	continue	to	further	pursue	Prader-Willi	syndrome	as	an	indication.		A	study	is	currently	
underway	 in	 our	 lab	 of	 a	 mouse	 model	 of	 Prader-Willi	 syndrome	 using	 D-tagatose	 as	
monotherapy.		A	pediatric	study	is	also	being	sought	as	the	safety	profile	of	D-tagatose	makes	it	
an	 interesting	candidate	for	early	 treatment	 in	 individuals	with	a	high	 likelihood	of	developing	
T2DM.	
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Appendix	A	
Safety	and	Efficacy	of	D-Tagatose	in	Glycemic	Control	in	Subjects	with	Type	2	Diabetes1	
Mark	Ensor,	Amy	B.	Banfield,	Rebecca	R.	Smith,	Jarrod	Williams,	and	Robert	A.	Lodder	
Department	of	Pharmaceutical	Sciences,	College	of	Pharmacy,	University	of	Kentucky,	USA	
Abstract1	
The	 primary	 objectives	 of	 this	 study	 were	 to	 evaluate	 the	 treatment	 effect	 of	 D-tagatose	 on	
glycemic	control,	determined	by	a	statistically	significant	decrease	 in	hemoglobin	A1c	(HbA1c),	
and	safety	profile	of	D-tagatose	compared	to	placebo.	The	secondary	objectives	were	to	evaluate	
the	 treatment	effects	on	 fasting	blood	glucose,	 insulin,	 lipid	profiles,	 changes	 in	BMI,	 and	 the	
proportion	of	subjects	achieving	HbA1c	targets	of	<7%.	Type	2	diabetic	patients	not	taking	any	
blood	 glucose	 lowering	medications	were	 administered	 either	 15	 g	 of	D-tagatose	 dissolved	 in	
125–250	ml	of	water	three	times	a	day	or	placebo	with	meals.	Reduction	in	HbA1c	was	statistically	
significant	 compared	 to	 placebo	 at	 all	 post-baseline	 time	 points	 in	 the	 ITT	 population.	
Additionally,	secondary	endpoints	were	achieved	in	the	ITT	population	with	regard	to	LDL,	total	
cholesterol,	fasting	blood	glucose,	and	proportion	of	subjects	achieving	HbA1c	targets	of	<7%.	D-
tagatose	was	unable	to	lower	triglycerides	or	raise	HDL	compared	to	placebo.	A	subgroup	LOCF	
analysis	on	the	ITT	US	population	showed	a	greater	and	statistically	significant	LS	mean	reduction	
in	HbA1c	in	the	D-tagatose	group	at	all	post-baseline	visits.	Based	on	these	results	it	is	concluded	
that	in	the	ITT	population	D-tagatose	is	an	effective	single	agent	at	treating	many	of	the	therapy	
targets	of	type	2	diabetes	including	lowering	fasting	blood	glucose	and	HbA1c,	and	lowering	of	
LDL	and	total	cholesterol.	
Keywords	
HbA1c;	Triglycerides;	Insulin;	LDL;	HDL;	Cholesterol;	Blood	glucose	
Introduction1	
According	to	the	American	Diabetes	Association,	diagnosed	diabetes	cost	Americans	$245	billion	
in	2012.	This	includes	$176	billion	for	direct	medical	costs	as	well	as	$69	billion	in	reduction	of	
productivity.2	The	National	Diabetes	Statistics	Report,	2014,	estimates	that	29.1	million	people,	
or	9.3%	of	the	United	States	population,	have	diabetes	(an	estimated	8.1	million	of	these	were	
undiagnosed).3	 From	2009–2012,	 The	 Centers	 for	Disease	 Control	 and	 Prevention	 determined	
that	37%	of	U.S.	adults	aged	20	years	or	older	had	prediabetes,	as	did	51%	of	adults	aged	65	years	
or	older	(based	on	fasting	glucose	or	hemoglobin	A1c	levels).	Extrapolating	this	percentage	to	the	
entire	U.S.	population	during	that	 time,	 the	prevalence	of	prediabetes	can	be	estimated	to	be	
around	86	million	American	adults.3	
Two	abnormalities	that	typically	characterize	the	pathogenesis	of	type	2	diabetes	are	peripheral	
insulin	resistance	and	progressive	 failure	of	pancreatic	β-cell	 function	 leading	to	 loss	of	 insulin	
secretion.	 These	 complications	 eventually	 lead	 to	 chronic	 hyperglycemia	 and	 associated	 long-
term	disease	complications.4	 Insulin	 resistance	does	not	progress	 in	parallel	with	 loss	of	β-cell	
function,	 but	 occurs	 first.	 Most	 type	 2	 diabetes	 patients	 who	 are	 initially	 treated	 by	 diet	
management	or	oral	 blood	glucose	 lowering	 agents	 eventually	 require	 insulin	 as	 loss	of	β-cell	
function	progresses.	None	of	the	therapies	currently	available	appear	to	be	able	to	slow	or	stop	
the	progression	of	β-cell	loss	once	it	begins.	Therefore,	there	is	clearly	a	need	for	therapies	for	
the	long-term	treatment	of	type	2	diabetes	that	can	prevent	patients	from	reaching	this	current	
“point	of	no	return”	of	loss	of	β-cell	function.	
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Currently	the	approach	to	the	treatment	of	type	2	diabetes	is	stepwise	and	systematic	with	early	
treatment	consisting	of	having	patients	alter	and	manage	their	diet,	adhere	to	a	regular	exercise	
program	and,	 if	 overweight,	 control	 their	weight.	 If	 the	disease	progresses	 and	blood	 glucose	
remains	uncontrolled,	then	pharmacologic	therapy	is	initiated,	usually	with	one	or	two	oral	anti-
hyperglycemic	drugs.	Additional	medications	or	insulin	may	be	added	if	the	disease	continues	to	
progress.	Many,	 if	 not	most,	 patients	with	 type	2	 diabetes	will	 eventually	 require	 insulin	 as	 a	
primary	therapy	with	or	without	adjuvant	drug	therapy	in	order	to	control	their	blood	glucose.5	
Despite	 the	 introduction	 in	 recent	 years	 of	 new	 drugs	 for	 the	 treatment	 of	 diabetes,	 glucose	
control	in	many	patients	remains	unsatisfactory.	Metformin	remains	the	first	drug	of	choice	for	
the	 treatment	 of	 type	 2	 diabetes.	 A	 recent	 review	 that	 included	 140	 controlled	 trials	 and	 26	
observational	 studies	 comparing	diabetes	medications,	 both	 as	monotherapy	 and	 in	 two-drug	
combinations,	 concluded	 that	 the	 long-term	 benefits	 and	 harms	 of	 current	 drug	 treatments	
remain	unclear.6	The	study	concluded	that	there	was	not	enough	evidence	to	clearly	support	the	
use	of	one	drug	or	drug	combination	over	another	for	stemming	the	complications	of	diabetes,	
including	macrovascular	and	microvascular	complications,	and	for	mortality.	Metformin	remains	
the	 initial	 drug	 of	 choice,	 however,	 because	 compared	 to	 the	 newer	 drugs	 it	 has	 the	 highest	
benefit-to-risk	ratio	for	intermediate	outcomes,	such	as	moderate	HbA1c	reduction,	less	weight	
gain	and	less	risk	of	hypoglycemia.	Many	of	the	other	therapies	have	limiting	side	effects	such	as	
weight	gain,	hypoglycemia,	and	edema,	and	have	restrictions	for	use.7	
This	 information	 illustrates	 the	 limitations	 of	 drug	 therapies	 currently	 available	 for	 the	
progression	of	diabetes.	Further,	even	with	aggressive	intervention,	it	 is	estimated	that	60%	of	
diabetics	 do	 not	 achieve	 target	 blood	 sugar	 levels	 with	 their	 current	 treatment	 regimen.5	
Moreover,	current	drugs	available	for	treatment	of	diabetes	may	result	in	unwanted	weight	gain	
(long	 and	 rapid	 acting	 Insulin,	 sulfonylureas,	 thiazolidinediones,	 repaglinide,	 nateglinide),	
hypoglycemia	 (insulin,	 sulfonylureas),	 gastrointestinal	 distress	 (metformin,	 α-glucosidase	
inhibitor,	amylin	mimetics,	bile	acid	sequestrant,	bromocriptine),	or	more	serious	adverse	events	
such	as	pancreatitis	(short	and	long-acting	glucagon-like	peptide-1	(GLP-1)	agonists	and	dipeptidyl	
peptidase-4	(DDP-4)	inhibitors).8,9	From	the	statistics	showing	a	high	percentage	of	diabetics	are	
not	able	to	consistently	control	their	blood	sugar	levels	within	recommended	limits,	it	is	evident	
that	 there	 is	a	medical	need	 for	a	drug	 that	can	slow	and/or	halt	 the	progression	of	diabetes.	
Preferably,	such	a	drug	should	exhibit	a	unique	mode	of	action	to	enable	additive	or	synergistic	
use	 with	 current	 therapies;	 produce	 no	 weight	 gain,	 hypoglycemia,	 or	 other	 limiting	 or	
unmanageable	side	effects;	preserve	or	enhance	β-cell	function;	and	reduce	cardiovascular	risk	
factors	that	potentially	lead	to	morbidity	and	mortality.	
D-tagatose	 is	 an	 isomer	of	 fructose	 that	 is	~90%	as	 sweet	as	 sucrose.	 In	2001	D-tagatose	was	
designated	as	a	Generally	Recognized	as	Safe	(GRAS)	product	by	the	United	States	Food	and	Drug	
Administration,	 and	 subsequently	 has	 been	 used	 as	 a	 nutritive	 or	 low-calorie	 sweetener.10	
Currently,	D-tagatose	may	be	used	as	a	sweetener	in	diet	beverages,	light	ice	creams	or	yogurts,	
and	 regular	or	dietetic	hard	candies.11	 Subsequently	 it	was	hypothesized	 from	observations	 in	
food	use,	and	then	demonstrated	experimentally	that,	when	consumed,	D-tagatose	functions	as	
a	 “sugar	 blocker”	 and	 inhibits	 lipid	 formation	 from	 carbohydrates	 without	 stimulation	 of	
pancreatic	 beta	 cells	 for	 insulin	 production	 or	 secretion.12	 Preliminary	 animal	 and	 pre-clinical	
studies	of	D-tagatose	demonstrated	its	ability	to	lower	blood	glucose	and	lipoprotein	levels.	D-
tagatose	 has	 been	 shown	 to	 reduce	 total	 cholesterol	 and	 VLDL	 and	 LDL-cholesterol	 when	
compared	 to	 sucrose,13	 and	 increase	 HDL-cholesterol	 levels.14	 A	 number	 of	 clinical	 trials	
demonstrating	the	ability	of	D-tagatose	to	blunt	postprandial	rises	in	blood	glucose	and	reduce	
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HbA1c	have	been	conducted	in	both	healthy	subjects	and	diabetic	patients.14–19	A	phase	2	study	
designed	to	estimate	the	lowest	dose	of	D-tagatose	capable	of	 lowering	HbA1c	found	that	the	
dose	was	5	g	TID.19	Single-dose	and	repeated-dose	studies	in	healthy	and	diabetic	human	subjects	
have	shown	that	the	predominant	adverse	effects	associated	with	excessive	consumption	of	D-
tagatose	 are	 gastrointestinal	 disturbances	 attributed	 to	 osmotic	 effects	 from	 incomplete	
absorption.14–18	Such	effects	are	also	commonly	associated	with	excessive	consumption	of	other	
poorly	 digestible	 carbohydrates	 including	 polyols.	 In	 short,	 D-tagatose	 provides	 glycemic	 and	
lipoprotein	control	through	a	mechanism	of	action	unlike	any	agent	that	is	currently	available	on	
the	market	in	the	United	States.		
Here	we	report	the	results	of	a	phase	3	clinical	trial	with	D-tagatose	and	demonstrate	statistically	
significant	 reductions	 in	hemoglobin	A1c	 levels	 (HbA1c)	 in	patients	with	mild	 type	2	diabetes.	
HbA1c	 levels	 are	 an	 indicator	 of	 glycolated	 hemoglobin	 in	 the	 blood	 and	 reflect	 a	 patient’s	
glycemic	control	over	a	six	to	twelve	week	period.20	If	blood	glucose	levels	have	been	elevated	
over	recent	weeks,	there	will	likely	be	a	concomitant	rise	in	HbA1c	levels.	
The	primary	objective	of	this	Phase	3	clinical	trial	was	to	evaluate	the	placebo-controlled	effect	of	
D-tagatose	on	glycemic	control	and	safety	in	subjects	with	type	2	diabetes	over	the	course	of	a	
10-month	treatment.	The	secondary	objectives	of	this	clinical	trial	were	to	evaluate	the	placebo-
controlled	effects	of	D-tagatose	on	fasting	blood	glucose,	 insulin,	 lipid	profiles,	and	changes	 in	
BMI.	D-tagatose	effectively	lowered	HbA1c	levels	in	type	2	diabetic	patients	compared	to	placebo;	
thus,	results	of	this	phase	3	clinical	trial	illustrate	the	potential	for	D-tagatose	to	fulfill	a	need	in	
current	diabetes	treatment.		
Patients	and	Methods1	
Ethical	Conduct	of	the	Study		
The	protocol	and	protocol	amendment(s)	were	reviewed	and	approved	by	an	Institutional	Review	
Board	(IRB)	before	the	study	was	initiated.	This	trial	was	conducted	in	accordance	with	regulations	
governing	 clinical	 trials	 including	 the	 US	 Code	 of	 Federal	 Regulations	 (CFR),	 Title	 21,	 Part	 50;	
regulations	governing	IRBs,	Title	21,	Part	56;	and	the	Declaration	of	Helsinki	concerning	medical	
research	 in	 humans	 (Recommendations	 Guiding	 Physicians	 in	 Biomedical	 Research	 Involving	
Human	Patients:	adopted	by	the	18th	World	Medical	Assembly	 (WMA),	Helsinki,	Finland,	 June	
1964	and	amended	by	the	29th	WMA,	Tokyo,	Japan,	October	1975,	the	35th	WMA,	Venice,	Italy,	
October	 1983,	 the	 41st	WMA,	 Hong	 Kong,	 September	 1989,	 the	 48th	WMA,	 Somerset	West,	
Republic	of	South	Africa,	October	1996,	and	the	52nd	WMA,	Edinburgh,	Scotland,	October	2000).	
Additional	governing	regulations	included	US	CFR	Title	21,	Part	54	and	US	CFR	Title	21,	Part	312.	
This	 study	was	 also	 conducted	 according	 to	 International	 Conference	 on	Harmonization	 (ICH)	
Good	Clinical	Practices	(GCP).	
Eligibility		
Subjects	were	required	to	meet	the	following	criteria	for	inclusion	in	this	study:	male	or	female	
between	the	ages	of	18	and	75	diagnosed	with	type	2	diabetes	(according	to	WHO	criteria)	who	
were	being	treated	with	diet	and	exercise	alone,	and	not	on	any	medication	for	diabetes;	a	HbA1c	
level	 at	 screening	 and	 baseline	 greater	 than	 6.6%	 and	 less	 than	 9.0%;	 a	 fasting	 glucose	
concentration	less	than	240	mg/dL	(13.3	mmol/l);	a	BMI	of	less	than	or	equal	to	45	kg/m2;	and	a	
stable	 weight	 (±10%)	 for	 3	 months	 prior	 to	 entry	 into	 the	 study.	 Exclusion	 criteria	 included:	
treatment	 with	 any	 sulfonylureas,	 or	 other	 antidiabetic	 medications	 (e.g.,	 thiazolidinediones,	
metformin,	acarbose,	exenatide,	or	insulin)	within	the	prior	3	months;	chronic	(lasting	longer	than	
14	consecutive	days)	systemic	glucocorticoid	treatment	within	4	weeks	of	the	baseline	visit;	use	
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of	any	weight	loss	drugs	within	the	prior	3	months;	proliferative	retinopathy;	known	or	suspected	
abuse	 of	 alcohol	 or	 narcotics;	 any	 experience	 with	 hypoglycemic	 unconsciousness;	 impaired	
hepatic,	 renal	 or	 cardiac	 function;	 uncontrolled	 hypertension;	 pregnancy,	 breastfeeding,	 or	
intention	of	becoming	pregnant	or	 judged	to	be	using	 inadequate	contraception;	documented	
gastrointestinal	 disease,	 or	 taking	 of	 medications	 to	 alter	 gut	 motility	 or	 absorption;	 and	
treatment	with	any	investigational	drug	within	30	days	of	the	screening	visit.		
Three	populations	were	evaluated:		
• The	Intent-to-Treat	(ITT)	population	consisted	of	all	randomized	subjects	who	received	at	
least	one	dose	of	their	randomized	treatment	and	had	at	least	one	post-treatment	visit	
evaluating	efficacy.		
• The	 Per	 Protocol	 (PP)	 population	 consisted	 of	 all	 ITT	 subjects	 who	 had	 at	 least	 80%	
compliance	with	medication	for	75%	of	the	dosing	time	points	and	had	no	major	protocol	
violations.	Subjects	who	had	a	screening	and	visit	2	HbA1c	value	≤	6.6%	and	≥	9.0%	and	
who	were	put	on	other	diabetes	medications	were	excluded	from	PP	population.		
• The	Safety	population	consisted	of	all	randomized	subjects	who	received	at	least	one	dose	
of	 their	 randomized	 treatment	 and	 had	 at	 least	 one	 post-treatment	 visit	 evaluating	
safety.		
Treatment	protocol		
This	was	 a	 Phase	 3,	multicenter,	 randomized,	 double-blind,	 placebo-controlled,	 parallel-group	
study	to	evaluate	the	efficacy,	safety,	and	tolerability	of	D-tagatose.		
Subjects	were	screened	for	eligibility	using	physical	examination	and	clinical	laboratory	tests.	The	
basic	physical	examination	included	physical	measurements,	general	examination	by	observation	
(inspection),	palpation,	percussion,	auscultation,	blood	pressure	measure,	and	heart	rate	check.	
The	 clinical	 laboratory	 tests	 included:	 (1)	 hematology	 (hematocrit,	 hemoglobin,	MCH,	MCHC,	
MCV,	total	white	blood	cells,	platelets,	and	differential);	(2)	clinical	chemistry	(sodium,	chloride,	
potassium,	carbon	dioxide,	BUN,	uric	acid,	albumin,	creatinine	clearance,	SGOT,	SGPT,	bilirubin	
(total	and	direct),	phosphorus,	calcium,	alkaline	phosphatase,	total	protein,	and	glucose	(fasting);	
(3)	 HbA1c;	 (4)	 serum	 lipid	 profile	 including	 total	 cholesterol,	 HDL,	 LDL,	 and	 triglycerides;	 (5)	
urinalysis	(appearance,	volume,	specific	gravity,	pH,	glucose,	protein,	and	microscopic	evaluation	
of	urinary	sediment).	Those	determined	to	be	provisionally	eligible	participated	in	an	8-week	lead-
in	period	prior	to	the	start	of	the	study	during	which	diabetes	education	was	provided	and	diet	
and	exercise	treatment	stabilized.		
Patients	 recorded	 their	 food	 intake	 and	 exercise	 in	 nutrition	 diaries.	 After	 the	 8	week	 lead-in	
period,	fasting	(minimum	of	8	hours)	subjects	returned	to	the	study	sites	and	underwent	medical	
history	review	followed	by	baseline	tests	including	ECG	(or	EKG),	pregnancy	test	for	females,	and	
hematology,	clinical	chemistry,	and	urinalysis	tests.	The	clinical	laboratory	tests	were	the	same	as	
those	performed	during	the	screening	visit.	Subjects	continued	on	a	weight-maintaining	diet	plus	
exercise	 under	 physician’s	 recommendation.	 In	 addition,	 subjects	 received	 their	 randomized	
study	treatment	and	detailed	instructions	about	its	use.	A	total	of	494	subjects	were	randomized	
into	 the	 study.	 Randomization	was	 stratified	 according	 to	 screening	HbA1c	 values	 (<7.5%	and	
≥7.5%)	to	achieve	a	balanced	distribution	of	subjects	across	two	arms	(treatment	and	placebo).		
The	 treatment	 period	 consisted	 of	 12	monthly	 visits,	 the	 first	 (Visit	 2,	 designated	month	 0	 in	
figures)	of	which	was	used	to	gather	the	baseline	data	for	the	efficacy	and	safety	parameters	and	
also	included	the	first	distribution	of	test	and	placebo	treatments.	Baseline	was	defined	as	the	
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last	available	value	before	the	first	randomized	treatment.	Subsequent	visits	occurred	monthly	
and	 were	 of	 two	 types:	 (1)	 Supply	 Visits	 and	 (2)	 Supply	 and	 Procedures	 Visits.	 HbA1c	 was	
monitored	at	baseline	(Visit	2)	and	every	2	months	thereafter	as	were	the	secondary	end-point	
parameters	 (described	 below).	 Efficacy	 analyses	 were	 conducted	 on	 data	 from	 2,	 6,	 and	 10	
months.		
There	were	two	treatment	groups	in	this	trial:	drug	(D-tagatose),	and	placebo	(Splenda).	The	dose	
of	D-tagatose	was	15	g	dissolved	in	125	to	250	mL	of	water	TID;	the	dose	of	placebo	was	1.5	g	
dissolved	in	125	to	250	mL	of	water	TID.	The	placebo	amounts	were	chosen	to	match	sweetness	
for	 blinding.	 The	 powder	 packets	 were	 the	 same	 size	 and	 bore	 the	 same	 labeling	 with	 the	
exception	of	 the	designation	“Substance	A”	or	Substance	B”.	The	entire	drug/placebo	solution	
was	consumed	prior	to	each	main	meal	(breakfast,	lunch,	dinner).	If	severe	gastrointestinal	(GI)	
effects	were	seen,	the	tagatose	dosage	was	reduced	to	10	g	TID	temporarily	and	further	reduced	
to	5	g	TID	if	severe	GI	side	effects	were	not	resolved	within	24	hours.	The	dosage	of	D-tagatose	
would	then	be	increased	to	10	g	TID	and	further	increased	to	15	g	TID	when	patients	had	adapted	
to	 the	 treatment	 (i.e.,	GI	effects	 reduced	 to	mild).	The	placebo	dosage	would	be	 reduced	 in	a	
similar	 fashion	 if	 severe	GI	effects	were	 seen.	That	 is,	 the	dose	could	be	 reduced	 to	1.0	g	TID	
temporarily	and	then	further	reduced	to	0.5	g	TID	if	severe	GI	side	effects	were	not	resolved	within	
24	hours.	The	dosage	of	placebo	was	then	to	be	increased	to	1.0	g	TID	and	further	increased	to	
1.5	g	TID	when	patients	had	adapted	to	the	treatment	(i.e.,	GI	effects	reduced	to	mild).		
Removal	of	Subjects	from	Therapy	or	Assessment		
Premature	end-point:	A	premature	end-point	of	the	efficacy	analysis	for	the	trial	occurred	when	
additional	antidiabetic	medications	were	prescribed	to	a	patient	at	 the	sole	discretion	of	 their	
primary	care	physician.	However,	patients	were	advised	to	continue	in	the	trial	if	an	antidiabetic	
medication	was	added	after	the	start	of	the	trial,	even	though	the	HbA1c	data	were	not	used	in	
efficacy	analyses	at	the	time	points	subsequent	to	the	initiation	of	the	additional	medication(s).	
The	continuation	of	the	trial	was	solely	for	the	safety	analysis	of	D-tagatose	and	patient’s	data	
were	withdrawn	from	the	efficacy	analysis.		
Treatment	 failures:	 Subjects	 were	 categorized	 as	 treatment	 failures	 if	 both	 of	 the	 following	
criteria	were	met:		
1.	HbA1c	change	of	+1.0%	from	baseline	at	any	clinic	visit	or	an	HbA1c	≥10%	or	required	additional	
antidiabetic	medication	for	glycemic	control;		
2.	Received	at	least	80%	of	all	study	drug	doses	within	the	initial	3	month	dosing	period.		
The	need	 for	 additional	 antidiabetic	medication	was	determined	by	 an	elevated	 fasting	blood	
glucose	 value	 (>240	 mg/dL)	 not	 secondary	 to	 a	 readily	 identified	 illness	 or	 pharmacological	
treatment.	 Investigators	were	 to	withdraw	 subjects	 from	 study	 treatment	 (and	 therefore	 the	
evaluable	 population	 for	 assessment	 of	 efficacy	 as	 measured	 by	 HbA1c)	 after	 additional	
antidiabetic	medication	had	been	prescribed.	However,	 subjects	were	advised	to	continue	the	
rest	of	the	trial	procedures	for	the	assessment	of	safety	parameters.		
Criteria	for	Evaluation		
Efficacy:	 The	 primary	 efficacy	 variable	 was	 the	 change	 from	 baseline	 in	 HbA1c	 level	 when	
measured	at	pre-specified	time	points.	Efficacy	analyses	were	conducted	on	data	from	2,	6	and	
10	months	(visit	4,	8	and	12).	Statistical	analyses	were	conducted	on	the	2-month,	6-month	and	
10-month	data	separately.	The	primary	efficacy	endpoint	was	at	2	months	in	the	Intent-To-	Treat	
population.	 Secondary	 efficacy	 endpoints	 for	 change	 in	 HbA1c	 were	 at	 6	 and	 10	 months.	
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Additional	secondary	efficacy	end-points	were	measured	at	the	same	time	points	and	included	
changes	from	baseline	in	(1)	fasting	blood	glucose,	(2)	serum	insulin	levels,	(3)	lipid	profiles	(LDL,	
triglycerides,	total	cholesterol,	HDL),	and	(4)	BMI,	as	well	as	the	proportion	of	subjects	achieving	
HbA1c	targets	of	<7%.		
Safety:	The	safety	parameters	assessed	for	each	subject	included	adverse	events,	serious	adverse	
events,	 vital	 signs,	 results	 of	 physical	 exams,	 12-lead	 ECG,	 and	 clinical	 laboratory	 tests	
(hematology,	chemistry,	and	urinalysis).	
Statistical	 Methods:	 Three	 analysis	 populations	 were	 evaluated:	 (1)	 The	 Intent-to-Treat	 (ITT)	
population,	(2)	the	Per	Protocol	(PP)	population,	and	(3)	the	Safety	population.	The	ITT	population	
was	the	focus	of	the	efficacy	analyses	for	regulatory	purposes,	with	the	PP	population	being	used	
in	 supportive	 analyses.	 For	 the	 ITT	 population,	 missing	 data	 (including	 missing	 values	 at	
intermediate	visits)	were	to	be	imputed	from	scheduled	visits	using	the	last-observation-carried-
forward	(LOCF)	method.		
The	Safety	population	was	used	 for	analyses	of	all	 safety	parameters.	Secondary	efficacy	end-
points	were	evaluated	using	the	closed	test	procedure	(in	order	to	preserve	the	type	I	error	rate,	
α,	of	0.05).	Accordingly,	the	analysis	of	end-points	was	conducted	in	the	following	order:	(1)	body	
mass	index,	(2)	triglycerides,	(3)	LDL,	(4)	total	cholesterol,	(5)	fasting	blood	glucose,	(6)	proportion	
of	 subjects	with	HbA1c	 concentration	 of	 <7%,	 (7)	 insulin,	 and	 (8)	HDL.	 Analysis	 of	 continuous	
efficacy	 variables	 used	mixed-model	 repeated-measures	 analysis	 of	 covariance	 controlling	 for	
covariates	 and	 stratification	 factors	 identified	 as	 significant	 in	 preliminary	 explorations.	
Categorical	efficacy	variables	were	analyzed	using	general	estimating	equation	models.	
Results1	
Study	Population		
There	were	494	subjects	randomized,	185	subjects	in	the	US	and	309	subjects	in	India.	Of	these,	
480	were	treated,	248	with	placebo	and	232	with	D-tagatose	(Table	1).	The	mean	age	of	subjects	
in	 the	 ITT	 population	was	 52	with	 an	 age	 range	 between	 22	 and	 74.	 The	 ITT	 population	was	
approximately	evenly	divided	between	males	and	 females	and	 the	 racial	distribution	was	72%	
Asian,	12%	Caucasian,	11%	Latino	and	5%	Black,	with	approximately	equivalent	distributions	in	
the	D-tagatose	and	placebo	groups.	At	baseline,	approximately	90%	of	subjects	in	both	treatment	
groups	were	controlling	their	diet	and	exercising	in	order	to	control	their	diabetes.		
Table	11	
Analysis	Population	
	
Efficacy	Results		
Primary	Endpoint	Results:	Decrease	in	Hemoglobin	A1c	Level:	The	primary	efficacy	variable	was	
the	change	from	baseline	in	HbA1c	level	when	measured	at	pre-specified	time	points.	An	efficacy	
analysis	was	conducted	on	data	from	2,	6	and	10	months	(Visits	4,	8	and	12).	The	primary	efficacy	
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end-point,	set	at	the	2-month	time	point	in	the	ITT	population,	showed	a	statistically	significant	
difference	(p	=	0.0198)	between	D-tagatose	and	the	placebo	(Figure	1A).	In	the	ITT	population,	
the	 active	 treatment	 group,	 i.e.,	 subjects	 who	 received	 D-	 tagatose,	 showed	 greater	 and	
statistically	significant	reductions	in	HbA1c	levels	at	all	post-baseline	visits	when	compared	to	the	
placebo	group	(Figure	1B).	The	same	mixed	model	analysis	conducted	with	the	PP	population	data	
showed	 similar	 results	 insofar	 as	 the	 population	 receiving	 D-tagatose	 always	 showed	 greater	
decreases	in	HbA1c	compared	to	placebo	(Figure	1C).	The	differences	in	the	PP	population	did	not	
achieve	statistical	significance	until	month	6,	however,	but	then	remained	significant	throughout	
the	remainder	of	the	study.	
Analysis	 of	 subgroups:	 In	 light	 of	 the	 above	 results,	 subgroup	 analyses	 were	 conducted	 to	
examine	whether	 starting	 HbA1c	 levels	 (<	 7.5%	 or	 ≥	 7.5%)	 influenced	 the	 effectiveness	 of	 D-
tagatose.	The	results	of	these	analyses	for	the	ITT	population	(LOCF)	are	shown	in	Figure	2A	and	
2B.	A	significant	difference	between	D-tagatose-	and	placebo-treated	subjects	was	seen	earlier	in	
the	subgroup	entering	with	a	baseline	HbA1c	<	7.5%.,	although	both	subgroups	achieved	greater	
changes	from	baseline	than	those	observed	in	the	placebo	groups.		
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Figure	11	
(A)		Change	in	HbA1c	in	ITT	population	after	2	months	of	treatment.	The	primary	efficacy	endpoint	set	at	2	
months	 in	 the	 ITT	 population	 showed	 a	 significant	 difference	 between	 placebo	 and	 D-tagatose	 groups	
(p=0.0198)	(placebo	n=182,	D-tagatose	n=172).	(B)	Change	in	HbA1c	in	ITT	population.	Significant	differences	
were	seen	at	2	(p=0.0198),	4	(p=0.0160),	6	(p=0.0015),	8	(p=0.0002),	and	10	months	(p=<0.0001).		(C)	Change	
in	HbA1c	in	PP	population.	Significant	differences	were	seen	at	6	(p=0.0343),	8	(p=0.0148),	and	10	months	
(p=0.0021).	Zero	time	points	plotted	as	means,	remaining	time	points	plotted	as	least	squares	means	±SEM.1	
In	 the	 PP	 population	 the	 D-tagatose	 treatment	 for	 both	 subgroups	 demonstrated	 greater	
reductions	in	HbA1c	compared	to	placebo	(with	the	exception	at	6	months	in	the	≥	7.5%	subgroup)	
(Figure	2C	and	2D).	However,	 a	 statistically	 significant	difference	between	 the	D-tagatose	and	
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placebo-treatment	 groups	 was	 only	 achieved	 in	 the	 <7.5%	 subgroup	 (Figure	 2C).	 Statistical	
significance	between	D-tagatose	and	placebo	groups	was	achieved	after	6	months	of	treatment	
in	subjects	with	a	baseline	HbA1c	of	<7.5%	(Figure	2C,	p-values	of	0.0497,	0.029,	and	0.0121	after	
6,	 8,	 and	 10	 months	 of	 treatment,	 respectively),	 whereas	 statistical	 significance	 between	 D-
tagatose	and	placebo	groups	was	not	achieved	in	patients	with	a	higher	baseline	HbA1c	at	any	
time	point	(Figure	2D).		
Figure	21	
(A)	 	Results	of	analyses	for	the	 ITT	population	with	starting	HbA1c	baseline	<	7.5%.	Significant	differences	
between	 D-tagatose	 and	 placebo	were	 seen	 at	 6	 (p=0.0030),	 8	 (p=0.0004),	 and	 10	months	 (p=<0.0001).	
(B)		Change	in	HbA1c	in	ITT	subpopulation	with	baseline	>7.5%.	A	significant	difference	between	D-tagatose	
and	placebo	was	seen	at	10	months	(p=0.0277).	(C)	Change	in	HbA1c	in	PP	subpopulation	with	baseline	HbA1c	
<7.5%,	(D)	Change	 in	HbA1c	 in	PP	subpopulation	with	baseline	>7.5%.	Zero	time	points	plotted	as	means,	
remaining	time	points	plotted	as	least	squares	means	±SEM.1	
Further	 subgroup	analyses	were	conducted	 to	compare	 the	ability	of	D-tagatose	 to	effectively	
decrease	HbA1c	in	the	United	States	(US)	population	of	subjects	versus	subjects	of	Indian	origin.	
Interestingly,	 the	 effect	 on	 lowering	 HbA1c	was	more	 pronounced	 in	 US	 compared	 to	 Indian	
subjects	(Figure	3).	A	subgroup	analysis	on	the	ITT	US	population	(Figure	3A)	showed	a	greater	
and	 statistically	 significant	 LS	mean	 reduction	 in	 HbA1c	 in	 the	 D-tagatose	 groups	 than	 in	 the	
placebo	group	at	all	post-baseline	visits:	month	2	(reduction	of	0.23	vs.	an	increase	of	0.07,	Δ	=	
0.3	and	p	=	0.0273),	month	4	(reduction	of	0.15	vs.	an	increase	of	0.28,	Δ	=	0.4	and	p	=	0.0011),	
month	6	(reduction	of	0.17	vs.	an	increase	of	0.17,	Δ	=	0.3	and	p	=	<0.0001),	month	8	(reduction	
of	0.10	vs.	an	increase	of	0.29,	Δ	=	0.4	and	p	=	<0.0001),	and	month	10	(reduction	of	0.07	vs.	an	
increase	 of	 0.37,	 Δ	 =	 0.4	 and	 p	 =	 <0.0001).	 Analysis	 of	 the	 LOCF	 ITT	 data	 showed	 statistically	
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significant	reductions	in	the	India	population	only	at	month	10	(Δ	=	0.2,	p	=	0.0187)	(Figure	3B).	
PP	analyses	for	the	US	population	produced	similar	results	with	statistically	significant	differences	
being	 noted	 at	 all	 post-baseline	 time	 points	 (Figure	 3C).	 The	 effect	 of	 D-tagatose	 in	 reducing	
HbA1c	 was	 evident	 by	 2	 months	 of	 treatment	 in	 the	 US	 subjects.	 However,	 the	 effect	 of	 D-
tagatose	in	reducing	HbA1c	in	the	Indian	subjects	was	not	significantly	different	than	placebo	at	
any	time	point	in	the	PP	population	(Figure	3D).	
Figure	31	
(A)		Change	in	HbA1c	U.S.	subjects,	ITT	population.		(B)	Change	in	HbA1c,	Indian	subjects,	ITT	population.		(C)	
Change	in	HbA1c	U.S.	subjects,	PP	population.	p-values	for	2,	4,	6,	8,	and	10	months	of	treatment	are	0.0435,	
0.0016,	 <0.0001,	 <0.0001,	 and	 <0.0001,	 respectively.	 (D)	 Change	 in	 HbA1c,	 Indian	 subjects,	 PP	
population.		Zero	time	points	plotted	as	means,	remaining	time	points	plotted	as	least	squares	means	±SEM.1	
Proportion	 of	 Subjects	 Achieving	 HbA1c	 <	 7%:	 The	 data	 from	 the	 ITT	 population	 with	 LOCF	
indicated	that	the	D-tagatose	group	had	a	greater	proportion	of	subjects	achieving	an	HbA1c	level	
of	 less	 than	 7%	 at	 all	 post	 baseline	 time	 points	 compared	 to	 placebo,	 with	 the	 results	 being	
statistically	 significant	 at	 post-baseline	 months	 6,	 8	 and	 10	 (Table	 2).	 Thus,	 the	 percent	 of	
responders	in	the	D-tagatose	group	was	higher	than	in	the	placebo	group	at	6	months	(38.37%	vs	
22.4%),	 8	months	 (40.7%	vs	25.68%)	 and	10	months	 (43.02%	vs	26.23%,	 respectively).	 Similar	
results	 were	 observed	 in	 the	 analyses	 using	 the	 PP	 population	 except	 that	 in	 the	 latter	 case	
statistical	significance	was	observed	at	months	6	and	10	(Table	3).	
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Table	21	
Proportion	of	Subjects	Achieving	HbA1c	<7%,	ITT	Population	
 
Table	31	
Proportion	of	Subjects	Achieving	HbA1c	<7%,	PP	Population	
 
Secondary	 Endpoint	 Results:	 Changes	 in	 BMI,	 fasting	 blood	 glucose,	 insulin,	 blood	 lipids:	D-
tagatose	was	also	evaluated	for	 its	placebo-controlled	treatment	effects	on	BMI,	 fasting	blood	
glucose,	 insulin,	blood	 cholesterol,	 and	 triglyceride	 levels.	 There	was	no	observed	effect	of	D-
tagatose	treatment	on	changes	in	body	weight	or	BMI	(body	mass	index)	compared	to	placebo	in	
either	the	ITT	or	PP	populations.		
For	 the	 ITT	 population	 better	 reductions	 in	 fasting	 blood	 glucose	 levels	 from	 baseline	 were	
observed	in	the	D-tagatose	group	compared	to	the	placebo	group	at	all	post	baseline	time	points	
(Figure	4A),	with	the	differences	in	LS	mean	being	statistically	significant	for	post-baseline	month	
6	and	beyond,	i.e.,	month	6	(reduction	of	2.0	vs.	an	increase	of	4.1,	Δ	=	6.0	and	p	=	0.0440),	month	
8	(reduction	of	0.44	vs.	an	increase	of	2.5,	Δ	2.9	and	p	=	0.0340),	and	month	10	(reduction	of	0.25	
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vs.	 an	 increase	 of	 6.6,	 Δ	 =	 6.9	 and	 p	 =	 0.0079).	 Reductions	 were	 also	 seen	 in	 PP	 population	
analyses;	however,	none	were	statistically	significant	(Figure	4B).	Regardless	of	the	statistically	
significant	difference	in	fasting	blood	glucose	between	placebo	and	D-tagatose	groups,	there	was	
no	 detectable	 consistent	 change	 in	 serum	 insulin	 concentrations	 in	 this	 clinical	 trial	 (data	 not	
shown).	
Figure	41	
(A)	Change	in	fasting	blood	glucose,	ITT	population.	D-tagatose	significantly	decreased	fasting	blood	glucose	
compared	to	placebo	after	6	months	of	treatment.	(B)	Change	in	fasting	blood	glucose	levels,	PP	population.	
No	significant	difference	between	placebo	and	D-tagatose	groups	was	observed	at	any	time	point.	Zero	time	
points	plotted	as	means,	remaining	time	points	plotted	as	least	squares	means	±SEM.1	
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Figure	51	
(A)	Total	cholesterol,	ITT	population.	(B)	Total	cholesterol,	PP	population.	(C)	LDL,	ITT	population.	(D)	LDL,	PP	
population.	(E)	HDL,	ITT	population.	Significant	differences	between	D-tagatose	and	placebo	were	seen	at	2	
(p=0.0126),	4	(p=0.00040,	6	(p=0.0002),	8	(p=0.0003),	and	10	months	(p=0.0008).	(F)	HDL,	PP	population.	The	
only	significant	difference	was	at	4	months	(p=0.0397).		Zero	time	points	plotted	as	means,	remaining	time	
points	plotted	as	least	squares	means	±SEM.1	
Particularly	 interesting	 findings	of	 this	phase	3	clinical	 trial	 include	 the	effect	of	D-tagatose	 to	
significantly	reduce	total	cholesterol	and	LDL-cholesterol	compared	to	placebo.	The	D-tagatose	
group	(ITT	population)	showed	better	reductions	in	total	cholesterol	from	baseline	compared	to	
placebo	at	all	post	baseline	time	points	(Figure	5A),	with	the	differences	becoming	statistically	
significant	after	4	months	of	treatment.	This	effect	was	maintained	for	the	duration	of	the	trial	
(differences	in	LS	means	being	statistically	significant	starting	from	month	4	(reductions	of	8.5	vs.	
3.2,	Δ	=	5.3	and	p	=	0.0402),	month	6	(reductions	of	6.9	vs.	3.2,	Δ	=	3.7	and	p	=	0.0217),	month	8	
(reductions	of	8.1	vs.	5.3,	Δ	=	2.8	and	p	=	0.0157),	and	month	10	(reductions	of	6.9	vs.	5.4,	Δ	=	1.5	
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and	p	=	0.0176).	In	the	PP	population	analyses,	reductions	were	also	seen;	however,	none	were	
statistically	significant	(Figure	5B).	
Better	reductions	from	baseline	in	LDL	levels	were	observed	in	the	D-tagatose-treated	group	(ITT	
population)	than	the	placebo	at	post	baseline	time	points	(Figure	5C),	with	the	differences	in	LS	
mean	being	at	month	6	a	reduction	of	4.8	vs.	0.96,	Δ	=	3.8	and	p	=	0.0211;	at	month	8	a	reduction	
of	6.6	vs.	3.6,	Δ	=	3.0	and	p	=	0.0100;	and	at	month	10	a	reduction	of	7.1	vs.	4.2,	Δ	=	2.9	and	p	=	
0.0057.	Smaller	reductions	were	seen	in	the	PP	population	analyses	and	none	were	statistically	
significant	(Figure	5D).	
The	 results	 of	 analyses	 of	 serum	 HDL	 concentrations	 in	 the	 ITT	 population	 showed	 greater	
decreases	 in	 the	 D-tagatose	 group	 than	 in	 the	 placebo	 group	 with	 the	 differences	 being	
statistically	significant	at	all	post-treatment	time	points	in	the	ITT	population	and	at	the	month	4	
time	 point	 in	 the	 PP	 population	 (Figure	 5E	 and	 5F).	 However,	 the	 mean	 HDL	 values	 always	
remained	 above	 the	 target	 value	 of	 40	mg/dL	 so	 it	 is	 unclear	 whether	 the	 reduction	 in	 HDL	
concentrations	observed	in	the	D-tagatose	group	has	any	clinical	significance.	
Figure	61	
Serum	triglycerides.	(A)	ITT	population.	(B)	PP	population.		Zero	time	points	plotted	as	means,	remaining	time	
points	plotted	as	least	squares	means	±SEM.1	
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Triglyceride	levels	showed	no	benefit	from	D-tagatose	treatment,	i.e.,	the	placebo	group	showed	
greater	reductions	in	triglyceride	levels	than	the	D-tagatose	group	with	the	differences	becoming	
statistically	significant	from	month	8	onward	(i.e.,	at	month	8	a	reduction	of	12.7	vs.	an	increase	
of	1.46,	Δ	=	14.2	and	p	=	0.0301;	and	at	month	10	a	reduction	of	10.8	vs.	an	increase	of	11.2,	Δ	=	
22	 and	 p	 =	 0.0048	 (Figure	 6A)).	 No	 statistically	 significant	 differences	 were	 seen	 in	 the	 PP	
population	analyses	(Figure	6B).	Additionally,	subgroup	analyses	for	subjects	who	had	baseline	
triglyceride	 levels	 1)	 less	 than	 200	mg/dL,	 2)	 between	 200	 and	 500	mg/dL,	 and	 3)	 above	 500	
mg/dL,	 revealed	 no	 statistically	 significant	 differences	 between	 the	 D-tagatose	 and	 placebo	
treatment	groups	(data	not	shown).	
Safety	Results:	D-tagatose	was	reasonably	well	tolerated	by	the	subjects	in	this	trial	with	most	of	
the	adverse	events	(AEs)	experienced	being	mild	to	moderate	in	intensity.	Adverse	events	in	the	
D-tagatose	treatment	group	were	similar	to	that	of	the	placebo	group,	with	most	instances	noted	
as	 GI	 disturbances.	 Importantly,	 there	 were	 no	 reported	 episodes	 of	 hypoglycemia	 or	
pancreatitis.		
The	incidence	of	SAEs	in	the	D-tagatose	group	was	about	one-half	that	seen	in	the	placebo	group.	
The	incidences	of	AEs	by	system	organ	class	were	generally	similar	between	the	placebo	and	D-
tagatose	groups,	the	one	exception	being	AEs	in	the	gastrointestinal	disorders	class.	Most	of	the	
subjects	in	both	treatments	experienced	GI	symptoms;	however,	the	incidence	was	higher	in	the	
D-tagatose	group,	and	the	GI	AEs	were	more	frequently	severe	in	the	D-tagatose	group.	There	
were	no	remarkable	effects	in	other	safety	parameters	with	very	few	clinically	significant	changes	
in	safety	laboratory	values,	ECG	parameters,	vital	signs	or	physical	examinations.		
Discussion	
This	trial	met	its	primary	objective	of	demonstrating	that	D-tagatose	was	effective	at	reducing	the	
HbA1c	level	when	administered	for	two	months	at	doses	of	15	g	TID.	The	secondary	end-point	of	
significant	 reductions	 in	 the	 HbA1c	 level	 at	 six	 and	 ten	months	were	 also	met.	Mixed	model	
analyses	using	the	ITT	population	and	LOCF	imputation	of	missing	values	indicated	significantly	
greater	reductions	in	the	mean	HbA1c	levels	in	the	D-tagatose	group	than	in	the	placebo	group	at	
all	post-baseline	visits.	The	same	mixed	model	analysis	conducted	with	the	PP	population	data	
showed	 similar	 results	 insofar	 as	 the	 population	 receiving	 D-tagatose	 always	 showed	 greater	
decreases	 in	HbA1c	 compared	 to	 placebo.	 Additionally,	 subgroup	 analyses	were	 done	 for	 the	
primary	 end-point	 on	 different	 subgroups	 of	 subjects	 to	 see	 if	 the	 reduction	 in	 HbA1c	 is	
significantly	different	between	the	treatment	groups	in	the	different	subgroups	i.e.,	1)	subjects	
whose	 baseline	 HbA1c	 level	 was	 less	 than	 7.5%,	 2)	 subjects	whose	 baseline	 HbA1c	 level	 was	
greater	than	or	equal	to	7.5%,	3)	subjects	who	were	randomized	 in	 India,	and	4)	subjects	who	
were	randomized	in	US.	In	these	analyses	the	results	were	generally	agreement	with	the	primary	
results	although	in	the	India	subgroup	the	results	were	statistically	significant	at	far	fewer	time	
points.	Additionally,	it	was	observed	that	a	greater	proportion	of	subjects	in	the	D-tagatose	group	
had	achieved	HbA1c	targets	of	<7%;	this	difference	was	also	found	to	be	statistically	significant	
for	the	majority	of	the	post-baseline	time	points.	Regardless	of	the	subgroup	analyzed,	the	effect	
of	D-tagatose	to	decrease	HbA1c	 levels	was	robust	and	could	be	seen	with	differing	analytical	
approaches.	These	results	demonstrate	the	ability	of	D-tagatose	to	effectively	aid	in	the	control	
of	blood	sugar	levels	for	type	2	diabetics	and	suggest	D-tagatose	as	a	potential	drug	therapy	in	
this	area.		
Statistically	significant	differences	were	observed	between	the	D-tagatose	and	placebo	treatment	
groups	 for	 the	 secondary	 end-points	 LDL,	 total	 cholesterol,	 and	 fasting	 blood	 glucose	 when	
examining	 the	 ITT	 population.	 Reductions	were	 also	 seen	 in	 PP	 population	 analyses,	 however	
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none	were	 statistically	 significant.	 Numerous	 studies	 have	 demonstrated	 that	 increased	 total	
cholesterol	and	particularly	elevated	LDL-cholesterol	are	associated	with	amplified	 risk	 for	 the	
development	 of	 cardiovascular	 disease.	 Thus,	 this	 finding	 is	 especially	 important	 for	 type	 2	
diabetic	patients	that	may	also	battle	dyslipidemia	and/or	the	metabolic	syndrome.21		
There	were	also	two	end-points,	 triglycerides	and	HDL	 levels,	where	the	D-tagatose	treatment	
produced	greater	and	statistically	significant	increases	in	the	case	of	triglycerides	and	decreases	
in	the	case	of	HDL	levels	compared	to	the	placebo	group	in	the	ITT	population.	The	PP	population	
however,	 showed	 no	 significant	 difference	 in	 triglycerides	 or	 HDL	 between	 placebo	 and	 D-
tagatose.	Of	note,	a	recent	study	by	Donner	et	al.	demonstrated	a	striking	and	significant	effect	
of	D-tagatose	to	increase	HDL	from	a	baseline	level	of	30.5	±	15.8	to	41.7	±	12.1	mg/dL	(p<0.001)	
after	10	months	of	treatment	in	6	subjects	who	did	not	take	lipid	medications	during	the	study.14	
Beginning	HDL	levels	in	the	current	study	were	higher	(mean	placebo	45.8,	D-tagatose	44.5	in	ITT	
and	mean	placebo	45.5,	D-tagatose	45.5	in	PP)	than	in	the	Donner	study.	The	differences	in	results	
between	these	studies	could	be	from	this	initial	HDL	level	discrepancy,	and	any	elevations	in	HDL	
that	D-tagatose	is	able	to	provide	may	only	manifest	if	HDL	levels	are	below	recommended	values.	
Consequently,	 further	studies	are	needed	to	elucidate	 the	direct	effects	of	D-tagatose	on	HDL	
cholesterol	levels.	HDL-cholesterol	levels	are	inversely	related	to	risk	of	developing	cardiovascular	
disease.	
There	was	no	observed	effect	of	D-tagatose	treatment	on	changes	in	body	weight	or	BMI	(body	
mass	index)	compared	to	placebo	in	either	the	ITT	or	PP	populations.	In	contrast	to	these	findings,	
previous	 studies	 in	 humans14	 and	 rodents13	 have	 demonstrated	 significant	 weight	 loss	 and	 a	
reduction	in	body	weight	gain	with	D-tagatose,	respectively.	The	mean	body	weight	of	subjects	
(both	D-tagatose	and	placebo	groups)	included	in	this	phase	3	clinical	trial	at	baseline	was	73.8	
kg,	 or	 162	 pounds;	 with	 an	 average	 BMI	 of	 28.3	 mg/m2	 (overweight	 category).	 However,	 in	
previous	studies	which	have	demonstrated	an	effect	of	D-tagatose	to	promote	weight	loss,	the	
mean	body	weight	of	all	 subjects	at	baseline	was	much	higher	 (mean	body	weight	at	baseline	
~109	kg,	or	240	pounds.14	 Thus,	 it	 is	plausible	 that	 the	 subject	population	within	 this	phase	3	
clinical	trial	was	not	adequately	overweight	to	demonstrate	an	effect	of	D-tagatose	to	promote	
weight	loss.		
D-tagatose	appeared	to	be	reasonably	well	tolerated	by	the	subjects	in	this	trial	with	most	of	the	
AEs	experienced	being	mild	 to	moderate	 in	 intensity.	 The	 incidence	of	 SAEs	 in	 the	D-tagatose	
group	was	about	one-half	that	seen	in	the	placebo	group.	The	incidences	of	AEs	by	system	organ	
class	were	generally	similar	between	the	placebo	and	D-tagatose	group,	the	one	exception	being	
AEs	in	the	gastrointestinal	disorders	class.	Most	of	the	subjects	in	both	treatments	experienced	
GI	symptoms;	however,	the	incidence	was	generally	higher	in	the	D-tagatose	group,	and	the	GI	
AEs	were	more	frequently	severe	in	the	D-tagatose	group.	There	were	no	remarkable	effects	in	
other	safety	parameters	with	very	few	clinically	significant	changes	in	safety	laboratory	values,	
ECG	parameters,	 vital	 signs	 or	 physical	 examinations.	 Previous	 single-dose	 and	 repeated-dose	
studies	 in	 healthy	 and	diabetic	 human	 subjects	 showed	 that	 the	predominant	 adverse	 effects	
associated	 with	 consumption	 of	 high	 levels	 D-tagatose	 were	 gastrointestinal	 disturbances	
attributed	to	osmotic	effects	from	incompletely	absorbed	tagatose.14–19,22–24	At	single	doses	of	up	
to	 25	 g	 D-tagatose	 per	 meal,	 flatulence	 was	 generally	 the	 only	 side	 effect,	 with	 nausea,	
borborygmi	 (i.e.,	 rumbling	 or	 gurgling	 noises,	 colic,	 and	 laxation	 noted	 at	 higher	 doses).	 Such	
effects	 are	 also	 commonly	 associated	 with	 excessive	 consumption	 of	 other	 poorly	 digestible	
carbohydrates.		
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In	 summary,	 results	 of	 this	 phase	 3	 clinical	 trial	 demonstrate	 an	 effect	 of	 D-tagatose	 to	
significantly	decrease	HbA1c	levels	over	time	compared	to	placebo.	The	longer	subjects	remained	
on	 the	 treatment,	 the	 further	HbA1c	was	 reduced.	D-tagatose	 treatment	also	 reduced	 fasting	
blood	glucose	levels	and	total	and	LDL-cholesterol	concentrations.	
Conclusions	
• D-tagatose	was	effective	at	lowering	HbA1c	levels	when	administered	at	a	daily	dose	of	
15	g	in	125-	250	mL	of	water	three	times	per	day	just	prior	to	meals.		
• Unlike	 many	 other	 diabetes	 drugs,	 the	 longer	 a	 patient	 is	 on	 D-tagatose	 therapy	 in	
compliance	with	instructions,	the	better	the	efficacy.		
• The	effect	on	HbA1c	 levels	was	robust	and	could	be	demonstrated	 in	both	subgroups,	
various	subpopulations,	and	with	differing	analytical	approaches.		
• D-tagatose	appeared	to	be	reasonably	well	tolerated	with	most	of	the	AEs	experienced	in	
both	treatment	groups	being	mild	or	moderate	in	severity.		
Bloomgarden	et	al.’s	analysis	of	61	studies	shows	that	the	degree	of	decrease	in	HbA1c	produced	
by	drugs	for	treating	type	2	diabetes	is	dependent	on	the	baseline	HbA1c;	the	higher	the	baseline	
the	greater	the	decrease.	When	the	baseline	HbA1c	was	<8.0%,	the	reduction	from	active	therapy	
is	only	0.1–0.2%	greater	than	in	the	control	group.	When	the	HbA1c	was	>8.0	to	11.8	the	reduction	
in	HbA1c	was	 between	 -0.6	 and	 -1.2%,	 and	 the	 greater	 the	HbA1c,	 the	 greater	 the	 reduction	
overall.25		
In	this	study	the	mean	HbA1c	baselines	were	7.6%	±	0.75	(±	stdev)	and	7.4%	±	0.59	for	placebo	
and	D-tagatose	groups	respectively	 in	the	ITT	population,	and	7.7%	±	0.64	and	7.5%	±	0.53	for	
placebo	and	D-tagatose	groups	respectively	in	the	PP	population.	Based	on	Bloomgarden’s	study	
(see	 Table	 1	 in	 Bloomgarden)25,	 other	 drugs	 show	 an	 average	 of	 only	 half	 the	 efficacy	 of	 D-
tagatose	in	similar	patients.	Overall	results	of	this	phase	3	clinical	trial	suggest	a	strong	potential	
for	D-tagatose	as	an	adjunct	in	the	management	of	type	2	diabetes.		
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Appendix	B	
Effects	 of	 Three	 Low-Doses	 of	 D-Tagatose	 on	 Glycemic	 Control	 Over	 Six	Months	 in	
Subjects	with	Mild	Type	2	Diabetes	Mellitus	Under	Control	with	Diet	and	Exercise1	
Mark	Ensor,	Jarrod	Williams,	Rebecca	Smith,	Amy	Banfield,	and	Robert	A.	Lodder	
Department	of	Pharmaceutical	Sciences,	College	of	Pharmacy,	University	of	Kentucky,	USA	
Abstract1	
The	primary	objective	of	this	study	was	to	evaluate	the	safety	and	the	effect	of	D-tagatose	on	the	
glycemic	control	of	subjects	with	type	2	diabetes	as	determined	by	HbA1c	levels	at	the	end	of	6	
months	 of	 therapy	 using	 the	 subject’s	 own	 baseline	 HbA1c	 level	 as	 a	 comparator.	 The	
determination	of	the	minimal	dose	required	to	cause	a	statistically	significant	reduction	in	HbA1c	
was	of	particular	interest.	Eight	weeks	after	screening,	the	qualifying	subjects	were	randomized	
to	receive	one	of	three	doses	of	D-tagatose:	2.5	g	TID,	5.0	g	TID	or	7.5	g	TID.	Blood	levels	of	HbA1c,	
fasting	blood	glucose	concentrations,	plasma	lipids,	changes	in	body	weight,	changes	in	body	mass	
index,	and	change	in	insulin	levels	were	checked	at	each	study	visit	and	at	the	end	of	the	study.	
Treatment	success,	as	measured	by	the	reduction	of	HbA1c,	was	greatest	for	the	7.5	g	D-tagatose	
dose	group,	although	the	difference	between	the	treatments	was	not	statistically	significant.	For	
fasting	glucose,	only	the	7.5	g	dosage	group	exhibited	reductions	from	baseline	at	the	3-	and	6-
month	time	points.	Mean	body	weights	reduced	in	a	dose-response	fashion,	with	the	5.0	g	and	
the	7.5	g	D-tagatose	doses	providing	the	greatest	reductions.	D-tagatose	at	dosages	of	2.5	g,	5.0	
g,	and	7.5	g	TID	for	six	months	were	well	tolerated	by	this	subject	population.	D-tagatose	at	5.0	g	
TID	was	the	minimal	dose	required	to	reduce	HbA1c.	D-tagatose	at	7.5	g	TID	provided	the	greatest	
effect	in	most	measured	efficacy	parameters.	
Introduction1	
Peripheral	 insulin	 resistance	 and	 progressive	 failure	 of	 pancreatic	 β-cell	 function	 leading	 to	
inadequate	 insulin	 secretion	 are	 the	 two	 principal	 abnormalities	 that	 characterize	 the	
pathogenesis	 of	 type	2	diabetes.2	 Early	 intervention	 at	 the	onset	of	 type	2	diabetes	 generally	
consists	of	maintaining	a	proper	diet	and	weight,	along	with	regular	exercise.	If	control	of	blood	
glucose	 deteriorates	 further,	 then	 pharmacological	 intervention	 with	 one	 or	 more	 oral	 anti-
diabetic	agents	is	required.	Unfortunately	for	many,	type	2	diabetes	will	continue	to	progress	and	
exogenous	 insulin	 treatment	 as	 primary	 therapy	 with	 oral	 anti-diabetic	 agents	 as	 adjunctive	
therapy	are	required	in	order	to	achieve	glycemic	control.	Treatment	with	insulin	is	usually	a	point	
of	no	return	for	these	patients	and	a	major	treatment	goal	is	to	prevent	progression	to	this	point.	
Despite	 all	 of	 these	 interventions	 including	 insulin	 and	 the	 introduction	of	 a	 number	of	 novel	
agents	 for	 the	treatment	of	 type	2	diabetes	 in	recent	years,	glucose	control	 for	many	remains	
unsatisfactory.	
Recently,	 a	 review	 that	 included	140	 controlled	 trials	 and	26	observational	 studies	 comparing	
diabetes	medications,	both	as	monotherapy	and	in	two-drug	combinations,	concluded	that	there	
was	not	enough	evidence	to	clearly	support	the	use	of	one	drug	or	drug	combination	over	another	
for	 stemming	 the	 complications	 of	 diabetes,	 including	 macrovascular	 and	 microvascular	
complications	and	mortality.3	Metformin,	a	drug	introduced	in	the	United	States	in	1994	and	as	
early	as	1958	in	other	countries,	is	still	the	most	common	first	drug	of	choice	for	the	treatment	of	
type	2	diabetes.	Compared	to	the	newer	drugs,	metformin	is	the	drug	that	has	the	highest	benefit-
to-risk	ratio	for	intermediate	outcomes,	such	as	HbA1c	reduction,	less	weight	gain	and	less	risk	of	
hypoglycemia.	However,	no	currently	available	therapy	has	been	shown	to	slow	the	decline	in	β-
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cell	function	in	established	type	2	diabetes.	Even	with	aggressive	intervention,	it	is	estimated	that	
60%	of	diabetics	don’t	achieve	target	blood	sugar	levels	with	their	current	treatment.4	Moreover,	
particular	drugs	available	for	treatment	of	diabetes	may	result	in	unwanted	weight	gain	(long	and	
rapid	 acting	 insulin,	 sulfonylureas,	 thiazolidinediones,	 repaglinide,	 nateglinide),	 hypoglycemia	
(insulin,	 sulfonylureas),	 gastrointestinal	 distress	 (metformin,	 α-glucosidase	 inhibitor,	 amylin	
mimetics,	 bile	 acid	 sequestrant,	 bromocriptine),	 or	 more	 serious	 adverse	 events	 such	 as	
pancreatitis	 (short	 and	 long-acting	 glucagon-like	 peptide-1	 (GLP-1)	 agonists	 and	 dipeptidyl	
peptidase-4	 (DDP-4)	 inhibitors).5,6	 These	 findings	 illustrate	 the	 limitations	 of	 drug	 therapies	
currently	available	for	the	progression	of	diabetes.	
The	observation	that	many	diabetics	are	not	able	to	consistently	control	their	blood	sugar	levels	
within	recommended	limits	using	the	best	available	treatments,	uncovers	the	serious	need	for	a	
drug	that	can	slow	and/or	halt	the	progression	of	diabetes.	Preferably,	such	a	drug	should	exhibit	
a	unique	mode	of	action	to	enable	additive	or	synergistic	use	with	current	therapies;	produce	no	
weight	gain,	hypoglycemia,	or	other	limiting	or	unmanageable	side	effects;	preserve	or	enhance	
β-cell	function;	and	reduce	cardiovascular	risk	factors	that	lead	to	morbidity	and	mortality.	
D-tagatose	 is	an	 isomer	of	fructose	and	 is	~90%	as	sweet	as	sucrose,	or	sugar.	D-tagatose	was	
designated	in	2001	as	a	Generally	Recognized	as	Safe	(GRAS)	product	by	the	United	States	Food	
and	 Drug	 Administration	 and	 is	 used	 as	 a	 nutritive	 or	 low-calorie	 sweetener.7,8	 Currently,	 D-
tagatose	may	be	used	as	a	sweetener	in	diet	beverages,	light	ice	creams	or	yogurts,	and	regular	
or	dietetic	hard	candies	[Rulis	Agency	response	letter	GRAS	notice].	Preliminary	animal	and	pre-
clinical	studies	of	D-tagatose	have	demonstrated	its	ability	to	lower	blood	glucose	and	lipoprotein	
levels.	When	consumed,	D-tagatose	functions	as	a	“sugar	blocker”	by	inhibiting	lipid	formation	
from	 carbohydrates	 without	 stimulation	 of	 pancreatic	 beta	 cells	 for	 insulin	 production	 or	
secretion.8	Regarding	lipoprotein	levels,	D-tagatose	has	been	shown	to	reduce	total	cholesterol	
and	VLDL	and	LDL-cholesterol	when	compared	to	sucrose,9	and	increase	HDL-cholesterol	levels.10	
A	number	of	clinical	trials	demonstrating	the	ability	of	D-tagatose	to	blunt	postprandial	rises	in	
blood	 glucose	 and	 reduce	 HbA1c	 have	 been	 conducted	 on	 healthy	 subjects	 and	 diabetic	
patients.10–15	Single-dose	and	repeated-dose	studies	in	healthy	and	diabetic	human	subjects	have	
shown	 that	 the	 predominant	 adverse	 effects	 associated	 with	 excessive	 consumption	 of	 D-
tagatose	 are	 gastrointestinal	 disturbances	 attributed	 to	 osmotic	 effects	 from	 incompletely	
absorbed	D-tagatose.10–15	Such	effects	are	also	commonly	associated	with	excessive	consumption	
of	other	poorly	digestible	carbohydrates	including	polyols.	Therefore,	D-tagatose	shows	promise	
in	multiple	clinical	applications,	including	the	treatment	of	diabetes.	In	short,	D-tagatose	provides	
glycemic	and	lipoprotein	control	through	a	mechanism	of	action	unlike	any	agent	that	is	currently	
available	on	the	market	in	the	United	States.	
The	primary	objective	of	this	study	was	to	evaluate	the	effect	of	three	low-doses	of	D-tagatose	on	
the	glycemic	control	of	subjects	with	type	2	diabetes.	The	purpose	was	to	determine	the	minimum	
dose	able	to	reduce	HbA1c.	The	secondary	objectives	were	to	evaluate	the	effect	of	these	three	
doses	of	D-tagatose	compared	to	the	subject’s	own	baseline	levels	for:	
• HbA1c	at	each	study	visit	
• fasting	plasma	glucose	
• fasting	lipid	profiles	
• insulin	concentration	
• changes	in	body	weight	
• the	number	of	subjects	requiring	additional	anti-diabetic	medications	and/or	withdrawal	
from	the	study	due	to	high	glycemic	measurements	
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In	addition,	the	safety	of	D-tagatose	 in	regards	to	hypoglycemic	episodes,	gastrointestinal	side	
effects,	other	adverse	events,	clinical	laboratory	abnormalities,	and	physical	examinations	were	
evaluated.	
Subjects	and	Methods1	
Ethics	
The	protocol	was	reviewed	and	approved	by	an	Institutional	Review	Board	(IRB)	before	the	study	
was	 initiated.	 This	 trial	was	 conducted	 in	 accordance	with	 regulations	 governing	 clinical	 trials	
including	the	US	Code	of	Federal	Regulations	(CFR),	Title	21,	Part	50;	regulations	governing	IRBs,	
Title	 21,	 Part	 56;	 and	 the	 Declaration	 of	 Helsinki	 concerning	 medical	 research	 in	 humans.	
Additional	governing	regulations	included	US	CFR	Title	21,	Part	54	and	US	CFR	Title	21,	Part	312.	
This	 study	was	 also	 conducted	 according	 to	 International	 Conference	 on	Harmonization	 (ICH)	
Good	Clinical	Practices	(GCP).	
Subject	Information	and	Consent	
Prior	to	entry	into	the	study,	the	nature	and	risks	of	the	study	were	reviewed	with	each	subject.	
Each	subject	or	each	subject’s	 legal	 representative	was	given	the	opportunity	 to	read	the	 IRB-
approved	consent	form	and	to	ask	questions.	
Criteria	for	Evaluation	
The	populations	analyzed	for	efficacy	endpoints	were	the	intent-to-treat	(ITT)	population	and	the	
efficacy	 evaluable	 (EE)	 population.	 The	 population	 used	 to	 analyze	 safety	 parameters	 was	
identical	to	the	ITT	population.	Analysis	of	demographic	and	baseline	for	the	ITT,	EE	and	Safety	
populations	 indicated	 no	 gross	 dissimilarities	 between	 the	 three	D-tagatose	 dose	 groups.	 The	
majority	 of	 subjects	 in	 each	of	 the	 treatment	 groups	 and	populations	were	male,	 Asian,	 non-
smoking,	non-drinking,	around	50	years	of	age,	weighing	approximately	150	 lbs,	with	diet	and	
exercise	for	control	of	their	diabetes.	Usage	of	allowable	medications	during	the	trial	was	also	
similar	across	the	three	treatment	groups.	
Primary	 Efficacy	 Endpoint—The	 primary	 endpoint	 for	 this	 Phase	 2	 dose-ranging	 study	 was	 a	
decrease	of	≥	0.5%	in	HbA1c	level	after	6	months	of	the	study	treatment.	
Secondary	Efficacy	Endpoints—Secondary	endpoints	for	this	study	 included	assessment	of	the	
effects	of	D-tagatose	on	other	glycemic	control	measurements.	These	measurements	 included	
the	proportions	of	subjects	at	each	visit	who	achieved	a	decrease	in	HbA1c	of	≥	0.5%;	proportions	
of	subjects	at	each	visit	who	achieved	a	decrease	in	HbA1c	level	of	≥	1%;	change	from	baseline	to	
each	 study	 visit	 in	 fasting	 blood	 glucose	 concentrations,	 and	 plasma	 lipids	 (triglycerides,	 low	
density	 lipoprotein,	 total	 cholesterol,	 and	 high	 density	 lipoprotein);	 changes	 in	 body	 weight;	
changes	in	body	mass	index;	and	change	in	insulin	levels.	
Safety—Descriptive	statistics	and	by-subject	data	listings	were	prepared	for	all	safety	parameters.	
No	inferential	statistics	were	performed	for	safety	parameters.	Safety	was	assessed	through	the	
entire	duration	of	the	study,	and	in	the	event	of	an	adverse	event	(AE)	or	serious	adverse	event	
(SAE),	safety	was	to	be	monitored	until	 the	AE/SAE	resolved,	or	until	 the	AE/SAE	was	deemed	
chronic	or	stable	by	the	investigator.	
Study	Design	and	Plan	
This	 study	was	 designed	 as	 a	 prospective,	 randomized,	 6-month,	 parallel	 dose-ranging	 trial	 in	
subjects	with	mild	type	2	diabetes	who,	at	the	time	of	randomization,	were	not	taking	any	oral	
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anti-diabetic	or	anti-hyperglycemic	medication	or	parenteral	anti-diabetic	medication	and	were	
controlling	their	diabetes	with	diet	and	exercise	alone.	This	Phase	2	parallel	dose-ranging	trial	was	
designed	to	evaluate	the	dose-response	effect	of	minimal	doses	of	D-tagatose	(2.5,	5.0,	or	7.5	g,	
TID)	on	glycemic	control	in	subjects	with	type	2	diabetes,	who	had	undergone	an	8-week	run-in	
period	 of	 standardized	 diet	 and	 exercise.	 This	 8-week	 stabilization	 period	 was	 considered	 a	
sufficient	 duration	 of	 standardized	 diet	 and	 exercise	 to	 provide	 a	 homogenous	 population	 of	
subjects	with	type	2	diabetes.	No	active	control	group	was	utilized	in	the	design	as	the	study	was	
intended	as	a	dose-ranging	trial.	The	data	from	this	trial	was	not	intended	to	provide	evidence	of	
equivalence	or	superiority	to	any	currently	marketed	medication.	
A	total	of	112	subjects	were	planned	to	be	randomized	into	the	study	(i.e.,	34	subjects	to	each	of	
three	 treatment	 groups:	 2.5	 g,	 5.0	 g,	 and	 7.5	 g	 D-tagatose	 given	 orally,	 three	 times	 daily,	
immediately	prior	to	meals).	Eight	weeks	after	screening	and	stabilization,	qualified	subjects	were	
randomized	to	receive	one	of	three	doses	of	D-tagatose.	All	doses	of	D-tagatose	were	premixed	
with	drinking	water	into	a	solution	of	4	ounces	per	dose.	The	study	design	is	depicted	in	Figure	1.	
At	the	initial	visit	(Visit	1)	subjects	were	screened	for	eligibility	for	entering	the	study.	Subjects	
who	were	eligible	were	those	diabetic	subjects	treated	solely	with	diet	and	exercise	and	who	had	
mildly	elevated	HbA1c	levels	but	were	otherwise	in	good	health	and	were	not	suffering	from	any	
serious	complications	of	diabetes	or	any	other	significant	concurrent	disease.	Subjects	were	not	
to	be	taking	any	medications	for	the	treatment	of	type	2	diabetes.	The	screening	visit	consisted	
of	each	subject	undergoing	a	review	of	their	relevant	medical	history	and	a	physical	examination,	
both	of	these	primarily	aimed	at	finding	any	abnormalities	related	to	complications	of	diabetes.	
Additionally,	clinical	laboratory	testing	(including	comprehensive	hematology,	clinical	chemistry,	
liver	function	tests,	 lipid	profile,	HbA1c	levels	and	urinalysis)	was	performed.	At	the	end	of	the	
screening	visit,	potentially	eligible	study	subjects	were	instructed	to	follow	a	weight-maintaining	
diet	and	a	daily	exercise	program	under	the	supervision	of	the	investigator.	They	were	given	a	
blank	subject	diary	and	a	nutritional	diary,	and	were	scheduled	for	the	second	visit	(Visit	2)	after	
8	weeks	of	stabilization.	No	study	drug	was	distributed	at	the	screening	visit	(Visit	1).	
Figure	11	
Study	Schedule	
Subjects	underwent	an	8-week	run-in	period	of	standardized	diet	and	exercise	to	provide	a	homogenous	
population	of	subjects	with	type	2	diabetes	prior	to	randomization	into	three	treatment	groups.	Treatment	
lasted	for	6	months.	Total	duration	of	the	study	for	subjects	was	24	weeks	with	five	study	visits	during	the	
trial.1	
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All	subjects	who	were	eligible	were	randomized	during	Visit	2	which	took	place	within	8	weeks	(±	
7	days)	of	Visit	1.	This	was	a	single-blind	study,	in	which	subjects	were	blinded	to	dose	group.	At	
Visit	2,	prior	to	randomization,	baseline	procedures	including	a	complete	medical	evaluation	with	
a	review	of	medical	history	changes	since	Visit	1	and	a	physical	examination	were	performed	on	
qualifying	 subjects.	 In	 addition,	 subjects	 had	 blood	 drawn	 for	 clinical	 laboratory	 testing	 and	
urinalysis.	
Table	11	
Schedule	of	Events	
	
Visit	1	
Screening	
Visit	2	
Randomization	
Visit	3	
Month	1	
Visit	4	
Month	3	
Visit	5	
End	of	Study	
Subject	Registration	to	Study	 X	 	 	 	 	
Inclusion	and	Exclusion	Criteria	 X	 	 	 	 	
Informed	Consent*		 X	 	 	 	 	
Physical	Examination	 X	 X	 	 	 X	
Medical	History/Update	 X	 X	 X	 X	 X	
Record	Concomitant	Medications	 X	 X	 X	 X	 X	
Record	Adverse	Events	 	 X	 X	 X	 X	
Hematology	Panel	 X	 X	 X	 X	 X	
Chemistry	Panel†		 X	 X	 X	 X	 X	
Liver	Function	Tests‡	 X	 X	 X	 X	 X	
Lipid	Profile§		 X	 X	 X	 X	 X	
HbA1c	levels	 X	 X	 X	 X	 X	
Urinalysis	Panel	 X	 X	 X	 X	 X	
Dispense	Study	Drug	 	 X	 X	 X	 	
Dispense	diaries	 X	 X	 X	 X	 	
Compensation	 X	 X	 X	 X	 X	
Collect	empty	study	drug	
vials/packages	 	 	 X	 X	 X	
Collect	completed	subject	diaries	 	 X	 X	 X	 X	
*	Explained	to	and	signed	by	subject	
†	SMA-18	(or	equivalent),	creatinine	clearance,	and	insulin	levels		
‡	Alanine	transaminase	(ALT),	aspartate	aminotransferase	(AST),	total	bilirubin,	alkaline	phosphatase,	total	
protein,	and	albumin	
§	Total	cholesterol,	high-density	lipoprotein	(HDL),	low-density	lipoprotein	(LDL),	and	triglycerides1	
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Randomization	was	stratified	by	site	and	baseline	HbA1c	 levels	 (<	7.5%	or	≥	7.5%)	 to	obtain	a	
balanced	distribution	of	subjects	across	the	three	arms	of	the	trial.	In	addition	to	a	supply	of	study	
medication,	subjects	received	a	diary	and	diary	completion	instructions	for	recording	side	effects,	
intercurrent	illnesses/symptoms,	and	concomitant	medications.	
For	Visits	3	and	4,	subjects	returned	to	the	clinic	for	diary	assessment,	blood	tests,	and	study	drug	
compliance	assessment	and	dispensation	of	additional	study	drug.	Each	of	these	visits	had	a	±	7	
day	window.	Subjects	had	blood	drawn	for	clinical	laboratory	testing	and	urinalysis.	
During	the	final	visit	(Visit	5),	the	diary	and	all	used	and	unused	medication	packets	were	collected	
and	 all	 assessments	 conducted	 at	 Visits	 3	 and	 4	 were	 repeated.	 Additionally,	 a	 final	 physical	
examination	was	 conducted.	 Subjects	were	 instructed	 to	 return	 to	 their	primary	physician	 for	
subsequent	diabetes	care	and	follow-up.	This	visit	had	a	±	7	day	window.	The	efficacy	and	safety	
measurements	 that	were	 evaluated	 throughout	 the	 study	 are	 provided	 in	 the	 study	 schedule	
(Table	1).	
In	the	event	a	subject	was	discontinued	for	any	reason,	an	attempt	was	to	be	made	to	keep	the	
subject	 on	 the	 safety	 arm	 of	 the	 study.	 Study	 treatment	 for	 discontinued	 subjects	was	 to	 be	
stopped	but	the	subject	was	to	continue	with	the	protocol	assigned	study	visits	but	not	the	interim	
study	drug	supply	visits.	In	the	event	the	subject	declined	participation	in	the	safety	arm	of	the	
trial,	after	treatment	discontinuation,	Visit	5	(the	End	of	Study	Visit)	was	to	be	scheduled	at	least	
30	days	after	the	last	dose.	
Clinical	Samples	
Blood	 samples	 used	 to	 assay	 HbA1c,	 blood	 glucose,	 insulin	 concentrations	 and	 lipids	 (total	
cholesterol,	triglycerides,	HDL,	and	LDL)	were	taken	at	each	study	visit,	 including	the	screening	
visit	prior	to	the	run-in	period.	All	samples	were	collected	and	processed	at	the	study	center	and	
then	forwarded	to	the	central	laboratory	(ICON	Central	Laboratories,	Inc.,	Farmingdale,	NY),	by	
overnight	courier,	for	assay.	
Statistical	Method	
Three	analysis	populations	were	evaluated:	
Intent-to-Treat	 (ITT)	 Population—The	 main	 efficacy	 analysis	 was	 conducted	 using	 the	 ITT	
Population.	The	ITT	population	included	all	subjects	who	had	signed	the	study	Informed	Consent	
Form,	 received	 the	 protocol-specified	 treatment,	 and	 had	 a	 baseline	 and	 at	 least	 one	 post-
baseline	HbA1c	value.	
Efficacy	Evaluable	(EE)	Population—The	EE	population	was	used	for	supportive	analyses.	The	EE	
population	consisted	of	all	randomized	subjects	who	completed	treatment	periods,	received	at	
least	80%	of	the	study	medication,	and	had	no	major	protocol	violations	or	eligibility	violations.	
All	protocol	violations	were	to	be	identified	prior	to	database	lock.	
Safety	Population—The	safety	population	was	used	for	the	analysis	of	safety	variables.	The	safety	
population	 consisted	 of	 all	 randomized	 subjects	 who	 received	 at	 least	 one	 dose	 of	 study	
medication	and	had	at	least	one	post	treatment	visit	of	safety	assessment.	
Determination	of	Sample	Size	
The	 sample	 size	 calculation	was	 based	 on	 a	 reduction	 of	 at	 least	 0.5%	 in	HbA1c	 level	 after	 6	
months	of	the	study	treatment	compared	to	baseline	for	each	dose	group,	a	standard	deviation	
of	1.0	for	each	treatment	group,	and	an	80%	statistical	power	with	a	two-sided	analysis	at	a	Type	
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I	error	rate	of	0.05.	The	required	number	of	evaluable	subjects	was	about	102	(34	for	each	D-
tagatose	dose	group)	based	on	nQuery	Advisor,	version	6.01.	A	total	of	40	subjects	per	treatment	
group	(120	subjects	for	the	study)	were	to	be	recruited,	as	it	was	expected	to	observe	a	15%	drop	
out	rate	 in	this	study	population,	and	a	total	of	150	subjects	(50	for	per	treatment	group)	was	
screened	based	on	the	estimated	screen	failure	rate	of	20%.	
Descriptive	statistics	and	by-subject	data	listings	were	prepared	for	all	efficacy	parameters.	For	
continuous	 data,	 summaries	 included	 number	 of	 observations,	 mean,	 standard	 deviation,	
median,	minimum,	 and	maximum	values.	 For	 categorical	 data,	 summaries	 included	 frequency	
counts	and	percentages.	All	statistical	tests	used	in	efficacy	assessments	were	2-sided,	with	no	p-
value	adjustment.	Data	are	presented	as	the	mean	±	standard	deviation.	
The	primary	efficacy	variable	was	change	in	HbA1c	level	from	baseline	to	6	months.	Baseline	was	
defined	as	the	last	value	obtained	prior	to	the	first	randomized	treatment.	Changes	from	baseline	
HbA1c	 level	 were	 assessed	 using	 the	 general	 linear	 model	 (ANCOVA)	 to	 adjust	 for	 baseline	
differences	and	the	stratification	factor.	Factors	in	the	model	included	treatment	and	stratum	of	
baseline	HbA1c	(<	7.5%	or	≥	7.5%).	The	least	square	means	and	standard	error	were	derived	from	
the	general	linear	model	for	each	dose	group.	
For	 secondary	 efficacy	 endpoints,	 (1)	 logistic	 regression	was	 used	 to	 investigate	 the	 effect	 of	
treatment	on	the	endpoint	(i.e.,	decrease	of	≥	0.5%	HbA1c	reduction	at	each	visit)	and,	decrease	
of	≥	0.5%	HbA1c	reduction	at	each	visit,	and	(2)	analysis	of	covariance	(with	stratification	factor	
as	covariate)	was	used	to	compare	changes	from	baseline	in	fasting	blood	glucose,	triglycerides,	
low	density	lipoprotein,	total	cholesterol,	high	density	lipoprotein,	body	weight,	body	mass	index,	
and	insulin	level.	
Results1	
Study	Population	
The	study	evaluated	the	data	from	18	clinical	study	sites	(11	sites	in	the	United	States	and	7	sites	
in	India)	and	161	subjects	were	randomized	to	one	of	the	three	D-tagatose	dosages	(2.5	g:	n	=	57,	
5.0	g:	n	=	51,	and	7.5	g:	n	=	53).	Of	the	161	randomized	subjects,	60	(37%)	were	withdrawn	before	
completing	 the	 6-month	 treatment	 period.	 The	 most	 common	 reasons	 for	 withdrawal	 were	
subject	 request	 (18/161,	 11%)	 and	 subject	 lost	 to	 follow	 up	 (11/161,	 7%).	 The	 populations	
analyzed	 for	 efficacy	 endpoints	were	 the	 ITT	 population	 (145	 total;	 52	 in	 the	 2.5	 g	 treatment	
group,	46	in	the	5.0	g	treatment	group	and	47	in	the	7.5	g	treatment	group)	and	the	EE	population	
(87	total,	31	in	the	2.5	g	treatment	group,	29	in	the	5.0	g	treatment	group,	and	27	in	the	7.5	g	
treatment	 group).	 The	 population	 used	 to	 analyze	 safety	 parameters	was	 identical	 to	 the	 ITT	
population.	 There	 were	 no	 indicators	 of	 dissimilarity	 between	 the	 treatments	 in	 any	 of	 the	
analysis	populations	in	terms	of	demographic	or	baseline	characteristics,	concomitant	medication	
usage,	or	compliance	with	treatment,	diet,	or	exercise.	
Efficacy	Results	
Incidence	 of	 ≥	 0.5	 HbA1c	 decrease	 after	 six	 months	 of	 treatment—Treatment	 success,	 as	
measured	by	the	incidence	of	a	0.5	minimum	HbA1c	decrease	from	baseline	after	six	months	of	
treatment,	was	greatest	for	the	7.5	g	TID	dose	of	D-tagatose	in	both	the	ITT	(25%,	12/47)	and	the	
EE	 (33%,	 9/27)	 populations	 (see	 Figure	 2).	 Treatment	 success,	 as	 measured	 by	 the	 primary	
endpoint	(a	reduction	from	baseline	of	0.5	in	HbA1c	after	six	months	of	treatment)	was	greatest	
for	the	7.5	g	D-tagatose	dose	group,	although	the	difference	between	the	treatments	was	not	
statistically	significant.	For	the	7.5	g	dose	group	25%	of	the	population	achieved	this	treatment	
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success	parameter	compared	to	19%	in	the	2.5	g	dose	group	and	15%	in	the	5.0	g	dose	group.	The	
difference	across	the	three	dose	groups	was	not	statistically	significant	for	either	of	the	analysis	
populations	(p	>	0.05,	logistic	regression).	
Incidence	of	 ≥	0.5	HbA1c	decrease	after	one,	 three	and	 six	months	of	 treatment—Incidence	
summaries	of	≥	0.5	HbA1c	reduction	from	baseline	after	one,	three,	and	six	months	of	treatment	
for	each	of	the	D-tagatose	dose	groups	are	provided	in	Table	2	for	the	ITT	population	and	in	Table	
3	for	the	EE	population.	Only	the	7.5	g	D-tagatose	dose	group	indicated	a	dose-response	trend	
over	time;	i.e.,	for	the	ITT	population,	treatment	success	was	indicated	for	4/47	(8%)	after	one	
month	of	treatment,	for	5/47	(11%)	after	three	months	of	treatment,	and	12/47	(25%)	after	six	
months	of	treatment.	For	the	EE	population,	success	was	indicated	for	2/27	(7%)	at	the	one	and	
three	month	treatment	time	points	and	for	9/27	(33%)	subjects	at	the	six	month	time	point.	By	
logistic	 regression,	 the	 incidences	across	 the	 three	 treatments	at	a	 single	 time	point	were	not	
statistically	significantly	different.	
	
Figure	21	
Incidence	of	≥	0.5	HbA1c	Decrease	After	Six	Months	of	Treatment,	ITT	and	EE	Populations		
	
Table	21	
Incidence	of	≥	0.5	HbA1c	Decrease	from	Baseline	After	One,	Three,	and	Six	Months	of	Treatment,	
ITT	population	
	 D-tagatose	2.5g	 D-tagatose	5.0g	 D-tagatose	7.5g	
Treatment	Duration	
N	=	51	
n	(%)	
N	=	46	
n	(%)	
N	=	47	
n	(%)	
One	Month	 8	(15.38%)	 9	(19.57%)	 4	(8.51%)	
Three	Months	 11	(21.15%)	 8	(17.39%)	 5	(10.64%)	
Six	Months	 10	(19.23%)	 7	(15.22%)	 12	(25.53%)	
N	=	denominator	for	all	percentages1	
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Table	31	
Incidence	of	≥	0.5	HbA1c	Decrease	from	Baseline	After	One,	Three,	and	Six	Months	of	Treatment,	
EE	Population	
	 D-tagatose	2.5g	 D-tagatose	5.0g	 D-tagatose	7.5g	
Treatment	Duration	
N	=	31	
n	(%)	
N	=	29	
n	(%)	
N	=	27	
n	(%)	
One	Month	 6	(19.35%)	 7	(24.14%)	 2	(7.41%)	
Three	Months	 9	(29.03%)	 8	(27.59%)	 2	(7.41%)	
Six	Months	 7	(22.58%)	 6	(20.69%)	 9	(33.33%)	
N	=	denominator	for	all	percentages1	
Effect	of	D-tagatose	on	HbA1c	values—The	mean	HbA1c	levels	for	the	three	D-tagatose	groups	
after	1,	3,	and	6	months	of	treatment	for	the	ITT	and	the	EE	populations	are	depicted	in	Figures	
3A	and	3B,	respectively.	For	both	analysis	populations,	a	dose-response	trend	was	observed	for	
the	5.0	g	and	7.5	g	D-tagatose	doses	after	3	months	and	6	months	of	 treatment.	 Statistically,	
significant	 differences	 between	 the	 doses,	 however,	 were	 not	 achieved	 at	 any	 of	 the	 post-
treatment	time	points	(p	>	0.5,	ANCOVA	with	baseline	as	covariate).	
Reductions	from	baseline	to	six	months	in	mean	HbA1c	were	observed	for	the	5.0	g	and	the	7.5	g	
dose	groups	but	not	for	the	2.5	g	dose	group;	i.e.,	mean	baseline	and	6-month	values	were	7.6	±	
0.66%	 and	 7.6	 ±	 1.01%,	 respectively,	 for	 the	 2.5	 g	 dose	 group;	 7.4	 ±	 0.63%	 and	 7.3	 ±	 0.85%,	
respectively,	for	the	5.0	g	dose	group;	and	7.3	±	0.60%	and	7.1	±	0.75%,	respectively,	for	the	7.5	
g	 dose	 group	 (Figure	 3B).	 These	 reductions	 indicate	 a	 positive	 dose	 response,	 although	 the	
differences	in	the	observed	mean	reductions	were	not	statistically	significant	between	the	three	
D-tagatose	doses.	
101
Figure	31	
Effect	of	D-tagatose	on	Mean	HbA1c	Values	After	1,	3,	and	6	Months	of	Treatment	
ITT	population	(A)	and	EE	population	(B).	Data	are	presented	as	the	mean	±	standard	deviation.1		
Effect	of	D-tagatose	on	fasting	glucose	values—For	fasting	glucose,	only	the	7.5	g	dosage	group	
exhibited	 reductions	 from	 baseline	 at	 the	 3-	 and	 6-month	 time	 points	 in	 both	 analyzed	
populations	(ITT	and	EE,	Figures	4A	and	4B,	respectively).	For	the	EE	population,	baseline	and	6-
month	means	in	fasting	glucose	were	130.4	±	28.8	mg/dL	and	136.3	±	31.9	mg/dL,	respectively,	
for	the	2.5	g	treatment;	129.5	±	24.0	mg/dL	and	131.2	±	26.3	mg/	dL,	respectively,	for	the	5.0	g	
treatment;	and	136.7	±	22.8	mg/dL	and	123.1	±	17.1	mg/dL,	respectively,	for	the	7.5	g	treatment	
(p	=	0.0268)	 (Figure	4B).	 For	 the	 ITT	and	 the	EE	populations,	 the	7.5	g	D-tagatose	dose	group	
provided	a	mean	reduction	in	fasting	glucose	level	after	six	months	of	treatment.	
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Figure	41	
Effect	of	D-tagatose	on	Mean	Fasting	Glucose	Values	After	1,	3,	and	6	Months	of	Treatment	
ITT	(A)	and	EE	(B)	populations.	Data	are	presented	as	the	mean	±	standard	deviation.1		
Incidence	of	decreases	in	fasting	glucose	levels—Results	indicate	a	dose-response	trend	for	the	
incidence	of	fasting	glucose	decreases	at	6	months	in	both	the	ITT	and	the	EE	populations.	For	the	
ITT	population,	the	incidences	of	fasting	glucose	decreases	after	six	months	of	treatment	were	
45%	(21/47),	39%	(18/46),	and	36%	(19/52)	for	the	7.5	g,	5.0	g,	and	2.5	g	D-tagatose	treatment	
groups,	 respectively.	 For	 the	 EE	 population,	 the	 incidences	 of	 glucose	 decreases	 were	 70%	
(19/27),	 55%	 (16/29),	 and	 42%	 (13/31),	 respectively.	 These	 data	 are	 depicted	 in	 Figure	 5.	 No	
statistically	 significant	 differences	 across	 the	 treatments	 (p>0.5,	 logistic	 regression)	 were	
observed	for	either	population	at	any	of	the	post	treatment	time	points.	
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Figure	51	
Effect	of	D-tagatose	on	the	Incidence	of	Fasting	Blood	Sugar	(i.e.,	Glucose)	Decreases	After	1,	3,	
and	6	Months	of	Treatment	
ITT	(A)	and	EE	(B)	populations.1		
Effect	of	D-tagatose	on	serum	insulin—The	mean	insulin	levels	(μIU/mL)	for	the	three	D-tagatose	
dose	groups	after	1,	3	and	6	months	of	treatment	and	the	two	analysis	populations	are	depicted	
in	Figure	6.	For	both	analysis	populations,	 the	7.5	g	D-tagatose	dose	group	showed	consistent	
reductions	from	the	mean	baseline	insulin	level	after	three	and	six	months	of	treatment.	For	the	
ITT	population	(Figure	6A),	the	7.5	g	D-tagatose	dose	group	demonstrated	a	mean	baseline	insulin	
level	of	8.5	±	8.2	μIU/mL;	and	after	three	and	six	months	of	treatment	the	mean	insulin	levels	for	
this	dose	group	were	7.3	±	7.0	μIU/mL	and	5.0	±	3.6	μIU/mL,	respectively.	For	the	EE	population	
(Figure	6B),	the	7.5	g	D-tagatose	dose	group	demonstrated	a	mean	baseline	insulin	level	of	9.1	±	
10.6	μIU/mL;	and	after	three	and	six	months	of	treatment	the	mean	insulin	levels	for	this	dose	
group	were	7.2	±	7.7	μIU/mL	and	5.1	±	3.4	μIU/mL,	respectively.	Statistically	significant	differences	
between	the	doses,	however,	were	not	achieved	at	any	of	the	post-treatment	time	points	(p	>	
0.5,	ANCOVA	with	baseline	as	covariate)	for	either	the	ITT	or	the	EE	populations.	
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Figure	61	
Effect	of	D-tagatose	on	Mean	Insulin	Values	After	1,	3,	and	6	Months	of	Treatment	
ITT	(A)	and	EE	(B)	populations.	Data	are	presented	as	the	mean	±	standard	deviation.1		
Effect	of	D-tagatose	on	lipids—No	statistically	significant	differences	between	treatments	at	any	
measured	time	point	were	observed	for	total,	LDL,	or	HDL	cholesterol	measurements	(data	not	
shown);	and	all	dosages	provided	some	measure	of	reduction	from	mean	baseline	values	at	one	
or	more	time	points.	There	was	a	striking	elevation	in	mean	triglyceride	level	after	three	months	
of	treatment	with	the	5.0	g	D-tagatose	dose	group	in	both	ITT	and	EE	populations	(Figure	7).	For	
the	ITT	population,	the	mean	triglyceride	concentrations	at	baseline	and	three	months	for	the	5.0	
g	dose	were	181	±	92.7	mg/dL	and	218	±	149	mg/dL,	respectively;	162	±	89.8	mg/dL	and	179	±	
93.4	 mg/dL,	 respectively,	 for	 the	 2.5	 g	 dose;	 and	 179	 ±	 99.8	 mg/dL	 and	 165	 ±	 74.7	 mg/dL,	
respectively,	 for	 the	7.5	g	dose.	The	difference	between	the	treatment	groups	at	 the	3-month	
time	point	was	statistically	significant	in	the	ITT	population	(p	=	0.0296,	ANCOVA	with	baseline	as	
covariate).	 Similar	 results	 were	 observed	 with	 the	 EE	 population;	 however,	 the	 difference	
between	treatments	at	three	months	was	not	statistically	significant	with	the	EE	population.	
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Figure	71	
Effect	of	D-tagatose	on	Mean	Triglyceride	Values	After	1,	3,	and	6	Months	of	Treatment	
 
ITT	(A)	and	EE	(B)	populations.	Data	are	presented	as	the	mean	±	standard	deviation.1		
Effect	of	D-tagatose	on	body	weight—Mean	body	weights,	over	time,	reduced	in	a	dose-response	
fashion,	with	the	5.0	g	and	the	7.5	g	D-tagatose	doses	providing	the	greatest	reductions	(Figure	
8).	Mean	body	weights	at	baseline,	3-months,	and	6-months	for	the	5.0	g	D-tagatose	dose	group	
were	165.4	±	33.0	 lbs,	161.5	±	29.5	 lbs,	and	161.7	±	27.5	 lbs,	respectively;	and	the	mean	body	
weights	for	the	7.5	g	D-tagatose	dose	group	were	167.4	±	33.0	lbs,	165.1	±	30.5	lbs,	and	160.6	±	
29.3	 lbs,	 respectively.	The	mean	body	weights	 for	the	2.5	g	D-tagatose	dose	group	and	the	EE	
population	remained	within	1	lb	of	mean	baseline	weight	at	all	post	baseline	time	points.	There	
was	a	statistically	significant	difference	between	the	mean	weights	of	the	three	treatments	at	the	
3-month	time	point	for	the	EE	population	(p	=	0.0345,	ANCOVA	with	baseline	as	covariate).	
106
Figure	81	
Effect	of	D-tagatose	on	Mean	Body	Weight	After	1,	3,	and	6	Months	of	Treatment	
ITT	(A)	and	EE	(B)	populations.	Data	are	presented	as	the	mean	±	standard	deviation.1		
Safety	results—D-tagatose	at	all	doses	was	well-tolerated.	None	of	the	reported	adverse	events	
were	unexpected	and	the	majority	was	of	a	gastrointestinal	nature,	as	expected.	The	incidences	
of	all	reported	events	were	similar	for	all	treatments.	There	were	no	disparities	between	the	three	
treatments	 in	 any	of	 the	assessed	 safety	parameters.	Nearly	 all	 reported	AEs	were	of	mild	or	
moderate	severity.	Severe	AEs	occurring	during	the	study	are	summarized	in	Table	4.	There	did	
not	appear	to	be	a	dose-response	relationship	in	terms	of	AE	severity.	As	expected,	the	highest	
incidences	of	probably	or	possibly	related	AEs	were	gastrointestinal	disorders.	No	dose-response	
trends	were	observed	for	any	of	the	AEs	that	were	assessed	as	possibly	or	probably	related	to	
study	treatment.	
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Table	41	
Incidence	of	Severe	Adverse	Events,	Safety	Population	
 
Disposition	of	subjects—The	study	disposition	of	randomized	subjects	is	provided	in	Table	5.	One	
hundred	and	 sixty	one	 (161)	 subjects	were	 randomized	and	analyzed.	Of	 the	161	 randomized	
subjects,	57/161	(35%)	were	randomized	to	the	2.5	g	dose	group,	51/161	(32%)	were	randomized	
to	the	5.0	g	dose	group,	and	53/161	(33%)	were	randomized	to	the	7.5	g	dose	group.	
Table	51	
Study	Disposition	of	Randomized	Subjects	
	
D-tagatose	
2.5g	
D-tagatose	
5.0g	
D-tagatose	
7.5g	 Total	
Number	Randomized	
(N)*	 57	 51	
53	 161	
	 n	(%)	 n	(%)	 n	(%)	 n	(%)	
Received	≥	1	Dose	 55	(96.5%)	 49	(96.1%)	 51	(96.2%)	 155	(96.3%)	
Completed	Study†	 35	(61.4%)	 32	(62.7%)	 34	(64.2%)	 101	(62.7%)	
Withdrawn	 22	(38.6%)	 19	(37.3%)	 19	(35.8%)	 60	(37.3%)	
*Denominator	for	all	percentages.	
†Completed	study	through	the	end	of	the	6-month	treatment	period.1 
All	treatment	groups	had	a	median	study	medication	compliance	of	approximately	80%,	and	full	
to	good	compliance	with	the	study-mandated	diet	and	exercise,	as	assessed	by	the	investigator,	
was	77%	to	87%	after	the	first	month,	70%	to	79%	after	three	months,	and	63%	to	74%	after	six	
months.	 Given	 the	 similarity	 of	 the	 treatment	 groups	 in	 terms	 of	 demographics,	 baseline	
characteristics,	concomitant	medication	usage,	and	compliance	with	treatment,	diet	and	exercise,	
the	resulting	efficacy	and	safety	analyses	were	considered	reliable	for	comparisons	between	three	
D-tagatose	dose	groups.	
Sixty	 (60)	 randomized	 subjects	 (37.3%)	 were	 withdrawn	 before	 completing	 the	 6-month	
treatment	period.	Two	subjects,	from	each	of	the	dose	groups	were	withdrawn	prior	to	receiving	
the	 first	dose	of	 study	medication,	 resulting	 in	a	 similar	withdrawal	 rate	 for	each	of	 the	 three	
doses.	However,	when	individual	reasons	for	withdrawal	were	evaluated,	two	interesting	dose-
response	trends	were	noted:	one	for	subject-initiated	withdrawals	and	one	for	withdrawals	due	
to	AEs/SAEs	(Table	6).	
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Table	61	
Reasons	for	Withdrawal,	Randomized	Subjects	
Reason	for	Withdrawal	 D-tagatose	2.5g	
N	=	57	
n	(%)	
D-tagatose	5.0g	
N	=	51	
n	(%)	
D-tagatose	7.5g	
N	=	53	
n	(%)	
Total	
N	=	161	
n	(%)	
Subject	Request	 3	(5.3%)	 5	(9.8%)	 10	(18.9%)	 18	(11.2%)	
Lost	to	Follow-up	 3	(5.3%)	 3	(5.9%)	 5	(9.4%)	 11	(6.8%)	
AE/SAE	 5	(8.8%)	 2	(3.9%)	 1	(1.9%)	 8	(5.0%)	
Protocol	Deviation	 3	(5.3%)	 2	(3.9%)*	 2	(3.8%)	 7	(4.3%)	
Termination	by	Sponsor	 2	(3.5%)	 0	(0.0%)	 0	(0.0%)	 2	(1.2%)	
Other	 6	(10.5%)†	 7	13.7%)	 1	(1.9%)	 14	(8.7%)	
Total	Withdrawn	 22	(38.6%)	 19	(37.3%)	 19	(35.8%)	 60	(37.3%)	
N	=	Randomized	subjects;	denominator	for	all	percentages.	
*One	randomized	subject	in	this	dose	group	had	a	recorded	reason	for	withdrawal	of	“screen	failure”	and	
was	therefore	tabulated	with	those	withdrawn	for	a	protocol	deviation.	
†One	 randomized	subject	 in	 this	dose	group	had	no	 reason	 for	withdrawal	 specified	on	 the	CRF	and	was	
therefore	tabulated	with	“Other”.1	
Subject-initiated	withdrawals—Of	the	randomized	subjects,	18.0%	(29/161)	were	withdrawn	due	
to	subject	request	or	lost	to	follow	up.	The	highest	incidence	for	these	two	reasons,	combined,	
was	with	the	7.5	g	dose	group;	i.e.,	6/57	(10.5%)	in	the	2.5	g	dose	group,	8/51	(15.7%)	in	the	5.0	
g	dose	group,	and	15/53	(28.3%)	in	the	7.5	g	dose	group	(Table	6).	These	data	suggest	that	as	the	
dosage	increased	so	did	the	drop-outs	due	to	“subject	request”	and	“lost	to	follow-up,”	combined	
(i.e.,	subject-initiated	withdrawals).	This	observation	is	supported	by	the	fact	that,	when	the	two	
reasons	(subject	request	and	lost	to	follow-up)	were	analyzed	separately,	each	of	the	responses	
also	indicated	a	positive	dose-response.	These	results	all	appear	to	indicate	that	as	the	dosage	
increased,	so	did	the	incidence	of	subject-initiated	withdrawals.	
Withdrawals	due	to	AEs/SAEs—The	incidence	of	withdrawals	due	to	AEs	and	SAEs	for	all	dose	
groups	 combined	 was	 8/161	 (5.0%)	 with	 what	 appears	 to	 be	 an	 inverse	 dose-response	
relationship;	i.e.,	as	the	dosage	increased	the	incidence	of	withdrawals	due	to	AEs	decreased.	The	
highest	 incidence	of	withdrawals	due	to	AEs	was	 in	the	2.5	g	dose	group	(5/57,	8.8%)	and	the	
lowest	 incidence	 of	 withdrawals	 due	 to	 AEs	 was	 in	 the	 7.5	 g	 group	 (1/53,	 1.9%)	 (Table	 6).	
Withdrawals	due	to	protocol	deviations	were	less	than	5%	for	all	doses,	combined.	The	individual	
dose	groups	all	had	similar	incidences,	ranging	from	approximately	4%	to	approximately	5%.	
Discussion1	
This	dose-ranging	trial	was	conducted	to	evaluate	the	effect	of	three	doses	of	D-tagatose	(2.5	g,	
5.0	g,	and	7.5	g),	taken	three	times	daily	over	a	period	of	six	months,	on	various	glycemic	control	
measures	and	safety	parameters	in	type	2	diabetic	patients.	In	this	trial,	the	5.0	g	TID	dose	of	D-
tagatose	was	assumed	 (based	on	previous	 trials)8	 to	be	a	minimally	effective	dose	 in	 reducing	
HbA1c,	 a	 primary	measurement	 of	 glycemic	 control.	 The	 2.5	 g	 TID	 dose	 of	D-tagatose	 (which	
served	as	a	nominal-effect	comparator)	and	the	7.5	g	TID	dose	were	selected	to	bracket	the	5.0	g	
TID	dosage	level.	
The	efficacy	parameters	selected	for	evaluation	in	this	trial	are	all	common	measures	of	glycemic	
control	for	diabetic	patients:	HbA1c,	fasting	glucose	levels,	lipid	parameters,	blood	insulin	levels,	
and	 body	 weight.	 The	 primary	 efficacy	 parameter	 selected	 for	 this	 trial	 was	 a	 dichotomous	
variable:	the	treatment	success	as	measured	by	a	reduction	from	baseline	HbA1c	by	at	least	0.5	
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units	after	six	months	of	treatment	(i.e.,	0.5%	reduction	in	HbA1c	after	six	months	of	treatment).	
Dichotomous	variables,	by	nature,	are	not	the	most	sensitive	metric	by	which	to	assess	treatment	
differences;	nevertheless,	a	treatment	difference	was	noted	in	that	12/47	(26%)	of	the	7.5	g	D-
tagatose	dose	group	(ITT	population)	and	9/27	(33%)	EE	population	in	the	dose	groups	met	the	
endpoint	(Tables	2	and	3).	For	both	populations,	of	the	three	studied	dosages,	the	7.5	g	D-tagatose	
dose	exhibited	the	greatest	incidence	of	success,	as	measured	by	this	parameter.	Interestingly,	a	
dose	response	was	not	observed	in	the	primary	endpoint.	For	the	ITT	population	and	the	primary	
endpoint,	the	2.5	g	and	the	5.0	g	D-tagatose	doses	had	a	success	incidences	of	10/52	(19%)	and	
7/46	 (15%),	 respectively	 and	 the	 difference	 between	 the	 three	 dosages	were	 not	 statistically	
significant.	Similar	results	for	the	lower	doses	were	observed	with	the	EE	population.	Continuous	
variables	 are	 traditionally	more	 sensitive	 in	 detecting	 differences	 between	 treatments.	Mean	
HbA1c	reductions	after	six	months	of	treatment	within	the	ITT	population	were	greatest	for	the	
7.5	g	D-tagatose	group	(Figure	3A).	The	minimum	dosage	at	which	HbA1c	reductions	were	evident	
was	the	5.0	g	TID	dosage.	The	mean	baseline	and	the	mean	6-month	HbA1c	values	for	the	2.5	g	
treatment	group	remained	the	same.	The	differences	between	the	treatment	groups	 in	HbA1c	
measurements	were	not	statistically	significant	at	any	post	treatment	time	point.	Similar	results	
with	HbA1c	reduction	were	observed	with	the	EE	population	(Figure	3B).	
Regarding	fasting	glucose	mean	values	and	mean	changes	from	baseline	over	time,	a	reduction	
from	baseline	was	observed	only	in	the	7.5	g	D-tagatose	dose	group,	beginning	after	three	months	
of	 treatment	 with	 increasing	 reduction	 at	 the	 6-month	 time	 point,	 at	 which	 time	 statistical	
significance	was	observed	 (Figure	4),	 thereby	supporting	 the	analysis	of	 the	primary	endpoint.	
Additionally,	 for	 the	 EE	 population,	 the	 incidence	 rates	 of	 subjects	 achieving	 any	 decrease	 in	
fasting	glucose	values	indicated	consistent	increases	throughout	the	treatment	period	for	the	7.5	
g	dose	group,	although	the	differences	across	the	groups	was	not	statistically	significant	at	any	
time	 point.	 This	 observation	 provided	 further	 support	 of	 the	 primary	 endpoint	 results.	 The	
observed	increases	and	reductions	in	fasting	glucose	levels	over	time	for	the	2.5	g	and	the	5.0	g	
treatments	are	most	likely	due	to	the	inherent	variability	of	the	fasting	glucose	parameter.	
Each	of	the	doses	had	some	measure	of	mean	insulin	reduction	at	one	or	more	post-baseline	time	
points	in	both	analyzed	populations.	After	six	months	of	treatment,	however,	only	the	5.0	g	and	
the	7.5	g	dosages	had	mean	levels	that	were	lower	than	that	of	baseline	(Figure	6A).	There	were	
no	statistically	significant	differences	between	treatments	at	any	of	the	measured	time	points.	
Similar	results	were	observed	with	the	EE	population	(Figure	6B).	
No	 statistically	 significant	 difference	 between	 treatments	 at	 any	 measured	 time	 point	 was	
observed	 for	 total,	 LDL,	 or	 HDL	 cholesterol	 measurements;	 and	 all	 dosages	 provided	 some	
measure	of	reduction	from	mean	baseline	values	at	one	or	more	time	points.	There	was	a	striking	
elevation	 in	mean	triglyceride	 level	after	three	months	of	treatment	with	the	5.0	g	D-tagatose	
dose	group	in	both	the	ITT	and	the	EE	populations	(Figure	7).	This	rise	in	triglycerides	at	the	5.0	g	
dose	warrants	further	research.	
Mean	body	weights,	over	time,	were	reduced	in	a	positive	dose-response	fashion,	with	the	5.0	g	
and	 the	 7.5	 g	 D-tagatose	 doses	 providing	 the	 greatest	 reductions	 (Figure	 8).	 The	mean	 body	
weights	for	the	2.5	g	D-tagatose	dose	group	remained	within	1	lb	of	mean	baseline	weight	at	all	
post	baseline	time	points.	
D-tagatose	at	all	doses	was	well	tolerated.	None	of	the	reported	adverse	events	were	unexpected	
and	 the	majority	was	of	 a	 gastrointestinal	 nature,	 as	 expected.	 The	 incidences	of	 all	 reported	
events	 were	 similar	 for	 all	 treatments.	 Finally,	 there	 were	 no	 disparities	 between	 the	 three	
treatments	in	any	of	the	assessed	safety	parameters.	
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Although	not	always	statistically	significant,	the	high	dose	(7.5	g	TID	of	D-tagatose)	appeared	to	
provide	the	greatest	efficacy	of	 the	three	tested	doses	 in	 terms	of	 incidence	rates	achieving	≥	
0.5%	 decrease	 in	 HbA1c,	 reductions	 in	 fasting	 glucose	 values,	 reductions	 in	 lipid	 parameters,	
reduction	in	insulin	concentration,	and	reduction	in	body	weight.	Additionally,	it	appears	that	5.0	
g	TID	of	D-tagatose	was	the	minimally	effective	dose	for	providing	reduction	in	glycemic	measures	
within	this	type	2	diabetic	population.	
Future	 research	 might	 investigate	 the	 inverse	 dose-response	 relationships	 for	 constipation,	
nausea,	headache,	vomiting,	and	eructation	(Table	6).	
Conclusions1	
Several	points	can	be	concluded	from	this	study	designed	to	determine	the	minimum	dose	of	D-
tagatose	required	to	affect	HbA1c:	
• D-tagatose	at	dosages	of	2.5	g,	5.0	g,	and	7.5	g	TID	for	six	months	were	well	tolerated	by
this	subject	population.
• D-tagatose	at	5.0	g	TID	was	the	minimal	dose	required	to	reduce	HbA1c.
• D-tagatose	 at	 7.5	 g	 TID	 provided	 the	 greatest	 effect	 in	 most	 measured	 efficacy
parameters.
• Future	research	might	 investigate	the	elevation	of	mean	triglycerides	with	the	5.0	g	D-
tagatose	 dose	 group	 after	 three	 months	 of	 treatment.	 However,	 this	 elevation	 was
transient	 and	 did	 not	 appear	 at	 the	 6	month	 timepoint.	 This	 elevation	was	 also	 only
observed	in	the	ITT	population.	If	it	were	a	drug	effect,	it	would	also	likely	appear	in	the
EE	population.
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Appendix	C	
Effect	of	BSN272	on	Hyperlipidemia	and	Atherosclerosis	in	LDLr-/-	Mice1	
Ensor	M,	Williams	J,	Banfield	A,	Smith	R,	Lodder	R	
Pharmaceutical	Sciences,	College	of	Pharmacy,	University	of	Kentucky,	United	States	of	America	
Introduction1	
The	two	objectives	of	this	study	were	to	(1)	compare	the	effect	of	D-tagatose	with	the	effect	of	a	
combination	of	D-tagatose	and	polydatin	on	serum	triglycerides	and	cholesterol,	and	(2)	compare	
the	effect	of	these	two	treatments	on	the	development	of	atherosclerosis	in	LDLr-/-	mice.	
In	western	countries,	 cardiovascular	disease	 is	 the	 leading	cause	of	mortality.	While	 there	are	
multiple	 factors	 that	 increase	 the	 risk	 of	 developing	 cardiovascular	 disease,	 there	 is	 evidence	
supporting	 a	 strong	 link	 between	 abnormal	 blood	 lipids	 (dyslipidemia)	 and	 increased	 risk	 for	
cardiovascular	disease.	Dyslipidemia	is	typically	characterized	by	elevated	levels	of	triglycerides	
and	low-density	lipoprotein	(LDL)	cholesterol	and	by	low	levels	of	high-density	lipoprotein	(HDL)	
cholesterol.	 Atherosclerotic	 lesions	 form	 from	 lipoproteins,	macrophages,	 and	 lymphocytes	 in	
arterial	blood	vessels.2	Blood	cholesterol	moves	into	damaged	vessel	endothelium	layers.	These	
modified	lipids,	changed	by	oxidation,	cause	macrophages	and	lymphocytes	to	enter	the	area	to	
remove	the	LDLs.	Over	time,	these	components	develop	into	plaque.	Macrophages	will	display	
the	lipoproteins	on	their	cell	surface	and	form	foam	cells	initiating	the	plaque	formation.	
BSN272	is	a	combination	drug	therapy	composed	of	a	carbohydrate,	D-tagatose,	and	polydatin,	a	
glucoside	 derivative	 of	 resveratrol.	 D-tagatose,	 a	 naturally	 occurring	 epimer	 of	 fructose,	 was	
originally	developed	as	a	low-calorie	sweetener	(1.5	kcal/g	compared	to	4	kcal/g	for	sucrose)	but	
was	 found	 to	 have	 an	 antihyperglycemic	 effect	 in	 animal	 and	 in	 human	 studies	 and	 showed	
promise	as	a	treatment	for	type	2	diabetes	and	obesity.3,4	Clinical	studies	have	shown	D-tagatose	
to	be	a	potential	anti-diabetic	drug	through	its	beneficial	effects	on	postprandial	hyperglycemia	
and	 hyperinsulinemia.4	 	 In	 addition	 to	 treating	 diabetes,	 D-tagatose	may	 also	 be	 an	 effective	
treatment	 for	 obesity4–6	 and	 for	 reducing	 cardiovascular	 risks	 by	 increasing	 high-density	
lipoprotein	 (HDL)	 levels.4	 After	 over	 10	 years	 of	 animal	 and	 human	 studies,	 D-tagatose	 was	
classified	as	being	“generally	recognized	as	safe	(GRAS)”	by	the	FDA7	and	has	been	used	since	in	
food	and	beverage	products.	
Police	 et	 al.8	 found	 that	 the	 equivalent	 substitution	 of	 D-tagatose	 for	 sucrose	 as	 a	 dietary	
carbohydrate	did	not	result	 in	 the	same	extent	of	obesity,	hyperglycemia,	hyperlipidemia,	and	
atherosclerosis	 in	 LDLr-/-	 mice.	 Mice	 fed	 standard	 lab	 chow	 and	 mice	 fed	 D-tagatose	 chow	
exhibited	similar	energy	intake,	body	weights	and	blood	glucose	and	insulin	concentrations,	while	
sucrose-chow	 fed	 mice	 exhibited	 increased	 energy	 intake	 and	 became	 obese	 and	
hyperglycemic.	 	Sucrose-fed	mice	had	 increased	serum	cholesterol,	 triglyceride	concentrations	
and	atherosclerosis	compared	to	mice	fed	D-tagatose	or	a	standard	diet.	
Polydatin	 is	a	natural	substance	that	 is	a	glucoside	form	of	resveratrol.	Evidence	suggests	 that	
resveratrol,	a	naturally	occurring	polyphenol	commonly	found	in	a	variety	of	plants	and	foods,	
most	 notably	 grapes,	 can	 produce	 a	 variety	 of	 beneficial	 effects,	 including	 the	 promotion	 of	
weight	 loss,9	 anti-oxidant	 properties10	 and	 cardioprotective,11,12	 anti-inflammatory	 and	
neuroprotective	properties.13		Recently,	it	was	found	that	the	concentration	of	polydatin	in	grapes	
is	 as	much	 as	 seven	 times	 that	 of	 resveratrol14,15	 and	 is	 probably	 the	most	 abundant	 form	of	
resveratrol	 in	 nature.16	 	 Polydatin	 has	 a	 number	 of	 advantageous	 properties	 that	 increase	 its	
bioavailability	 compared	 to	 resveratrol,	 including	 a	 greater	 resistance	 to	 enzymatic	 oxidation.	
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Polydatin	enters	cells	by	an	active	transport	mechanism	using	glucose	carriers,	unlike	resveratrol	
which	penetrates	the	cell	passively.14		A	number	of	studies	suggest	that	polydatin	has	biological	
properties	 similar	 to	 those	 of	 resveratrol.17	 Current	 evidence	 suggests	 polydatin	 may	 inhibit	
platelet	 accumulation,	 improve	 microcirculation,	 decrease	 lipid	 peroxidation,	 and	 reduced	
neutrophil-endothelial	aggregation.18	These	proactive	factors	may	limit	the	growth	of	plaque	in	
arteries.	
There	 is	 considerable	 interest	 in	 the	 use	 of	 trans-resveratrol	 and	 its	 derivatives,	 including	
polydatin,	 for	 the	 treatment	 of	 many	 human	 diseases.19	 Extracts	 derived	 from	 Polygonum	
cuspidatum	have	long	been	a	part	of	traditional	Chinese	herbal	medicine,	being	used	to	treat	pain,	
fever,	coughs,	inflammation	and	a	variety	of	other	ailments.20	Polydatin,	a	glucoside	derivative	of	
resveratrol,	 is	the	major	component	of	these	extracts.	In	addition	to	Polygonum,	polydatin	has	
been	 found	 in	wines	 and	 grapes,14,21–23	 cocoa,24	 peanuts	 and	peanut	butter,25	 pistachios26	 and	
almonds27.	As	a	derivative	of	resveratrol,	polydatin	is	believed	to	have	many	of	the	same	beneficial	
effects,	but	also	has	some	properties	that	may	make	 it	more	effective	from	a	pharmacological	
standpoint	than	resveratrol.	Polydatin	is	structurally	the	same	as	resveratrol	except	that	it	has	a	
glucoside	group	attached	to	the	C-3	position	in	place	of	a	hydroxyl	group.	This	substitution	makes	
polydatin	more	water	 soluble	and	 in	 some	ways	more	 resistant	 to	enzymatic	breakdown	than	
resveratrol.	It	is	also	actively	taken	up	by	cells	via	glucose	carriers	in	the	cell	membrane	instead	
of	being	passively	transported	like	resveratrol.10,28		These	properties	suggest	that	polydatin	would	
have	greater	bioavailability	than	resveratrol.	
Claims	 for	 health	 benefits	 of	 polydatin	 abound.	 Studies	 almost	 too	 numerous	 to	 count	 have	
presented	 evidence	 that	 polydatin	 has	 many	 positive	 effects	 including	 anti-inflammatory,29,30	
hepatoprotective,31–34	 anti-cancer,35–38	 neuroprotective,29,39–41	 and	 cardioprotective	
activities.11,12,20,42,43	 Pharmacological	 studies	 and	 clinical	 practice	 have	 demonstrated	 that	
polydatin	 also	 has	 protective	 effects	 against	 shock,44–46	 ischemia/reperfusion	 injury,34,47	
congestive	 heart	 failure,48	 endometriosis,49	 and	 prevention	 of	 fatty	 liver	 disease	 and	 insulin	
resistance,50	 and	 that	 it	 can	 regulate	 glucose	 and	 lipid	 metabolism.51	 	 Polydatin	 has	 recently	
participated	 in	 clinical	 trials	 for	 the	 treatment	 of	 hemorrhagic	 shock	 and	 irritable	 bowel	
syndrome.30,52	
The	way	in	which	polydatin	is	able	to	have	all	of	these	activities	is	still	being	studied,	but	multiple	
mechanisms	 of	 action	 are	 evident,	 including;	 an	 antioxidant,	 free	 radical-elimination	
mechanism,53,54	activation	of	protein	kinase	C,18,55	suppression	of	NF-kappaB,56	inhibition	of	the	
activation	of	renin-angiotensin-aldosterone	system	and	decreasing	the	excretion	of	endothelin	1,	
TNF-α,	 and	 angiotensin	 II,42	 reduction	 of	 lipid	 peroxidation	 levels,10,56	 up	 regulation	 of	 the	
expression	of	hippocampal	brain-derived	neurotrophic	 factor,41	 	enhanced	 insulin	sensitivity	 in	
the	 liver	 as	 shown	 by	 improved	 insulin	 receptor	 substrate	 2	 expression	 levels	 and	 Akt	
phosphorylation,51	 	 decreasing	 the	 content	 of	 malonydialdehyde	 (MDA),40	 promoting	 the	
activities	of	total	superoxide	dismutase	(T-SOD),	catalase	(CAT)	and	glutathione	peroxidase	(GSH-
Px)	 in	 plasma,	 increasing	 the	 content	 of	 glutathione	 (GSH)	 in	 myocardial	 tissue,54	 restoring	
decreased	 deacetylase	 sirtuin-1	 activity	 and	 protein	 expression	 in	 liver	 tissue	 following	
severe		shock57	and	activation	of	sirtuin,58,59	and	suppressing	oxidative	stress-induced	lysosomal	
instability	and	mitochondrial	injury	by	increasing	the	protein	expression	of	SOD2.57	
The	treatment	of	dyslipidemia	using	polydatin	has	been	suggested	by	a	number	of	studies	using	
animal	models.11,12,60	Polydatin	given	orally	at	100	mg/kg	lowered	low-density	lipoprotein	(LDL)	
cholesterol	by	approximately	18%	and	serum	triglycerides	by	40%	in	rats	consuming	a	standard	
chow	containing	a	mixture	of	corn	oil,	10%	cholesterol,	and	1%	cholic	acid.60		Lower	doses	of	trans-
114
polydatin	(50	mg/kg	body	weight)	were	ineffective	at	preventing	hyperlipidemia,	however	they	
were	able	 to	prevent	 the	accumulation	of	cholesterol	and	triglycerides	 in	 the	 liver.	 	 In	a	study	
using	Syrian	golden	hamsters,	polydatin	decreased	total	cholesterol	levels	and	total	triglyceride	
levels	by	47%	and	63%,	respectively,	in	hamsters	on	a	high	fat,	high	cholesterol	diet.12	In	a	study	
using	rabbits,	polydatin	lowered	the	serum	levels	of	total	cholesterol,	triglycerides,	and	LDL.11	The	
ratio	 of	 total	 cholesterol	 to	 HDL	 was	 reduced	 as	 well.	 In	 our	 laboratory,	 the	 combination	 of	
polydatin	and	D-tagatose	has	been	shown	to	reduce	cholesterol,	triglycerides,	and	the	extent	of	
atherosclerosis	 in	ApoE-/-	mice.61,62	 	 The	ApoE-/-	mouse	model	 is	 generally	 resistant	 to	obesity,	
shows	 increased	VLDL	and	LDL,	and	decreased	HDL,	and	not	particularly	subject	 to	developing	
insulin	resistance.63	
In	the	present	study,	we	have	examined	the	effect	of	BSN272,	a	combination	of	D-tagatose	and	
polydatin,	on	blood	 lipids	and	atherosclerosis	 in	LDLr-/-	mice.	 	 In	contrast	 to	the	ApoE-/-	mouse	
model,	in	the	LDLr	-/-	mouse	model	obesity,	increased	LDL,	and	insulin	resistance	are	induced	by	a	
high	fat	diet.	VLDL	does	not	increase	in	the	LDLr-/-	mouse	as	it	does	in	the	ApoE-/-	mouse.			These	
differences	might	affect	the	development	of	atherosclerosis	in	this	model,	and	lead	to	differences	
between	the	ApoE-/-	and	LDLr	-/-	mouse	results.1	
Methods1	
Mice	
Male	6-7	weeks	old	C57BL6-LDLr	knockout	(LDLr-/-)	mice	(JAX	Strain	Name:	B6.129S7-Ldlrtm1Her/J)	
were	used	for	this	study.	Mice	were	acclimated	for	2	weeks	prior	to	start	of	the	study	and	were	
individually	housed	in	solid	bottom	cages	and	kept	on	a	standard	light	cycle:	12-hours	light,	12-
hours	dark	at	72	±	8oF.	
Treatment	
This	study	was	carried	out	at	Covance	Laboratories	(Madison,	WI).	Animals	were	randomized	by	
body	weight	into	four	groups	(Illustration	1).	Mice	in	group	1	(Control	group,	n=10)	were	dosed	
with	water,	while	mice	in	group	2	(n=10)	were	dosed	with	50%	glucose	+	50%	fructose	(see	Table	
1).	The	remaining	mice	were	placed	into	groups	3	and	4	and	randomly	selected	doses	for	animals	
21-30	 (group	 3)	 and	 31-40	 (group	 4)	 were	 forced	 to	 be	 uncorrelated	 by	 principal	 axis
transformation.	 	 This	 orthogonalization	 of	 doses	 allowed	 the	 contribution	 to	 the	 reduction	 of
lipids	by	polydatin	and	each	sugar	to	be	measured	independently	while	still	being	in	the	presence
of	the	other	molecules.
For	treatment	groups	3	and	4,	D-tagatose	was	added	to	ground	feed	(meal)	each	day.	Groups	1	&	
2	had	ground	TD.2014	(Teklad,	Harlan	Laboratories,	Madison,	WI)	with	no	D-tagatose	added.		The	
dose	 in	 the	 feed	of	D-tagatose	 for	groups	3	and	4	was	 increased	by	~7.1%	daily	during	 the	D-
tagatose	 lead-in	phase	until	 the	final	maximum	dose	was	reached.	 Individual	animal	feed	bags	
were	provided	for	each	day	of	the	lead-in	phase	of	the	study	for	all	animals.	Remaining	feed	was	
disposed	of	daily	and	the	cages	cleaned	of	the	remaining	crumbled	feed.	Duration	of	lead-in	phase	
was	14	days.	During	the	lead-in	period	all	mice	were	handled	daily	to	acclimate	the	animals	to	
dosing	 by	 scuffing	 the	 animal	 to	 simulate	 gavage	 dosing.	 The	 study	 design	 is	 summarized	 in	
Illustration	1.	
On	Day	15	all	animals	were	placed	on	TD.2014	for	the	remainder	of	the	study.	Mice	were	dosed	
by	gavage	based	upon	the	most	recent	body	weight,	twice	per	week	for	9	weeks.	Table	1	shows	
the	components	in	the	solutions	given	to	the	mice	by	gavage.		Each	animal	in	groups	3	and	4	had	
a	different	formulation	as	shown	in	Table	2	“Glucose,	Fructose,	D-tagatose,	and	Polydatin	(Piceid)	
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Doses	for	the	Groups	2	-	22”.	Inside	each	dose	group,	the	doses	ranged	from	0	to	0.853	g/kg/dose	
for	the	sugars	and	0	–	0.150	g/kg/dose	for	polydatin.	Dose	volume	was	10	mL/kg.	Animals	were	
weighed	and	food	consumption	was	measured	weekly.	Blood	samples	were	taken	from	the	tail	
vein.	Animals	were	not	fasted	prior	to	taking	blood	samples.	On	day	78	animals	were	anesthetized	
with	isoflurane,	bled	by	cardiac	puncture,	and	the	tissues	removed.	
Illustration	11	
Study	Design	
Table	11	
Compositions	of	Test	Articles	
Group	 Test	Article	 Dose	(g/kg/dose)	 No.	of	animals	 Animal	Numbers	
1	 Water	 0	 10	 1-10
2	 Glucose	(50%)	+	Fructose	(50%)	 See	Table	4.2	 10	 11-20
3-12 Glucose	+	Fructose	+		D-tagatose	 See	Table	4.2	 10	 21-30
13-22 Glucose	+	Fructose	+	BSN272	 See	Table	4.2	 10	 31-40
Serum	Lipids	
Blood	samples	were	obtained	through	tail	cuts	every	two	weeks	throughout	the	experiment,	and	
triglycerides,	 cholesterol,	 and	 free	 fatty	acids	were	measured	at	Covance	 Laboratories	using	a	
Roche	Hitachi	917	or	Cobas	6000	analyzer	using	a	photometric:enzymatic	method.	Animals	were	
not	fasted	prior	to	bleeding,	but	were	bled	approximately	1	hour	post	dosing.	On	the	final	day	of	
the	study,	mice	were	anesthetized	with	isoflurane	and	bleed	by	cardiac	puncture.	Body	weights	
and	food	consumption	were	measured	weekly.		
At	the	end	of	the	study	mice	were	sacrificed	via	cardiac	puncture.	Aortic	arches	were	harvested	
nine	weeks	after	treatments	began	and	the	extent	of	atherosclerotic	lesions	was	determined	by	
false	color	imaging.	Lesion	area	was	measured	as	a	fraction	of	the	aortic	arch	area.		The	percent	
of	 atherosclerotic	 lesions	 in	 the	 BSN272	 treated	 group	was	 determined	 by	 dividing	 the	mean	
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atherosclerotic	 lesion	 in	 the	Glu/Fruc/BSN272	group	by	 the	mean	atherosclerotic	 lesion	 in	 the	
Glu/Fruc	group.	
The	amount	of	VLDLs,	LDLs,	and	HDLs	were	determined	by	collecting	serum	nine	weeks	after	the	
treatments	began,	resolving	the	lipoprotein	complexes	by	FLPC,	and	quantifying	the	amount	of	
cholesterol	in	each	FPLC	fraction	using	an	enzymatic	cholesterol	assay.		Samples	for	analysis	were	
chosen	from	5	mice	in	each	of	the	glucose	+	fructose	and	glucose	+	fructose	+	BSN272	groups.	The	
samples	selected	had	total	cholesterol	values	closest	to	the	mean.	
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Table	21	
Glucose,	Fructose,	D-tagatose,	and	Polydatin	(Piceid)	Doses	for	the	Groups	2	-	22	
Glucose	 Fructose		 D-tagatose Piceid	
Max	Dose	g/kg/dose	 0.85	 0.85	 0.85 0.15	
Treat-
ment	
Group	
Animal	
ID	#	
Glucose	
%	of	Max	
Dose	
Fructose	
%	of	Max	
Dose	
D-tag	%	of
Max	Dose
Piceid	
%	of	
Max	
Dose	
Glucose	
g/kg	per	
dose	
Fructose	
g/kg	per	
dose	
D-tag
g/kg
per
dose
Piceid	
g/kg	
per	
dose	
2	 11	 100	 100	 0.853	 0.853	
2	 12	 100	 100	 0.853	 0.853	
2	 13	 100	 100	 0.853	 0.853	
2	 14	 100	 100	 0.853	 0.853	
2	 15	 100	 100	 0.853	 0.853	
2	 16	 100	 100	 0.853	 0.853	
2	 17	 100	 100	 0.853	 0.853	
2	 18	 100	 100	 0.853	 0.853	
2	 19	 100	 100	 0.853	 0.853	
2	 20	 100	 100	 0.853	 0.853	
3	 21	 80.400	 62.898	 57.269	 0.686	 0.537	 0.489	
4	 22	 51.045	 50.295	 26.541	 0.435	 0.429	 0.226	
5	 23	 30.795	 56.061	 62.352	 0.263	 0.478	 0.532	
6	 24	 29.005	 73.871	 24.031	 0.247	 0.630	 0.205	
7	 25	 81.740	 30.755	 28.551	 0.697	 0.262	 0.244	
8	 26	 84.530	 53.531	 51.408	 0.721	 0.457	 0.439	
9	 27	 28.240	 100.000	 66.251	 0.241	 0.853	 0.565	
10	 28	 47.517	 59.586	 64.954	 0.405	 0.508	 0.554	
11	 29	 36.231	 80.392	 52.726	 0.309	 0.686	 0.450	
12	 30	 63.580	 64.693	 99.000	 0.542	 0.552	 0.844	
13	 31	 70.349	 98.153	 58.858	 32.229	 0.600	 0.837	 0.502	 0.048	
14	 32	 60.832	 44.416	 77.855	 65.495	 0.519	 0.379	 0.664	 0.098	
15	 33	 54.023	 38.120	 27.662	 68.525	 0.461	 0.325	 0.236	 0.103	
16	 34	 74.222	 54.630	 72.261	 59.700	 0.633	 0.466	 0.616	 0.090	
17	 35	 64.854	 26.207	 24.886	 31.961	 0.553	 0.224	 0.212	 0.048	
18	 36	 19.168	 59.020	 57.426	 95.572	 0.164	 0.503	 0.490	 0.143	
19	 37	 52.884	 75.504	 56.847	 55.287	 0.451	 0.644	 0.485	 0.083	
20	 38	 15.852	 34.153	 80.537	 15.447	 0.135	 0.291	 0.687	 0.023	
21	 39	 37.104	 70.449	 15.971	 46.317	 0.316	 0.601	 0.136	 0.069	
22	 40	 83.795	 32.432	 60.780	 62.550	 0.715	 0.277	 0.518	 0.094	
Table	was	obtained	 from	Covance	Protocol	8242054.	Gavage	 formulation/dosing	 table	 for	each	animal	 in	
each	 group.	 	 The	 water	 group	 (negative	 control)	 is	 not	 shown.	 	 Doses	 in	 the	 Glucose/Fructose	 group	
(Treatment	2,	positive	control)	are	not	orthogonalized.		Doses	in	the	Glucose/Fructose/Tagatose	treatment	
group	 and	 the	 Glucose/Fructose/BSN272	 treatment	 group	 are	 orthogonalized	 using	 principal	 axis	
transformation	so	multiple	linear	regression	of	treatment	responses	yields	coefficients	that	do	not	change	
when	one	term	(e.g.,	one	drug)	is	added	or	dropped	from	the	model.		In	MLR	modeling,	D-tagatose	lowers	
triglycerides	 by	 -3.1	 mg/dl	 per	 g/kg/dose	 of	 the	 sugar	 in	 the	 combination,	 while	 the	 polydatin	 lowers	
triglycerides	by	-372	mg/dl	per	g/kg/dose	of	the	drug	in	the	combination.			D-tagatose	lowers	cholesterol	by	
-3.9	mg/dl	per	g/kg/dose	of	 the	sugar	 in	 the	combination,	while	 the	polydatin	 lowers	cholesterol	by	-629
mg/dl	per	g/kg/dose	of	the	drug	in	the	combination.			Note	that	the	mass	of	the	dose	of	D-tagatose	is	about
an	order	of	magnitude	greater	than	polydatin	in	BSN272,	so	the	net	reductions	of	triglycerides	and	cholesterol
due	to	tagatose	in	actual	formulations	would	be	about	10x	greater.		Paradoxically,	in	some	animal	models
without	D-tagatose,	polydatin	alone	can	raise	serum	triglycerides.	In	these	animals	adding	D-tagatose	causes
polydatin	to	lower	triglycerides.1
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Results	and	Discussion1	
Food	Intake 
There	was	no	significant	difference	in	amount	of	food	eaten	between	mice	in	the	different	groups	
once	treatments	were	started.	There	were	differences	in	amount	of	food	eaten	during	the	two-
week	D-tagatose	lead-in	(Illustration	2).	Mice	being	fed	the	D-tagatose	during	the	lead-in	phase	
ate	less	(1.9	±	0.10	g	for	Groups	3-13	and	2.1	±	0.11	g	for	Groups	13-22)	than	mice	in	Group	1	(3.2	
±	0.052	g)	or	2	(3.3	±	0.04	g).	This	was	somewhat	expected	as	studies	in	humans	have	found	D-
tagatose	produced	a	 feeling	of	satiety.4,64–66	 	Once	mice	were	place	on	the	standard	chow	and	
gavage	treatments	began,	food	consumption	was	the	same	for	all	three	groups	(Illustration	3).	
Illustration	21	
Food	Consumption	During	D-tagatose	Run-In	
Food	consumption	during	the	14-day	D-tagatose	lead-in	period	during	which	animals	in	Groups	3	and	4	
were	given	increasing	amounts	of	D-tagatose	each	day	to	acclimate	them	to	the	sugar.1	
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Illustration	31	
Food	Consumption	During	Treatment	
Food	intake	measured	by	weight	of	food	eaten	per	day	was	the	same	for	all	four	groups	after	the	14-day	D-
tagatose	lead-in	period.1	
Body	Weights	
Mice	in	the	D-tagatose	and	BSN272	groups	weighed	slightly	less	at	the	start	of	the	study	before	
any	 treatment	 began	 than	 mice	 in	 the	 water	 or	 Glu/Fruc	 groups.	 This	 slight	 difference	 was	
maintained	throughout	the	course	of	the	experiment.	Even	though	mice	in	the	groups	receiving	
the	D-tagatose	 during	 the	 2-week	 lead-in	 phase	 ate	 less	 (see	 Illustration	2),	 their	weight	 gain	
during	 the	 lead-in	 phase	 was	 no	 different	 than	 mice	 not	 receiving	 the	 D-tagatose	 that	 ate	
more.		There	were	no	significant	differences	in	body	weights	of	the	mice	in	the	four	groups	during	
the	course	of	the	study	(Illustration	4).	The	rate	of	weight	gain	was	similar	for	all	mice	during	the	
course	of	the	study.	
Tagatose	and	BSN272	Reduce	Serum	Lipids	in	LDLR-/-	Mice	
Cholesterol	
Day	 78,	 end	 of	 study	 result.	 	 Glucose/Fructose	 raised	 total	 serum	 cholesterol	 in	 LDLr-/-	 mice	
compared	to	control	mice.	Treatment	with	D-tagatose	or	BSN272	prevented	the	increase	due	to	
the	 glucose/fructose	 (Illustration	 5).	 End	 point	mean	 cholesterol	 was	 322	 ±	 18	mg/dl	 for	 the	
control	 group,	 378	 ±	 18	 mg/dl	 for	 the	 Glucose/Fructose	 group,	 309	 ±	 27	 mg/dl	 for	
Glucose/Fructose/Tagatose	group,	and	305	±	16	mg/dl	for	the	Glucose/Fructose/BSN272	group	
(Illustration	5).	
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Illustration	41	
Body	Weights	of	Mice	Throughout	Study	
Illustration	51	
Total	Serum	Cholesterol	
The	total	serum	cholesterol	of	fed	mice	treated	with	D-tagatose	or	BSN272	is	always	lower	than	for	mice	
treated	with	glucose/fructose	or	even	water.1	
Triglycerides	
Day	78,	end	of	study	result.	Glucose/Fructose	did	not	change	serum	triglyceride	levels	compared	
to	control	mice	(118	±	14	mg/dl	for	Glucose/Fructose	mice	compared	to	114	±	13	mg/dl	for	control	
mice).	However,	treatment	with	D-tagatose	or	BSN272	reduced	serum	triglyceride	levels	(81	±	6	
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mg/dl	 and	 71	 ±	 4	 mg/dl,	 respectively),	 with	 the	 BSN272	 having	 the	 lowest	 study	 end	 point	
triglyceride	level	(Figure	5.6).	
Illustration	61	
Serum	Triglycerides	
The	total	serum	triglycerides	of	mice	treated	with	D-tagatose	or	BSN272	is	always	lower	than	for	mice	treated	
with	glucose/fructose	or	even	water.1	
Free	Fatty	Acids 
Free	fatty	acid	levels	in	all	groups	on	Day	14	look	approximately	the	same	as	their	respective	levels	
on	Day	78	when	the	study	ended	(Illustration	7).	In	the	middle	of	the	study	(days	36	and	50)	values	
for	all	groups	go	up	by	about	50%.	On	day	14	the	D-tagatose	and	BSN272	groups	have	significantly	
lower	fatty	acid	levels	than	the	glucose/fructose	or	water	control	groups,	which	could	be	due	to	
the	D-tagatose	given	during	the	lead-in	phase.			Fatty	acids	drop	considerably	for	all	four	groups	
from	Day	50	to	64,	and	then	go	back	up	in	the	group	on	water	(control)	and	drop	in	the	BSN272	
group.	 The	 drop	 in	 all	 groups	 makes	 it	 difficult	 to	 determine	 if	 any	 change	 is	 treatment	
related.		There	is	no	statistically	significant	difference	between	the	D-tagatose	and	BSN272	groups	
at	any	time	point.	
BSN272	Reduces	VLDL	and	LDL	in	LDLR-/-	Mice	
The	amount	of	VLDLs,	LDLs,	and	HDLs	were	determined	by	collecting	serum	nine	weeks	after	the	
treatments	began,	resolving	the	lipoprotein	complexes	by	FLPC,	and	quantifying	the	amount	of	
cholesterol	in	each	FPLC	fraction	using	an	enzymatic	cholesterol	assay.	A	25%	trimmed	mean	FPLC	
chromatogram	was	calculated	using	the	total	cholesterol	values	from	the	enzymatic	cholesterol	
assay.	 	BSN272	 reduced	VLDL	and	 LDL	by	35%	and	17%,	 respectively	 (p<0.05).	HDLs	were	not	
significantly	altered	by	treatment	(Illustration	8).	
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Illustration	71	
Free	Fatty	Acids	
There	is	no	statistically	significant	difference	between	the	D-tagatose	and	BSN272	respective	groups	at	days	
14	and	78.1	
Illustration	81	
VLDL,	LDL,	and	HDL	Measurements	
(A) Trimmed	mean	VLDL,	LDL	and	HDL	FPLC	chromatograms	at	9	Weeks.	(B)	Treatment	with	BSN272
significantly	reduces	VLDL	and	LDL	while	leaving	HDL	essentially	unchanged.1
BSN272	Reduces	Atherosclerotic	Lesions	in	LDLr-/-	Mice 
Aortic	arches	were	harvested	9	weeks	after	treatments	began	and	the	amount	of	atherosclerotic	
lesion	was	 determined	 by	 false	 color	 imaging	 (Illustration	 9).	 Lesion	 area	was	measured	 as	 a	
fraction	of	the	aortic	arch	area.	The	percent	of	atherosclerotic	lesions	in	the	BSN272	treated	group	
was	determined	by	dividing	the	mean	atherosclerotic	lesion	area	in	the	Glu/Fruc/BSN272	group	
by	 the	 mean	 atherosclerotic	 lesion	 area	 in	 the	 Glu/Fruc	 group.	 BSN272	 in	 the	 diet	 reduced	
atherosclerotic	lesions	to	less	than	one-half	of	their	original	level.	
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Illustration	91	
Aortic	Arch	Lesion	Area	
Effects	of	combination	of	D-tagatose	and	BSN272	on	atherosclerosis	in	LDLr-deficient	mice.	Atherosclerotic	
lesion	area	was	determined	by	false	color	imaging.1	
Factor	Analysis	Results	for	the	LDLr-/-	Mice	
The	 use	 of	 oral	 gavage	 doses	 orthogonalized	 by	 transformation	 to	 principal	 axes	 permits	 the	
efficacy	of	each	molecule	(D-tagatose	and	trans-polydatin)	to	be	calculated	in	the	presence	of	the	
other.		The	BSN272	combination	is	the	most	effective	of	the	treatments	for	lowering	triglycerides.	
• Both	glucose	and	fructose	raise	triglycerides.
• D-tagatose	 lowers	 triglycerides	 by	 -3.1	 mg/dl	 per	 g/kg/dose	 of	 the	 sugar	 in	 the
combination	 of	 BSN272,	 while	 the	 polydatin	 lowers	 triglycerides	 by	 -372	 mg/dl	 per
g/kg/dose	of	the	drug	in	the	combination.
The	polydatin/tagatose	combination	(BSN272)	is	the	most	effective	of	the	treatments	for	lowering	
cholesterol.	
• Both	glucose	and	fructose	raise	cholesterol.
• D-tagatose	 lowers	 total	 cholesterol	 by	 -3.9	 mg/dl	 per	 g/kg/dose	 of	 the	 sugar	 in	 the
combination,	while	the	polydatin	lowers	total	cholesterol	by	-629	mg/dl	per	g/kg/dose	of
the	drug	in	the	combination.
Paradoxically,	 in	 some	 animal	 models,	 D-tagatose	 and	 polydatin	 alone	 can	 raise	 serum	
triglycerides.	 Polydatin	 administered	 alone	 in	 the	 Syrian	 Golden	 hamster	 on	 Western	 diet	
increases	serum	triglycerides.	 	D-tagatose	administered	alone	in	the	Syrian	Golden	hamster	on	
Western	diet	increases	serum	triglycerides.	Polydatin	co-administered	with	D-tagatose	(BSN272)	
in	the	Syrian	Golden	hamster	on	Western	diet	decreases	serum	triglycerides	(unpublished	study).	
Unlike	 the	 LDLr-/-	 mouse,	 the	 hamster	 has	 cholesterylester	 transfer	 protein	 (CETP),	 similar	 to	
humans.		CETP	transports	cholesteryl	esters	and	triglycerides	between	the	lipoproteins.	CETP	can	
pick	 up	 triglycerides	 from	 very-low-density	 (VLDL)	 or	 low-density	 lipoproteins	 (LDL)	 and	 swap	
them	for	cholesteryl	esters	from	high-density	lipoproteins	(HDL),	and	vice	versa.67	
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BSN272	Results	Summary	
• Serum	 triglycerides	 (TG)	were	 reduced	by	almost	one-half.	However,	 there	was	also	a
reduction	 in	 TG	 in	mouse	on	water	 treatment,	making	 it	 difficult	 to	 conclude	 that	 TG
reduction	is	treatment	related	in	the	LDLr-/-	mouse.
• Reduction	on	VLDL	 cholesterol	was	 the	next	 largest,	 followed	by	 the	 reduction	 in	 LDL
cholesterol.
• Reduction	in	TG,	VLDL,	and	LDL	may	explain	the	reduction	in	atherosclerotic	lesion	area
in	the	aortic	arch.
Conclusions1	
This	study	was	designed	to	compare	the	effects	of	D-tagatose	alone	and	in	BSN272	on	the	levels	
of	 cholesterol	 and	 triglycerides	 and	on	preventing	 atherosclerosis	 in	 LDLr-/-	mice.	 	 LDLr-/-	mice	
maintained	on	a	high-fat	diet	provide	a	model	of	hypercholesterolemia	with	somewhat	elevated	
plasma	cholesterol.68	In	addition,	Zadelaar	et	al.	found	that	the	lipoprotein	profile	in	LDLr-/-	mice	
closely	mimics	that	of	humans,	with	the	cholesterol	mainly	tied	up	in	the	LDL	fraction.69	LDLr-/-	
mice	were	used	to	study	the	effects	of	BSN272	versus	D-tagatose	alone	on	lipid	levels	in	these	
mice,	and	to	compare	the	LDLr-/-	model	with	results	provided	by	the	ApoE-/-	model	used	in	other	
published	studies.	
A	diet	 that	was	 supplemented	with	Glucose/Fructose	and	D-tagatose	or	BSN272	produced	no	
significant	change	in	the	food	intake	or	body	weight	of	LDLr-/-	mice.	However,	free	fatty	acids	and	
lipids,	including	triglycerides	and	total	cholesterol,	significantly	decreased	in	mice	given	BSN272.	
Serum	 triglycerides	 (TG)	were	 cut	almost	 in	half.	 LDL	and	VLDL,	but	not	HDL,	 levels	were	also	
decreased.	 Not	 surprisingly,	 aortic	 atherosclerotic	 lesions	 were	 reduced	 by	 57%,	 as	 BSN272	
reduced	the	amount	of	lipids	moving	through	the	blood.			
Castelli	 found	that	cardiac	events	peak	in	 individuals	with	LDL	levels	of	150	mg/dl.70	 	BSN272’s	
ability	 to	 suppress	 LDL	 formation	 could	 significantly	 deter	 future	 cardiac	 impairment.	 	 Castelli	
postulated	 that	 small	dense	VLDL	particles	 settle	 in	 vessels	and	participate	 in	 forming	plaque,	
while	“fluffy”	VLDLs	simply	travel	back	to	the	liver	for	excretion.70	These	dense	VLDLs	are	likely	to	
become	 circulating	 LDLs	 at	 some	point.	 As	 such,	 suppression	 of	 VLDL	 formation	 could	 reduce	
arterial	plaque	formation.			It	is	thought	that	at	a	triglyceride	level	of	150	mg/dl,	only	small	dense	
pattern	B	LDLs	are	being	formed	as	opposed	to	fluffy	“likely	to	be	excreted”	LDLs.	BSN272	reduced	
VLDL	by	35%.			
It	 is	well	documented	that	elevated	 levels	of	LDLs	can	contribute	to	 lipoprotein	retention,	and	
higher	 levels	 of	 anti-inflammatory	 markers.71	 Presently,	 statins	 are	 often	 prescribed	 as	 lipid	
lowering	therapies,	however,	in	a	study	of	over	4000	patients,	only	40%	of	patients	being	treated	
with	a	statin	drug	regimen	were	able	to	meet	target	LDL-C	levels.72	Additionally,	statins	are	mostly	
ineffective	 in	 reducing	 triglycerides.	 In	 a	 study	of	 LDLr-/-	mice	 fed	 a	 high	 cholesterol	 (1%)	 diet	
described	by	Wang	et	al,	simvastatin	dosed	at	300	mg/kg	decreased	serum	LDL	cholesterol	levels	
from	917±	80	mg/dl	in	control	mice	to	322	±	27	mg/dl	in	simvastatin	treated	mice	and	reduced	
aortic	 lesion	 area	 by	 fifteen	 percent.	However,	 the	 treatment	 had	 no	 effect	 upon	 triglyceride	
levels.		In	the	same	study,	ApoE	mice	fed	the	same	diet	and	given	the	same	dosage	of	statin,	had	
an	increase	of	27%	in	serum	cholesterol.73	 	Apolipoprotein	E,	which	transports	cholesterol	 into	
cells,	 is	 believed	 to	 ferry	 cholesterol	 into	 hepatocytes	 for	 metabolic	 clearance.	 	 Additionally,	
statins,	including	simvastatin,	work	by	inhibiting	HMG-CoA	reductase,	an	enzyme	responsible	for	
catalyzing	cholesterol	production.	In	other	studies	with	LDLr	deficient	mice,	LDL	and	total	plasma	
cholesterol	were	significantly	lowered	with	atorvastatin	(-41	and	-27%),	lovastatin	(-27	and	-21%)	
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and	simvastatin	(-22	and	-15%),	but	not	with	control	(+8	and	+11%),	and	there	was	no	significant	
change	in	triglycerides,74	whereas	in	this	study	BSN272	produced	a	17%	decrease	in	LDL	levels.	
BSN272	 differs	 from	 Lovaza	 and	 other	 omega-3-acid	 ethyl	 esters	 in	 that	 it	 not	 only	 reduces	
triglycerides	it	also	reduces	LDLs.	Triglyceride	levels	have	been	found	to	be	particularly	important	
to	women	as	the	Farmingham	Study	found	women	with	triglyceride	levels	greater	than	150	mg/dl	
and	HDL	cholesterol	levels	below	50	mg/dl	have	one	the	highest	rates	of	coronary	heart	disease	
(CHD).70	 	 Various	 studies	 have	 found	 that	Omacor	 does	 significantly	 reduce	mean	 triglyceride	
concentrations,	including	the	Harris	study	(1997)	which	reported	a	45%	reduction	in	triglycerides,	
increased	HDL	cholesterol	by	13%	and	LDL	cholesterol	by	31%,	dosed	at	3.4	g	eicosapentaenoic	
acid	 (EPA)	 and	docosapentaenoic	 acid	 (DHA)	 and	18	mg	 vitamin	E	per	day.75	Additionally,	 the	
Pownall	(1999)	study	reported	a	38.9%	decrease	from	baseline	fasting	triglyceride	levels	and	an	
increase	 in	 HDLs	 of	 5.9%	 and	 an	 increase	 in	 LDLs	 of	 16.7%.76	 EPA	 and	 DHA	 inhibit	 acyl-COA,	
resulting	 in	 decreased	 triglyceride	 synthesis,	 while	 increasing	 fatty	 acid	 metabolism,	 and	
increasing	lipase	production	which	results	in	increased	triglyceride	binding.77		
Foam	cell	formation	is	one	of	the	early	steps	in	the	process	of	atherosclerosis.78	Free	metal	ions	
can	help	 to	oxidize	 the	 LDL	and	 convert	 it	 into	a	 form	 that	 can	be	 taken	up	by	macrophages.	
BSN272	seems	to	prevent	LDL	oxidation	and	may	prevent	oxidation	caused	by	macrophages	at	
the	atherosclerotic	site.			
Although	 glucose	 and	 fructose	 had	modest	 effects	 on	 serum	 lipids	 and	 body	weight	 over	 the	
course	 of	 the	 study,	 the	 levels	 of	 serum	 cholesterol	 and	 triglycerides	 in	 the	 groups	 receiving	
glucose,	 fructose,	 and	 D-tagatose,	 and	 glucose,	 fructose,	 D-tagatose,	 and	 BSN272	 were	
consistently	equal	to	or	less	than	the	levels	in	the	groups	receiving	either	water	or	glucose	and	
fructose.	Furthermore,	the	combination	of	D-tagatose	and	polydatin	appeared	to	be	more	potent	
than	D-tagatose	 alone	 in	 reducing	 serum	 cholesterol	 and	 triglycerides	 over	 the	 course	 of	 the	
experiment.	D-tagatose	and	polydatin	also	prevented	the	increase	in	serum	cholesterol	induced	
by	glucose	and	fructose,	and	was	capable	of	reducing	atherosclerosis	in	LDLr-deficient	mice.		
Importantly,	the	sera	collected	on	days	14,	22,	36,	50,	and	64	were	from	fed	(not	fasted)	mice,	
making	 it	 difficult	 to	 clearly	 define	 a	 role	 for	 D-tagatose	 and	 polydatin	 on	 the	metabolism	 of	
endogenous	lipids.	However,	considering	that	the	levels	of	serum	triglycerides	and	cholesterol	in	
the	mice	treated	with	either	glucose,	fructose,	and	D-tagatose	or	glucose,	fructose,	D-tagatose,	
and	BSN272	were	always	less	than	or	equal	to	those	in	mice	receiving	either	water	or	mixtures	of	
glucose	and	fructose	and	that	blood	samples	were	collected	one	hour	after	gavaging,	these	results	
suggest	 that	 supplementing	 high	 carbohydrate	 meals	 with	 D-tagatose	 or	 combinations	 of	 D-
tagatose	 and	 BSN272	 may	 be	 effective	 at	 reducing	 postprandial	 carbohydrate-induced	
hyperlipidemia	and	lowering	serum	cholesterol	and	triglycerides	over	time.	
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Appendix	D	
4-Week	Toxicity	and	Toxicokinetic	Oral	Gavage	Study	with	Polydatin	in	Rats1	
Williams	J,	Banfield	A,	Ensor	M,	Smith	R,	Lodder	R	
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Introduction1	
There	 is	 considerable	 interest	 in	 the	use	of	polydatin	 for	 the	 treatment	of	a	variety	of	human	
diseases.3	Polydatin	((PD)	also	known	as	trans-polydatin,	piceid,	and	3,4',5-trihydroxystilbene-3-
β-mono-D-glucoside)	 is	 a	 glucoside	 derivative	 of	 resveratrol.	 It	 is	 purified	 from	 the	 root	 of	
Polygonum	cuspidatum	but	can	also	be	found	in	wines	and	grapes,4–7	cocoa,8	peanuts	and	peanut	
butter,9	pistachios10	and	almonds.11		Extracts	derived	from	Polygonum	cuspidatum	have	long	been	
a	part	of	traditional	Chinese	herbal	medicine	being	used	to	treat	pain,	fever,	coughs,	inflammation	
and	a	variety	of	other	ailments.12	Polydatin	is	found	to	be	the	major	component	of	these	extracts.	
As	a	derivative	of	resveratrol,	it	is	believed	to	have	many	of	the	same	beneficial	effects	but	has	
some	 properties	 that	 may	 make	 it	 more	 effective	 from	 a	 pharmacological	 standpoint	 than	
resveratrol.	Polydatin	is	structurally	the	same	as	resveratrol	except	that	it	has	a	glucoside	group	
attached	to	the	C-3	position	in	place	of	a	hydroxyl	group.	This	substitution	makes	polydatin	more	
water	soluble	and	resistant	to	enzymatic	breakdown	than	resveratrol.13	It	is	also	actively	taken	up	
by	 cells	 via	 glucose	 carriers	 in	 the	 cell	 membrane	 instead	 of	 being	 passively	 transported	 like	
resveratrol.14,15	 	 These	properties	 suggest	 that	polydatin	may	have	greater	bioavailability	 than	
resveratrol.	
Studies	have	presented	evidence	that	polydatin	has	many	positive	health	effects.	These	effects	
include	anti-inflammatory,16,17	hepatoprotective,18–21	anti-cancer,22–25	neuroprotective16,26–28	and	
cardioprotective	 activities.12,29–32	 Additional	 studies	 demonstrated	 that	 polydatin	 also	 has	
protective	effects	against	shock,33–35	 ischemia/reperfusion	 injury,36,21	congestive	heart	 failure,37	
endometriosis,38	 prevents	 fatty	 liver	 disease	 and	 insulin	 resistance,39	 and	 that	 it	 can	 regulate	
glucose	and	lipid	metabolism.40	Polydatin	has	been	studied	in	clinical	trials	for	the	treatment	of	
hemorrhagic	shock	and	irritable	bowel	syndrome.17,41		
The	use	of	polydatin	as	a	potential	therapy	for	dyslipidemia	has	been	suggested	by	studies	using	
animal	 models.	 Arichi	 et	 al.	 discovered	 that	 orally	 administered	 polydatin	 (100	 mg/kg	 body	
weight)	 significantly	 lowered	 serum	 triglycerides	 by	 40%	 and	 low-density	 lipoprotein	 (LDL)-
derived	cholesterol	by	approximately	18%.	This	study	was	performed	in	rats	consuming	standard	
chow	containing	a	mixture	of	corn	oil,	10%	cholesterol,	and	1%	cholic	acid.	Although	lower	doses	
of	 trans-polydatin	 (50	mg/kg	body	weight)	were	 ineffective	at	preventing	hyperlipidemia,	 they	
were	able	to	prevent	the	accumulation	of	cholesterol	and	triglycerides	 in	the	 liver,	which	may	
suggest	that	lower	doses	will	also	be	effective	but	to	a	much	lesser	extent.42	In	a	study	using	Syrian	
golden	hamsters,	polydatin	decreased	total	cholesterol	levels	and	total	triglyceride	levels	by	47%	
and	63%,	 respectively,	when	 compared	 to	 standard	diet.30	 In	 another	 study	using	 rabbits,	 the	
administration	of	polydatin	decreased	serum	total	cholesterol,	triglycerides,	and	LDL.29	The	ratio	
of	total	cholesterol	to	HDL	was	also	reduced.	
Insulin	 is	 a	major	 component	of	metabolic	 regulation	 through	activation	of	 the	Akt	 and	other	
metabolic	pathways.43	Hao	et	al.	recently	found	in	diabetic	rats	that	polydatin	activated	the	Akt	
signaling	 pathway,	 possibly	 by	 phosphorylation	 of	 the	 insulin	 receptor	 substrate	 (IRS),	 thus	
reducing	 blood	 glucose	 levels.40	 Polydatin	 may	 also	 decrease	 the	 expression	 of	 intercellular	
adhesion	molecule	1	(ICAM-1)	which	could	reduce	white	blood	cell	adhesion	thought	to	be	active	
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in	early	atherosclerotic	development.13		Polydatin	is	also	thought	to	provide	protection	from	cell	
damaging	oxidative	peroxidation14,44	and	inhibit	oxidation	of	LDL	particles,	which	may	also	play	a	
role	in	atherosclerosis.12		
Both	human	and	animal	studies	suggest	that	orally	administered	polydatin	is	absorbed	in	minutes,	
metabolized	 in	minutes	 to	 hours,	 and	 eliminated	 in	 24	 hr.45–47	Metabolites	 of	 trans-polydatin	
include	glucuronidated	and/or	sulfonated	trans-polydatin,	trans-resveratrol,	and	glucuronidated	
and/or	sulfonated	trans-resveratrol.	
This	 study	determined	 the	 toxicity	 and	 toxicokinetics	 of	 polydatin	when	administered	 via	 oral	
gavage	to	Sprague	Dawley	rats	daily	for	4	weeks.	
Methods1	
Regulatory	Guidelines	
The	study	was	conducted	according	to	Good	Laboratory	Practice	(GLP)	and	based	on	the	principles	
of	 the	 Food	 and	 Drug	 Administration	 Center	 for	 Drug	 Evaluation	 and	 Research	
(CDER)/International	Conference	on	Harmonisation	(ICH)	Harmonised	Tripartite	Guidelines	ICH-
M3,	Nonclinical	Safety	Studies	for	the	conduct	of	Human	Clinical	Trials	for	Pharmaceuticals	(CDER,	
July	 1997)	 and	 S3A,	 Toxicokinetics:	 The	 Assessment	 of	 Systemic	 Exposure	 in	 Toxicity	 Studies	
(CDER,	March	1995).	
Animals	
Male	 and	 female	 Crl:CD(SD)	 rats	 were	 received	 from	 Charles	 River	 Laboratories,	 Portage,	
Michigan.	At	initiation	of	dosing,	the	animals	were	6	to	7	weeks	old,	and	their	body	weights	ranged	
from	238	to	303	g	for	males	and	143	to	238	g	for	females.	Animals	were	randomized	to	the	study	
groups	using	a	computerized	procedure	designed	to	achieve	body	weight	balance	with	respect	to	
subgroup	 assignment,	 within	 a	 5%	 probability	 of	 homogeneity	 of	 variance.	 Following	
randomization,	each	study	animal	was	assigned	a	unique	number	by	means	of	an	 implantable	
microchip	identification	device	and/or	cage	card.		The	oral	route	of	administration	was	selected	
because	it	is	the	intended	route	of	administration	in	humans.	
Male	and	female	rats	were	housed	individually	in	stainless	steel	cages	in	the	following	conditions:	
temperature	 range	 of	 20	 to	 26°C,	 relative	 humidity	 range	 of	 30	 to	 70%,	 10	 or	 greater	 air	
changes/hour,	and	a	12-hour	light/12-hour	dark	cycle.		The	light/dark	cycle	was	interrupted	for	
study-related	activities.		
Diets	and	Test	Materials	
Animals	were	offered	Certified	Rodent	Diet	#2016C	(Harlan	Laboratories,	Inc.)	ad	libitum	unless	
fasted	for	study	procedures.		Water	was	provided	ad	libitum.	
Experimental	Design	
Testing	was	performed	by	Covance	Laboratories	(Madison,	Wisconsin).	The	test	article,	polydatin,	
was	supplied	by	Biotivia	(purity	98.36%	by	HPLC,	Lot.	No.	BIPL110714)	and	was	stored	at	2	to	8oC.	
The	vehicle	control	article	was	reverse	osmosis	water.	Test	article	formulations	were	prepared	
daily	on	Days	1	through	5	of	the	dosing	phase	and	once	weekly	from	day	6	through	the	remainder	
of	 the	 dosing	 phase.	 Formulations	 prepared	 prior	 to	 the	 day	 of	 dosing	 were	 stored	 in	 a	
refrigerator,	 set	 to	 maintain	 2	 to	 8°C,	 and	 protected	 from	 light	 until	 removed	 for	 dosing.		
Formulations	prepared	on	the	day	of	dosing	were	stirred	continuously	using	a	magnetic	stir	bar	
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and	stir	plate	and	stored	protected	from	light	at	room	temperature.	Formulations	were	kept	at	
approximate	room	temperature	no	longer	than	8	hours.	
Animals	were	weighed	3	days	prior	to	receiving	their	first	dose,	on	the	day	they	received	their	first	
dose,	and	weekly	thereafter.	All	animals	were	checked	twice	daily	(a.m.	and	p.m.)	for	mortality,	
abnormalities,	and	signs	of	pain	or	distress.	At	a	minimum,	clinical	observations	made	from	cage	
side	were	recorded	daily	during	the	dosing	phase.	Detailed	clinical	observations	were	recorded	
on	toxicity	animals	once	during	the	predose	phase,	prior	to	dosing	on	Day	1,	and	weekly	(based	
on	 Day	 1)	 throughout	 the	 dosing	 phase,	 and	 the	 termination	 date.	 Food	 consumption	 was	
measured	for	the	toxicity	groups.	Ophthalmic	evaluations	were	performed	once	during	prephase	
and	on	Day	29	of	the	dosing	phase	by	a	qualified	veterinarian.		
Polydatin	was	administered	by	oral	gavage	once	daily	for	29	days	(dosing	phase)	at	a	dose	volume	
of	10	mL/kg.	according	to	Table	1	-	Study	Groups.		Doses	were	stirred	for	at	least	one	hour	prior	
to	and	during	the	dosing.	The	dose	levels	selected	were	based	on	available	data	from	the	literature	
of	toxicity	of	resveratrol48	 in	addition	to	studies	evaluating	efficacy	of	polydatin.49–51	 	Statistical	
power	analysis	suggests	30	mg/kg	is	the	minimum	dose	capable	of	causing	a	statistically	significant	
reduction	in	cholesterol	and	triglycerides	based	on	results	in	the	LDLr-/-	mouse.52	The	dose	level	
of	300	mg/kg	is	an	order	of	magnitude	larger	and	is	the	dose	for	which	there	are	published	kinetic	
data	in	the	literature.46,53		The	upper	limit	of	3000	mg/kg	is	another	order	of	magnitude	larger	and	
a	level	at	which	some	effects	on	the	kidney	have	been	reported.54	
Table	11	
Study	Groups	
 
After	29	days	of	dosing,	all	surviving	toxicity	animals	were	sacrificed	and	necropsied.		Terminal	
body	 weights	 were	 recorded.	 Animals	 were	 anesthetized	 with	 sodium	 pentobarbital	 and	
exsanguinated.	 	An	examination	of	the	external	 features	of	the	carcass,	external	body	orifices,	
abdominal,	thoracic,	and	cranial	cavities,	organs,	and	tissues	were	performed.		A	pathologist	was	
available	for	consultation.		
Organ	weights,	including	adrenal	(2),	brain,	epididymis	(2),	heart,	kidney	(2),	liver,	lung,	ovary	(2)	
pituitary	gland,	prostate,	salivary	gland,	mandibular	(2),	seminal	vesicle,	spleen,	testis	(2),	thymus,	
thyroid	(2	lobes)	with	parathyroid,	and	uterus,	were	recorded	for	toxicity	animals.	Paired	organs	
were	weighed	together.	Adrenal	 (2),	aorta,	brain,	cecum,	cervix,	colon,	duodenum,	epididymis	
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(2),	esophagus,	eye	(2),	a	femur	with	bone	marrow	(articular	surface	of	the	distal	end),	Harderian	
gland,	heart,	ileum,	muscle	(biceps	femoris),	optic	nerve	(2),	ovary	(2),	pancreas,	pituitary	gland,	
prostate,	 rectum,	 salivary	 gland	 [mandibular	 (2)],	 sciatic	 nerve,	 seminal	 vesicle,	 skin/subcutis,	
spinal	 cord	 (cervical,	 thoracic,	 and	 lumbar),	 spleen,	 sternum	 with	 bone	 marrow,	 stomach,	
jejunum,	kidney	(2),	lesions,	liver,	lung	with	large	bronchi,	lymph	node	(mandibular),	lymph	node	
(mesenteric),	mammary	gland	 (females),	 testis	 (2),	 thymus,	 thyroid	 (2	 lobes)	with	parathyroid,	
tongue,	trachea,	urinary	bladder,	uterus,	and	vaginal	tissues	(when	present)	from	each	toxicity	
animal	 were	 preserved	 in	 10%	 neutral	 buffered	 formalin,	 with	 the	 exception	 of	 the	 eyes,	
Harderian	gland,	optic	nerves,	and	testes,	which	were	collected	in	modified	Davidson’s	fixative	
and	stored	in	10%	neutral-buffered	formalin.	
For	 histopathology,	 tissues	 were	 embedded	 in	 paraffin,	 processed	 to	 slide,	 and	 stained	 with	
hematoxylin	 and	 eosin.	 All	 preserved	 tissues	 (see	 above)	 were	 examined	 for	 histopathologic	
irregularities	 from	 toxicity	 animals	 in	 the	 control	 and	 high-dose	 groups	 and	 kidney,	 liver,	 and	
macroscopic	lesions	from	all	animals	in	the	low-,	mid-,	and	mid-high	dose	groups	were	examined	
microscopically	 by	 a	 veterinary	 pathologist.	 	 In	 addition,	 based	on	microscopic	 findings	 in	 the	
control	and	high	dose	groups,	the	urinary	bladders	from	2	females	in	Group	3,	Subgroup1	and	the	
spleen	from	males	in	the	low-,	mid-,	and	mid-high	dose	groups	were	examined	microscopically	by	
the	same	veterinary	pathologist.	Additionally,	any	macroscopic	lesions	or	suspected	target	organs	
of	note	at	the	high	dose	range,	were	examined.	
Blood	 samples	 were	 collected	 from	 toxicity	 animals	 (see	 Table	 1)	 for	 hematology,	 clinical	
chemistry,	 and	 coagulation	 via	 a	 jugular	 vein	 from	 animals	 fasted	 overnight.	 	 Samples	 were	
collected	on	 the	day	of	 scheduled	 sacrifice.	 Sodium	citrate	and	potassium	EDTA	were	used	as	
anticoagulants	for	coagulation	and	hematology	tests,	respectively.		Samples	for	clinical	chemistry	
were	collected	without	anticoagulant.	Urine	samples	for	urinalysis	were	collected	chilled	on	wet	
ice	during	the	overnight	period	from	fasted	toxicity	animals.		Samples	were	collected	on	the	day	
of	scheduled	termination.	
Blood	 samples	 (approximately	0.25	mL)	were	 collected	prior	 to	dosing	 via	 a	 jugular	 vein	 from	
toxicokinetic	animals	(Group	2,	Subgroup	2,	nine	animals/sex,	see	Table	1)	given	300	mg/kg/day	
predose	(Day	25	only).	Nine	animals	per	sex	were	used	with	blood	samples	collected	from	three	
animals/sex/time	point.	Blood	samples	were	collected	from	three	animals/sex/timepoint	on	Days	
1	and	25	at	the	following	time	points:	predose	(Day	25	only)	and	at	approximately	0.167,	0.333,	
0.5,	1,	2,	4,	8,	12,	and	24	hours	postdose.	Samples	were	collected	in	tubes	containing	potassium	
EDTA	and	maintained	on	chilled	cryoracks	until	centrifugation.		Samples	were	centrifuged	within	
1	 hour	 of	 collection,	 and	 plasma	 was	 harvested.	 	 Following	 centrifugation,	 samples	 were	
processed	under	yellow	light.		Plasma	samples	were	stored	in	a	freezer,	set	to	maintain	-60	to	-
80°C,	 until	 analyzed.	 Plasma	 analysis	 for	 trans-polydatin	 (also	 known	 as	 polydatin)	 and	 trans-
resveratrol	was	 performed	 by	 Covance-Madison	 using	 a	method	 (Method	 SPXRPP)	 previously	
validated	under	Covance	Study	No.	8251389.	Incurred	sample	reproducibility	was	conducted	in	
accordance	with	Covance	standard	operating	procedures.	
Toxicokinetic	analysis	included	(when	appropriate),	but	was	not	limited	to,	maximum	observed	
concentration	(Cmax),	time	to	peak	concentration	(Tmax),	and	area	under	the	concentration-time	
curve	(AUC).	Area	under	the	concentration-time	curve	from	hour	0	to	infinity	for	Day	1	calculated	
as	follows:	AUC0-∞	=	AUC0-t	+	Ct/λz	.	Where	Ct	is	the	last	measurable	concentration	and	λz	is	the	
elimination	rate	constant	estimated	using	 log-linear	regression	during	the	terminal	elimination	
phase.	The	number	of	points	used	 in	λz	calculation	was	determined	by	visual	 inspection	of	the	
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data	describing	the	terminal	phase.	At	 least	 the	 last	 three	time	points	with	measurable	values	
were	used	in	λz	calculation.	
Statistical	Analysis	
Data	for	each	sex	were	analyzed	separately;	only	data	collected	on	or	after	the	first	day	of	dosing	
were	analyzed	statistically.		Only	data	from	toxicity	animals	(Subgroup	1)	were	evaluated.		Analysis	
of	variance	(ANOVA)55	and	pairwise	comparisons	were	used	to	analyze	the	following;	absolute	
body	weight,	body	weight	change,	quantitative	food	consumption,	continuous	clinical	pathology	
values,	terminal	body	weight,	absolute	organ	weight,	organ	to	body	weight	percentage,	and	organ	
to	brain	weight	percentage.	
Levene’s	test56,57	was	done	to	test	for	equality	of	variances	between	groups.	Where	Levene’s	test	
was	significant	(p	<	0.05),	a	rank	transformation	(to	stabilize	the	variances)	was	applied	before	
the	ANOVA	was	conducted	(note:	Levene’s	test	was	not	applied	to	the	rank-transformed	data).	
Where	Levene’s	test	was	not	significant	(p	>	0.05),	ANOVA	was	conducted.	
One-way	ANOVA	was	used	(if	applicable)	to	analyze	continuous	clinical	pathology	values,	absolute	
organ	weight	data,	food	consumption,	and	body	weight	data.	If	the	group	effect	of	the	ANOVA	
was	significant	(p	<	0.05),	Dunnett’s	t-test58,59	was	used	for	pairwise	comparisons	between	each	
treated	 and	 control	 groups.	 	 Group	 comparisons	 (Groups	 2	 through	 5	 versus	 Group	 1)	 were	
evaluated	at	the	5.0%,	two-tailed	probability	level.	
Results1	
Body	Weights	
Animals	given	600,	1200,	or	3000	mg	polydatin/kg/day	showed	lower	mean	body	weights	which	
were	 dose	 dependent	 (Figure	 1).	 Decreases	 were	 of	 small	 magnitude	 (≤10%	 compared	 with	
control)	 and	 correlated	with	 lower	 body	weight	 gain	 in	 these	 animals	 (Figure	 2).	 	 Statistically	
significant	decreases	included	lower	mean	body	weight	for	all	4	weeks	of	the	dosing	phase	for	
males	given	3000	mg/kg/day.	While	the	decreases	were	not	always	statistically	significant,	dose	
dependency	and	a	correlating	decrease	in	food	consumption	suggested	decreases	in	body	weight	
and	body	weight	gain	were	polydatin	related.	Due	to	the	absence	of	relevant	clinical	observations	
and	small	magnitudes	of	the	changes,	decreases	in	body	weight	and	body	weight	gain	were	not	
considered	adverse.		In	addition,	polydatin	is	a	prodrug	of	resveratrol,	and	resveratrol	is	a	caloric	
restriction	mimetic.60,61		For	this	reason,	a	dose-dependent	decrease	in	body	mass	is	not	surprising	
(See	Table	2).	
Food	Consumption	
Males	and	females	given	3000	mg	polydatin/kg/day	consumed	less	food	during	Week	1	of	the	
dosing	 phase	 (Table	 3).	 This	 decrease	 was	 statistically	 significant	 for	 males.	 Lower	 food	
consumption	continued	to	be	observed	for	males	and	females	for	Weeks	2	and	3	of	the	dosing	
phase;	 however,	 it	 was	 not	 statistically	 significant	 and	 the	 difference	 became	 smaller	 in	
magnitude	with	each	week.		During	Week	4	of	the	dosing	phase,	food	consumption	for	males	and	
females	given	3000	mg/kg/day	was	comparable	with	control	rats.	Lower	food	consumption	was	
also	observed	during	Weeks	1,	2,	3,	and	4	(females	only)	of	the	dosing	phase	for	animals	given	
600	or	1200	mg/kg/day	(Table	3).	 	However,	this	was	not	statistically	significant.	This	decrease	
was	considered	polydatin-related	given	that	a	correlating	decrease	in	body	weight	was	observed	
for	these	animals.	Due	to	the	absence	of	relevant	clinical	observations	and	small	magnitudes	of	
the	changes,	decreases	in	food	consumption	were	not	considered	adverse.	
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Figure	11	
	
Weight	gain	of	rats	based	upon	polydatin	dose	over	the	course	of	the	experiment.	Rats	received	their	first	
dose	of	polydatin	on	Day	1.	(A)	Female	rats,	n=10	(B)	Male	rats,	n=10	per	group.	Results	are	shown	as	mean	
±	stdev.1	
Figure	21	
	
Body	weights	on	Day	29	prior	to	study	termination.	A)	Female	rats,	n=10	per	group;	B)	Male	rats,	n=10	per	
group.	*	P<0.05	compared	to	control.	Results	are	shown	as	mean	±	stdev.	1	
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Table	21	
Percent	Decrease	in	Body	Weight	
Group	Dose	Level	(mg/kg/day)	 Males	 Females	
Day	8	Day	15	Day	22	Day	29	Day	8	Day	15	Day	22	Day	29	
2	 300	 -	 -	 -	 -	 -	 -	 -	 -	
3	 600	 -	 1.6	 1.5	 2.5	 -	 2.6	 2.9	 5.0	
4	 1200	 4.3	 5.3	 5.9	 5.9	 1.4	 2.6	 3.7	 6.6	
5	 3000	 6.8*	 7.5*	 9.1*	 10.0*	 2.4	 4.4	 6.6	 8.1	
-	=	No	noteworthy	differences.*	=	Statistically	significant	at	P	<=	0.05.	
Body	weight	for	animals	given	300	mg/kg/day	as	comparable	with	controls.1	
Table	31	
Percent	Decrease	in	Food	Consumption	
Group	Dose	(mg/kg/day)	 Males	 Females	
Week	1	Week	2	Week	3	Week	4	Week	1	Week	2	Week	3	Week	4	
1	 0	 -	 -	 -	 -	 -	 -	 -	 -	
2	 300	 -	 -	 -	 -	 -	 -	 -	 -	
3	 600	 2.3	 3.6	 2.2	 1.9	 1.4	 2.0	 3.0	 4.5	
4	 1200	 6.5	 3.6	 3.5	 -	 6.8	 7.9	 7.8	 5.7	
5	 3000	 11.1*	 6.7	 4.4	 -	 10.2	 7.9	 6.6	 3.2	
-	=	No	noteworthy	differences.*	=	Statistically	significant	at	P	<=	0.05.	
Food	Consumption	(%	lower	compared	with	control)1	
Toxicokinetic	Analyses	
Polydatin	
Mean	 concentration	 time	 profiles	 for	 males	 and	 females	 showed	 mean	 concentrations	 of	
polydatin	were	generally	 similar	 after	 a	 single	dose	and	multiple	doses	of	polydatin	 (Table	4).		
After	oral	administration,	polydatin	was	readily	absorbed,	with	Tmax	values	ranging	from	0.500	
to	 1.00	 hours	 on	 Days	 1	 and	 25	 of	 the	 dosing	 phase.	 	 Polydatin	 was	 readily	 eliminated,	 and	
concentration	values	for	polydatin	were	below	the	limit	of	quantitation	by	12	hours	postdose	on	
Days	1	and	25	of	the	dosing	phase.	
Table	41	
Toxicokinetic	Parameters	for	Polydatin	and	Trans-Resveratrol	in	Rat	Plasma	
Analyte	 Polydatin	Dose	Level	
(mg/kg/day)	
Day	 Sex	 Cmax	
(ng/mL)	
Tmax	
(hr)	
AUC0-t	
(ng·hr/mL)	
AUC0-24	
(ng·hr/mL)	
AUC0-∞	
(ng·hr/mL)	
M/P	
AUC0-24	
Ratio	
polydatin	 300	 1	 M	 2857	 1.00	 9699	 10291	 NC	 	
	 	 	 F	 3183	 0.500	 10640	 10964	 11003	 	
	 	 25	 M	 2690	 1.00	 7629	 7741	 NA	 	
	 	 	 F	 4700	 0.500	 9472	 9593	 NA	 	
trans-	 300	 1	 M	 467	 2.00	 3235	 3619	 NC	 0.352	
resveratrol	 	 	 F	 333	 2.00	 2064	 2139	 NC	 0.195	
	 	 25	 M	 302	 2.00	 2171	 2773	 NA	 0.358	
	 	 	 F	 292	 0.500	 1630	 1827	 NA	 0.190	
NA	=	Not	applicable;	NC	=	Not	calculated.1	
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Cmax	and	AUC0-24	values	for	polydatin	were	higher	for	females	than	for	males,	but	the	differences	
were	less	than	2-fold.		Values	for	Cmax	and	AUC0-24	were	lower	on	Day	25	compared	with	Day	1	
of	the	dosing	phase,	indicating	no	accumulation	of	polydatin	after	multiple	dosing.	
Trans-Resveratrol	
Mean	concentration	time	profiles	for	males	and	females	showed	mean	concentrations	of	trans-
resveratrol	were	generally	similar	after	a	single	dose	and	multiple	doses	of	polydatin	(Table	4).		
After	oral	administration,	trans-resveratrol	readily	appeared	in	the	plasma,	with	Tmax	values	of	
2.00	hours	on	Days	1	and	25	of	the	dosing	phase.		Plasma	levels	readily	declined	and	were	below	
the	limit	of	quantitation	by	24	hours	post-dose	on	Days	1	and	25	of	the	dosing	phase.		Cmax	and	
AUC0-24	values	for	trans-resveratrol	were	higher	for	males	than	for	females,	but	the	differences	
were	less	than	2-fold.		Values	for	Cmax	and	AUC0-24	were	lower	on	Day	25	compared	with	Day	1	
of	the	dosing	phase,	indicating	no	accumulation	of	polydatin	after	multiple	dosing.		Mean	AUC0-24	
ratios	 of	 trans-resveratrol	 to	 polydatin	 (metabolite-to-parent	 ratio)	 were	 0.352	 and	 0.358	 for	
males	and	0.195	and	0.190	for	females	on	Days	1	and	25	of	the	dosing	phase,	respectively.	
Although	maximum	serum	levels	of	polydatin	were	slightly	 less	 in	males	than	 in	 females,	both	
sexes	absorbed	polydatin	with	similar	kinetics,	reaching	peak	 levels	(approximately	3.0	mg/ml)	
within	1	hr	of	dosing	(Figure	3).	Serum	trans-resveratrol	levels	were	10-fold	less	than	polydatin	
and	 attained	 maximal	 levels	 in	 both	 male	 and	 females	 approximately	 2	 hr	 after	 dosing.	
Importantly,	the	levels	of	both	polydatin	and	trans-resveratrol	were	below	the	limit	of	detection	
24	hr	after	dosing.	Similar	results	were	also	found	on	day	25	of	the	toxicokinetic	study	indicating	
that	there	was	no	accumulation	of	polydatin	or	resveratrol	after	repeat	dosing.	
Figure	31	
Pharmacokinetic	Concentrations	of	Polydatin	and	Trans-Resveratrol	
Serum	concentrations	of	 polydatin	 and	 trans-resveratrol	 after	 the	oral	 gavage	of	 0.3	 g/kg	of	 polydatin	 in	
female	 (A)	 and	male	 (B)	 rats.	 Nine	 animals	 per	 sex	 were	 used	with	 blood	 samples	 collected	 from	 three	
animals/sex/time	 point.	 Graphs	 represent	 the	 results	 obtained	 on	 the	 first	 day	 of	 dosing.	 The	 levels	 of	
polydatin	and	trans-resveratrol	were	assumed	to	be	0	at	time	zero	because	the	rats	had	not	been	previously	
exposed	to	polydatin.	Results	are	shown	as	mean	±	standard	deviation.	1	
Clinical	Pathology,	Hematology	and	Coagulation	
No	polydatin-related	effects	were	observed	in	hematology	and	coagulation	data.	
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Minimally	shortened	prothrombin	time	in	males	given	>1200	mg/kg/day	was	of	small	magnitude	
(<0.5	sec)	and,	considering	the	normal	variability	in	coagulation	times,	was	not	considered	test	
article-related	or	toxicologically	important.	Shortened	prothrombin	time	was	slightly	surprising	as	
others	have	found	polydatin	protects	again	thrombosis	possibly	by	decreasing	platelet-neutrophil	
interactions.	62	
Clinical	Chemistry	
Several	minor	polydatin-related	findings	were	observed	in	clinical	chemistry	test63	results	but	they	
were	of	 small	magnitude	and	not	 considered	adverse	or	 toxicologically	 important.	 Findings	 at	
>600	mg/kg/day	included	the	following.	
• Minimally	 lower	 glucose	 in	males	 given	 >600	mg/kg/day	 and	 females	 (not	 statistically	
significant)	given	3000	mg/kg/day	
• Minimally	higher	albumin	in	males	given	>1200	mg/kg/day	
• Minimally	 lower	 globulin	 and	 higher	 albumin-to-globulin	 ratio	 in	 males	 given	 >600	
mg/kg/day	
• Minimally	higher	ALT	activity	in	males	and	females	given	>600	mg/kg/day	
• Minimally	higher	alkaline	phosphatase	(ALP)	activity	in	females	given	>600	mg/kg/day	
• Minimally	lower	potassium	in	females	given	3000	mg/kg/day	
Minimally	higher	alanine	aminotransferase	(ALT)	activity	in	males	was	the	only	clinical	chemistry	
finding	at	300	mg/kg/day.	 	Overall,	elevations	 in	ALT	(1.2	to	2.1x	control)	and	ALP	(1.3	to	1.6x	
control)	were	of	small	magnitude	and	not	associated	with	microscopic	findings	in	the	liver.	No	rise	
was	detected	 in	total	bilirubin,	also	a	strong	 indicator	of	drug	 induced	 liver	 injury	(DILI).	Other	
studies	 have	 shown	 polydatin	 to	 have	 a	 protective	 hepatic	 mechanism	 in	 mice	 dosed	 up	 to	
300mg/kg64	and	100	mg/kg.65	
Figure	41	
Glucose	Serum	Levels	
Glucose	serum	levels	of	male	and	female	rats	on	Day	29.	Female	rats,	n=10	per	group;	Male	rats,	n=10	per	
group.	*=	Statistically	significant	at	P	<=	0.05.1	Normal	value	range	based	on	Charles	River	historical	data	of	
Crl:CD(SD)	Rats.63	
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Lower	 glucose	 (see	 Figure	 4)	 and	 potassium	 may	 have	 been	 associated	 with	 reduced	 feed	
consumption	observed	in	these	animals.	However,	as	we	discussed	earlier,	previous	studies	have	
identified	polydatin	as	capable	of	lowering	glucose	levels	in	diabetic	models	of	mice40	and	rats13	
by	stimulating	insulin	secretion.	High	albumin	(See	Figure	5)	commonly	occurs	with	dehydration,	
however,	dehydration	was	not	evident	clinically	or	in	other	clinical	pathology	data	(serum	urea	
nitrogen	and	creatinine).	It	should	be	noted	that	lower	albumin	levels	are	more	often	associated	
with	liver	disease,66	nephrotic	syndrome,67	and	malnutrition.68	
Figure	51	
Albumin	Serum	Levels	
Albumin	serum	levels	of	male	and	female	rats	on	Day	29.	Female	rats,	n=10	per	group;	Male	rats,	n=10	per	
group.	*=	Statistically	significant	at	P	<=	0.05.1	Normal	value	range	based	on	Charles	River	historical	data	of	
Crl:	CD	(SD)	Rats.63	
Urinalysis	
None	of	the	urinalysis	findings	were	considered	adverse	or	toxicologically	important.		Minimally	
lower	urine	pH	in	males	and	females	given	>1200	mg/kg/day	and	higher	incidence	or	severity	of	
urine	 occult	 blood	 and	 presence	 of	 red	 blood	 cells	 in	 the	 urine	 of	 a	 few	 males	 given	 3000	
mg/kg/day	and	presence	of	white	blood	cells	in	the	urine	of	a	few	females	given	3000	mg/kg/day	
were	 considered	 polydatin-related	 findings	 but	 not	 adverse.	 	 The	 change	 in	 pH	 appeared	
consistently	 present	 in	 most	 animals,	 but	 the	 remaining	 urinalysis	 findings	 were	 observed	 in	
individual	animals	and	most	were	not	associated	with	correlative	microscopic	findings.	
One	female	given	3000	mg/kg/day	had	increased	severity	of	white	blood	cell	in	the	urine,	which	
correlated	 with	 marked	 chronic	 active	 pelvic	 inflammation	 observed	 microscopically	 in	 the	
kidneys	(see	Figure	6).		However,	one	male	given	1200	mg/kg/day	with	microscopic	evidence	of	
marked	acute	renal	hemorrhage	had	no	occult	blood	or	presence	of	red	blood	cells	in	the	urine.		
Additionally,	 two	 females	 given	 600	 mg/kg/day	 with	 microscopic	 findings	 of	 chronic	 active	
inflammation	in	renal	pelvis	(see	Figure	6)	had	no	increase	in	evidence	or	severity	of	white	blood	
cells	in	the	urine,	although	another	animal	had	presence	of	red	blood	cells	in	the	urine.	
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Figure	61	
Chronic	Active	Pelvic	Inflammation	
Chronic	active	pelvic	inflammation	in	male	and	female	rats.	Female	rats,	n=10	per	group;	Male	rats,	n=10	per	
group.1	
Test	results	of	interest	included	increased	incidence	and	severity	of	tubular	dilatation	(see	Figure	
7),	increased	incidence	and	severity	of	hyaline	(protein)	droplets	in	the	tubule	cells	(males	only)	
(see	Figure	8),	erosion/ulceration	of	the	transitional	epithelium	(see	Figure	9),	and	inflammation	
of	the	renal	pelvis	(see	Figure	6).	
Figure	71	
	
Tubular	dilation	in	kidneys	in	male	and	female	rats.	Female	rats,	n=10	per	group;	Male	rats,	n=10	per	group.	
Abbreviations:	min-minimal;	sli-slight;	mod-moderate.1	
Statistically	significant	or	otherwise	notable	differences	observed	for	other	clinical	pathology	test	
results	were	 considered	 incidental	because	 they	were	usually	of	 very	 small	magnitude	and/or	
lacked	a	relationship	to	dose.	
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Figure	81	
Hyaline	Droplets	in	the	Tubule	Cells	
	
Hyaline	droplets	in	the	tubule	cells	of	male	and	female	rats.	Female	rats,	n=10	per	group;	Male	rats,	n=10	per	
group.	Abbreviations:	min-minimal;	sli-slight;	mod-moderate;	mark-marked.1	
Figure	91	
Ulcer/Erosion	of	the	Transitional	Epithelium	
	
Ulceration	of	the	transitional	epithelium	in	male	and	female	rats.	Female	rats,	n=10	per	group;	Male	rats,	
n=10	per	group.	Abbreviations:	min-minimal;	sli-slight.1	
Anatomic	Pathology	
Polydatin	 related	 terminal	body	weight	 changes	were	noted	 in	animals	given	3000	mg/kg/day	
compared	with	controls.		Mean	terminal	body	weight	was	10%	lower	in	males	and	8%	lower	in	
females;	 the	 change	was	 only	 significant	 in	males.	 	 Brain-to-body	weight	 and	 kidney-to-body	
weight	ratios	were	significantly	higher	in	males	given	3000	mg/kg/day,	which	were	attributed	to	
the	 lower	 terminal	 body	 weight.	 	 Absolute	 liver	 weight	 in	 males	 given	 3000	 mg/kg/day	 was	
significantly	 lower	 (12.9%)	 than	 controls;	 these	 findings	 were	 considered	 spurious	 since	 no	
microscopic	correlate	was	present.	
Absolute	and	relative	mean	spleen	and	thymus	weights	were	also	 lower	 in	males	and	 females	
given	 3000	mg/kg/day,	 though	 not	 significantly.	 	 There	 was	 no	microscopic	 correlate	 for	 the	
spleen	or	thymus	weight	changes;	they	were	attributed	to	biological	variation.		Individual	spleen	
weights	did	not	correlate	with	the	lymphocyte	depletion	noted	below.	
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Macroscopically,	at	3000	mg/kg/day,	large	cecum	was	noted	in	2/10	males	and	3/10	females,	and	
a	 large	colon	was	noted	 in	1/10	males.	 	At	1200	mg/kg/day,	a	 large	cecum	was	noted	 in	1/10	
females.		This	finding	was	considered	test	article-related,	although	no	microscopic	correlate	was	
present.	
Polydatin-related	microscopic	kidney	findings	were	limited	to	males	given	>1200	mg/kg/day	and	
females	given	600	or	3000	mg/kg/day.		Kidney	findings	were	sporadic,	varied	between	animals,	
and	did	not	often	show	a	clear	dose	response	relationship.		The	only	microscopic	finding	that	was	
considered	adverse	was	 the	marked	bilateral	 chronic	 active	 inflammation	and	 transitional	 cell	
hyperplasia	in	one	female	given	3000	mg/kg/day	(see	Figure	6).		Although	chronic	inflammation	
was	only	noted	in	the	aforementioned	animal,	it	was	considered	test	article-related	because	of	
the	presence	of	minimal	to	slight	acute	or	chronic/active	inflammation	in	several	other	treated	
animals	given	lower	doses,	the	marked	severity	of	the	lesion,	and	the	lack	of	evidence	of	any	other	
inciting	 cause	 (i.e.,	 a	 calculus	 causing	 chronic	 irritation).	 	 Similar	 inflammation	 in	 two	 females	
given	600	mg/kg/day	was	not	considered	adverse	due	to	the	 lower	severity	and	the	unilateral	
nature	of	the	inflammation.		The	hyaline	protein	droplets	in	the	tubular	cells	of	the	males	were	
also	not	considered	adverse,	even	at	a	marked	severity,	because	there	was	no	clinical	pathology	
evidence	of	renal	protein	loss.	
An	unusual	finding	of	uncertain	relationship	to	the	test	article	was	the	presence	of	marked	acute	
hemorrhage	in	the	kidney	of	one	male	given	1200	mg/kg/day.		The	cause	of	the	hemorrhage	was	
not	evident	in	examined	sections.		This	animal	also	was	noted	to	have	a	urinary	bladder	that	was	
discolored	and	filled	with	red	fluid	at	necropsy.	
Lymphocyte	depletion	was	observed	in	the	mantle	zone	of	the	spleens	in	4/10	males	in	the	test	
article	group	given	3000	mg/kg/day	(see	Figure	10).		This	finding	was	not	considered	a	primary	
test	article	related	effect,	and	was	attributed	to	stress.		Lymphocyte	depletion	was	not	seen	in	
any	other	examined	lymphoid	organs	(thymus,	mesenteric	lymph	node,	mandibular	lymph	node,	
and	gastrointestinal	lymphoid	tissue	present	on	examined	sections	of	intestine).	
Figure	101	
Depletion	of	Lymphocytes	in	Mantle	Zone	of	Spleen	
	
Depletion	of	 lymphocytes	 in	mantle	zone	of	spleen	in	male	and	female	rats.	Female	rats,	n=10	per	group;	
Male	rats,	n=10	per	group.1	
Discussion1	
In	 this	 study,	 administration	of	 polydatin	up	 to	3000	mg/kg/day	did	not	 result	 in	 any	 adverse	
effects	 on	 the	 general	 health	 of	 the	 animals.	 	 Although	 administration	 of	 polydatin	 caused	
reductions	in	body	weight,	body	weight	gain,	and	food	consumption,	decreases	in	body	weight	
and	food	consumption	were	of	small	magnitude.		Furthermore,	decreases	in	food	consumption	
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were	primarily	noted	during	the	first	3	weeks	of	dosing,	suggesting	animals	were	starting	to	adapt	
by	Week	4	of	the	dosing	phase.	
Reduction	 in	 lymphocytes	 appears	 to	 be	 systemic	 and	 likely	 related	 to	 stress.	 One	 cortisol	
treatment	 has	 been	 shown	 to	 reduce	 lymphocytes	 by	 as	 much	 as	 70%	 in	 humans.69	 Other	
occurrences	 in	 the	 study	which	 could	 be	 interpreted	 as	 stress-related	 include	 changes	 in	 the	
spleen	 cellularity	 and	 lymph	node	 cellularity	 in	males,	 and	 increases	 in	 circulating	neutrophils	
compared	to	control	(although	not	significant).70	
Other	test	related	findings	included	minimally	higher	ALT	in	females	dosed	at	≥600	mg/kg/day	but	
there	was	 no	 increase	 in	 liver	weight,	 or	 rate	 of	 hepatocellular	 changes	 denoting	 necrosis	 or	
degeneration	of	the	bile	duct	greater	than	seen	in	the	control	group.	Similar	studies	in	humans	
have	been	reported	in	which	weight	loss	in	women	was	associated	with	an	increase	in	ALT	and	
AST	but	no	hepatic	histological	changes	were	noted.71	
Urinary	 related	 findings	 included	dilated	 tubules,	 presence	of	 hyaline	droplets,	 dilation	of	 the	
renal	 pelvis,	 inflammation	 of	 the	 pelvis,	 and	 hyperplasia	 and	 or	 ulceration	 of	 the	 transitional	
epithelium.	Dilated	 tubules	may	be	 regarded	as	normal	 if	 present	 in	 small	 amounts.72	Hyaline	
droplets	are	also	of	little	concern	if	restricted	to	younger	male	animals	as	seen	in	the	study	and	
appear	 in	equal	rates	 in	the	treated	and	control	groups.73	The	only	adverse	test	article-related	
finding	noted	in	one	female	given	3000	mg/kg/day	was	chronic	active	pelvic	 inflammation	and	
transitional	cell	hyperplasia.		Based	on	these	results,	the	no	observed	adverse	effect	level	(NOAEL)	
is	1200	mg/kg/day	for	females	and	3000	mg/kg/day	for	males.	
All	animals	 in	the	toxicokinetic	phase	of	the	study	(300	mg/kg/day)	were	exposed	to	polydatin	
and	 its	metabolite,	 trans-resveratrol	 as	 verified	by	 the	presence	of	 these	 two	materials	 in	 the	
plasma	samples.	 	No	marked	sex	differences	were	observed	 in	polydatin	and	trans-resveratrol	
Cmax	and	AUC0-24	values.		No	accumulation	of	polydatin	or	trans-resveratrol	was	observed	after	
multiple	dosing	of	polydatin.	
Conclusion	
All	 animals	 survived	 to	 the	 end	 of	 the	 study.	 No	 polydatin-related	 clinical	 observations	 or	
ophthalmic	findings	were	noted.	No	marked	sex	differences	were	observed	in	polydatin	Cmax	and	
AUC0-24	 values.	 	 No	 accumulation	 of	 polydatin	 was	 observed	 after	 multiple	 dosing.	 The	 only	
adverse	test	article-related	finding	noted	in	one	female	given	3000	mg/kg/day	was	chronic	active	
pelvic	 inflammation	and	 transitional	 cell	 hyperplasia.	Based	on	 these	 results,	 the	no	observed	
adverse	effect	level	(NOAEL)	is	1200	mg/kg/day	for	females	and	3000	mg/kg/day	for	males.	
*	This	is	an	open-access	article	distributed	under	the	terms	of	the	Creative	Commons	Attribution	
License	(CC-BY),	which	permits	unrestricted	use,	distribution,	and	reproduction	in	any	medium,	
provided	the	original	author	and	source	are	credited.			
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Study	Summary	
Title	 An	exploratory	phase	1	clinical	pharmacokinetic	study	of	BSN272	in	healthy	volunteers.	
Short	Title	 Pharmacokinetic,	single	dose	study	of	BSN272	in	healthy	volunteers.	
Protocol	Number	 XXXXXX-001	
Phase	 Phase	1	
Methodology	 2-arm	single	dose	of	trans-polydatin	(100	µg)	and	D-lyxo-hexulose	(0.03	g/kg)	pharmacokinetic	study	over	24	hours.	
Study	Duration	 24-36	hours	
Study	Center(s)	 University	of	Kentucky	
Objectives	
To	test	the	hypothesis	that	the	tmax	and	cmax	of	a	single	dose	of	trans-polydatin	
(100	µg)	does	not	change	when	administered	with	a	single	dose	of	D-lyxo-
hexulose	(0.03	g/kg).			
Number	of	Subjects	 Screen	up	to	32	to	enroll	a	total	of	16	healthy	subjects	(18-30	yrs.	old),	4	alternates	and	12	needed	to	complete	the	trial.	
Diagnosis	and	Main	
Inclusion	Criteria	 Healthy	Volunteers	
Study	Product,	Dose,	
Route,	Regimen	
Single	oral	dose	of	trans-polydatin	(100	µg)	and	D-lyxo-hexulose	(0.03	g/kg)	in	a	
2-arm	study.	
Duration	of	
administration	 Single	dose	
Reference	therapy	 None	
Statistical	
Methodology	
A	t-test	(p=0.05)	will	be	used	to	calculate	the	significance	of	the	difference	
between	the	Cmax	and	Tmax	of	t-PD	with	and	without	DLH.	
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AE	 	 adverse	event	
apoB	 	 apolipoprotein	B	
ALT	 	 Alanine	transaminase	
BSN272	 D-lyxo-hexulose	+	trans-polydatin	combination	
BUN	 	 blood	urea	nitrogen	
CO2	 	 carbon	dioxide	
CRF	 	 case	report	form	
CRO	 	 contract	research	organization	
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Abstract	
	
The	 primary	 objective	 of	 this	 phase	 1	 exploratory,	 microdose	 study	 is	 to	 determine	
whether	 the	 tmax	 and	 Cmax	 of	 trans-polydatin	 (t-PD)	 change	 significantly	 when	
coadministered	with	D-lyxo-hexulose	(DLH)	in	healthy	male	and	female	volunteers	over	
a	24-hour	period.	BSN272	is	a	potential	drug	therapy	for	the	treatment	of	persons	with	
Prader	Willi	Syndrome	(PWS).	 	Healthy	volunteers	will	be	administered	doses	of	trans-
polydatin	or	BSN272.	Blood	samples	will	be	taken	pre-dose	(t	=	0)	and	at	approximately	
0.167	 (10	 min),	 0.333	 (20	 min),	 0.5,	 1,	 2,	 4,	 6,	 8,	 12	 and	 24-36	 hours	 post	 drug	
administration.	Urine	 samples	will	 also	 be	 collected	 during	 the	 12	 hour	 onsite	 clinical	
period,	with	one	subsequent	sample	collected	at	visit	3,	which	should	approximate	the	
24	 hour	 post-treatment	 period.	 Serum	 and	 urine	 samples	 will	 be	 assayed	 for	 trans-
polydatin	 and	 the	 metabolite	 trans-resveratrol	 at	 each	 time	 point	 to	 determine	 the	
pharmacokinetic	effects	of	the	combination	BSN272	drug.	
Introduction		
Background:	
Prader-Willi	Syndrome	
Persons	with	Prader-Willi	Syndrome	(PWS)	are	at	risk	of	premature	death	(Einfeld,	et	al.,	
2006;	 Stevenson,	 et	 al.,	 2007).	 In	 one	 study	 using	 the	 demographic	 data	 on	 178	
deceased	individuals	with	PWS,	the	median	and	average	age	at	death	was	27	years	and	
>25%	of	 individuals	were	<19	 years	 (Stevenson,	 et	 al.,	 2007).	 In	 a	 second	 study	of	 36	
adults	with	PWS	 in	Australia,	 there	were	10	deaths	at	a	mean	age	of	33	years	 (Smith,	
2003).	 PWS	 is	 the	 most	 commonly	 known	 genetic	 cause	 of	 life-threatening	 obesity.	
Estimates	of	the	prevalence	of	PWS	range	between	1	in	12,000	to	1	in	52,000,	with	the	
most	 likely	 figure	 being	 1:15,000	 (Burd,	 et	 al.,	 1990;	 Whittington	 et	 al.,	 2001:	
www.pwsausa.org).	One	of	the	characteristics	of	PWS	is	an	insatiable	appetite	resulting	
in	obesity.	Obesity	 is	associated	with	an	 increased	risk	 for	diabetes	and	cardiovascular	
disease	and	markers	 for	 these	obesity	 related	diseases,	 such	as	 insulin	 resistance	and	
dyslipidemia,	are	commonly	exhibited	by	patients	with	PWS.	 	Because	of	 the	complex	
nature	 of	 PWS,	 and	 the	multiple	 symptoms	 exhibited	 by	 patients	 with	 PWS,	 there	 is	
currently	 no	 single	 drug	 available	 that	 can	 successfully	 treat	 all	 of	 the	 symptoms.	 For	
example,	 growth	hormone	 can	 increase	 stature	 and	muscle	 tone,	 but	 does	 not	 affect	
hyperphagia.		D-lyxo-hexulose	(DLH,	also	known	as	D-tagatose)	has	been	shown	in	both	
animal	 and	 human	 studies	 to	 have	 a	 beneficial	 effect	 on	 many	 of	 the	 symptoms	
exhibited	by	PWS	patients	including	satiety,	weight	control,	blood	lipids,	atherosclerosis,	
and	type	2	diabetes	mellitus.	Studies	with	trans-polydatin	indicate	positive	results	for	a	
number	of	health	 issues	that	commonly	 impact	patients	with	PWS,	such	as	preventing	
diet	induced	increases	in	cholesterol	and	triglycerides	(Arichi	et	al	1982;	Du	et	al	2009;	
Xing	et	al	2009).	Studies	have	shown	that	the	combination	of	DLH	and	t-PD	is	synergistic,	
and	 have	 even	 shown	 that	 undesirable	 side	 effects	 of	 one	 can	 be	 eliminated	 by	 the	
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other	 (Lodder	 et	 al	 2015).	 	 This	makes	 BSN272,	 the	 combination	 of	 D-lyxo-hexulose	
(DLH)	 and	 trans-polydatin	 (t-PD),	 an	 excellent	 drug	 candidate	 for	 the	 treatment	 of	
patients	with	PWS.	
	
PWS	is	a	complex	multisystem	genetic	disease	characterized	by	hypothalamic-pituitary	
dysfunction	with	 varying	degrees	of	penetrance	 in	humans.	Hypothalamic	dysfunction	
has	 been	 implicated	 in	many	manifestations	 of	 this	 syndrome	 including	 hyperphagia,	
temperature	 instability,	 high	 pain	 threshold,	 sleep	 disordered	 breathing,	 and	multiple	
endocrine	 abnormalities.	 These	 endocrine	 abnormalities	 include	 growth	 hormone	
deficiency	 with	 resulting	 short	 stature,	 central	 adrenal	 insufficiency,	 hypogonadism,	
hypothyroidism,	 central	 obesity	 and	 complications	 of	 obesity	 such	 as	 type	 2	 diabetes	
mellitus	 (Emerick	 and	Vogt,	 2013).	Multiple	 studies	have	 indicated	high	prevalence	of	
central	adrenal	insufficiency	(CAI)	(Corrias	et	al.,	2012)	and	CAI	as	the	apparent	cause	of	
sudden	 deaths	 in	 PWS	 patients	 (de	 Lind	 van	 Wijngaarden,	 2008).	 The	 evidence	
presented	above	has	led	some	to	hypothesize	hypothalamic-pituitary-adrenal	(HPA)	axis	
dysfunction	as	the	cause	of	PWS	(Farholt	et	al.,	2011).	
	
The	major	medical	concern	for	patients	with	PWS	is	morbid	obesity.	Compulsive	eating	
and	obsession	with	food	usually	begins	between	the	ages	of	1	and	6.	The	urge	to	eat	is	
physiological	 and	 overwhelming;	 it	 is	 difficult	 to	 control	 and	 requires	 constant	
vigilance.	 Weight	 control	 depends	 on	 food	 restriction	 and	 daily	 exercise.	 Currently	
there	 is	 no	medication	or	 surgical	 intervention	 that	 can	eliminate	 the	need	 for	 strict	
dieting	and	supervision	around	food.	Studies	have	repeatedly	shown	that	PWS	patients	
are	at	risk	of	premature	death.	Mortality	in	children	is	most	commonly	associated	with	
respiratory	 infection	 and	 high	 temperature	 resulting	 in	 sudden	 death.	 Common	 in	
adults	 with	 PWS	 are	 obesity-related	 problems	 such	 as	 respiratory	 failure	 and	
pulmonary	hypertension,	obstructive	 sleep	apnea,	hypertension,	 and	 type	2	diabetes	
mellitus	(T2DM)	(Einfeld,	et	al.,	2006;	Lionti,	2012;	Whittington,	et.al.,	2001;	Vogels,	et.	
al.,	2004).	The	cause	of	death	in	adults	is	usually	related	to	failures	of	the	circulatory	or	
respiratory	systems.	
	
A	 high	 incidence	 of	 alterations	 in	 glucose	 metabolism	 including	 impaired	 fasting	
glucose,	 impaired	 glucose	 tolerance,	 and	 T2DM,	 has	 been	 observed	 in	 patients	with	
PWS,	particularly	after	adolescence	(Butler	et	al.,	2002).	Mean	age	at	onset	of	diabetes	
is	about	20	years	of	age.	A	prevalence	rate	of	20	to	25%	for	T2DM	is	found	in	patients	
with	long	standing	PWS	(Butler	et	al.,	2002;	Donaldson	et	al.,	1994).	
	
Obesity	 and	 diabetes	 are	 well-established	 risk	 factors	 for	 premature	 cardiovascular	
disease.	A	limited	number	of	studies	have	looked	at	cardiovascular	fitness	and	disease	
markers	in	PWS	patients.	Cardiovascular	risk	factors	are	evident	in	a	large	percentage	
of	 children	 with	 PWS.	 de	 Lind	 van	 Wijngaarden	 et	 al.	 (2010)	 looked	 at	 the	
cardiovascular	 and	 metabolic	 risk	 profile	 in	 85	 children	 with	 Prader-Willi	 syndrome	
(PWS).	 They	 found	 that	 infants	 and	 prepubertal	 children	 had	 at	 least	 one	
cardiovascular	risk	factor.	 In	63%	of	the	 infants	and	73%	of	prepubescent	children,	at	
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least	 one	 of	 the	 following	 factors	 was	 present:	 elevated	 systolic	 or	 diastolic	 blood	
pressure;	 elevated	 serum	 total	 cholesterol,	 low	 density	 lipoprotein	 cholesterol,	
triglycerides,	 or	 lipoprotein(a)	 levels;	 or	 reduced	 high	 density	 lipoprotein	 cholesterol	
levels	in	addition	to	a	high	fat%,	indicating	an	unfavorable	cardiovascular	profile.	Patel,	
et	al.	(2007)	assessed	cardiac	and	vascular	structure	and	function	in	nine	PWS	patients	
and	 found	 significantly	 elevated	 high-sensitivity	 C-reactive	 protein	 (hs-CRP),	 (hs-CRP	
has	 been	 shown	 to	 be	 significantly	 elevated	 in	 patients	 dying	 suddenly	 with	 severe	
coronary	 artery	 disease	 (Burke,	 et	 al.,	 2002)),	 and	 evidence	 of	 microcirculatory	
dysfunction	 as	 evidenced	 by	 decreased	 peak	 hyperaemic	 flow	 response.	 	 In	 a	 small	
study	 involving	 36	 adults	 with	 PWS	 who	 were	 followed	 for	 10	 years	 there	 were	 10	
deaths	(Smith,	2003).	The	average	age	at	death	was	33.2	years	with	60%	of	the	deaths	
due	to	cardiovascular	reasons	including	“strokes,	coronary	occlusion,	or	heart	failure”.	
Lionti,	et	al.	(2012)	also	concluded	that	cardiac	or	respiratory	conditions	were	common	
causes	of	death	of	those	with	PWS	after	the	age	of	15	years.	
D-lyxo-hexulose	
Many	of	the	problems	faced	by	those	afflicted	with	PWS	stems	from	their	struggle	with	
obesity.	 Obesity	 is	 associated	with	 an	 increased	 risk	 for	 diabetes	 and	 cardiovascular	
disease,	and	markers	for	these	obesity	related	diseases	are	exhibited	by	patients	with	
PWS.	 D-lyxo-hexulose	 has	 been	 shown	 in	 both	 animal	 and	 human	 studies	 to	 have	 a	
beneficial	effect	on	many	of	the	symptoms	exhibited	by	PWS	patients	(although	there	
have	not	been	any	studies	of	D-lyxo-hexulose	in	PWS	to	date)	including	lack	of	satiety,	
weight	control,	dyslipidemia,	atherosclerosis,	and	type	2	diabetes	mellitus	(Tables	1-4).	
Table	1.	D-lyxo-hexulose	Effect	Upon	Satiety	
Type	of	
Study	
Species	 Dose	
Level	
Results	 Reference	
Human	pilot	
study	
Humans		(4♂4	
♀	with	T2DM)	
15	g	t.i.d.-
1	year	
duration	
Satiety	was	reported	as	a	side	effect	in	3	subjects	early	
in	the	experiment.	
Donner	
et	al	2010	
Human	
double	blind	
cross-over	
Normal	weight	
humans	
(3♂5♀	)	
30	g	QD-	
2	wk	
duration	
Fullness	evaluated	2.5	h	after	dinner	showed	an	
increase	from	39%-52%	compared	to	placebo	(P=0.02).	
Response	similar	on	Days	1&15.	
Buemann	
et	al.	
1998	
Human	
double	blind	
cross-over	
Healthy	
Humans	
(25♂25♀)	
20	g	QD-3	
days	over	
a	17	day	
duration	
	D-lyxo-hexulose	was	associated	with	significantly	
more	thirst	(P	<	0.01)	and	appetite	loss.	
Significantly	more	subjects	reported	grade	2	or	3	thirst	
and	appetite	loss	(P	<0.05).	
Lee	and	
Storey	
1999	
Human	
double	blind	
cross-over	
Healthy	
humans		
(19♂)	
29	g	QD	 Energy	intake	was	15%	lower	after	D-lyxo-hexulose	
consumption	compared	to	sucrose	after	supper	(P<	
0.05).	
		
Buemann	
et	al	
2000b	
Toxicology	
study	
Crl:	CDBR	rats		
(20	
rats/group/sex
Doses	of	
5,	10,	15,	
and	20%		
A	statistically	significant	reduction	in	mean	weekly	
food	consumption	relative	to	the	isocaloric	control	
group	for	a	large	proportion	of	weeks.	
Kruger	et	
al	1999c	
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)	 D-lyxo-
hexulose	
for	90	
days	
		
		
Mouse	
study	
50	male	ApoE	-
/-	(C57BL/6	
background)	
8	weeks	 Energy	consumption	for	the	D-lyxo-hexulose	group	
was	11.65	±	1.33	Kcal/	day	vs	15.77	±	1.13	Kcal/day	for	
mice	on	the	western	diet.	(P	<	0.001).	
Unpublis
hed	
report	
Table	2.	D-lyxo-hexulose	Effect	Upon	Weight	Control	
Type	of	
Study	
Species	 Dose	Level	 Results	 Reference	
Human	
Phase	2	
clinical	trial	
161	
randomized	
humans	
2.5	g,	5.0	g,	
and	7.5	g	
t.i.d.	for	6	
mo	
Mean	body	weights	at	baseline,	3-months,	and	6-
months	for	the	5.0	g	D-lyxo-hexulose	dose	group	were	
165.4	±	33.0	lbs,	161.5	±	29.5	lbs,	and	161.7	±	27.5	lbs,	
respectively;	and	the	mean	body	weights	for	the	7.5	g	D-
lyxo-hexulose	dose	group	were	167.4	±	33.0	lbs,	165.1	±	
30.5	lbs,	and	160.6	±	29.3	lbs,	respectively.	
Ensor	et	al.	
2014	
Human	pilot	
study	
Humans	(4♂4	
♀	with	T2DM)	
15	g	t.i.d.-	1	
yr	duration	
Mean	body	weight	decreased	from	108.4	kg	to	103.3	kg	
(P=.001).	
Donner	et	
al	2010	
Rat	
toxicology	
study	
80	Sprague	
Dawley	male	
Crl:CD	BR	rats		
20%		D-lyxo-
hexulose	for	
28	days	
Body	weights	were	significantly	reduced	
in	the	20%	D-lyxo-hexulose	groups	compared	to	control.	
		
Bar	et	al	
1999	
Rat	
toxicology	
study	
Sprague-	
Dawley	rats	
15%		D-lyxo-
hexulose	for	
60	days	
>	7%	less	weight	gain	for	D-lyxo-hexulose-fed	rats	than	
controls.	Sucrose-fed	rats	gained	an	average	of	86	g	as	
opposed	to	28	g	gained	by	the	rats	fed		D-lyxo-hexulose.	
		
Levin	et	al	
1995	
Rat	
toxicology	
study	
Crl:CDBR	rats	
(20	
rats/group/sex
)	
Doses	of	5,	
10,	15,	and	
20%		D-lyxo-
hexulose	for	
90	days	
Mean	body	weight	values	were	statistically	significantly	
decreased,	compared	to	controls,	in	the	20%	dose-group	
males	on	Days	21–91,	the	15%	dose-group	males	on	
Days	42–70	and	Day	84,	and	the	20%	dose	group	
females	on	Days	63,	84,	and	91.	
		
Kruger	et	
al	1999c	
Mouse	study	 LDLr-/-	mice	(6	
mice	
sex/group)	
(backcrossed	
10	times	on	a	
C57BL/6J)	
16	week	
duration	
Male	body	weights	were	27	g	for	D-lyxo-hexulose	groups	
vs	30	g	for	the	control	and	40	±	2	g	for	the	sucrose	
group.	Female	weights	were	24	±	1,	24	±	1,	and	31	±	1g,	
for	the	D-lyxo-hexulose,	control,	and	sucrose	groups	
respectively.P	<	0.01	compared	to	TAG.	
Police	et	al	
2009	
Mouse	
study	
50	male	ApoE	-
/-	(C57BL/6	
background)	
8	week	
duration	
Body	weights	were	29.5	±	1.4	g,	31.24	±	2.7	g,	37.	±	4.6	g		
for	the	D-lyxo-hexulose,	standard	chow	and	western	
chow	groups,	respectively.	
Unpublish
ed	study	
		
Table	3.	D-lyxo-hexulose	Effect	Upon	Lipids	
Type	of	 Species	 Dose	Level	 Results	 Reference	
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Study	
Human	
Phase	3	
clinical	trial	
356	humans	in	
the	ITT	
population	
15	g	t.i.d.	
for	1	year	
LDL	differences	in	LS	mean	for	the	D-lyxo-hexulose	ITT	
population	at	month	6	include	a	reduction	of	4.8	vs.	0.96,	
Δ	=	4.1	(p	=	0.0211)	at	month	8	a	reduction	of	6.6	vs.	3.6,	Δ	
=	3.1	(	p	=0.0100)	and	at	month	10	a	reduction	of	7.1	vs.	
4.2,	Δ	=	2.9	(p	=	0.0057).	
Total	cholesterol	ITT	reduction	vs.	baseline	was		-14.8	
mg/dl	at	month	12	(p=0.005)	
Ensor	et	al	
2015	
Human	
Pilot	study	
Humans	(4♂4	
♀	with	Type	II	
DM)	
15	g	t.i.d.-	1	
yr	duration	
HDL	rose	from	30.5	±	15.8	to	41.7	±	12.1	mg/dL	(in	6	
subjects	not	on	lipid	modifying	medication)	(P<.001).	
Donner	et	
al.	2010	
Human	
double	
blind	
cross-over	
Normal	weight	
humans	(3♂5	
♀	)	
30	g	daily-	2	
wk	duration	
Triglycerides	measurements	of	D-lyxo-hexulose	vs	Sucrose	
d	1:	1.20	±	0.13	vs.	1.38	±	0.19;	d	7:	1.37	±	0.13	vs.	1.41	±	
0.17;	d	15:	1.46	±	0.22	vs.	1.70	±	0.39	mmol/L	(P	=		0.04).	
Buemann	
et	al.	1998	
Mouse	
Study	
LDLr-/-	mice	(6	
mice	
sex/group)(ba
ckcrossed	10	
times	on	a	
C57BL/6J)	
16	week	
duration	
Male	triglycerides	were	162	±	29,	110	±	20,	822	±	148	
mg/dl	for	the	D-lyxo-hexulose,	control,	and	sucrose	
groups,	respectively.	Female	triglycerides	were	54±8,	79	±	
16,	and	326	±	37	mg/dl	for	the		D-lyxo-hexulose,	control,	
and	sucrose	groups,	respectively	(P	<	0.01).	
		
Police	et	
al.	2010	
Mouse	
study	
50	male	ApoE	
-/-	(C57BL/6	
background)	
8	week	
duration	
By	day	71,	triglyceride	results	were	less	than	1/2	of	either	
the	Standard	or	Western	diet	groups	(Standard	diet,	263.7	
±	33.1	mg/dL;	Western	diet,	256.0	±	31.9	mg/dL;		D-lyxo-
hexulose,	102.9	±	5.65	mg/dL)	
Unpublish
ed	report	
		
Table	4.	D-lyxo-hexulose	Effects	Upon	Type	2	Diabetes	Mellitus	
Type	of	
Study	
Species	 Dose	Level	 Results	 Reference	
Human	pilot	
trial	
Humans	(8	
normal	and	8	
with	T2DM)	
		
		
		
		
		
		
		
		
		
Humans	(10	
T2DM	patients)	
75	g		D-lyxo-
hexulose	
		
		
		
		
		
		
0,10	g,	15	g,	
20	g,	and	30	
g	of		D-lyxo-
hexulose	
Lower	postprandial	increases	in	blood	glucose	and	
insulin.	
Pre-OGTT	treatment	with	75	g	D-lyxo-hexulose	
attenuated	the	rise	in	glucose	levels	in	patients	
with	DM	(p	<	0.02	at	60	and	180	min,	and	p	<	0.01	
at	120	min).	The	glucose	area	under	the	curve	
(AUC)	was	reduced	significantly	also	by	pre-
treatment	with	D-lyxo-hexulose	in	a	dose-
dependent	manner	in	patients	with	DM	(p	<	0.05	
for	10	g	D-tag,	p	<	0.001	for	20	g	D-tag,	and	p	=	
0.0001	for	30	g	D-tag).	
		
A	3-hour		glucose		AUC		of		20,152	±	6125	
mg/dl/min	following	a	75-g	OGTT,	compared	with	
pretreatment	with	D-lyxo-hexulose	reduced	the	
glucose	AUC	to	17,510	±	4811	mg/min/dl	with	10	g	
D-lyxo-hexulose	(p	<	0.05),	to	15,779	±	5703	
mg/min/dl	with	20	g	D-tag	(p	<	0.001)	and	to	
15,018	±	5461	mg/min/dl	with	30	g	D-lyxo-hexulose	
Donner	et	
al.	1999	
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(p	=	0.0001).	
Human	pilot	 Human	
(8	subjects	
with	T2DM	
patients	
completed	the	
study)	
15	g	D-tag	
t.i.d.	for	1	
year	
Decrease	in	GlyHb	was	observed	in	the	8	subjects	
who	completed	the	study	from	
11.2%	±	2.0%	to	9.5%	±	2.0%.	Three	patients	were	
given	rescue	medications.	
		
		
Donner	et	al	
2010	
Phase	3	
clinical	trial	
356	humans	in	
the	ITT	
population	
15	g	t.i.d.	for	
1	year	
For	the		ITT	population		better		reductions	in	fasting	
blood	glucose	levels	from	baseline	were	observed	
in	the	D-lyxo-hexulose	group	compared	to	the	
placebo	group	at	all	post	baseline	time	
points(month	6	(reduction	of	2.0	vs.	an	increase	of	
4.1,	Δ	=	6.0	and	p	=0.0440),	month	8	(reduction	of	
0.44	vs.	an	increase	of	2.5,	Δ	2.9	and	P	=0.0340),	
and	month	10	(reduction	of	0.25	vs.	an	increase	of	
6.6,	Δ	=	6.9	and	P	=	0.0079).	
Ensor	et	al	
2015	
		
Trans-polydatin	
Studies	have	presented	evidence	that	trans-polydatin	has	many	positive	health	effects	
on	 conditions	 that	 are	 commonly	 encountered	 by	 patients	 with	 PWS.	 Many	 of	 the	
problems	 faced	 by	 those	 afflicted	 with	 PWS	 stems	 from	 their	 struggle	 with	 obesity.	
Obesity	is	associated	with	an	increased	risk	for	diabetes	and	cardiovascular	disease,	and	
markers	for	these	obesity	related	diseases	are	exhibited	by	patients	with	PWS.	Multiple	
trans-polydatin	 studies	 indicate	 positive	 results	 in	 the	 following	 areas	 likely	 to	 impact	
patients	 with	 PWS:	 anti-inflammatory	 actions	 (Ji	 et	 al	 2012;	 Cobellis	 et	 al	 2011),	
cardioprotective	activities	(Du	et	al	2009;	Xing	et	al	2009;	Zhang	et	al	2014;	Deng	et	al	
2012;	Liu	et	al	2012),	protection	against	ischemia/reperfusion	injury	(Cheng	et	al	2006;	
Zhang	et	al	2008),	benefits	for	congestive	heart	failure	(Gao	et	al	2010),	and	prevention	
of	 fatty	 liver	 disease	 and	 insulin	 resistance	 (Zhang	 et	 al	 2015).	 Additionally,	 trans-
polydatin	can	regulate	glucose	and	lipid	metabolism	(Hao	et	al	2014).		
Table	5.	Trans-Polydatin	in	Preclinical	Hyperlipidemia	
Reference	
and	Purpose	
Model	system	
and	Route	of	
Administration	
Dosing/Dose	range	
	
[Source/Purity]	
Results	
	
	
	
Arichi	H	et	
al.,	1982	
	
	
To	study	
effects	of	
trans-
polydatin	
Male	Wistar-
King	rats,	150	g;	
7	rats/group	
Male	ddY	strain	
mice,	~20	g;	8	
mice/group	
	
	
	
Mice-	
Intraperitoneal	
Rats	were	given	a	standard	diet	and	an	
oral	dose	of	0	or	10	mL/kg	corn	oil	
containing	10%	cholesterol	and	1%	
cholic	acid	for	7	days.	In	subgroups	of	7	
animals	receiving	oil,	one	group	received	
50	mg	trans-resveratrol/kg	body	weight	
(bw)	and	2	groups	were	given	either	50	
or	100	mg/kg	bw	piceid	30	min	prior	to	
oil	intubation.	
	
Study	duration	7	days.	
	
7	day	rat	study:	Both	RES	and	piceid	were	
unable	to	prevent	diet	induced	increases	
in	levels	of	total	cholesterol,	free	fatty	
acids	or	phospholipids,	or	prevent	
reductions	in	HDL-cholesterol	levels	with	
significance	compared	to	positive	control.	
However,	piceid	significantly	prevented	
accumulation	of	LDL-ch	(both	doses)	and	
rises	in	TG	(100	mg/kg	only)	to	the	level	of	
the	positive	control	where	RES	did	not.	
This	resulted	in	a	significantly	lower	
atherogenic	index	for	the	100	mg/kg	
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(piceid)	and	
resveratrol	
(RES)	on	
dietetically-
induced	
hyperlipidem
ia	
or	oral	
	
Rat-Oral	
intubation	
(gavage)	
	
Mice	were	fed	a	standard	chow.	RES	
groups	received	25	mg/kg	or	50	mg/kg.	
Piceid	groups	received	50	or	100	mg/kg.	
14C-palmitate	was	injected	2	hours	after	
the	last	injection	of	stilbenes.	
	
Study	duration	3	days.	
	
RES	or	piceid	were	extracted	and	
purified	from	Polygonum	cuspidatum.	
Purity	NS*.	
piceid	dosing	group	only,	although	not	to	
the	level	of	negative	control.	
	
	
3	day	mouse	study:	Evaluation	of	
lipogenesis	in	mice	by	measurements	of	
incorporation	of	14C-palmitate	in	liver	
and	adipose	tissue	showed	that	25	or	50	
mg/kg	RES	given	by	i.p.	injection	or	by	
oral	gavage	significantly	(p<0.001	to	0.05)	
reduced	lipogenesis	in	liver	but	only	the	
highest	dose	of	RES	significantly	(p<0.05)	
reduced	lipogenesis	in	adipose	tissue.	
Du	J	et	al.,	
2009	
	
	
To	evaluate	
the	effects	of	
polydatin	
(Piceid)	in	
dietetically-
induced	
hyperlipidem
ia	
Male	Syrian	
golden	
hamsters;	6	
groups	of	10	
animals	
	
	
Dietary	
One	group	of	10	hamsters	was	fed	a	
control	(normal	fat)	diet	and	4	groups	
were	fed	high,	fat-high	cholesterol	(2%)	
diet	(HFC)	and	either	0,	25,	50	or	100	
mg/kg	bw	polydatin;	one	additional	
group	was	given	10	mg/kg	bw	
Fenofibrate	as	a	positive	(anti-lipidemic)	
control.	
	
Study	duration:	15	days.	
[Polydatin	isolated	from	Polygonum	
cuspidatum	roots	and	purified	by	high	
speed,	countercurrent	chromatography;	
purity	91.3%]	
HFC	diet	produced	significant	(p<0.01)	
increases	in	total	cholesterol	(TC),	
triglycerides	(TG),	HDL,	and	LDL	
cholesterol	levels.	In	comparisons	to	the	
HFC	animals,	polydatin	significantly	
prevented,	diet-induced	elevations	in	TC,	
TG	and	LDL	levels	at	dosage-related	
levels.	Polydatin	did	not	significantly	
affect	levels	of	HDL	cholesterol	in	the	
range	of	doses	studied.	
	
Polydatin	significantly	prevented	diet-
induced	increases	in	LDL/HDL	and	TC/HDL	
ratios	and	in	hepatic	TG	in	comparisons	to	
animals	given	HFC	diet.	
The	authors	speculated	that	decreased	
lipid	and	cholesterol	effects	from	
ingestion	of	polydatin	involve	modulating	
roles	in	lipid	metabolism	and	liver	
protection.	
Xing	W.W.	et	
al.,	2009	
	
	
To	
determine	
effects	of	
Polydatin	on	
dietetically-
induced	
hyperlipidem
ia	
Male	Japanese	
Giant	Ear	
rabbits;	8	
animals/group	
	
	
Dietary	
Groups	of	rabbits	were	fed	standard	or	
high	fat	diets	(HFD;	15%	egg	yolk,	1%	
cholesterol	and	5%	lard)	for	3	weeks.	
Animals	in	the	HFD	group	were	then	
given	oral,	gavage	doses	of	Polydatin	of	
0,	25,	50	or	100	mg/kg	bw/day.	Study	
duration	=	3	weeks.	
Polydatin	isolated	and	purified	from	
Polygonum	cuspidatum	root;	purity	
91.3%.	
HFD	produced	significant	(p<0.001)	
increases	in	total	cholesterol	(TC),	HDL,	
LDL	and	TC/HDL	ratios	in	all	groups	
compared	to	rabbits	receiving	normal	
diet.	
	
In	comparison	to	HFD	controls,	Polydatin	
produced	dosage-related,	statistically	
significant	(p<0.05	to	p<0.01)	decreases	in	
TC,	LDL	and	TC/HDL	ratios	but	did	not	
affect	HDL	levels	in	comparisons	to	the	
HFD	control	animals.	
	
The	decrease	in	TC/HDL	ratios	in	HFD	
animals	given	Polydatin	suggested	a	
cardioprotective	role	for	Polydatin	in	
modulating	lipidemias	associated	with	
high	fat	diet.	
	
Other	endpoints:	There	were	no	
significant	effects	on	body	weight	during	
the	study	in	any	of	the	treated	groups	
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compared	to	the	control	animals	fed	
standard	diets.	However,	the	50	and	100	
mg/kg	dosings	were	able	to	lower	the	
liver	weight	coefficients	compared	to	
control.		
*NS	=	Not	specified	
BSN272	
	
Biospherics.net	LLC	has	conducted	a	number	of	studies	with	BSN272	(combination	of	t-
PD	and	DLH)	in	multiple	animal	models	designed	to	evaluate	the	beneficial	effects	of	
preventing	diet	induced	increases	in	cholesterol	and	triglyceride	models.		The	results	are	
summarized	in	Table	6	below.	
Table	6.	Oral	Administration	of	BSN272	and	Hyperlipidemia	
Study	Title		
and	Purpose	
Model	System	and	
Route	of	
Administration,	dose,	
duration	
Endpoints	 Results	
BSN272	in	
apoE-deficient	
mice	
	
To	evaluate	
the	effect	of	a	
combination	of	
trans-polydatin	
and	D-lyxo-
hexulose		on	
development	
of	genetically	
and	dietetically	
induced	
hyperlipidemia	
and	
atherosclerosis	
ApoE-deficient	mice	fed	
a	diet	high	in	
carbohydrates,	fats,	and	
cholesterol	
	
Route	of	Administration:	
Dietary	
	
Dose:	Control	mice	
(n=14)	were	fed	a	diet	
containing	34%	Sucrose,	
21%	milk	fat,	and	0.15%	
cholesterol	
	
BSN272-treated	mice	
were	fed	34%	D-lyxo-
hexulose,	21%	milk	fat,	
and	0.15%	cholesterol	
	
Duration:	8	weeks	
1.	Serum	Lipids	
	
2.	Body	weight	
	
3.	Organ	and	fat	
deposit	weight	
	
4.	Atherosclerotic	
lesion	area	
	
5.	Food	Intake	
1.	BSN272	significantly	reduced	serum	cholesterol,	
VLDL	cholesterol,	and	HDL	cholesterol	and	although	
serum	triglycerides	and	LDL	cholesterol	were	
reduced,	the	reductions	were	not	statistically	
significant	
	
2.	BSN272	treated	mice	did	not	gain	weight	
	
3.	The	weight	of	epididymal,	retroperitoneal,	and	
subcutaneous	fatty	deposits	was	reduced	in	BSN272	
treated	mice	compared	to	the	control	mice	and	
there	was	no	difference	in	the	weights	of	the	
spleens,	heart,	and	livers	of	the	control	and	BSN272	
treated	mice.	
	
4.	BSN272	significantly	reduced	the	size	of	the	
atherosclerotic	lesions	at	the	Sinus	of	Valsalva,	
Aortic	Arch,	and	the	Thorax.	
	
5.	Control	and	BSN272	treated	mice	consumed	
similar	amounts	of	calories	over	the	course	of	the	6	
week	treatment.	
LDLr-deficient	
mice	
	
To	evaluate	
the	effect	of	a	
combination	of	
trans-polydatin	
and	D-lyxo-
hexulose	on	
development	
of	genetically	
and	dietetically	
LDLr-deficient	mice	fed	
normal	chow	and	
gavaged	with	water,	
glucose	and	fructose,	or	
uncorrelated	doses	of	
glucose,	fructose,	and	D-
lyxo-hexulose,	or	
glucose,	fructose,	and	
BSN272	
	
Route	of	Administration:	
Gavage	
1.	Serum	Lipids	
during	and	after	
treatment	(Blood	
was	harvested	from	
unfasted	mice	during	
treatment	and	from	
fasted	mice	at	
sacrifice	(day	78)).	
	
2.	Atherosclerotic	
lesion	area	
1.	Gavage	of	glucose	and	fructose	significantly	
increased	serum	cholesterol	on	day	78,	and	free	
fatty	acids	on	days	22	and	78.	
	
2.	Compared	to	those	receiving	glucose	and	
fructose,	gavage	of	uncorrelated	mixtures	of	D-lyxo-
hexulose,	glucose,	fructose	significantly	reduced	
serum	cholesterol	on	day	36,	triglycerides	on	days	
36,	78,	and	free	fatty	acids	on	days	36,	and	78	
	
3.	Compared	to	those	receiving	glucose	and	
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induced	
hyperlipidemia	
and	
atherosclerosis	
	
Dose:	
Control	mice	(n=14)	
were	gavaged	with	
water	
	
Glucose/Fructose-
treated	mice	were	
gavaged	with	25.6	g/kg	
Glucose	and	25.6	g/kg	
Fructose/day	
	
Glucose/Fructose/D-
lyxo-hexulose-treated	
mice	were	gavaged	with	
uncorrelated	doses	of	
glucose,	fructose,	and	D-
lyxo-hexulose/day	
	
Glucose/Fructose/BSN2
72-treated	mice	were	
gavaged	with	
uncorrelated	doses	of	
glucose,	fructose,	and	
BSN272/day	
	
Duration:	8	weeks	
	
3.	Body	weight	
	
4.	Food	Intake	
fructose,	gavage	of	uncorrelated	mixtures	of	D-lyxo-
hexulose,	glucose,	fructose	SPX-106T	significantly	
reduced	cholesterol	on	days	36,	50,	and	78,	
triglycerides	on	days	22,	36,	and	78,	and	free	fatty	
acids	on	days	14,	36,	and	78	
	
4.	Compared	to	those	receiving	water,	D-lyxo-
hexulose	significantly	reduced	triglycerides	on	day	
78,	and	free	fatty	acids	on	days	14,	50	and	78.	
	
5.	Compared	to	those	receiving	water,	BSN272	
significantly	reduced	cholesterol	on	days	36	and	50,	
and	triglycerides	on	day	78,	and	free	fatty	acids	on	
days	14	and	78.	
	
6.	Compared	to	the	group	receiving,	glucose	and	
fructose,	BSN272	significantly	reduced	VLDL,	and	
LDL	cholesterol	at	day	78	
	
7.	Compared	to	the	group	receiving	glucose	and	
fructose,	BSN272	significantly	reduced	
atherosclerotic	lesion	area	at	the	aortic	arch.	
	
8.	Neither	D-lyxo-hexulose	or	BSN272	affected	feed	
consumption	or	body	weight	gain.	
Syrian	Golden	
Hamsters	
	
To	evaluate	
the	effect	of	a	
combination	of	
trans-polydatin	
and	D-lyxo-
hexulose	on	
development	
of	dietetically	
induced	
hyperlipidemia	
and	
atherosclerosis	
Syrian	Golden	Hamsters	
fed	a	Western	diet	high	
in	fats	and	
carbohydrates	
	
Group	1	–	positive	
control	
	
Group	2	–	6	g/kg	BID	
tagatose	
	
Group	3	–	0.1	g/kg	BID	
polydatin	
	
Group	4	–	6	g/kg	
tagatose	+	0.025	g/kg	
polydatin	BID	
	
Group	5	–	6	g/kg	
tagatose	+	0.05	g/kg	
polydatin	BID	
	
Group	6	–	6	g/kg	
tagatose	+	0.1	g/kg	
polydatin	BID	
	
1.	Serum	
triglycerides	
	
2.	Serum	cholesterol	
In	all	D-tagatose	groups	the	drug	was	progressively	
run	in	to	acclimate	the	animals.	D-tagatose	dose	
was	reduced	on	day	10	of	the	study	to	3	g/kg	due	to	
gastrointestinal	disturbances.	
	
Although	gastrointestinal	intolerability	to	12	
g/kg/day	of	D-tagatose	developed	during	the	first	
days	of	dosing,	all	hamsters	survived	until	the	end	
of	the	study	once	the	dose	was	reduced	to	6	
g/kg/day.	Furthermore,	combinations	of	D-tagatose	
and	medium	to	high	doses	of	polydatin	reduced	
serum	cholesterol,	triglyceride,	and	free	fatty	acid	
levels	more	effectively	than	either	component	
alone.	Importantly,	due	to	the	lack	of	adverse	
events	from	day	11	to	day	23,	future	studies	should	
not	exceed	6	g/kg/day	without	a	proper	run-
in/adaptation	period.	
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Current	Treatment	of	PWS	
	
The	only	FDA/EMA	approved	medication	for	PWS	is	somatropin,	which	 is	 indicated	for	
the	pediatric	population	under	the	brand	names	Genotropin	by	Pfizer	and	Omnitrope	by	
Sandoz.		Somatropin	is	recombinant	human	growth	hormone	(rhGH).	It	is	prescribed	to	
combat	 below	 normal	 values	 of	 endogenous	 GH	 experienced	 by	 most	 patients	 with	
PWS.		This	has	led	to	improvements	in	the	health	of	children	with	regards	to	growth	rate	
and	 height,	 physical	 strength,	 and	 body	 composition	 (Sanchez-Ortiga	 et	 al,	 2012).		
However,	growth	hormone	supplementation	should	not	be	used	 for	 the	promotion	of	
growth	post	fusion	of	the	epiphysis	according	to	the	package	insert	for	both	Genotropin	
(Genotropin	2014)	and	Omnitrope	(Omnitrope	2006).		There	is	little	evidence	to	suggest	
that	the	use	of	growth	hormone	in	PWS	has	any	major	benefits	in	the	adult	population	
and	it	is	our	belief	that	the	risks	outweigh	any	possible	benefit.	
	
During	a	meta-analysis,	eight	studies	were	used	to	evaluate	the	use	of	growth	hormone	
in	adults	with	PWS	(comprising	a	total	of	only	134	patients,	114	actually	 finished	their	
respective	 trials)	only	2	of	which	were	randomized	placebo	controlled	 (Sanchez-Ortiga	
et	 al	 2012).	 Analysis	 was	 performed	 to	 address	 concerns	 about	 the	 use	 of	 growth	
hormone	 therapy	 in	obese	patients	due	 to	 the	anti-insulin	effects	of	growth	hormone	
and	in	patients	with	underlying	respiratory	impairment,	both	of	which	are	very	common	
phenotypes	in	PWS,	among	other	concerns.	 	Across	all	studies	notable	outcomes	were	
an	 increase	 in	 fasting	 plasma	 glucose,	 increases	 in	 fasting	 insulin	 and	 HOMA	 values	
trending	 towards	 significance,	 and	 around	 15%	of	 all	 participants	 experienced	 edema	
(Sanchez-Ortiga	et	al	2012).	One	study	even	showed	an	increase	in	left	ventricular	mass	
for	61%	of	 its	participants	and	a	mild	decrease	 in	 left	ventricle	ejection	fraction	(LVEF)	
on	 echocardiography	 (Marzullo	 et	 al.	 2007).	 	 While	 the	 meta-analysis	 did	 show	 a	
decrease	in	body	fat	percentage	and	an	increase	in	LBM	for	rhGH	treated	patients	these	
findings	were	consistent	with	other	studies	in	patients	with	simple	obesity,	not	obesity	
manifested	from	PWS	(Mekala	and	Tritos	2009).	 	rhGH	does	not	affect	hyperphagia	or	
satiety,	 but	 BSN272	 could	 based	 on	 its	 inclusion	 of	 DLH	 (see	 Table	 1).	 BSN272	 could	
reduce	body	fat	 in	the	adult	PWS	patients	without	the	concerns	that	growth	hormone	
supplementation	presents.	
	
In	addition	to	the	concerns	of	the	use	of	GH	in	the	overweight	population	(somatropin	
use	is	actually	contraindicated	in	severely	obese	patients	and	patients	with	uncontrolled	
diabetes)	there	are	concerns	of	an	increased	risk	of	mortality	with	prolonged	use	of	GH.		
Somatropin	 has	 been	 associated	 with	 tumor	 promoting	 potential.	 	 The	 French	 Sante	
Adulte	GH	Enfant	 (SAGHE)	 study	 showed	an	 increase	 in	all-cause	mortality	 in	 children	
treated	with	rhGH,	due	to	diseases	of	 the	circulatory	system	and	bone	tumors,	with	a	
standardized	mortality	ratio	of	1.33	(95%	CI	of	1.08	-	1.64)	(EMA	2012).	
	
167
 
 
 
 
 
Additionally,	somatropin	is	associated	with		progression	of	scoliosis	in	pediatric	patients	
per	package	insert	(Genotropin	2014).	Comorbidity	of	PWS	and	scoliosis	may	be	as	high	
as	 75%	 (Laurier	 et	 al.	 2014).	 	 An	observational	 study	of	 norditropin	with	 	 thirty-three	
PWS	 	 patients,	 listed	 scoliosis	 as	 an	 adverse	 event	 in	 19.5%	 of	 the	 population	
(Meinhardt	 et	 al.	 2013).	 In	 an	 additional	 study	 of	 GH	 treatment,	 	 scoliotic	 conditions	
worsened	 in	 six	 of	 the	 thirteen	 PWS	 patients	 with	 scoliosis	 (Murakami	 et	 al.	 2012).	
Colmenares	et	al.	 (2011)	 found	scoliosis	present	 in	27.8%	of	PWS	children	at	baseline,	
and	a	scoliosis	 rate	of	47.2%	three	years	 later	 in	a	prospective	cohort	study;	whereas,	
other	 studies	 have	 found	 little	 statistical	 difference	 in	 the	 rate	 of	 scoliosis	 between	
children	 receiving	 GH	 and	 those	 not	 receiving	 GH	 (Nagai	 et	 al.	 2006;	 de	 Lind	 van	
Wijngaarden	et	al.	2009;	Odent	et	al.	2008).	
Current	Hyperlipidemia	Medications	
	
Hyperlipidemia	may	also	be	a	 feature	of	Prader-Willi	 syndrome,	although	both	normal	
and	 elevated	 lipid	 levels	 have	 been	 reported	 in	 patients.	 	 In	 the	 treatment	 of	
hyperlipidemia,	 along	 with	 diet,	 there	 are	 numerous	 available	medications	 to	 reduce	
blood	 lipid	 concentrations.	 Statins	 (pravastatin,	 rosuvastatin,	 atorvastatin,	 and	
simvastatin)	 are	 the	 most	 commonly	 prescribed,	 which	 act	 by	 inhibiting	 cholesterol	
production	in	the	liver.	Most	circulating	cholesterol	comes	from	liver	production,	rather	
than	 diet.	 	 In	 addition,	 inhibition	 of	 cholesterol	 production	 in	 the	 liver	 stimulates	 the	
increased	uptake	of	 cholesterol	 from	 the	blood	 into	 the	 liver,	 further	 reducing	 serum	
cholesterol.	 Bile	 acid	 resins	 (cholestyramine,	 colestipol	 and	 colesevalem)	 exert	 their	
effects	by	binding	bile	acids	present	in	the	large	intestine	preventing	the	reabsorption	of	
the	 bile	 acids	 and	 the	 absorption	 of	 dietary	 cholesterol.	 Prevention	 of	 bile	 acid	
reabsorption	results	in	an	increased	production	of	bile	acids	in	liver	via	the	cytochrome	
P450-mediated	 oxidation	 of	 cholesterol	 drawn	 from	 the	 blood	 reducing	 serum	
cholesterol.	 Ezetimibe	 (Zetia	 or	 Ezetrol)	 localizes	 at	 the	 brush	 border	 of	 the	 small	
intestine,	 and	 functions	 by	 inhibiting	 cholesterol	 absorption	 from	 the	 intestine.	
Proprotein	 convertase	 subtilisin/kexin	 type	 9	 (PCSK9)	 is	 secreted	 by	 hepatocytes	 and	
binds	 to	 LDL	 receptors	 to	 mediate	 their	 uptake	 into	 hepatocytes	 and	 subsequent	
degradation.	 	 This	 process	 is	 targeted	by	PCSK9	 inhibitors.	 	 By	 inhibiting	PCSK9,	more	
LDL	receptors	are	left	available	to	bind	and	remove	LDL	particles	from	the	circulation.		
	
Despite	the	introduction	of	a	number	of	medications	such	as	statins	for	the	treatment	of	
hyperlipidemia,	most	patients	do	not	achieve	optimal	 LDL	 levels	and	drug	 side	effects	
remain	an	issue	(Mata	et	al	2011)	.	Therefore	there	is	a	need	for	a	therapy	that	is	highly	
effective	with	minimal	adverse	effects	and	based	upon	the	pre-clinical	and	clinical	data	
BSN272	(trans-polydatin	+	D-lyxo-hexulose)	therapy	could	be	beneficial	in	the	treatment	
of	hyperlipidemia.	
	
168
 
 
 
 
 
Table	7.	Currently	Available	Lipid	Lowering	Therapies	
Group	 Drug	 Benefits	 Possible	side	effects	and	cautions	
Statins:	 Altoprev	(lovastatin)	
Crestor	(rosuvastatin)	
Lescol	(fluvastatin)	
Lipitor	(atorvastatin)	
Mevacor	(lovastatin)	
Pravachol	(pravastatin)	
Zocor	(simvastatin)	
Decrease	LDL	and	
triglycerides;	slightly	
increase	HDL	
Constipation,	nausea,	diarrhea,	
stomach	pain,	cramps,	muscle	
soreness,	pain	and	weakness;	
possible	interaction	with	
grapefruit	juice	
Bile	acid	binding	
resins:	
Colestid	(colestipol)	
Questran	(cholestyramine	
sucrose)	
Welchol	(colesevelam)	
Decrease	LDL	 Constipation,	bloating,	nausea,	
gas;	may	increase	triglycerides	
Cholesterol	
absorption	
inhibitors:	
Zetia	(ezetimibe)	 Decrease	LDL;	slightly	
decrease	triglycerides;	
slightly	increase	HDL	
Stomach	pain,	fatigue,	muscle	
soreness	
Combination	
cholesterol	
absorption	inhibitor	
and	statin:	
Vytorin	(ezetimibe-
simvastatin)	
Decrease	LDL	and	
triglycerides;	increase	
HDL	
Stomach	pain,	fatigue,	gas,	
constipation,	abdominal	pain,	
cramps,	muscle	soreness,	pain	
and	weakness;	possible	
interaction	with	grapefruit	juice	
Fibrates:	 Lofibra	(fenofibrate)	
Lopid	(gemfibrozil)	
TriCor	(fenofibrate)	
Decrease	triglycerides;	
increase	HDL	
Nausea,	stomach	pain,	gallstones	
Niacin:	 Niaspan	(prescription	
niacin)	
Decreases	LDL	and	
triglycerides;	increase	
HDL	
Facial	and	neck	flushing,	nausea,	
vomiting,	diarrhea,	gout,	high	
blood	sugar,	peptic	ulcers	
Combination	statin	
and	niacin:	
Advicor	(niacin-lovastatin)	 Decreases	LDL	and	
triglycerides;	increases	
HDL	
Facial	and	neck	flushing,	dizziness,	
heart	palpitations,	shortness	of	
breath,	sweating,	chills;	possible	
interaction	with	grapefruit	juice	
Omega-3	fatty	acids:	 Lovaza	(prescription	
omega-3	fatty	acid	
supplement)	
Decreases	triglycerides	 Belching,	fishy	taste,	increased	
infection	risk	
PCSK9	Inhibitors	 Praluent	(alirocumab)	
Repatha	(evolocumab)	
Decrease	LDL	 Injection	site	reactions,	
nasopharyngitis,	neurocognitive	
events	
Mechanisms	of	Action	of	BSN272	
D-lyxo-hexulose	
	
D-lyxo-hexulose,	 a	 ketohexose,	offers	advantages	 to	other	 sugars	 such	as	 sucrose	and	
fructose	by	having	a	 reduced	energy	value,	 low	glycemic	 index,	prebiotic	 activity,	 and	
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non-cariogenic	 properties	 (Bertelsen	 1999).	 Structurally,	 D-lyxo-hexulose	 and	 fructose	
are	highly	similar	except	 for	an	 inversion	at	C-4	 in	the	optically	active	center	 (Normen	
2001).	Although	only	having	this	small	structural	alteration,	D-lyxo-hexulose	has	greatly	
reduced	absorption	in	comparison	to	fructose.	Studies	in	both	pigs	and	rats	have	shown	
that	 only	 20-25%	 of	 ingested	 D-lyxo-hexulose	 is	 absorbed	 by	 the	 small	 intestine.	 The	
remaining	 D-lyxo-hexulose	 is	 fermented	 by	 the	microbiota	 in	 the	 large	 intestine	 into	
short	 chain	 fatty	 acids	 and	 gaseous	 products	 (CO2,	methane,	 and	 hydrogen)	 (Saunder	
1999;	 Laerke	 1999).	 The	 absorption	 process	 of	 D-lyxo-hexulose,	 unlike	 the	 carrier	
mediated	 facilitated	diffusion	of	 fructose,	appears	 to	be	passive.	D-lyxo-hexulose	does	
not	bind	to	GLUT2	in	the	gut.			DLH	does	not	interfere	with	the	absorption	of	low	levels	
of	fructose	(Sigrist-Nelson	and	Hopfer,	1974;	Tatibouet	2000).		
	
Once	 absorbed,	 D-lyxo-hexulose	 metabolism	 occurs	 in	 the	 liver	 using	 the	 identical	
biochemical	 pathway	 as	 fructose.	 Initially	 D-lyxo-hexulose	 is	 phosphorylated	 by	
fructokinase	 to	 tagatose-1-phosphate,	 which	 is	 further	 split	 by	 aldolase	 B	 to	 yield	 D-
glyceraldehyde	(GA)	and	dihydroxyacetone	phosphate	(DHAP).		Aldolase	B	acts	on	both	
fructose-1-phosphate	 and	 tagatose-1-phosphate,	 although	 the	 cleavage	of	 tagatose-1-
phosphate	occurs	at	only	about	half	the	rate	of	that	of	fructose-1-phosphate	(Rognstad	
1982).	 Like	 fructose-1-phosphate,	 the	 increase	 of	 tagatose-1-phosphate	 concentration	
stimulates	glucokinase	activity	(Agius	1994;	Van	Schaftingen	and	Vandercammen	1989)	
leading	 to	 an	 increased	 phosphorylation	 of	 glucose	 to	 glucose-6-phosphate,	 which	
further	 activates	 glycogen	 synthase	 (Seoane	 et	 al	 1996).	 Along	 with	 fructose-1-
phosphate,	tagatose-1-phosphate	 inhibits	glycogen	phosphorylase	preventing	glycogen	
from	being	broken	down	into	glucose	subunits.	The	regulation	of	these	enzymes	enables	
the	 increase	of	glycogen	synthesis	and	 the	decrease	of	glycogen	utilization	having	 the	
overall	net	effect	of	lowering	of	serum	glucose	levels	(Gergely	1985;	Ercan-Fang	2002).		
	
There	 have	 been	 several	 other	 suggestions	 regarding	 how	 D-lyxo-hexulose	 exerts	 it	
effect.	Studies	have	proposed	that	D-lyxo-hexulose	may	suppress	 the	degradation	and	
absorption	of	carbohydrates	in	the	intestine	by	inhibiting	intestinal	enzymes	connected	
to	the	brush	border	membranes.	 Intestinal	enzyme	kinetic	studies	have	shown	that	D-
lyxo-hexulose	is	able	to	inhibit	maltase	activity	thereby	delaying	the	digestion	of	starch,	
and	 this	may	account	 for	 the	 lower	 total	 energy	 intake	of	 subjects	 consuming	D-lyxo-
hexulose	 (Seri	 1995).	 In	 addition	 to	 the	effect	 of	 glycogen	 regulation,	D-lyxo-hexulose	
inhibits	sucrase	activity	leading	to	a	reduction	of	sucrose	digestion	in	the	small	intestine	
(Seri	1995).		
	
In	humans,	D-lyxo-hexulose	has	been	orally	administered	up	to	0.64	g/kg/day	and	was	
safely	tolerated	in	the	Phase	3	study	conducted	by	our	group.	D-lyxo-hexulose	has	been	
shown	to	reduce	blood	glucose	levels	 in	the	treatment	of	type	2	diabetes	and	showed	
significant	reduction	of	hemoglobin	A1c	(HbA1c)	in	diabetic	patients.		
	
Some	 patients	 experience	 gastrointestinal	 intolerance	 to	 D-lyxo-hexulose	 but	 this	 has	
been	transient	and	not	associated	with	severe	or	persistent	morbid	conditions.	Adverse	
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events	in	a	Phase	2	study	at	doses	of	0.11-0.32	g/kg/day	in	107	patients	and	a	Phase	3	
study	 at	 a	 dose	 of	 0.64	 g/kg/day	 in	 494	 patients	 with	 diabetes	 included	 diarrhea,	
flatulence,	and	abnormal	gastrointestinal	sounds	after	chronic	dosing.	
	
In	 the	 United	 States,	 D-lyxo-hexulose	 has	 been	 granted	 generally	 recognized	 as	 safe	
(GRAS)	 status	 under	 the	 intended	 conditions	 of	 use	 in	 foods	 (GRAS	 78)	
(http://www.accessdata.fda.gov)	 currently	 permitting	 an	 estimated	 intake	 of	 6.6	
g/person/day	 at	 the	mean,	 and	14.9	 g/person/day	 at	 the	90th	percentile.	On	 July	 23,	
2003,	 the	 Korean	 Food	 &	 Drug	 Administration	 (KFDA)	 authorized	 the	 use	 of	 D-lyxo-
hexulose	in	foods.	In	February	18,	2004,	Food	Standards	Australia	New	Zealand	(FSANZ)	
issued	 a	 favorable	 final	 assessment	 report	 permitting	 the	 use	 of	D-lyxo-hexulose	 as	 a	
novel	 food	 ingredient	 (http://www.foodstandards.gov.au).	 The	 Joint	 FAO/WHO	Expert	
Committee	on	Food	Additives	(JECFA)	evaluated	D-lyxo-hexulose	at	its	55th,	57th,	61st	
and	63rd	meetings.	At	the	63rd	meeting	in	June	2004,	JECFA	stated	there	is	no	need	to	
limit	 the	 acceptable	 daily	 intake	 (ADI)	 of	 D-lyxo-hexulose.	 JECFA	 has,	 therefore,	
established	 an	ADI	 of	 “not	 specified,”	 the	 safest	 category	 in	which	 JECFA	 can	 place	 a	
food	 ingredient.	 On	December	 14,	 2005,	 D-lyxo-hexulose	was	 formally	 approved	 as	 a	
“novel	 food	 ingredient”	 in	 the	European	Union	 (EU)	without	any	 restriction	on	usages	
(http://www.food.gov.uk)	of	D-lyxo-hexulose.	
	
Trans-polydatin	
There	appear	 to	be	multiple	mechanisms	of	action	by	which	 trans-polydatin	exerts	 its	
actions.	 Activities	 include	 an	 antioxidant,	 free	 radical-elimination	mechanism	 (Hosada	
2013,	Wang	2015),	activation	of	protein	kinase	C	(Miao	2011,	Miao	2012),	suppression	
of	 NF-kappaB	 (Fresco	 2006),	 inhibition	 of	 the	 activation	 of	 renin-angiotensin-
aldosterone	 system	 and	 decreasing	 the	 excretion	 of	 endothelin	 1,	 TNF-α,	 and	
angiotensin	 II	 (Zhang	2014),	 reduction	of	 lipid	peroxidation	 levels	 (Fabris	2008,	 Fresco	
2006),	 up	 regulation	 of	 the	 expression	 of	 hippocampal	 brain‑derived	 neurotrophic	
factor	(Sun	2014),		enhanced	insulin	sensitivity	in	the	liver	as	shown	by	improved	insulin	
receptor	substrate	2	expression	levels	and	Akt	phosphorylation	(Hao	2014),	decreasing	
the	content	of	malonydialdehyde	(MDA)	(Chen	2015),	promoting	the	activities	of	 total	
superoxide	 dismutase	 (T-SOD),	 catalase	 (CAT)	 and	 glutathione	 peroxidase	 (GSH-Px)	 in	
plasma,	 and	 increasing	 the	 content	 of	 glutathione	 (GSH)	 in	 myocardial	 tissue	 (Wang	
2015),	 restoring	decreased	deacetylase	sirtuin1	activity	and	protein	expression	 in	 liver	
tissue	 following	 severe	 shock	 (Li	 2015)	 and	 activation	 of	 sirtuin	 (Huang	 2015,	 Zeng	
2015),	 suppressing	 oxidative	 stress-induced	 lysosomal	 instability	 and	 mitochondrial	
injury	by	increasing	the	protein	expression	of	SOD2	(Li	2015).	
	
The	 use	 of	 polydatin	 as	 a	 potential	 therapy	 for	 dyslipidemia	 has	 been	 suggested	
primarily	by	three	studies	using	animal	models	(Arichi	1982,	Du	2009,	Xing	2009).	Arichi	
et	 al	 (1982)	 discovered	 that	 orally	 administered	 polydatin	 (100	 mg/kg	 body	 weight)	
significantly	lowered	low-density	lipoprotein	(LDL)-derived	cholesterol	by	approximately	
18%	 and	 serum	 triglycerides	 by	 40%	 in	 rats	 consuming	 standard	 chow	 containing	 a	
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mixture	of	corn	oil,	10%	cholesterol,	and	1%	cholic	acid.	Although	lower	doses	of	trans-
polydatin	 (50	mg/kg	body	weight)	were	 ineffective	at	preventing	hyperlipidemia,	 they	
were	 able	 to	 prevent	 the	 accumulation	 of	 cholesterol	 and	 triglycerides	 in	 the	 liver,	
suggesting	that	lower	doses	may	also	be	effective	but	to	a	much	lesser	extent.	In	a	study	
using	Syrian	golden	hamsters,	polydatin	was	found	to	decrease	total	cholesterol	 levels	
and	 total	 triglyceride	 levels	by	47%	and	63%,	 respectively,	 compared	 to	 standard	diet	
(Du	2009).	In	another	study	using	rabbits,	the	administration	of	polydatin	decreased	the	
serum	 levels	 of	 total	 cholesterol,	 triglycerides	 and	 LDL	 (Xing	 2009).	 The	 ratio	 of	 total	
cholesterol	to	HDL	was	also	reduced.		
	
Insulin,	through	activation	of	the	Akt	pathway	and	other	metabolic	pathways,	is	a	major	
component	 of	metabolic	 regulation	 (Whiteman	 2002).	 Hao	 et	 al.	 recently	 found	 that	
polydatin	 activated	 the	 Akt	 signaling	 pathway	 in	 diabetic	 rats,	 possibly	 by	
phosphorylation	 of	 the	 insulin	 receptor	 substrate	 (IRS),	 thus	 reducing	 blood	 glucose	
levels	(Hao	2014).	Polydatin	may	also	decrease	the	expression	of	intercellular	adhesion	
molecule	1	(ICAM-1)	and	may	reduce	white	blood	cell	adhesion,	as	well	as	the	effects	of	
other	cell	adhesion	molecules	and	inflammatory	cytokines,	thought	to	be	active	in	early	
atherosclerotic	 development	 (Xie	 2012).	 Additionally,	 polydatin	 is	 also	 thought	 to	
provide	protection	from	oxidative	peroxidation	which	can	result	 in	cell	damage	(Fabris	
2008,	 Wen	 2012)	 and	 inhibition	 of	 oxidation	 of	 LDLs	 which	 may	 also	 play	 a	 role	 in	
atherosclerosis	(Liu	2012).	
Safety	of	BSN272	
	
D-lyxo-hexulose	
	
D-lyxo-hexulose	is	Safe	for	Oral	Ingestion	by	Humans:	
In	addition	to	in	vitro	and	animal	studies,	a	number	of	human	studies	were	conducted	in	
order	 to	 support	 the	 regulatory	 approvals	 for	 the	 use	 of	 D-lyxo-hexulose	 in	 foods.	
Detailed	description	of	these	studies	has	been	made	available	to	the	US	FDA	(GRN	78).	
The	estimated	daily	intake	(EDI)	of	D-lyxo-hexulose	under	the	intended	conditions	of	use	
in	foods	is	6.6	g/person/day	(g/p/d)	at	the	mean	and	14.9	g/p/d	at	the	90th	percentile.	
The	US	FDA	raised	no	questions	regarding	the	conclusion	that	D-lyxo-hexulose	is	GRAS	
under	 the	 intended	 conditions	 of	 use.	 Although	 the	 EDI	 of	 D-lyxo-hexulose	 in	 foods	
under	the	intended	conditions	of	use	is	6.6	g/p/d,	study	results	supported	the	safety	of	
D-lyxo-hexulose	when	it	 is	administered	at	a	dosage	of	15	g,	three	times	per	day	(tid),	
which	is	the	maximum	dosage	proposed	for	this	Phase	3	clinical	trial.	This	is	supported	
by	the	approval	of	the	use	of	D-lyxo-hexulose	 in	 foods	by	Australia,	New	Zealand,	and	
the	EU	with	no	restriction	on	usages.		
	
Single-dose	and	repeated-dose	studies	in	healthy	and	diabetic	human	subjects	showed	
that	the	predominant	adverse	effects	associated	with	excessive	consumption	of	D-lyxo-
172
 
 
 
 
 
hexulose	 were	 gastrointestinal	 disturbances	 attributed	 to	 osmotic	 effects	 from	
incompletely	 absorbed	D-lyxo-hexulose.	At	 single	doses	of	 up	 to	25	 g	D-lyxo-hexulose	
per	meal,	 flatulence	was	 generally	 the	only	 side	effect,	with	nausea,	borborygmi	 (i.e.,	
rumbling	or	gurgling	noises	in	the	gut),	colic,	and	laxation	noted	at	higher	doses	(Donner	
et	al.,	1996,	1999,	2010;	Buemann	et	al.,	1998,	1999a	&	b,	2000b;	Lee	and	Storey,	1999;	
Saunders	 et	 al.,	 1999a).	 Such	 effects	 are	 also	 commonly	 associated	 with	 excessive	
consumption	 of	 other	 poorly	 digestible	 carbohydrates	 including	 polyols.	 Liver	
enlargement	and	elevated	uric	acid	concentration	were	two	concerns	during	the	safety	
evaluation	 of	D-lyxo-hexulose	 by	 the	GRAS	 Expert	 Panel	 in	 the	US	 (D-lyxo-hexulose	 is	
self-affirmed	as	GRAS	by	a	panel	of	 independent	experts).	Standard	 toxicity	 tests	with	
high	 levels	 of	 D-lyxo-hexulose	 (i.e.,	 diets	 of	 10	 to	 20%	 D-lyxo-hexulose)	 showed	 a	
reversible	 enlargement	 of	 the	 liver	 in	 Sprague-Dawley	 rats	 without	 increase	 in	 liver	
enzymes	 (Bar	et	al.,	1999;	Kruger	et	al.,	1999c).	The	studies	were	reviewed	by	Dr.	Bar	
who	concluded	that	the	observed	liver	enlargement	in	D-lyxo-hexulose	fed	rats	had	no	
relevance	to	the	assessment	of	human	safety	of	D-lyxo-hexulose	(Bar,	1999).	However,	a	
clinical	trial	 in	humans	was	important	to	study	the	potential	effects	of	D-lyxo-hexulose	
on	the	volume	of	the	liver	and	postprandial	liver	glycogen	concentration.	Twelve	healthy	
male	 subjects	were	 studied	 in	a	double-blind	crossover	 study	with	 the	 ingestion	of	D-
lyxo-hexulose	(3	x	15	g	daily)	and	placebo	(sucrose,	3	x	15	g	daily)	for	a	period	of	28	days	
each.	 Liver	 volume	 and	 glycogen	 concentration	 were	 determined	 by	 magnetic	
resonance	 (MR)	 imaging	 and	 spectroscopy.	 MR	 examinations	 before	 and	 after	 the	
treatments	revealed	no	effects	of	treatment	on	liver	volume	or	glycogen	concentration.	
Steady	increases	in	liver	volumes,	independent	of	the	D-lyxo-hexulose	or	placebo	intake,	
were	observed	over	the	study.	The	treatment	with	D-lyxo-hexulose	was	not	associated	
with	 clinically	 relevant	 changes	 of	 the	 examined	 clinico-chemical	 and	 hematological	
parameters,	including	liver	enzymes	and	uric	acid	(Boesch	et	al.,	2001).		
	
The	presence	of	chronically	elevated	plasma	uric	acid	levels	(i.e.,	hyperuricemia)	is	one	
known	risk	factor	for	the	development	of	gout,	which	is	a	group	of	disorders	of	purine	
metabolism.	 The	 ingestion	 of	 single	 high	 bolus	 doses	 of	 D-lyxo-hexulose	 (≥30	 g)	 is	
associated	 with	 a	 mild,	 transient	 increase	 of	 plasma	 uric	 acid	 concentration	 in	 both	
healthy	subjects	and	patients	with	type-2	diabetes	(Buemann	et	al.,	2000c;	Saunders	et	
al.,	1999a;	Diamantis	and	Bar,	2001).	However,	repeated	daily	doses	of	3	x	15	g	D-lyxo-
hexulose	 ingested	with	 the	main	meals	 for	a	period	of	28	days	produced	no	effect	on	
fasting	plasma	uric	 acid	 levels	 in	 12	healthy	 volunteers	 (Boesch	et	 al.,	 2001).	Another	
clinical	trial	 in	both	normal	subjects	and	diabetic	patients	with	the	ingestion	of	D-lyxo-
hexulose	(3	x	25	g	daily)	for	8	weeks	did	not	show	an	increase	in	fasting	plasma	uric	acid	
(Saunders	et	al.,	1999a).	A	pilot	study	in	8	patients	with	type-2	diabetes	confirmed	the	
non-effect	of	D-lyxo-hexulose	on	fasting	plasma	uric	acid	at	a	dosage	of	3	x	15	g	daily	
taken	with	meals	for	a	period	of	one	year	(Donner	et	al.,	2010).	Furthermore,	a	clinical	
trial	on	12	hyperuricemic	and	gouty	subjects	showed	that	15	g	D-lyxo-hexulose	had	no	
effect	of	uricemic	potential	(Diamantis	and	Bar,	2002).	Thus,	it	is	concluded	that	there	is	
no	 reason	 to	 expect	 a	 postprandial	 increase	 of	 plasma	 uric	 acid	 concentrations	 in	
response	 to	 the	 ingestion	 of	 single	 15	 g	 dose	 of	 D-lyxo-hexulose	 in	 healthy,	 diabetic,	
173
 
 
 
 
 
hyperuricemic,	 or	 gouty	 individuals.	 Also,	 it	 was	 concluded	 in	 the	 above	 studies	 that	
there	were	no	cumulative	effects	on	fasting	serum	uric	acid	levels	after	chronic	intake	of	
D-lyxo-hexulose	(i.e.,	75	g/day	for	8	weeks,	or	45	g/day	for	12	months).	
Possible	Adverse	Events	From	D-lyxo-hexulose	
	
In	a	phase	 II	 trial	 in	which	D-lyxo-hexulose	was	administered	at	2.5	g,	5.0	g	and	7.5	g	
doses	 with	 no	 run	 in	 period,	 the	 main	 reason	 for	 failure	 to	 complete	 the	 trial	 was	
withdrawal	(37%),	subjects	asked	to	leave	or	were	lost	to	follow	up,	and	not	due	to	an	
adverse	 event	 (AE).	 The	 withdraw	 due	 to	 AE’s	 from	 2.5	 g,	 5.0	 g	 and	 7.5	 g	 D-lyxo-
hexulose	was	8.8%,	3.9%	and	1.9%	respectively.	AE’s	occurrence	was	found	to	decrease	
with	increasing	D-lyxo-hexulose	dosage.	The	three	most	prevalent	AE’s	reported	were	GI	
disorders,	infections,	and	metabolic	and	nutritional	disorders	(see	Table	8).	Data	from	a	
phase	III	placebo	vs.	15.0	g	D-lyxo-hexulose	trial	that	contained	an	8-week	run	in	period	
had	 a	 withdrawal	 rate	 due	 to	 AE	 occurrence	 of	 2.0%	 and	 4.6%	 respectively.	 The	
incidence	of	infections,	metabolic,	and	nutritional	disorders	were	highly	similar	in	both	
placebo	and	D-lyxo-hexulose	groups,	indicating	these	occurrences	were	not	study	drug	
related.	There	was	however	a	21.5%	increased	 incidence	of	GI	disorders	 in	the	D-lyxo-
hexulose	group	 in	comparison	with	the	placebo	(79.5%	vs.	58.0%).	Note:	Predominant	
populations	for	the	Phase	II	and	III	were	from	India.	
	
Table	8.	D-lyxo-hexulose	Adverse	Effects	
	
	 D-lyxo-hexulose	
	 Phase	II	(no	run	in)	 Phase	III	(8	wk	Run	in)	
Adverse	Event	
(AE)	 2.5	g	 5.0	g	 7.5	g	 placebo	 15	g	
Total	%	of	AE	
documented	for	
study	 8.80%	 3.90%	 1.90%	 2.00%	 4.60%	
%	of	AE	that	
were	
gastrointestinal	
disorders	 44.20%	 34.80%	 36.2	 58.00%	 79.50%	
%	of	AE	that	
were	infections	
and	infestations	 19.20%	 15.20%	 17.00%	 23.20%	 22.70%	
%	of	AE	that	
were	metabolic	
&	nutritional	
disorders		 3.80%	 8.70%	 10.60%	 16.40%	 16.80%	
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Trans-polydatin	
Possible	Adverse	Effects	of	Trans-polydatin	
Adverse	effects	of	trans-polydatin	 in	human	trials	are	few	and	minor	 in	nature,	mostly	
gastrointestinal	(Table	7)	(Indraccolo	et	al	2010;	Murina	et	al	2013).	In	a	small	pilot	study	
on	 the	 effects	 of	 phenylethylamine	 (PEA)	 and	 trans-polydatin	 in	 patients	 with	
endometriosis,	one	patients	 reported	 spotting	which	 the	 investigators	were	unable	 to	
determine	if	the	spotting	was	related	to	either	of	the	investigative	therapies	(Indraccolo	
et	al	2010).	
	
Table	9.	Trans-polydatin	Adverse	Effects	
	
	 trans-polydatin	
	 Pilot	Study	(n=61)1	 Pilot	Study	(n=4)2	 Pilot	Study	(n=20)3	
Adverse	Event	(AE)	
400	mg	PEA	+	40	mg	
Trans-polydatin	bid	
400	mg	PEA	+	40	mg	
Trans-polydatin	bid	
400	mg	PEA	+	40	mg	
Trans-polydatin	bid	 Placebo	
Total	%	of	AE	
documented	for	
study	 0	 50%	 20%	 10%	
%	of	AE	that	were	
gastrointestinal	
disorders	 	 50%	 100%	 100%	
%	of	AE	that	were	
gynecological	
disorders	 	 50%	 	 	
Cobellis	et	al	20111;	Indraccolo	et	al	20102;	Murina	et	al	20133	
	
In	 this	 Phase	 1	 pharmacokinetic	 study,	 the	 dose	 of	 D-lyxo-hexulose	would	 be	 far	 less	
than	the	dose	used	in	the	Phase	3	clinical	trial	and	the	dose	of	trans-polydatin	would	be	
6	orders	of	magnitude	lower	than	the	NOAEL	established	in	the	28-day	toxicology	study.	
	
	
	
Objective	
	
The	proposed	 indication	 for	BSN272	 is	 as	a	 combination	 therapy	 for	 the	 treatment	of	
patients	with	Prader-Willi	Syndrome.	
	
Primary	objective	
	
Determine	the	pharmacokinetics	of	a	single	dose	of	trans-polydatin	in	combination	with	
D-lyxo-hexulose.	Specifically	to	test	the	hypothesis	that	the	tmax	and	cmax	of	a	single	dose	
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of	trans-polydatin	(100	µg)	do	not	change	when	administered	with	a	single	dose	of	D-
lyxo-hexulose	(0.03	g/kg).	
Subject	Population	
	
Healthy	male	and	female	volunteers,	aged	between	18	and	30	years	old	will	be	recruited	
by	advertisement	at	the	University	of	Kentucky.	Acceptance	into	the	trial	will	be	based	
upon	the	full	inclusion	and	exclusion	criteria	listed	below.	After	giving	informed	consent,	
initial	screening	performed	(physical	exam,	blood	analysis	including	HIV	and	Hep	C,	and	
urinalysis)	 and	 when	 acceptability	 of	 the	 subject	 has	 been	 determined	 they	 will	 be	
invited	to	participate	in	the	study.	Subjects	will	be	compensated	for	their	time.	
Inclusion	Criteria	
	
1.	Healthy	volunteers	(male	and	female	between	18-30	years	old).	
2.	Volunteers	weight	≥	50kg	or	≤	100kg	(BMI	≤	18.5	or	≥	26)	
3.	Weight	stable	(±	10%)	for	the	3	months	prior	to	starting	the	study.	
4.	No	history	of	excessive	alcohol	consumption.	
5.	No	renal,	hepatic,	hematological,	cardiac	or	other	medical	abnormalities	detected	by	
basic	health	check,	blood	screening	by	urine	test.	
6.	 The	 subjects	 must	 be	 given	 signed	 informed	 consent	 before	 beginning	 any	 trial	
related	activities.	
7.	Individuals	have	normal	dietary	habits	without	restrictions	on	foods.	
8.	Negative	for	HepC,	HIV,	and	pregnancy.	
	
Exclusion	Criteria	
	
1.	Any	unexpected	weight	loss	(-10%)	during	the	last	3	months.	
2.	Volunteers	weight	≤	50	kg	or	≥	100	kg	(BMI	≤	18.5	or	≥	26)	
3.	Known	or	suspected	illicit	drug	or	alcohol	abuse.	
4.	Known	Impaired	hepatic	or	renal	functions.	
5.	Undergone	any	gastrointestinally-related	surgeries.	
6.	Any	hematological	or	cardiac	abnormalities.	
7.	Uncontrolled	hypertension	(systolic	pressure	>180	mm	Hg	and/or	diastolic	
pressure	>100	mm	Hg).	
8.	Recent	or	ongoing	major	disease	or	cancer.	
9.	Has	gastroesophageal	reflux	disease	(GERD)	
10.	Has	irritable	bowel	disease	(IBS)	
11.	Has	inflammatory	bowel	disease	(IBD)	
12.	Any	or	recent	gastric	bleeding.	
13.	Current	gastric	or	duodenal	ulcers.	
14.	History	of	esophageal	motility	disorders.	
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15.	 Concomitant	 usage	 of	 daily	 nonsteroidal	 anti-inflammatory	 drugs	 (aspirin	 >	 325	
mg/day).	
16.	Oral	corticosteroids	(prednisone	and	prednisolone).	
17.	 Anticholinergics.	 ((Benztropine	 (Cogentin),	 Ipratropium	 (Atrovent),	 Oxitropium	
(Oxivent),	 Diphenhydramine	 (Benadryl,	 Sominex,	 Equate	 Sleep	 Aid,	 Advil	 PM,	 etc.),	
Dimenhydrinate	(Dramamine)).	
18.	Usage	of	therapeutic	antacids	or	H2	receptor	antagonists.	
19.	Taking	enzyme	therapy	within	the	last	14	days,	proton	pump	inhibitor	within	the	last	
7	days,	or	octreotide	within	48	hours.	
20.	Any	known	hypersensitivity	to	formulation	ingredients.	
21.	Subject	history	of	viral,	bacterial,	or	fungal	infection	within	4	weeks	of	screening	
22.	Receiving	any	investigational	drug	within	30	days	of	the	screening	visit.	
23.	 Any	 behavioral	 or	 social	 problems	 that	 may	 interfere	 with	 the	 clinical	 study	
procedures.	
24.	Patient	is	unlikely,	in	the	investigator's	opinion,	to	complete	the	study	
25.	 Have	 consumed	 grapes,	 grape-containing	 products,	 peanuts,	 peanut-containing	
products,	 blueberries,	 blueberry-containing	 products,	 chocolate,	 and	 chocolate-
containing	 products,	 probiotics,	 prebiotics,	 and	 nutritional	 supplements	 in	 the	 last	 2	
days.	
26.	Pregnancy,	breastfeeding,	or	intention	of	becoming	pregnant	or	judged	to	be	using	
inadequate	contraceptive	measure.	
Subject	Withdrawal	
	
Subjects	have	the	right	to	withdraw	from	the	study	at	any	time	for	any	reason	without	
prejudice.	The	investigator	also	has	the	right	to	withdraw	subjects	from	the	study	in	the	
event	of	illness,	adverse	events,	protocol	deviations,	administrative,	and	other	reasons.	
The	subject	 should,	 if	possible,	 remain	 in	 the	 study	 (in	 the	absence	of	 treatment	with	
study	material)	for	the	collection	of	safety	parameters	at	the	end	of	the	trial.	
	
It	 is	understood	by	all	concerned	that	an	excessive	rate	of	withdrawals	can	render	the	
study	statistically	underpowered	for	interpretation.	Therefore,	unnecessary	withdrawal	
of	 subjects	 should	be	avoided.	Should	a	subject	decide	 to	withdraw,	all	efforts	will	be	
made	 to	 complete	 and	 report	 the	 observations	 as	 thoroughly	 as	 possible	 and	 collect	
study	 products.	 If	 a	 subject	 withdraws	 from	 the	 study	 due	 to	 an	 adverse	 event,	 the	
specific	event	will	be	 recorded	on	 the	Adverse	Event	Case	Report	Form	 (CRF)	and	 the	
subject	will	be	followed	until	the	event	is	resolved.	
Subject	Instruction	
	
Volunteers	will	receive,	read,	and	sign	a	copy	of	the	informed	consent	form	before	any	
trial	 related	 activities	 are	 undertaken.	 The	 consent	 form	 will	 outline	 all	 study	
appointments,	 health	 screening	 process,	 procedures	 requirements	 involved	 at	 each	
appointment.		
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Concomitant	Interventions	
	
As	the	trial	is	being	conducted	in	healthy	volunteers	they	will	be	prohibited	from	taking	
other	medications	
Study	Design	
	
The	 main	 objective	 of	 this	 phase	 1	 clinical	 trial	 is	 to	 test	 the	 hypothesis	 that	
administration	of	trans-polydatin	with	D-lyxo-hexulose	does	not	change	the	tmax	or	cmax	
of	trans-polydatin.	All	volunteers	will	be	healthy	male	and	female	aged	18-30	years	old,	
must	 not	 be	 taking	 other	 medications,	 prescription	 or	 nonprescription,	 with	 no	
excessive	alcohol	intake,	and	have	not	previously	participated	in	a	clinical	trial	within	the	
last	 30	 days.	 Those	 potentially	 eligible	 subjects	 meeting	 the	 initial	 inclusion	 and	
exclusion	 requirements,	 and	 after	 signing	 informed	 consent,	 will	 undergo	 a	 basic	
physical	 examination,	hematology,	blood	 chemistry,	 and	urinalysis.	 This	 screening	and	
recruitment	process	should	be	complete	within	3-5	days.	After	meeting	all	trial	criteria,	
eligible	subjects	are	 invited	to	participate	 in	the	trial.	They	will	be	asked	to	attend	the	
trial	 facility	and	will	be	randomly	assigned	to	one	of	the	two	treatment	groups	for	the	
duration	of	 the	 study.	 Randomization	 is	 to	 be	 stratified	 according	 to	 sex	 to	 achieve	 a	
balanced	distribution	of	subjects	across	the	2-treatment	groups.	The	treatment	groups	
will	 be	 (1)	 trans-polydatin	 and	 (2)	 BSN272	 (trans-polydatin	 +	 D-lyxo-hexulose).	 Six	
subjects,	3	male	and	3	female,	will	be	assigned	to	each	group	for	a	total	of	12	subjects.	
On	the	trial	day	subjects	will	be	given	study	medication	and	then	timed	blood	samples	
will	be	 taken	 for	pharmacokinetic	analysis.	Urine	samples	will	also	be	collected	during	
the	12	hours	 the	 volunteers	 are	 at	 the	CCTS,	with	one	 subsequent	urine	 collection	at	
visit	 3,	 which	 should	 approximate	 24	 hours	 post-treatment,	 and	 will	 be	 stored	 for	
contingent	 analysis.	 Serum	 and	 urine	 trans-polydatin	 and	 trans-resveratrol	 will	 be	
determined.	
	
For	this	study,	potential	subjects	will	be	screened	to	identify	16	study	healthy	volunteers	
(8	male,	8	female)	of	which	12	participants	(6	male,	6	female)	will	be	used	for	the	actual	
study	with	 4	 alternates	 (2	male,	 2	 female)	 in	 case	 a	 participant	 cannot	 complete	 the	
study.	Six	subjects,	3	male	and	3	female,	will	be	assigned	to	each	group.	
	
At	 the	 initial	 recruitment/screening	 a	 full	 explanation	 of	 the	 trial	 requirements	 and	
expectations	 will	 be	 given	 to	 the	 volunteers	 and	 a	 signed	 consent	 will	 be	 obtained	
before	beginning	the	screening	process.	 	Then	every	consenting	volunteer	will	provide	
medical	history,	have	their	vital	measurements	taken	(weight,	height,	and	BP),	undergo	
a	 basic	 physical	 examination,	 blood	 samples	 taken	 for	 hematology	 (hematocrit,	
hemoglobin,	 MCH,	 MCHC,	 MCV,	 total	 WBC,	 platelet	 count,	 and	 differential),	 clinical	
chemistry	(sodium,	potassium,	chloride,	CO2,	BUN,	albumin,	creatinine	clearance,	SGOT,	
ALT,	 glucose,	 total	 bilirubin,	 HIV,	 and	 Hep	 C)	 and	 urinalysis	 (appearance,	 pH	 specific	
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gravity,	glucose,	protein,	microscopic	evaluation	of	urinary	sediment).	When	all	of	 the	
data	from	these	screening	tests	have	been	analyzed	and	the	eligibility	of	the	volunteers	
determined,	they	will	be	asked	to	participate	and	scheduled	to	return	for	the	study.		
	
On	the	first	day	of	the	study	all	the	enrolled	subjects	will	attend	the	study	clinic	where	
they	will	be	administered	the	trial	drug	and	have	timed	blood	samples	taken.	They	will	
be	required	to	have	fasted	for	12	hours	prior	to	attending	the	trial	facility	at	the	start	of	
each	trial	arm.	On	the	first	trial	day	volunteers	will	be	randomly	assigned	into	2	groups	
(trans-polydatin	or	BSN272).	Once	assigned	to	a	treatment	group	volunteers	will	remain	
in	that	group	for	the	duration	of	the	study.	Each	subject	will	then	have	blood	tests	taken	
for	baseline	trans-polydatin	and	trans-resveratrol	levels.		
	
Each	subject	will	drink	the	study	drug(s)	assigned	to	their	group	dissolved	in	volume	of	
approximately	 4	 ounces	 of	 water	 per	 drug.	 Each	 drug	 will	 be	 dissolved	 separately	 in	
water	 and	 subjects	 will	 drink	 both	 solutions	 (trans-polydatin	 in	 the	 trans-polydatin	
group,	or	trans-polydatin	and	D-lyxo-hexulose	in	the	BSN272	group)	from	separate	cups	
in	rapid	succession.	The	study	dosage	is	shown	in	Table	10.	
Table	10.	Study	Drug	Dosage	Schedule	
Group	(Arm)	 Treatment	
Cup	#1	 Cup	#2	
Trans-polydatin	
(n	=	6;	3	male,	3	female)	
Trans-polydatin	(100	µg)	 Water	
BSN272	
(n	=	6;	3	male,	3	female)	
Trans-polydatin	(100	µg)	 D-lyxo-hexulose	(0.03	g/kg)	
	
After	 administration	 of	 the	 study	 drugs,	 blood	 samples	 will	 then	 be	 taken	 at	
approximately	0.167	(10	mins),	0.333	(20	mins),	0.5,	1,	2,	4,	6,	8,	12	and	once	between	
24-36	hours	post	dose.	Urine	samples	will	also	be	collected	during	the	12	clinical	period,	
with	 one	 subsequent	 collection	 at	 the	 24-hour	 time	 point	 (visit	 3).	 Subjects	 will	 be	
required	to	attend	the	trial	facility	after	a	12	hours	overnight	fast.	Subjects	will	remain	in	
the	 facility,	 and	 monitored	 constantly	 for	 safety	 for	 the	 duration	 of	 the	 timed	
pharmacokinetic	 blood	 collection	 (12	 hours).	 The	 subjects	 will	 receive	 a	 light,	 low	
polydatin	lunch	after	the	4	hour	blood	sample	has	been	taken.	After	the	12-hour	sample	
draw	they	will	be	allowed	to	 leave	but	will	be	required	to	return	for	the	following	day	
for	the	24-hour	sample	collection.		
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Figure	1.	Trial	Timeline	Overview	
	
	
Clinical	and	Laboratory	Evaluations	
	
The	 trial	 evaluations	 are	 illustrated	 in	 Table	 11.	 At	 visit	 1	 (screening)	 the	 volunteer’s	
medical	 history,	 medications,	 physical	 assessment,	 and	 laboratory	 evaluation	 will	 be	
performed.	 Laboratory	 tests	 include	 electrolytes	 (sodium,	 potassium,	 chloride,	 and	
bicarbonate),	renal	function	(BUN	and	creatinine),	Liver	function	(AST,	ALT,	CK)	albumin,	
alkaline	phosphatase,	total	bilirubin	and	LDH	at	baseline	and	then	at	the	end	of	the	trial.	
The	 study	 into	 the	 pharmacokinetic	 effects	 of	 increasing	 BSN272	 therapy	 will	 be	
performed	over	2	arms	of	 this	 trial.	Blood	samples	will	be	 taken	at	 the	 time	points	0,	
0.167,	0.333,	0.5,	1,	2,	4,	6,	8,	12	and	24-36	hours	post	study	drug,	and	a	24	hour	urine	
will	be	collected	during	the	trial.	Trans-polydatin	and	trans-resveratrol	will	be	measured	
in	both	the	plasma	and	urine	samples.		The	volunteers’	health	will	be	closely	monitored	
during	 the	 trial	 and	 any	 unexpected	 or	 adverse	 effects	 recorded.	 Any	 adverse	 results	
found	 during	 the	 initial	 screening	 during	 visit	 1	 the	 volunteer	 will	 be	 advised	 and	
omitted	from	proceeding	with	the	clinical	trial.	
	
The	clinical	samples	taken	during	the	screening	process	and	at	the	end	of	the	trial	will	be	
analyzed	at	the	University	of	Kentucky	clinical	chemistry	laboratory.	A	list	of	laboratory	
tests	is	summarized	in	Appendix	I.		The	analysis	of	trans-polydatin	and	trans-resveratrol	
levels	will	be	performed	in-lab	at	the	University	of	Kentucky.		
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Table	11.	BSN272	Trial	Evaluations	
	
Clinical	Supplies	
	
Study	Supplies	and	Labeling	
	
We	will	supply	the	following	
	
● trans-polydatin	
● D-lyxo-hexulose	
	
The	study	material	(trans-polydatin	and	D-lyxo-hexulose)	will	be	supplied	directly	to	the	
study	 clinic.	 Each	 subject	 will	 be	 supplied	 their	 own	 individual	 doses	 in	 water	 with	 a	
specific	amount	trial	drug	as	described	in	Table	10.	Each	dose	will	be	clearly	labeled	with	
its	contents	and	the	individual	subject’s	trial	number.	
Accountability	
	
All	materials	supplied	are	 for	use	only	 in	 this	clinical	 trial	and	will	not	be	used	for	any	
other	 purposes.	 The	 investigators	 or	 designees	 will	 maintain	 a	 full	 record	 of	 product	
accountability.	 A	 study	 dispensing	 log	 will	 be	 kept	 current	 and	 contain	 the	 following	
information:	
	
•	 The	identification	of	subject	to	whom	the	product	is	dispensed,	using	volunteer	
initials	and	number.	
•	 The	date	and	code	of	product	dispensed	for	treatment	for	each	volunteer.		
	
The	above	inventory	will	be	available	for	inspection	by	an	un-blinded	study	monitor	that	
is	not	responsible	for	monitoring	of	the	case	report	forms.	
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Trial	Drug	Storage	
	
The	 study	 products	 (D-lyxo-hexulose	 and	 trans-polydatin)	 will	 be	 stored	 at	 a	
temperature	 of	 15	 to	 25	 degrees	 C	 or	 59	 to	 77	 degrees	 F.	 	 Trans-polydatin	 is	 light	
sensitive	and	will	be	stored	in	light-tight,	opaque	containers.		
Visit	Schedule	
Visit	1	(Recruiting	and	Screening)	
	
Healthy	volunteers	are	eligible	for	screening	for	acceptance	into	this	clinical	trial.	Prior	
to	 screening	 and	 enrollment	 each	 volunteer	will	 be	 provided	both	 verbal	 and	written	
study	relevant	information	and	will	have	any	questions	or	concerns	they	have	answered.	
If	 the	volunteers	make	 the	decision	 to	participate	 in	 the	 trial,	 they	will	 then	complete	
and	 sign	 an	 informed	 consent	 form.	 At	 this	 point,	 based	 upon	 the	 inclusion	 and	
exclusion	criteria	the	potential	volunteer’s	medical	history	will	be	recorded,	have	initial	
blood	 samples	 taken	 and	 be	 given	 a	 basic	 physical	 exam.	 The	 basic	 physical	 exam	
includes	 physical	 measurements	 (weight,	 height	 and	 BMI),	 general	 examination	 by	
observation	 (inspection),	 blood	pressure,	 and	heart	 rate	 check.	 The	 clinical	 laboratory	
tests	 include	 (1)	 hematology	 (hematocrit,	 hemoglobin,	MCH,	MCHC,	MCV,	 total	white	
blood	 cells,	 platelets,	 and	 differential),	 and	 (2)	 clinical	 chemistry	 (sodium,	 chloride,	
potassium,	 CO2,	 BUN,	 uric	 acid,	 albumin,	 creatinine	 clearance,	 SGOT,	 ALT,	 bilirubin,	
phosphorus,	calcium,	alkaline	phosphatase,	total	protein,	and	glucose.	Also	HIV	and	Hep	
C	 screening	 will	 be	 performed.	 Urine	 analysis	 will	 also	 be	 performed	 that	 includes	
appearance,	 volume,	 specific	gravity,	pH,	glucose,	protein,	and	microscopic	evaluation	
of	 urinary	 sediment.	 Any	 samples	 that	 have	 a	 hematological,	 biochemical	 or	 physical	
component	that	is	outside	normal	ranges,	or	a	positive	HIV	or	Hep.	C	result	is	obtained	
the	volunteer	will	be	informed	but	omitted	from	proceeding	with	the	study.	
		
All	subjects	who	are	eligible	to	be	enrolled	in	the	study	will	be	informed	by	a	phone	call	
to	schedule	a	follow-up	appointment	approximately	1	week	from	the	screening	visit.	
Enrolled	volunteers	will	be	randomized	(stratified	across	all	groups	according	to	sex	into	
the	study).	Each	volunteer	will	be	assigned	a	volunteer	number.	The	volunteer’s	number	
and	the	volunteer’s	three	initials	(unless	they	only	have	two	initials)	will	be	the	
identifiers	recorded	on	the	CRFs.	
	
Visit	2	(Trial	Initiation)	
	
For	12	hours	prior	to	attending	the	trial	facility	the	volunteers	will	be	required	to	fast.	
No	food	to	be	consumed	from	10	pm	the	night	prior	to	the	trial.	On	day	1	of	the	trial,	
volunteers	 will	 be	 fitted	 with	 an	 angiocath	 for	 ease	 of	 timed	 pharmacokinetic	 blood	
sample	 collection.	 At	 this	 point	 a	 blood	 sample	will	 be	 taken	 for	 baseline	 analysis	 of	
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trans-polydatin,	and	trans-resveratrol.	Each	subject	will	then	be	given	the	study	drug(s)	
that	 has	 been	 individually	 prepared	 for	 them	 based	 upon	 the	 trial	 group	 and	 the	
individual’s	body	weight	(Table	12).	
Table	12.	Trial	Dosages	
Group	 Trans-polydatin	
(µg)		
D-lyxo-hexulose	
(g/kg)	
Trans-polydatin	 100		 -	
BSN272	 100		 0.03	
	
Pharmacokinetic	blood	samples	will	be	taken	at	the	time	points	0,	0.167,	0.333,	0.5,	1,	2,	
4,	6,	8,	12	and	once	between	24-36	hours	post	study	drug	administration.	Urine	samples	
will	 be	 collected	 during	 the	 12	 hours	 post-treatment	 period	 with	 a	 subsequent	 final	
urine	 sample	 to	 be	 collected	 during	 visit	 3.	 Blood	 samples	 will	 be	 collected	 in	
heparinized	 tubes	 and	 will	 be	 kept	 on	 ice	 until	 plasma	 separation	 by	 centrifugation.	
During	blood	collection	time	intervals	the	subject	will	remain	in	the	clinical	test	facility	
and	will	be	monitored	constantly	 for	any	adverse	 reactions.	After	 the	12	hour	 sample	
has	been	drawn	the	volunteer	will	have	the	angiocath	removed	and	be	discharged.	They	
will	be	asked	to	return	the	following	morning	for	the	24	hour	sample	time	point.	After	
the	4	hour	blood	sample	collection	all	volunteers	will	be	given	a	light,	low	sugar	lunch.	
Visit	3	(24	Hour	Follow-Up)	
	
All	volunteers	will	return	to	the	trial	facility	to	have	the	24-hour	time	point	blood	sample	
drawn	and	a	final	urine	collection.	
Determination	of	Sample	Size	
	
Potential	 subjects	will	 be	 screened	 to	 identify	 16	 study	 healthy	 volunteers	 (8	male,	 8	
female)	 of	which	12	participants	 (6	male,	 6	 female)	will	 be	used	 for	 the	 actual	 study.	
There	 will	 be	 2	 treatment	 groups	 each	 having	 6	 volunteers	 randomly	 assigned.	 The	
determination	 of	 the	 minimum	 study	 group	 numbers	 is	 based	 upon	 a	 28	 day	 rat	
toxicology	 study	 taken	 at	 1-hour	 post	 trans-polydatin,	 2-sided,	 confidence	 interval	 of,	
(alpha	0.025)	and	a	power	of	90%.		
Statistical	Analysis	
	
The	primary	objective	of	this	phase	1	microdose	study	is	to	determine	whether	the	tmax	
and	Cmax	of	t-PD	change	significantly	when	coadministered	with	DLH	in	healthy	male	and	
female	volunteers.	
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Non-compartmental	 analysis	 will	 be	 applied	 to	 the	mean	 plasma	 trans-polydatin	 and	
trans-resveratrol	concentration	data	from	the	volunteers.	The	following	parameters	will	
be	estimated	whenever	possible:	
	
1. Cmax	-	 Maximum	observed	concentration	
2. Tmax	-	 Time	to	maximum	observed	concentration.	
	
Cmax	and	Tmax	will	be	determined	by	visual	inspection	of	the	concentration-time	data.		If	
any	maxima	appear	identical,	a	computer	sort	will	identify	the	highest	data	value.	
	
AUC0-8	-	Area	under	the	concentration-time	curve	from	hour	0	to	hour	8,	estimated	by	
the	linear	trapezoidal	rule.	
AUC0-t		 -	Area	under	 the	concentration-time	curve	 from	hour	0	 to	 the	 last	measurable	
concentration,	estimated	by	the	linear	trapezoidal	rule.	
	
AUC0-∞	 -	 Area	 under	 the	 concentration-time	 curve	 from	 hour	 0	 to	 infinity	 for	 Day	 1	
calculated	as	follows:	
AUC0-∞	=	AUC0-t	+	Ct/λz	
	
Where	Ct	 is	 the	 last	measurable	 concentration	and	λz	 is	 the	elimination	 rate	 constant	
estimated	using	log-linear	regression	during	the	terminal	elimination	phase.	The	number	
of	 points	 used	 in	 λz	 calculation	 will	 be	 determined	 by	 visual	 inspection	 of	 the	 data	
describing	the	terminal	phase.	At	least	the	last	three	time	points	with	measurable	values	
will	be	used	in	λz	calculation.	
	
M/P	 ratio	 -	Metabolite	 to	 Parent	 ratio	 calculated	 as:	 AUC0-8	metabolite/AUC0-8	 parent	
pharmacokinetic	 analysis	 will	 be	 performed	 using	 WinNonlin	 Professional	 Edition	
(Pharsight	 Corporation,	 Version	 5.2).	 Nominal	 doses	 and	 sampling	 times	will	 be	 used.	
Dose	 normalized	 parameters,	 ratios,	 and	 descriptive	 statistics	will	 be	 calculated	 using	
WinNonlin	 and	Microsoft	 Excel	 (Version	 11.0).	 Concentration	 values	 found	 below	 the	
lower	 limit	 of	 quantification	 (<	 20.0	 ng/mL	 for	 trans-polydatin	 and	 <	 10.0	 ng/mL	 for	
trans-resveratrol)	 will	 be	 treated	 as	 zero	 for	 descriptive	 statistics	 and	 toxicokinetic	
analysis.	
	
A	t	test	(p=0.05)	will	be	used	to	calculate	the	significance	of	the	difference	between	the	
Cmax	and	Tmax	of	t-PD	with	and	without	DLH.	
Assay	
	
In	an	earlier	validation	study	for	a	of	rat	plasma	PK	study,	the	validated	range	of	trans-
polydatin	was	20	to	20000	ng/mL	(Biospherics	Study	No.	70971-0010).	It	is	expected	to	
be	similar	for	human	plasma	levels	but	the	UK	Clinical	laboratory’s	analytical	method	for	
supported-liquid	extraction	/	LC-MS/MS	of	trans-polydatin	will	require	validation.		
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Study	Sample	Handling	
	
Study	samples	will	be	transported	by	CCTS	personnel	to	the	Kentucky	Clinic	Laboratory.	
Samples	will	be	stored	in	a	freezer	set	to	maintain	-60	to	-80	0C.		
	
Quality	Control	
A	small	dilution	concentration	quality	control	 sample	of	 the	prepared	BSN	272	will	be	
collected	at	the	zero	time	point,	to	assess	dilution	QC.	Results	will	be	reported	to	study	
sponsor.		
	
Each	 batch	 of	 samples	 analyzed	 should	 include	 a	 calibration	 curve,	 a	 matrix	 blank,	 a	
control	zero	(matrix	blank	containing	internal	standard),	a	reagent	blank,	and	duplicate	
quality	 control	 (QC)	 samples	at	 three	concentrations	within	 the	calibration	 range.	The	
samples	were	interspersed	with	calibration	standards	and	QC	samples	within	the	batch.	
	
Sample	 results	 will	 be	 considered	 valid	 if	 calibration	 curve	 and	 QC	 data	 indicate	 the	
method	met	the	acceptance	criteria,	which	includes:	no	more	than	1/4	of	the	standards	
were	 excluded,	 1/2	 of	 the	 undiluted	 QC	 samples	 and	 2/3	 undiluted	 QC	 samples	 are	
within	the	85-115%	range,	and	at	least	2/3	of	the	original	results	are	within	20%	of	each	
other.		
Safety	Outcomes	
	
Adverse	Events	Monitoring	
Definitions:	
An	 adverse	 event	 (AE)	 is	 any	 untoward	medical	 occurrence	 in	 a	 patient,	 in	 a	 clinical	
investigation	administered	a	pharmaceutical	product,	which	does	not	necessarily	have	
to	have	a	causal	relationship	with	this	treatment.	
		
An	 AE	 is	 therefore	 any	 unfavorable	 and	 unintended	 sign	 (including	 an	 abnormal	
laboratory	finding),	symptom	or	disease	temporally	associated	with	the	administration	
of	an	investigational	product,	whether	or	not	related	to	that	investigational	product.		An	
unexpected	AE	 is	 one	of	 a	 type	not	 identified	 in	 nature,	 severity,	 or	 frequency	 in	 the	
current	Investigator’s	Brochure	or	of	greater	severity	or	frequency	than	expected	based	
on	the	information	in	the	Investigator’s	Brochure.	
		
A	Serious	Adverse	Event	is	any	untoward	medical	occurrence	at	any	dose	that:	
Results	in	death	or;	
·									Is	life-threatening	or;	
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Note:	 The	 term	 "life-threatening"	 in	 the	 definition	 of	 "serious"	 refers	 to	 an	
event	in	which	the	patient	was	at	risk	of	death	at	the	time	of	the	event;	it	does	
not	 refer	 to	 an	 event	 that	 hypothetically	might	 have	 caused	 death	 if	 it	 were	
more	severe.	
		
·									Requires	inpatient	hospitalization	or	prolongation	of	existing	hospitalization	or;	
·	 	 	 	 	 	 	 	 	 Results	 in	 persistent	 or	 significant	 disability/incapacity	 or;	  	 Is	 a	 congenital	
anomaly/birth	defect;	
·									Is	a	medically	important	event:	
		
Medical	 and	 scientific	 judgment	 should	 be	 exercised	 in	 deciding	 whether	 expedited	
reporting	is	appropriate	in	other	situations,	such	as	important	medical	events	that	may	
not	 be	 immediately	 life-threatening	 or	 result	 in	 death	 or	 hospitalization	 but	 may	
jeopardize	 the	 patient	 or	 may	 require	 intervention	 to	 prevent	 one	 of	 the	 other	
outcomes	listed	in	the	definition	above.	These	should	also	usually	be	considered	serious.	
		
The	 Common	 Terminology	 Criteria	 for	 Adverse	 Events	 (CTCAE)	 Version	 4.0	 should	 be	
used	 to	assess	and	grade	AE	 severity,	 including	 laboratory	abnormalities	 judged	 to	be	
clinically	 significant.	 The	 modified	 criteria	 can	 be	 found	 in	 the	 study	 manual.	 	 If	 the	
experience	 is	 not	 covered	 in	 the	 modified	 criteria,	 the	 guidelines	 shown	 in	 Table	 13	
below	should	be	used	to	grade	severity.		It	should	be	pointed	out	that	the	term	“severe”	
is	a	measure	of	intensity	and	that	a	severe	AE	is	not	necessarily	serious.	
Table	13.		AE	Severity	Grading	
Severity	(Toxicity	Grade)	 Description	
Mild	(Grade	1)	 Mild;	asymptomatic	or	mild	symptoms;	clinical	or	diagnostic	
observations	only;	intervention	not	indicated.	
Moderate	(Grade	2)	 Moderate;	minimal,	local	or	noninvasive	intervention	indicated;	
limiting	age-appropriate	instrumental	ADL*.	
Severe	(Grade	3)	 Severe	or	medically	significant	but	not	immediately	life-
threatening;	hospitalization	or	prolongation	of	hospitalization	
indicated;	disabling;	limiting	self-care	ADL**.	
Life-threatening	(Grade	4)	 Life-threatening	consequences;	urgent	intervention	indicated.	
Activities	of	Daily	Living	(ADL)	
*Instrumental	 ADL	 refer	 to	 preparing	 meals,	 shopping	 for	 groceries	 or	 clothes,	 using	 the	 telephone,	
managing	money,	etc.	
**Self	 care	 ADL	 refer	 to	 bathing,	 dressing	 and	 undressing,	 feeding	 self,	 using	 the	 toilet,	 taking	
medications,	and	not	bedridden.	
AE	Relationship	to	Study	Drug	
The	relationship	of	an	AE	to	the	study	drug	should	be	assessed	using	the	following	the	
guidelines	in	Table	14.	
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Table	14.		AE	Relationship	to	Study	Drug	
Relationship	
to	Drug	
Comment	
Definitely	 Previously	known	toxicity	of	agent;	or	an	event	that	follows	a	reasonable	
temporal	sequence	from	administration	of	the	drug;	that	follows	a	known	or	
expected	response	pattern	to	the	suspected	drug;	that	is	confirmed	by	stopping	
or	reducing	the	dosage	of	the	drug;	and	that	is	not	explained	by	any	other	
reasonable	hypothesis.	
Probably	 An	event	that	follows	a	reasonable	temporal	sequence	from	administration	of	
the	drug;	that	follows	a	known	or	expected	response	pattern	to	the	suspected	
drug;	that	is	confirmed	by	stopping	or	reducing	the	dosage	of	the	drug;	and	that	
is	unlikely	to	be	explained	by	the	known	characteristics	of	the	subject’s	clinical	
state	or	by	other	interventions.	
Possibly	 An	event	that	follows	a	reasonable	temporal	sequence	from	administration	of	
the	drug;	that	follows	a	known	or	expected	response	pattern	to	that	suspected	
drug;	but	that	could	readily	have	been	produced	by	a	number	of	other	factors.	
Unrelated	 An	event	that	can	be	determined	with	certainty	to	have	no	relationship	to	the	
study	drug.	
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Adverse	Events	Reporting	 	
	
Responsible	Parties	
Sponsor/Investigator/	Safety	Officer-	Robert	Lodder	
Other	Investigators	-	Medical	Investigators	(site	PIs)	
The	 Sponsor-Investigator/Safety	Officer	will	 inform	 the	 IRB	of	 any	 events	 of	which	he	
becomes	aware.	
Serious	Adverse	Event	Reporting	 	
Safety	 reports	will	 be	made	of	 potential	 serious	 risks,	 from	 clinical	 trials	 or	 any	other	
source,	as	soon	as	possible,	but	in	no	case	later	than	14	calendar	days	after	the	sponsor	
determines	that	the	information	qualifies	for	reporting.	
	
The	PI	will	report	any	suspected	adverse	reaction	that	is	both	serious	and	unexpected.	
The	sponsor	must	report	an	adverse	event	as	a	suspected	adverse	reaction	only	if	there	
is	 evidence	 to	 suggest	 a	 causal	 relationship	 between	 the	 therapeutic	 agent	 and	 the	
adverse	event,	such	as:	
		
(A)	 	 A	 single	 occurrence	 of	 an	 event	 that	 is	 uncommon	 and	 known	 to	 be	
strongly	 associated	 with	 drug	 exposure	 (e.g.,	 angioedema,	 hepatic	 injury,	
Stevens-Johnson	Syndrome);	
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(B)	 	 One	 or	more	 occurrences	 of	 an	 event	 that	 is	 not	 commonly	 associated	
with	drug	exposure,	but	is	otherwise	uncommon	in	the	population	exposed	to	
the	drug	(e.g.,	tendon	rupture);	
(C)	An	aggregate	analysis	of	specific	events	observed	in	a	clinical	trial	(such	as	
known	 consequences	 of	 the	 underlying	 disease	 or	 condition	 under	
investigation	 or	 other	 events	 that	 commonly	 occur	 in	 the	 study	 population	
independent	 of	 drug	 therapy)	 that	 indicates	 those	 events	 occur	 more	
frequently	in	the	drug	treatment	group	than	in	a	concurrent	or	historical.	
	
Life-threatening	suspected	adverse	reaction	as	soon	as	possible	but	in	no	case	later	than	
7	days	after	sponsor	determines	that	the	information.		
The	study	clinician	will	complete	a	SAE	Form	within	the	following	timelines:	
● All	deaths	and	immediately	life-threatening	events,	whether	related	or	unrelated,	
will	be	recorded	on	the	SAE	Form	and	submitted	to	the	study	sponsor	within	24	
hours	of	site	awareness.		
● Other	 SAEs	 regardless	 of	 relationship,	 will	 be	 submitted	 to	 the	 study	 sponsor	
within	24	hours	of	site	awareness.	
		
All	SAEs	will	be	followed	until	satisfactory	resolution	or	until	the	site	investigator	deems	
the	event	to	be	chronic	or	the	adherence	to	be	stable.	Other	supporting	documentation	
of	the	event	may	be	requested	by	the	study	sponsor	and	should	be	provided	as	soon	as	
possible.	
	
The	study	sponsor	will	be	responsible	for	notifying	 IRB	of	any	unexpected	fatal	or	 life-
threatening	suspected	adverse	reaction	as	soon	as	possible	but	in	no	case	later	than	7	
calendar	days	after	the	sponsor's	initial	receipt	of	the	information.	
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Unanticipated	Problem	Reporting	 	
Incidents	 or	 events	 that	 meet	 the	 OHRP	 criteria	 for	 UPs	 require	 the	 creation	 and	
completion	of	an	UP	report	form.	It	is	the	site	investigator’s	responsibility	to	report	UPs	
to	their	IRB.	The	UP	report	will	include	the	following	information:	
● Protocol	 identifying	 information:	protocol	 title	 and	number,	PI’s	name,	 and	 the	
IRB	project	number;	
● A	detailed	description	of	the	event,	incident,	experience,	or	outcome;	
● An	explanation	of	the	basis	for	determining	that	the	event,	incident,	experience,	
or	outcome	represents	an	UP;	
● A	description	of	any	changes	to	the	protocol	or	other	corrective	actions	that	have	
been	taken	or	are	proposed	in	response	to	the	UP.	
		
To	 satisfy	 the	 requirement	 for	 prompt	 reporting,	 UPs	 will	 be	 reported	 using	 the	
following	timeline:	
● UPs	that	are	SAEs	will	be	reported	to	 the	 IRB	 	within	7	days	of	 the	 investigator	
and	 to	 the	 sponsor	within	24	hours	of	 the	 investigator	becoming	aware	of	 the	
event.	
● Any	other	UP	will	be	reported	to	the	IRB	and	to	the	study	sponsor	within	14	days	
of	the	investigator	becoming	aware	of	the	problem.	
● All	UPs	should	be	reported	to	appropriate	institutional	officials	(as	required	by	UK	
per	 Serious	 or	 Continuing	Noncompliance	 or	Unanticipated	 Problems	 Involving	
Risks:IRB	Reporting	to	Federal	Agencies	using	the	UK	 IRB	reporting	form	within	
the	 timeline	 in	 accordance	 with	 the	 SOP	 for	 Unanticipated/Anticipated	
Problem/Adverse	Event	Reporting	(UK)	of	the	 IRB’s	receipt	of	the	report	of	the	
problem	from	the	investigator.	
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List	of	Regulatory	Agency	
IRB	
Responsible	Parties	
Sponsor/	Safety	Officer	-	Robert	Lodder	
Medical	investigators	(site	PIs)	
Sponsor/Safety	Officer	and	the	IRB	
Ethical	and	Regulatory	Standards	
Ethical	Principles	
This	Clinical	Trial	will	be	conducted	 in	accordance	with	the	principles	 laid	down	by	the	
18th	World	Medical	Assembly	(Helsinki,	1964)	and	all	applicable	amendments	laid	down	
by	 the	 World	 Medical	 Assemblies,	 and	 the	 ICH	 guidelines	 for	 Good	 Clinical	 Practice	
(GCP).	Those	Investigators	participating	as	leaders	in	this	trial,	including	members	of	the	
Executive	 and	 Operations	 Committees	 and	 National	 Coordinators,	 will	 receive	
compensation	 for	 their	 time	 but	 will	 receive	 no	 financial	 profit	 from	 their	 activities	
related	to	the	trial.		
Laws	and	Regulations		
This	 Clinical	 Trial	 will	 be	 conducted	 in	 compliance	 with	 all	 international	 laws	 and	
regulations,	and	national	laws	and	regulations	of	the	countries	in	which	the	clinical	trial	
is	 performed,	 as	 well	 as	 any	 applicable	 guidelines.	 The	 trial	 will	 be	 registered	 on	
www.clintrials.gov	and	on	other	sites,	as	appropriate.		
Informed	Consent		
The	 Investigator	 (according	 to	 applicable	 regulatory	 requirements),	 or	 a	 person	
designated	by	the	 Investigator,	and	under	the	 Investigator's	responsibility,	should	fully	
inform	 the	 patient	 of	 all	 pertinent	 aspects	 of	 the	 clinical	 trial,	 including	 the	 written	
information	given	approval/favorable	opinion	by	 the	 Institutional	Review	Board/Ethics	
Committee	 	Prior	 to	a	patient’s	participation	 in	 the	 clinical	 trial,	 the	written	 Informed	
Consent	Form	should	be	signed,	name	filled	in	and	personally	dated	by	the	patient	or	by	
the	patient’s	 legally	acceptable	 representative,	 and	by	 the	person	who	conducted	 the	
informed	consent	discussion.	A	copy	of	the	signed	and	dated	written	Informed	Consent	
Form	 will	 be	 provided	 to	 the	 patient.	 If	 informed	 consent	 is	 obtained	 under	 special	
circumstances	 (emergency,	 from	 a	 guardian,	 minor,	 etc.),	 the	 method	 should	 be	
specified	 following	 the	 ICH	 requirements.	 The	 first	 part	 of	 the	 section	 should	 be	
adapted,	 keeping	 the	 point	 as	 appropriate.	 The	 Informed	 Consent	 Form	 used	 by	 the	
Investigator	 for	 obtaining	 the	 patient's	 informed	 consent	 must	 be	 reviewed	 and	
approved	 by	 the	 Sponsor	 prior	 to	 submission	 to	 the	 appropriate	 IRB	 for	
approval/favorable	opinion.		
Institutional	Review	Board	(IRB)		
The	 Investigator	must	 submit	 this	Clinical	 Trial	 Protocol	 to	 the	appropriate	 IRB,	and	 is	
required	to	forward	to	the	Sponsor	a	copy	of	the	written	and	dated	approval/favorable	
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opinion	signed	by	the	Chairman	with	IRB	composition.	The	Clinical	Trial	(study	number,	
Clinical	Trial	Protocol	title	and	version	number),	the	documents	reviewed	(Clinical	Trial	
Protocol,	 Informed	Consent	 Form,	 Investigator’s	 Brochure,	 Investigator’s	 CV,	 etc.)	 and	
the	date	of	 the	 review	should	be	clearly	 stated	on	 the	written	 IRB	approval/favorable	
opinion.	 Investigational	 Product	will	 not	 be	 released	 at	 the	 study	 site	 and	 the	Clinical	
Trial	will	not	start	until	a	copy	of	this	written	and	dated	approval/favorable	opinion	has	
been	received	by	the	Sponsor.	During	the	Clinical	Trial,	any	amendment	or	modification	
to	the	Clinical	Trial	Protocol	should	be	submitted	to	the	IRB.	It	should	also	be	informed	
of	 any	 event	 likely	 to	 affect	 the	 safety	 of	 patients	 or	 the	 continued	 conduct	 of	 the	
Clinical	 Trial,	 in	 particular	 any	 change	 in	 safety.	 All	 updates	 to	 the	 Investigator’s	
Brochure	 will	 be	 sent	 to	 the	 IRB.	 If	 requested,	 a	 progress	 report	 is	 sent	 to	 the	 IRB	
annually	and	a	summary	of	the	Clinical	Trial’s	outcome	at	the	end	of	the	Clinical	Trial.		
Study	Monitoring	
Responsibilities	of	the	Investigator(s)	
The	 Investigator(s)	 undertake(s)	 to	 perform	 the	 Clinical	 Trial	 in	 accordance	 with	 this	
Clinical	 Trial	 Protocol,	 ICH	 guidelines	 for	 Good	 Clinical	 Practice	 and	 the	 applicable	
regulatory	 requirements.	 	 The	 Investigator	 is	 required	 to	 ensure	 compliance	 with	 all	
procedures	required	by	the	Clinical	Trial	Protocol	and	by	study	procedures	provided	by	
the	Sponsor	 (including	 security	 rules).	 The	 Investigator	agrees	 to	provide	 reliable	data	
and	all	 information	 requested	by	 the	Clinical	 Trial	Protocol	 (with	 the	help	of	 the	Case	
Report	Form	[CRF],	Discrepancy	Resolution	Form	[DRF]	or	other	appropriate	instrument)	
in	an	accurate	and	legible	manner	according	to	the	instructions	provided	and	to	ensure	
direct	access	to	source	documents	to	Sponsor	representatives.	If	any	particular	circuits	
have	 to	 be	 defined	 (e.g.,	 e-CRF,	 Fax),	 particular	 attention	 should	 be	 paid	 to	 the	
confidentiality	of	the	patient's	data	to	be	transferred.	The	Investigator	may	appoint	such	
other	 individuals	as	he/she	may	deem	appropriate	as	Sub-Investigators	to	assist	 in	the	
conduct	 of	 the	 Clinical	 Trial	 in	 accordance	 with	 the	 Clinical	 Trial	 Protocol.	 All	 Sub-
Investigators	 shall	 be	 timely	 appointed	 and	 listed.	 The	 Sub-Investigators	 will	 be	
supervised	 by	 and	 under	 the	 responsibility	 of	 the	 Investigator.	 The	 Investigator	 will	
provide	them	with	a	Clinical	Trial	Protocol	and	all	necessary	information.		
Responsibilities	of	the	Sponsor		
The	 Sponsor	 of	 this	 Clinical	 Trial	 is	 responsible	 to	 Health	 Authorities	 for	 taking	 all	
reasonable	steps	to	ensure	the	proper	conduct	of	the	Clinical	Trial	Protocol	as	regards	
ethics,	Clinical	Trial	Protocol	compliance,	 integrity	and	validity	of	the	data	recorded	on	
the	 Case	 Report	 Forms.	 Thus,	 the	 main	 duty	 of	 the	 Monitoring	 Team	 is	 to	 help	 the	
Investigator	 and	 the	 Sponsor	maintain	 a	 high	 level	 of	 ethical,	 scientific,	 technical	 and	
regulatory	 quality	 in	 all	 aspects	 of	 the	 Clinical	 Trial.	 At	 regular	 intervals	 during	 the	
Clinical	Trial,	 the	site	will	be	contacted,	through	monitoring	visits,	 letters	or	telephone	
calls,	by	a	representative	of	the	Monitoring	Team	to	review	study	progress,	Investigator	
and	 patient	 compliance	 with	 Clinical	 Trial	 Protocol	 requirements,	 and	 any	 emergent	
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problems.	During	these	monitoring	visits,	the	following	but	not	exhaustive	list	of	points	
will	be	scrutinized	with	the	Investigator:	patient	informed	consent,	patient	recruitment	
and	 follow-up,	 Serious	 Adverse	 Event	 documentation	 and	 reporting,	 outcome	 events	
documentation	and	reporting,	Investigational	Product	allocation,	Investigational	Product	
accountability,	concomitant	therapy	use	and	quality	of	data.	
Source	Document	Requirements		
According	 to	 the	 ICH	guidelines	 for	Good	Clinical	 Practice,	 the	Monitoring	Team	must	
check	the	Case	Report	Form	entries	against	the	source	documents,	except	for	the	pre-
identified	source	data	directly	recorded	in	the	Case	Report	Form.	The	Informed	Consent	
Form	will	include	a	statement	by	which	the	patient	allows	the	Sponsor’s	duly	authorized	
personnel,	 the	 Ethics	 Committee	 (IRB),	 and	 the	 regulatory	 authorities	 to	 have	 direct	
access	to	source	data	which	supports	the	data	on	the	Case	Report	Forms	(e.g.,	patient's	
medical	 file,	 appointment	 books,	 original	 laboratory	 records,	 etc.).	 These	 personnel,	
bound	by	professional	secrecy,	must	keep	confidential	all	personal	identity	or	personal	
medical	information	(according	to	confidentiality	rules).		
Use	and	Completion	of	Case	Report	Forms	(CRFs)	and	Additional	Requests		
It	 is	 the	 responsibility	 of	 the	 Investigator	 to	 maintain	 adequate	 and	 accurate	 CRFs	
designed	 by	 the	 Sponsor	 to	 record	 all	 observations	 and	 other	 data	 pertinent	 to	 the	
clinical	 investigation.	 All	 source	 documents	 should	 be	 completed	 in	 their	 entirety	 in	
electronic	 format	 to	 ensure	 accurate	 interpretation	 of	 data,	which	 should	 be	 entered	
within	48	hours	of	completion	or	any	modification	into	the	eCRF.	Should	a	correction	be	
made,	 the	 information	will	 be	 re-entered	with	 tracked	 changes	 that	 show	who	made	
which	changes	and	when.	The	corrected	information	will	be	entered	by	the	authorized	
person	 into	 the	 eCRF.	 The	 computerized	 handling	 of	 the	 data	 by	 the	 Sponsor	 after	
receipt	of	the	CRFs	may	generate	additional	requests	(DRF)	to	which	the	Investigator	is	
obliged	 to	 respond	 by	 confirming	 or	 modifying	 the	 data	 questioned.	 Unresolved	
requests	will	be	entered	at	least	every	2	weeks.	
Study	Documentation,	Case	Report	Forms,	and	Record	Keeping	
Investigator’s	File	
	
The	investigator	must	maintain	adequate	and	accurate	records	to	enable	the	conduct	of	
the	 study	 to	 be	 fully	 documented	 and	 the	 study	 data	 to	 be	 subsequently	 verified,	 in	
electronic	 format	with	 tracked	 changes.	 These	documents	 should	be	 classified	 as	 two	
types:	investigators	study	master	file	and	study/subject	clinical	source	documents.	
Source	Documentation	
	
Source	documents	are	defined	as	the	primary	source	for	all	study	related	data.	They	are	
considered	 original	 documents,	 data,	 and	 records.	 This	may	 include	 hospital	 records,	
clinical	 and	 office	 charts,	 laboratory	 data/information,	 and	 pharmacy	 dispensing	 and	
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other	records.	All	entries	in	the	CRF	must	be	supported	by	data	recorded	on	the	source	
documentation.	
	
Source	documentation	will	be	kept	in	the	individual	subject’s	file	during	the	conduct	of	
the	 clinical	 trial	 and	 stored	 in	 a	 secure	 electronic	 database.	 The	 investigator(s)	 will	
permit	 study-related	 monitoring,	 audits,	 IEC	 review,	 and	 regulatory	 inspection(s),	
providing	direct	access	to	source	documents.	
	
Case	Report	Forms		
	
All	forms	will	be	filled	out	in	electronic	format	with	automatic	version	control.	The	study	
monitor	at	the	study	site	will	review	CRFs.	Errors	detected	by	subsequent	in-house	CRF	
review	 may	 necessitate	 clarification	 or	 correction	 of	 errors.	 All	 changes	 will	 be	
documented	and	approved	by	the	investigator.	
Data	Handling	
	
All	 data	will	 be	 entered	 into	 electronic	 CRFs	with	 tracked	 changes.	 All	 data	manually	
entered	 in	 the	 database	 will	 be	 verified	 by	 a	 double-key	 entry	 procedure.	 After	
completion	 of	 the	 entry	 process,	 computer	 logic	 checks	will	 be	 run	 to	 check	 for	 such	
items	 as	 inconsistent	 study	 dates	 and	 outlying	 laboratory	 values.	 Any	 necessary	
corrections	 will	 be	 made	 to	 the	 database	 and	 documented	 via	 tracked	 changes.	 A	
manual	 review	of	selected	 line	 listings	will	also	be	performed	at	 the	end	of	 the	study.	
The	 data	 from	 clinical	 laboratory	will	 be	 provided	 electronically	 and	 entered	 into	 the	
CRF	by	a	double-key	entry	procedure.		In	the	event	of	conflicts,	a	third	person	will	meet	
with	the	first	two	to	resolve	the	conflict.		A	Discrepancy	Resolution	Form	(DRF)	will	track	
the	process	and	the	outcome.	
Protocol	Amendments	
	
All	amendments	must	be	reviewed	and	approved	by	the	applicable	IRB/ERB(s)	in	the	US	
before	the	revised	edition	can	be	implemented.	
Confidentiality		
	
The	 investigator	 will	 assure	 that	 subjects’	 anonymity	 will	 be	 maintained.	 On	 CRFs	 or	
other	documents	submitted	to	CRO,	subjects	will	not	be	identified	by	their	names,	but	
by	 an	 identification	 code.	 The	 investigator	will	 keep	 a	 separate	 log	 of	 subjects’	 codes	
and	names.	Documents	not	for	submission	to	CRO,	such	as	informed	consent	forms	and	
medical	records,	will	be	kept	in	strict	confidence.	
Study	Interventions,	Administration,	and	Duration	
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After	initial	screening	(Visit	1)	the	volunteers	will	be	randomly	divided	into	two	groups.	
One	will	be	given	trans-polydatin,	which	will	be	administered	as	a	single	oral	dose	of	100		
µg.	The	second	group	will	receive	BSN272	(100	µg	trans-polydatin	and	D-lyxo-hexulose	
at	0.03	g/kg	in	separate	cups).	Blood	samples	for	pharmacokinetic	study	and	toxicology	
monitoring	will	be	taken	at	the	proposed	time	points	for	the	following	24	hours.	Urine	
samples	will	also	be	collected	for	the	initial	12	hours	so	that	elimination	of	the	trial	drug	
can	be	monitored,	with	one	subsequent	urine	sample	during	visit	3.	Post	study	subjects	
will	 be	monitored/asked	 to	 report	 and	 adverse	 effects.	Medical	 intervention	will	 take	
place	if	toxicological	symptoms	arise.	
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Appendix	1	-	Clinical	Laboratory	Tests	
	
Serum	Chemistry	 Hematology	 Urinalysis	
Sodium	 Hematocrit	 Appearance	
Chloride	 Hemoglobin	 Volume	
Potassium	 MCH	 Specific	Gravity	pH	
CO2	 MCHC	 Glucose	
BUN	 MCV	 Protein	
Albumin	 Total	WBC	 Microscopic	evaluation	
of	urinary	sediment	
Creatinine	Clearance	 Platelet	Count	 Trans-polydatin*	
SGOT	 Differential	 Trans-resveratrol*	
SGPT	 	 	
Total	Bilirubin	 	 	
Direct	Bilirubin	 	 	
Hep	C	 	 	
HIV	 	 	
Trans-polydatin*	 	 	
Trans-resveratrol*	 	 	
*=	Pharmacokinetic	analysis	only	during	timed	blood/urine	samples	on	trial	days	
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Appendix	2	-	Clinical	Laboratory	Normal	Results	
	
Parameter	 Normal	Range	
Sodium	 135-145	mmol/L	
Chloride	 98-108	mmol/L	
Potassium		 3.5-5.0	mmol/L	
CO2	 21-32	mmol/dL	
BUN	 10-20	mg/dL	
Uric	Acid	 3.6-8.3	mg/dL	
Albumin	 3.5-5.0	g/dL	
Creatinin	 0.6-1.2	mg/L	(Male)	0.5-1.1	mg/L	(female)	
SGOT	 8-40	IU/L	(male)	6-34	IU/L	(Female)	
ALT	 10-50	IU/L	(male)	5-38	IU/L	(female)	
Bilirubin	 0.05-1.2	mg/dL	
Serum	total	protein	 6-8.5	g/dL	
Glucose	 4.4-6.1	mmol/L	
Neutrophil	 >	1500/mm3	
Hematocrit	 42-54%	(Male)	38-46%	(Female)	
Hemoglobin	 11.5-19.0	g/dL	(Male)	10.5-17.5	g/dL	(Female)	
MCH	 30-37	g/dL	
MCHC	 4.9-5.5mmol/L	
MCV	 80-99	fL	
White	blood	cells.	 0.4-1.1	x10^10/L	
Platelets	 120,000-450,000/mm3	
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